

LYCOPENE: PROTECTIVE POTENTIAL AGAINST DIET-INDUCED METABOLIC DERANGEMENTS IN WISTAR RATS



Mercy Omoye Shafe

A thesis submitted to the Faculty of Health Sciences, School of Physiology, University of the Witwatersrand, in fulfilment of the requirements for the degree of Doctor of Philosophy.


Johannesburg, 2025

DECLARATION

I, **Mercy Omoye Shafe**, student number **2404174**, declare that this thesis, titled **“Lycopene: Protective Potential Against Diet-Induced Metabolic Derangements in Wistar Rats”** is my original work. It is being submitted for the degree of **Doctor of Philosophy (Ph.D.)** at the **University of the Witwatersrand, Johannesburg, Republic of South Africa**. It has not been submitted, in whole or in part, for any degree or examination at any other university or institution. All sources used or cited have been appropriately acknowledged in the references.

Signed.....  Date10/06/2025.....

Name of Primary Supervisor:Professor Eliton Chivandi.....

Signature of Primary Supervisor: ... Date10/06/2025...

Agreement by Co-Authors





By signing this declaration, the co-authors listed below, including the student's supervisors, confirm their consent to the inclusion of the collaboratively authored review paper on lycopene, primarily written by the student, as part of this thesis.

Article 1

Title: Lycopene: A potent Antioxidant with Multiple Health Benefits

Journal of Nutrition and Metabolism Volume 2024, Article ID 6252426, 17 pages

<https://doi.org/10.1155/2024/6252426>

Authors	Name	Signature	Date
1 st author	Mercy O. Shafe		10/06/2025
2 nd author	Nontobeko M. Gumede		10/06/2025
3 rd author	Trevor T. Nyakudya		10/06/2025
4 th author	Eliton Chivandi		10/06/2025

Comments by the primary supervisor: As the PhD candidate, Mercy Shafe actively participated in the study design and data collection. It is from the study concept that she came up with the frame/structure of the review article. She wrote the first draft of the review article, made corrections following input from the supervisors. She submitted the article to the journal, made corrections following reviewer inputs, and published the article as first and corresponding author.

DEDICATION

I dedicate this thesis to **Almighty God**, whose guidance, wisdom, and grace have been my constant source of strength and inspiration throughout this journey.

Without His blessings, this achievement would not have been possible.

CONFERENCE PRESENTATIONS ARISING FROM THIS RESEARCH

Oral presentations

1. **M.O. Shafe**, N.M. Gumede, T.T. Nyakudya and E. Chivandi. Lycopene: effects on body and liver mass, haematology, and metabolic substrate content of female Wistar Rats fed a high-fructose diet. **14th cross-Faculty Postgraduate Symposium**, 6th-8th September 2023, University of Witwatersrand, Johannesburg, Republic of South Africa.
2. **M.O. Shafe**, N.M. Gumede, T.T. Nyakudya and E. Chivandi. Lycopene: supplementation mitigated dietary fructose-induced increase liver lipid content in male Wistar Rats. **School of Physiology Research Day**, 13th September 2023, University of Witwatersrand, Johannesburg. Republic of South Africa.

Postal presentation

1. **M.O. Shafe**, N.M. Gumede, T.T. Nyakudya and E. Chivandi. Supplemental lycopene promotes bone and gastrointestinal tract growth, prevent bone loss, in growing male Wistar Rats fed a high-fructose diet. **Faculty of Health Sciences Research Day and Postgraduate Expo**, 5th September 2024, University of Witwatersrand, Johannesburg. Republic of South Africa.

PUBLICATIONS BASED ON THIS RESEARCH

Published review article

1. **M.O. Shafe**, N.M. Gumede, T.T. Nyakudya and E. Chivandi. (2024). Lycopene a potent antioxidant with multiple health benefits. *Journal of Nutrition and Metabolism*, pp. 1-17. <https://doi.org/10.1155/2024/6252426>

Research article submitted for publication

1. **M.O. Shafe**, N.M. Gumede, T.T. Nyakudya and E. Chivandi (2025). Supplemental lycopene reduces feed intake, increases fluid consumption, and enhances bone and stomach growth in growing Wistar Rats fed a high-fructose diet. Submitted to *Journal of Medicinal Food*.

ABSTRACT

Early-life nutrition and dietary supplements significantly impact long-term health by either increasing the risk of metabolic disorders or enhancing well-being in adulthood. Lycopene has potent antioxidant activity hence this study evaluated its potential to protect against dietary fructose-induced metabolic derangements in Wistar rats mimicking adolescents fed an obesogenic diet. Ninety-six 21-day-old Wistar rats (48 females and 48 males) were assigned to different groups at random and received treatment regimens for 12 weeks as follows: (1) standard rat chow (SRC) with plain drinking water (PDW) and plain gelatine cubes (PG), (2) SRC with a 20% fructose solution (FS) and PG, (3) SRC with FS and 100 mg/kg/day fenofibrate in gelatine cubes. Groups 4, 5, and 6 had SRC, FS, and lycopene in gelatine cube at 30, 60, and 100 mg/kg/day, respectively. Feed and fluid consumption, and body mass, were measured. Terminally, the fasted rats were weighed and euthanised. Collected blood was used to assess treatment effects on general health and oxidant and antioxidant status. Gastrointestinal viscera macro-morphometry, visceral and epididymal fat, liver fat, and kidney and liver macro- and micro-morphometry and femora and tibiae indices were determined.

Female and male rats fed the control diet had higher ($p < 0.05$) feed intake compared to high fructose diet fed, fenofibrate treated and lycopene supplemented counterparts. Compared to control diet fed and fenofibrate-treated, lycopene-supplemented rats had lower feed intake but higher fluid intake ($p < 0.05$). Both female and male rats showed significant growth during the trial ($p < 0.05$). Lycopene increased the small intestine and stomach masses in male rats. Treatment regimens did not affect visceral fat in either male or female rats, nor epididymal fat mass in males ($p > 0.05$). Fenofibrate increased the females' high-density lipoprotein (HDL), glycated haemoglobin (HbA1c), and fasting blood glucose (FBG) concentrations, and the males' FBG concentration ($p < 0.05$). The rats' haemoglobin, haematocrit, triglycerides, serum total cholesterol, low-density lipoprotein (LDL), leptin, creatinine, blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), and thiobarbituric acid reactive substances (TBARS) concentrations, BUN/creatinine ratio, alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), and glutathione peroxidase 1 (GPX-1) activities, glomerular tuft area, proximal convoluted tubule outer and epithelial areas showed no significant changes across treatment groups ($p > 0.05$). Lycopene prevented fructose-induced increase in urinary space observed in male rats. In females, treatments did not affect serum

globulin, total protein, albumin, bile acids and uric acid concentrations ($p > 0.05$). Supplemental lycopene attenuated dietary fructose-induced serum albumin, total protein, globulin, total bile acids, and uric acid increases concentrations in males. High-dose supplemental lycopene increased hepatic GPX-1 and catalase (CAT) activities in male rats. In both sexes fenofibrate caused hepatocyte hypertrophy. Lycopene mitigated dietary fructose-induced increases in liver lipid content and steatosis.

Dietary fortification with lycopene showed significant prophylactic potential against metabolic disturbances caused by dietary fructose in Wistar rats. It improved bone, kidney, liver, and gastrointestinal health and enhanced antioxidant activity, supporting better metabolic outcomes and overall well-being in both sexes.

ACKNOWLEDGMENTS

First and foremost, I offer my deepest gratitude to my Father, ‘The Eleburuiké’ (God whose care for us overflows), for His abundant grace, unfailing love, and constant guidance throughout this academic pursuit. His presence has been my foundation and source of strength in overcoming every challenge along the way.

To my supervisors, **Professors Eliton Chivandi, Trevor T, Nyakudya and Dr. Nontobeko M. Gumede**, I sincerely thank you for your invaluable mentorship. Your guidance, patience, and support have not only shaped my academic journey but also helped me grow as a person. The lessons learnt will continue to guide me throughout my life and career.

Special thanks to **Professor Kennedy Erlwanger, Dr. Bernice Asiedu, and Mrs. Mmahiine Mosana** for their technical support, and to **Dr. Monica Gomes** for her assistance with the ELISA procedure.

Thanks to **Associate Professor Pilani Nkomozepe** for his technical guidance in histological analysis.

I extend my gratitude to the **Wits Research Animal Facility** staff for their care and maintenance of the rats used in this study.

I sincerely appreciate the **School of Physiology, Faculty of Health Sciences**, and the **Faculty Research Committee** at the University of the Witwatersrand, South Africa, for their financial support. I also thank Bingham University, Nigeria, for granting me the opportunity to pursue my PhD.

Thanks to my postgraduate colleagues, **Malebogo Bopape, Toluwase Olanipekun, Xitsakiso Mabasa, Jelani Muhammad**, and **Rozette Tladi**, for their assistance with terminal procedures, and to **Gomotsegang Motlhale** for her collaboration as a co-worker for this study.

To my **family, Mum, my siblings**, and the memory of my late father, **Pa Raymond Akhiwu Ohuh**, whose love, guidance, and prayers continue to inspire me. I also express my deepest gratitude to my loving, caring, and understanding husband, **Engr. Dirisu Shafe**, for your support and encouragement, and for allowing me to come to South Africa to pursue my PhD.

TABLE OF CONTENTS

TITLE PAGE.....	i
DECLARATION.....	ii
DEDICATION	iv
CONFERENCE PRESENTATIONS ARISING FROM THIS RESEARCH.....	v
PUBLICATIONS BASED ON THIS RESEARCH	vi
ABSTRACT	vii
ACKNOWLEDGMENTS.....	ix
CHAPTER ONE: INTRODUCTION AND JUSTIFICATION	1
1.0 Introduction and justification	2
1.1 Aims and objectives	5
1.2 Hypothesis	6
1.3 References	7
CHAPTER TWO: LITERATURE REVIEW	15
2.0 Introduction.....	16
2.1 Metabolic syndrome: a historical perspective	16
2.2 Metabolic syndrome trends	17
2.3 Components of metabolic syndrome.....	18
2.3.1 Central obesity.....	18
2.3.2 Insulin resistance	19
2.3.3 Dyslipidaemia	20
2.4 Complications of metabolic syndrome	21
2.4.1 Metabolic dysfunction-associated steatotic liver disease.....	21
2.4.2 Type 2 diabetes mellitus	22
2.4.3 Chronic kidney disease.....	23
2.4.4 Cardiovascular diseases.....	23
2.4.5 Bone disorders and osteoporosis	24
2.4.6 Haematological changes	24
2.5 Metabolic programming	24
2.6 Experimental models of metabolic programming	25
2.6.1 Chemical intervention models	25

2.6.2 Genetic models	26
2.6.3 Diet-based models	27
2.7 High fructose diets and their role in metabolic syndrome pathogenesis	27
2.8 Management strategies for metabolic disorders	29
2.8.1 Lifestyle interventions.....	29
2.8.2 Conventional pharmacological treatment	30
2.8.3 Phytotherapy	30
2.9 References	32
2.10 Lycopene: A potent antioxidant with multiple health benefits – Published review article.....	58
2.10.1 Summary	59
2.10.2 Introduction	59
2.10.3 Lycopene: Biochemistry and physical properties	61
2.10.4 Lycopene: Absorption, transportation, and distribution	62
2.10.5 Lycopene autoxidation.....	65
2.10.6 Biological activities of lycopene	66
2.10.6.1 Antiobesity effects	68
2.10.6.2 Antioxidant effects.....	69
2.10.6.3 Hypocholesterolaemic effects	70
2.10.6.4 Hepatoprotection	71
2.10.6.5 Osteoprotection	74
2.10.6.6 Anti-inflammatory effects	75
2.10.6.7 Antidiabetic effects.....	76
2.10.6.8 Anticancer effects	77
2.10.6.9 Gastroprotection	77
2.10.6.10 Neuroprotection	78
2.10.6.11 Cardioprotection	79
2.10.6.12 Lung protection.....	79
2.10.6.13 Sperm quality enhancement and fertility promotion	80
2.10.6.14 Protection of skin health.....	81
2.10.6.15 Protective effect on vision	81
2.10.7 Lycopene: Protective effects against toxins	82
2.10.8 Lycopene: Safety and potential toxicity	82
2.10.9 Conclusion	82

2.10.10 References.....	84
CHAPTER THREE: EFFECT OF LYCOPENE ON GROWTH PERFORMANCE AND GASTROINTESTINAL VISCERA MACROMORPHOMETRY OF WISTAR RATS FED A HIGH-FRUCTOSE DIET	112
3.0 Introduction.....	113
3.1 Materials and methods	114
3.1.1 Ethical approval.....	114
3.1.2 Chemicals and reagents	114
3.1.3 Animals, housing, and general care	114
3.1.4 Experimental design	115
3.1.5 Measurements: body mass, feed, fluid, and calorie intake	118
3.1.6 Terminal procedures and sample collection	118
3.1.7 Measurement of bone morphometry	118
3.1.8 Statistical analysis.....	119
3.2 Results	119
3.2.1 Body mass	119
3.2.2 Feed, fluid, and calorie intake	121
3.2.3 Long bone indices	127
3.2.4 Visceral organ macro-morphometry	130
3.3 Discussion.....	135
3.3.1 Growth performance: body mass, feed and fluid intake, and calorie consumption	135
3.3.2 Long Bone Growth	139
3.3.3 Morphometry of Visceral Organs	140
3.4 Conclusion	142
3.5 References	143
CHAPTER FOUR: EFFECT OF LYCOPENE ON BLOOD GLUCOSE, GLYCATED HAEMOGLOBIN, HAEMOGLOBIN, HAEMATOCRIT, SERUM LEPTIN CONCENTRATION AND LIPID PROFILE IN GROWING WISTAR RATS FED A HIGH FRUCTOSE DIET	151
4.0 Introduction.....	152
4.1 Materials and methods	154
4.1.1 Ethical approval.....	154
4.1.2 Chemicals and reagents	154
4.1.3 Animals, housing, and general care	154
4.1.4 Experimental design	154
4.1.5 Terminal procedures, sample collection and measurements.....	154

4.1.6 Determination of serum lipoproteins, and total cholesterol	155
4.1.7 Determination of glycated haemoglobin concentrations	155
4.1.8 Determination of serum leptin concentration.....	155
4.1.9 Statistical analysis.....	156
4.2 Results	156
4.2.1 Haemoglobin and haematocrit concentrations	156
4.2.2 Fasting blood glucose and glycated haemoglobin concentrations	158
4.2.3 Lipid profile	161
4.2.4 Serum leptin concentration.....	163
4.3 Discussion.....	165
4.3.1 Haemoglobin and Haematocrit Concentrations	165
4.3.2 Glucose and Lipid Profile	165
4.3.3 Leptin concentration	168
4.4 Conclusion	169
4.5 References	171
CHAPTER FIVE: EFFECT OF LYCOPENE ON KIDNEY HEALTH IN GROWING WISTAR RATS FED A HIGH FRUCTOSE DIET.....	178
5.0 Introduction.....	179
5.1 Materials and methods	181
5.1.1 Ethical approval.....	181
5.1.2 Chemicals and reagents	181
5.1.3 Animals, housing, and general care	181
5.1.4 Experimental design	181
5.1.5 Terminal procedures, sample collection, and measurements.....	181
5.1.6 Determination of kidney function and injury biomarkers	182
5.1.7 Determination of kidney micromorphometry	182
5.1.8 Statistical analysis.....	183
5.2 Results	183
5.2.1 Kidney mass.....	183
5.2.2 Serum biomarker concentrations	185
5.2.3 Kidney histomorphology	188
5.3 Discussion.....	198
5.3.1 Kidney masses.....	198

5.3.2 Renal function and injury biomarkers	199
5.3.3 Kidney histomorphometry.....	202
5.4 Conclusion	205
5.5 References	206
CHAPTER SIX: EFFECT OF LYCOPENE ON LIVER HEALTH IN GROWING WISTAR RATS FED A HIGH FRUCTOSE DIET	217
6.0 Introduction.....	218
6.1 Materials and methods	219
6.1.1 Ethical approval.....	219
6.1.2 Chemicals and reagents	220
6.1.3 Animals, housing, and general care	220
6.1.4 Experimental design	220
6.1.5 Terminal procedures, sample collection and measurements.....	220
6.1.6 Determination of hepatic lipid content	221
6.1.7 Determination of serum and hepatic oxidative stress and antioxidant status.....	221
6.1.8 Determination of serum surrogate markers for liver function	222
6.1.9 Liver histology assessment	222
6.1.10 Statistical analysis.....	222
6.2 Results	223
6.2.1 Liver, visceral fat pad, and epididymal fat pad masses.....	223
6.2.2 Liver lipid content	226
6.2.3 Systemic and hepatic oxidative stress and antioxidant status	228
6.3 Discussion.....	244
6.3.1 Abdominal fat and liver mass	244
6.3.2 Hepatic lipid yield	245
6.3.3 Oxidative stress and systemic antioxidant response.....	246
6.3.4 Serum biomarkers of hepatic function	247
6.3.5 Hepatic microarchitecture	251
6.4 Conclusion	252
6.5 References	254
CHAPTER SEVEN: CONCLUSIONS, LIMITATIONS AND RECOMMENDATIONS FOR FUTURE RESEARCH	266
7.0 Introduction.....	267
7.1 Summary of key findings, limitations, and recommendations.....	267

7.2 Overall conclusion	270
7.3 References	271
APPENDICES	273
Appendix 1: Animal ethics approval certificate.....	274
Appendix 2: First amendment to ethics clearance	275
Appendix 3: Second amendment to ethics clearance	276
Appendix 4: Published review article (Chapter 2).....	277

LIST OF TABLES

CHAPTER TWO

Table 2. 1: Diagnostic criteria for metabolic syndrome across different organisation	17
Table 2. 2: Lycopene concentration in fresh fruits and processed food products	60
Table 2. 3: Physical properties of lycopene	64
Table 2. 4: Lycopene concentration in some human tissues	65
Table 2. 5: Meta-Analyses and Clinical Trials of Lycopene in Human Studies	66

CHAPTER THREE

Table 3. 1: Effect of lycopene on the lengths, masses and seedor ratio of tibiae and femora in growing female Wistar rats fed a high-fructose diet	128
Table 3. 2: Effect of lycopene on the lengths, masses and seedor ratio of tibiae and femora in growing male Wistar rats fed a high-fructose diet	129
Table 3. 3: Effect of lycopene on absolute and relative masses and length of the visceral organs in growing female rats fed a high-fructose diet	131
Table 3. 4 Effect of lycopene on absolute and relative masses and length of the visceral organs in growing male rats fed a high-fructose diet.	133

CHAPTER FOUR

Table 4. 1: Effect of lycopene on haemoglobin and haematocrit concentration in growing female and male Wistar rats fed a high-fructose diet.....	157
Table 4. 2: Effect of lycopene on lipid profile in growing female and male Wistar rats fed a high-fructose diet.....	162

CHAPTER FIVE

Table 5. 1: Effect of lycopene on absolute and relative kidney masses in growing female and male Wistar rats fed a high-fructose diet	184
---	-----

Table 5. 2: Effect of lycopene on serum concentrations of creatinine, BUN, BUN/creatinine ratio, KIM-1 and NGAL in growing female and male Wistar rats fed a high-fructose diet	186
Table 5. 3: Effect of lycopene on kidney morphometry in growing female Wistar rats fed a high-fructose diet.....	189
Table 5. 4: Effect of lycopene on kidney morphometry in growing male Wistar rats fed a high-fructose diet.....	192

CHAPTER SIX

Table 6. 1: Effect of lycopene on absolute and relative masses of the liver and visceral fat pads of growing female Wistar rats fed a high-fructose diet.....	224
Table 6. 2: Effect of lycopene on the absolute and relative masses of the liver, visceral fat pads, and epididymal fat pads of growing male Wistar rats fed a high-fructose diet	225
Table 6. 3: Effect of lycopene on serum markers of hepatic function in growing female Wistar rats fed a high fructose diet.....	234
Table 6. 4: Effect of lycopene on serum markers of hepatic function in growing male Wistar rats fed a high fructose diet.....	235
Table 6. 5: Effect of lycopene on liver steatosis, lobular inflammation, and hepatocyte hypertrophy scores in growing female Wistar rats fed a high-fructose diet	242
Table 6. 6: Effect of lycopene on liver steatosis, lobular inflammation, and hepatocyte hypertrophy scores in growing male Wistar rats fed a high-fructose diet	243

LIST OF FIGURES

CHAPTER TWO

Figure 2. 1 : Molecular structure of lycopene.....	63
--	----

CHAPTER THREE

Figure 3. 1: Flowchart of study design	117
Figure 3. 2: Weekly body masses (A) and induction and terminal body masses (B) of female Wistar rats	120
Figure 3. 3: Weekly body masses (A) and induction and terminal body masses (B) of male Wistar rats.....	121
Figure 3. 4: Effect of lycopene on weekly feed (A), total feed (B), weekly fluid (C), total fluid (D), weekly calorie (E), and total calorie intake (F) of female Wistar rats fed a high-fructose diet.	125
Figure 3. 5: Effect of lycopene on weekly feed (A), total feed (B), weekly fluid (C), total fluid (D), weekly calorie (E), and total calorie intake (F) of male Wistar rats fed a high-fructose diet.	127

CHAPTER FOUR

Figure 4. 1: Effect of lycopene on fasting blood glucose (A) and glycated haemoglobin (B) concentration in growing female Wistar rats fed a high-fructose diet.	159
Figure 4. 2: Effect of lycopene on fasting blood glucose (A) and glycated haemoglobin (B) concentration in growing male Wistar rats fed a high-fructose diet.	160
Figure 4. 3A: Effect of lycopene on serum leptin concentration in growing female Wistar rats fed a high-fructose diet.	163
Figure 4. 3B: Effect of lycopene on serum leptin concentration in growing male Wistar rats fed a high-fructose diet.....	164

CHAPTER FIVE

Figure 5. 1 Representative photomicrographs illustrating the effect of lycopene on kidney histology (H&E staining, 40x magnification, scale bar = 50 μ m) in growing female Wistar rats fed a high-fructose diet.	194
--	-----

Figure 5. 2: Representative photomicrographs illustrating the effect of lycopene on kidney histology (H&E staining, 40x magnification, scale bar = 50 μ m) in growing male Wistar rats fed a high-fructose diet. 196

CHAPTER SIX

Figure 6.1A: Effect of lycopene on liver lipid content in growing female Wistar rats fed a high-fructose diet.....226

Figure 6.1B: Effect of lycopene on liver lipid content in growing male Wistar rats fed a high-fructose diet.....227

Figure 6. 2: Effect of lycopene on serum TBARS (A) concentration and GPX-1 (B) activity and hepatic TBARS (C) concentration, GPX-1 (D) and CAT (E) activities in growing female Wistar rats fed a high-fructose diet..... 230

Figure 6. 3: Effect of lycopene on serum TBARS (A) concentration and GPX-1 (B) activity and hepatic TBARS (C) concentration, GPX-1 (D) and CAT (E) activities in growing male Wistar rats fed a high-fructose diet..... 232

Figure 6.4: Representative photomicrographs showing the effects of lycopene on liver histology in growing female Wistar rats fed a high-fructose diet (H&E staining, 40x magnification, scale bar = 50 μ m). 237

Figure 6.5: Representative photomicrographs showing the effects of lycopene on liver histology in growing male Wistar rats fed a high-fructose diet (H&E staining, 40x magnification, scale bar = 50 μ m)..... 239

LIST OF ABBREVIATION

ADP:	Adenosine diphosphate
AESC:	Animal Ethics Screening Committee
ALB:	Albumin
ALP:	Alkaline phosphatase
ALT:	Alanine aminotransferase
AMP:	Adenosine monophosphate
ARRIVE:	Animal Research: Reporting of In Vivo Experiment
AST:	Aspartate aminotransferase
AOAC:	Association of Official Analytical Chemists
ATP:	Adenosine triphosphate
BM:	Body mass
BMI:	Body mass index
BUN:	Blood urea nitrogen
CA:	Corpuscular area
CAT:	Catalase
CKD:	Chronic kidney disease
CVD:	Cardiovascular disease
CYP7A1:	Cholesterol 7 α -hydroxylase
DCTEA:	Distal convoluted tubules epithelial area
DCTIA:	Distal convoluted tubules inner area
DCTOA:	Distal convoluted tubules outer area
DNA:	Deoxyribonucleic acid
ELISA:	Enzyme-Linked Immuno-Sorbent Assay
F:	Females
FBG:	Fasting blood glucose
FENO:	Fenofibrate
FS:	Fructose solution
FXR:	Farnesoid X receptor
GFR:	Glomerular filtration

GGT:	Gamma-glutamyl transferase
GIT:	Gastrointestinal tract
GLOB:	Globulin
GLUT:	Glucose transporter
GLP-1:	Glucagon-like peptide-1
GPX-1:	Glutathione peroxidase-1
GSH:	Glutathione
GTA:	Glomerular tuft area
H ₀ :	Null hypothesis
H ₁ :	Alternative hypothesis
H & E:	Haematoxylin and eosin
HbA1c:	Glycated haemoglobin
Hb:	Haemoglobin
HCT:	Haematocrit
HDL:	High-density lipoprotein
HDL-C:	High-density lipoprotein Cholesterol
HDLY:	High dose lycopene
HepG2:	Human liver cancer cell line
HFCS:	High fructose corn syrup
IDF:	International Diabetes Federation
IL-6:	Interleukin 6
JNK:	c-Jun N-terminal kinase
KIM-1:	Kidney injury molecule-1
L:	Large
LDL:	Low-density lipoprotein
LDLY:	Low dose lycopene
M:	Males
MAFL:	Metabolic dysfunction-associated fatty liver
MAPK:	Mitogen-activated protein kinase
MASH:	Metabolic dysfunction-associated steatohepatitis
MASLD:	Metabolic dysfunction-associated steatotic liver disease

MCP-1:	Monocyte chemoattractant
MDA:	Malondialdehyde
MDLY:	Medium dose lycopene
MetS:	Metabolic syndrome
mRNA:	Messenger ribonucleic acid
n:	Number
NCEP ATP:	National Cholesterol Education Program Adult Treatment Panel
NF-kB:	Nuclear factor-kappa B
NGAL:	Neutrophil gelatinase-associated lipocalin
OPG:	Osteoprotegerin
PDW:	Plain drinking water
PCTEA:	Proximal convoluted tubules epithelial area
PCTIA:	Proximal convoluted tubules inner area
PCTOA:	Proximal convoluted tubules outer area
PG:	Plain gelatine cube
PND:	Postnatal day
PPAR:	Peroxisome proliferator-activated receptor
RANKL:	Receptor activator of nuclear factor kappa B ligand
ROS:	Reactive oxygen species
S:	Small
SD:	Standard deviation
SGLT2:	Sodium-glucose cotransporter 2
SOD:	Superoxide dismutase
SRC:	Standard rat chow
SST:	Serum separator tube
TBA:	Total bile acids
TBARS:	Thiobarbituric acid reactive substances
TBIL:	Total bilirubin
TC:	Total cholesterol
TCI:	Total calorie intake
TFI:	Total feed intake

TG:	Triglycerides
TNF:	Tumour necrosis factor
TP:	Total protein
T2DM:	Type 2 diabetes mellitus
UA:	Uric acid
USA:	Urinary space area
VAT:	Visceral adipose tissue
VLDL:	Very low-density lipoprotein
w/v:	Weight/volume
WC:	Waist circumference
WHO:	World Health Organisation
WHR:	Waist-to-hip ratio
WRAF:	Wits Research Animal Facility
%BM:	Percentage body mass
α :	Alpha
β :	Beta

CHAPTER ONE: INTRODUCTION AND JUSTIFICATION

1.0 Introduction and justification

Obesity, a growing global concern affecting both children and adults (Koliaki et al., 2023), significantly elevates susceptibility to metabolic disorders and related diseases (Rhee, 2022). The condition develops when dietary energy intake surpasses energy expenditure (Lean et al., 2018). This imbalance in energy metabolism is exacerbated by excessive intake of high-calorie diets and sedentary lifestyles; the major contributors to the rapid increase in obesity worldwide (Heindel et al., 2024). Notably, the global rise in childhood obesity (Pulungan et al., 2024), serves as significant predictor of adult obesity, with affected children facing a higher risk than their non-obese peers (Hampl et al., 2023). As obesity persists into adulthood, it becomes closely linked to metabolic syndrome (MetS), a combination of metabolic abnormalities that heighten the risk of cardiovascular diseases, type 2 diabetes mellitus (T2DM), and stroke (Sharif et al., 2024). MetS is characterised by high blood pressure, elevated lipid levels, gynoid obesity, and increased fasting blood glucose levels (Pluta et al., 2022; Ma et al., 2023). Metabolic syndrome impacts between 25.3% and 34.2% of the adult human global population (Saklayen, 2018) and is projected to increase to 53% by 2035 (Engin, 2017). It affects 22%, 24%, 3%, and 5% of women, men, children and adolescents, respectively (Lovre & Mauvais-Jarvis, 2015; Noubiap et al., 2022). Children in low-income countries experience a higher prevalence of MetS (Noubiap et al., 2022), as people age, the prevalence increases affecting nearly 40% of individuals in their sixties (Swarup et al., 2024). While men generally have a higher prevalence, certain ethnic groups of women show slightly higher rates (Jahangiry et al., 2019; Rus et al., 2023).

This widespread prevalence underscores the role of diet-induced metabolic disorders, which drive the overproduction of reactive oxygen species (ROS) during the metabolism of fuel biomolecule, ultimately resulting in oxidative stress (Jiang et al., 2021). Such oxidative stress is mainly attributed to the excessive intake of corn-fructose-sweetened foods and beverages (Ma et al., 2022), whose metabolism creates a highly oxidative environment that leads to these metabolic disorders (Vona et al., 2021). Fructose is naturally found in fruits, beetroots, sugar cane, and honey and is also industrially produced for use in various food and beverage products (Carvalho et al., 2018; Dholariya & Orrick, 2022). Excessive fructose consumption, particularly during prenatal life has been associated with the onset of obesity, dyslipidaemia, insulin resistance, T2DM, metabolic dysfunction-associated steatotic liver disease (MASLD), and Mets in adulthood (Pereira et al., 2017; Zhou et al., 2020; Tamimi et al., 2021). These conditions can further be complicated

by cardiovascular (Busnatu et al., 2022), renal (Nakagawa & Kang, 2021) and haematologic diseases (Wang et al., 2021). Upon absorption from the small intestine, fructose is largely metabolised in the liver to generate energy, fat and or glucose (Merino et al., 2020) as determined by the energy balance and metabolic requirements of the body. While the liver is the key organ where fructose metabolism takes place, the kidneys also contribute to its metabolism (Dholariya & Orrick, 2022). Excessive fructose consumption has been linked to increased body mass and abnormal enlargement of gastrointestinal organs, including the stomach and intestines (Guney et al., 2023). This abnormal growth can impact the digestive system's overall function. Additionally, fructose disrupts the delicate balance of gut microbiota, the ecosystem of beneficial bacteria residing in the intestines (Beisner et al., 2020). These disruptions can alter digestion, nutrient absorption, and overall gut health (Dong et al., 2023; Sánchez-Terrón et al., 2023). Excessive fructose intake contributes to reduced bone mineral density resulting in a weakened skeletal system (Han et al., 2022). The dietary fructose induced metabolic imbalance leads to oxidative stress which exacerbates dyslipidaemia (Tangvarasittichai, 2015). Specifically, oxidative stress from excessive dietary fructose intake promotes the buildup of triglycerides and total cholesterol, elevates the levels of low-density lipoprotein (LDL) cholesterol and reduces high-density lipoprotein (HDL) cholesterol (Zhang et al., 2017; Baumann et al., 2022). This disruption in lipid metabolism contribute to metabolic dysfunction and increasing the risk of cardiovascular and other metabolic diseases (Chakraborty et al., 2023).

The global burden of metabolic disorders is exacerbated by the high cost of synthetic medications and inadequate healthcare systems, particularly in developing countries, making these treatments largely inaccessible (Mwanza et al., 2023). This has sparked a growing interest in medicinal plants and natural phytochemicals which are known for their diverse biological effects (Theodoridis et al., 2023).

Synthetic pharmaceuticals like fenofibrate and metformin, are commonly prescribed to treat MetS and its associated complications (Dutta et al., 2023; Deerochanawong et al., 2024). However, these widely used medications can be cost-prohibitive in low-income population and are associated with notable side effects (He et al., 2021; Nguyen et al., 2022). This has led to a growing interest in more affordable, plant-based ethnomedicines (Hiben et al., 2019). Despite their benefits, some medicinal plants can be inherently toxic potentially harming vital organs like the liver, heart and

kidneys (Mensah et al., 2019; Philips & Theruvath, 2024). However, many of the medical plants contain bioactive phytochemicals, such as carotenoids, which provide numerous health benefits without the associated toxicity (Nyirenda et al., 2023).

Among these carotenoids, lycopene, a liposoluble compound predominantly found in fruits and vegetables (Pathak & Sagar, 2023), has potent antioxidant properties (Ge et al., 2023). It also exhibits anti-inflammatory (Divyadharsini et al., 2023), hepatoprotective (Abdel-Rahman et al., 2018), cardioprotective (Hsieh et al., 2022), neuroprotective (Paul et al., 2020), and anticancer effects (Sahin et al., 2019). Lycopene also shows benefits against obesity and T2DM (Figueiredo et al., 2024), by reducing oxidative stress and inflammation (Chen et al., 2019) via mechanisms that target critical pathways like c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK), and nuclear factor-kappa B (NF-kB) (Long et al., 2024; Song et al., 2024). Furthermore, lycopene prevents bone mineral loss associated with osteoporosis by promoting an increase in the osteoprotegerin (OPG) to receptor activator of nuclear factor kappa B ligand (RANKL) ratio, thereby inhibiting bone resorption (Qi et al., 2021; Xia et al., 2024).

Despite these therapeutic benefits, the disease-preventing potential of lycopene has not been fully explored. Most research has focused on therapeutic interventions, including plant-based ethnomedicines, to combat metabolic disorders (Korivi & Liu, 2021). However, these studies often utilise chemically induced models, like streptozotocin and alloxan-induced diabetes mellitus models (Athmuri & Shiekh, 2023), which do not effectively replicate the metabolic derangements typically caused by diet. Additionally, these studies predominantly involve male animals (Queiroz et al., 2021; Sasongko et al., 2022; Rehman et al., 2023), despite the known differences in metabolic responses between sexes.

Considering the growing prevalence of diet-induced metabolic disorders in children and adolescents, coupled with the extensive health benefits of lycopene, it is crucial to explore its potential for prevention. This highlights the urgent need to evaluate the prophylactic effects of orally administered lycopene in mitigating dietary fructose-induced metabolic derangements in growing female and male Wistar rats.

1.1 Aims and objectives

The primary aim of the study was to evaluate the potential protective effect of orally administered lycopene against metabolic derangements induced by a high-fructose diet, from weaning to adulthood in Wistar rats. The study was structured to explore the effect of lycopene on four specific sub-study areas:

1. **Growth performance**, assessed by determining effects on:
 - a) body mass
 - b) feed, fluid, and calorie consumption
 - c) long bone growth
 - d) morphometry of gastrointestinal tract visceral organs
2. **Metabolic and haematological markers**, assessed by determining effects on:
 - a) fasting blood haematocrit, haemoglobin, and glycated haemoglobin
 - b) fasting blood glucose concentrations
 - c) fasting blood triglycerides (TG) and serum total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL)
 - d) fasting serum leptin concentration
3. **Kidney health**, evaluated by determining effects on:
 - a) kidney mass (absolute and relative)
 - b) serum kidney function biomarkers [blood urea nitrogen (BUN), creatinine, and BUN/creatinine ratio]
 - c) serum markers indicating kidney tubular damage, including neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1)
 - d) kidney histomorphology
4. **Liver health**, assessed by:
 - a) liver mass (absolute and relative)
 - b) absolute and relative mass of the visceral fat pad (in both sexes) and epididymal fat pad (in males) as indicators of obesity
 - c) hepatic lipid content
 - d) antioxidant and oxidant markers [Fasting serum and hepatic glutathione peroxidase-1 (GPX-1), hepatic catalase (CAT), and serum and hepatic thiobarbituric acid reactive substances (TBARS)]

- e) hepatic steatosis, inflammation, and hypertrophy scores
- f) serum markers of hepatic function [total bilirubin, globulin, albumin, total protein, total bile acids, uric acid, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)]
- g) liver histomorphology

1.2 Hypothesis

H₀: Orally administered lycopene has no protective effect against metabolic derangements induced by a high fructose diet in growing Wistar rats.

H₁: Orally administered lycopene has a protective effect against metabolic derangements induced by a high fructose diet in growing Wistar rats.

1.3 References

- Abdel-Rahman, H. G., Abdelrazek, H. M. A., Zeidan, D. W., Mohamed, R. M., & Abdelazim, A. M. (2018). Lycopene: Hepatoprotective and Antioxidant Effects toward Bisphenol A-Induced Toxicity in Female Wistar Rats. *Oxidative Medicine and Cellular Longevity*, 2018(1), 5167524. <https://doi.org/10.1155/2018/5167524>
- Athmuri, D. N., & Shiekh, P. A. (2023). Experimental diabetic animal models to study diabetes and diabetic complications. *MethodsX*, 11, 102474. <https://doi.org/10.1016/J.MEX.2023.102474>
- Baumann, A., Brandt, A., & Bergheim, I. (2022). Fructose, a trigger of metabolic diseases? a narrative review. *Exploration of Digestive Diseases*, 1(1), 51–71. <https://doi.org/10.37349/EDD.2022.00005>
- Beisner, J., Gonzalez-Granda, A., Basrai, M., Damms-Machado, A., & Bischoff, S. C. (2020). Fructose-Induced Intestinal Microbiota Shift Following Two Types of Short-Term High-Fructose Dietary Phases. *Nutrients*, 12(11), 1–21. <https://doi.org/10.3390/NU12113444>
- Busnatu, S. S., Salmen, T., Pana, M. A., Rizzo, M., Stallone, T., Papanas, N., Popovic, D., Tanasescu, D., Serban, D., & Stoian, A. P. (2022). The Role of Fructose as a Cardiovascular Risk Factor: An Update. *Metabolites*, 12(1), 67. <https://doi.org/10.3390/METABO12010067>
- Carvalho, C. T., Souza, M. Z. de, Arbex, N., Sá, D., Rodrigues, L. C. de S. R. de S., Sá, D. A. R. de, Sá, L. B. P. C. de S. de, & Arbex, A. K. (2018). The Role of Fructose in Public Health and Obesity. *Health*, 10(4), 434–441. <https://doi.org/10.4236/HEALTH.2018.104035>
- Chakraborty, S., Verma, A., Garg, R., Singh, J., & Verma, H. (2023). Cardiometabolic Risk Factors Associated With Type 2 Diabetes Mellitus: A Mechanistic Insight. *Clinical Medicine Insights: Endocrinology and Diabetes*, 16, 11795514231220780. https://doi.org/10.1177/11795514231220780/ASSET/IMAGES/LARGE/10.1177_11795514231220780-FIG6.JPEG
- Chen, D., Huang, C., & Chen, Z. (2019). A review for the pharmacological effect of lycopene in central nervous system disorders. *Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie*, 111, 791–801. <https://doi.org/10.1016/J.BIOPHA.2018.12.151>

- Deerochanawong, C., Kim, S. G., & Chang, Y. C. (2024). Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review. *Diabetes & Metabolism Journal*, 48(2), 184–195. <https://doi.org/10.4093/DMJ.2023.0168>
- Dholariya, S. J., & Orrick, J. A. (2022). Biochemistry, Fructose Metabolism. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK576428/>
- Divyadharsini, V., Maheswari, T. N. U., & Rajeshkumar, S. (2023). Anti-Inflammatory Property of Lycopene, Vitamin E and their Combination – In Vitro Study. *Journal of Population Therapeutics and Clinical Pharmacology*, 30(16), 288–294. <https://doi.org/10.47750/JPTCP.2023.30.16.039>
- Dong, Y., Li, W., & Yin, J. (2023). The intestinal-hepatic axis: a comprehensive review on fructose metabolism and its association with mortality and chronic metabolic diseases. *Critical Reviews in Food Science and Nutrition*, 64(33), 1247312486. <https://doi.org/10.1080/10408398.2023.2253468>
- Dutta, S., Shah, R. B., Singhal, S., Bansal, S., Sinha, S., Haque, M., & Dutta, S. B. (2023). Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. *Drug Design, Development and Therapy*, 17, 1907–1932. <https://doi.org/10.2147/DDDT.S409373>
- Engin, A. (2017). The definition and prevalence of obesity and metabolic syndrome. *Advances in Experimental Medicine and Biology*, 960, 1–17. https://doi.org/10.1007/978-3-319-48382-5_1
- Figueiredo, I. D., Lima, T. F. O., Carlstrom, P. F., Assis, R. P., Brunetti, I. L., & Baviera, A. M. (2024). Lycopene in Combination with Insulin Triggers Antioxidant Defenses and Increases the Expression of Components That Detoxify Advanced Glycation Products in Kidneys of Diabetic Rats. *Nutrients*, 16(11), 1580. <https://doi.org/10.3390/NU16111580/S1>
- Ge, B., Wang, W., Gao, Y., & Chen, X. (2023). Optimization of extraction of lycopene from carrot and determination of its antioxidant activity. *Journal of Food Measurement and Characterization*, 17(5), 5497–5505. <https://doi.org/10.1007/S11694-023-02046-9/FIGURES/9>
- Guney, C., Banu Bal, N., & Akar, F. (2023). The impact of dietary fructose on gut permeability, microbiota, abdominal adiposity, insulin signaling and reproductive function. *Heliyon*, 9(8), e18896. <https://doi.org/10.1016/j.heliyon.2023.e18896>

- Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Edwards, K. C. A., Eneli, I., Hamre, R., Joseph, M. M., Lunsford, D., Mendonca, E., Michalsky, M. P., Mirza, N., Ochoa, E. R., Sharifi, M., Staiano, A. E., Weedn, A. E., Flinn, S. K., ... Okechukwu, K. (2023). Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. *Pediatrics*, *151*(2). <https://doi.org/10.1542/PEDS.2022-060640/190443>
- Han, X., Feng, Z., Chen, Y., Zhu, L., Li, X., Wang, X., Sun, H., & Li, J. (2022). Effects of High-Fructose Corn Syrup on Bone Health and Gastrointestinal Microbiota in Growing Male Mice. *Frontiers in Nutrition*, *9*, 829396. <https://doi.org/10.3389/FNUT.2022.829396>
- He, Y., Qin, M. zhao, & Chen, Y. wen. (2021). Liver injury caused by fenofibrate within 48 h after first administration: a case report. *BMC Gastroenterology*, *21*(1), 1–3. <https://doi.org/10.1186/S12876-021-01874-7/TABLES/1>
- Heindel, J. J., Lustig, R. H., Howard, S., & Corkey, B. E. (2024). Obesogens: a unifying theory for the global rise in obesity. *International Journal of Obesity*, *48*(4), 449–460. <https://doi.org/10.1038/s41366-024-01460-3>
- Hiben, M. G., Louisse, J., de Haan, L. H. J., & Rietjens, I. M. C. M. (2019). Ethnomedicine and ethnobotany of *Maerua subcordata* (Gilg) DeWolf. *Journal of Ethnic Foods*, *6*(1), 1–8. <https://doi.org/10.1186/S42779-019-0032-4/FIGURES/1>
- Hsieh, M. J., Huang, C. Y., Kiefer, R., Lee, S. Da, Maurya, N., & Velmurugan, B. K. (2022). Cardiovascular Disease and Possible Ways in Which Lycopene Acts as an Efficient Cardio-Protectant against Different Cardiovascular Risk Factors. *Molecules*, *27*(10), 3235. <https://doi.org/10.3390/MOLECULES27103235>
- Jahangiry, L., Khosravi-Far, L., Sarbakhsh, P., Kousha, A., Entezarmahdi, R., & Ponnet, K. (2019). Prevalence of metabolic syndrome and its determinants among Iranian adults: evidence of IraPEN survey on a bi-ethnic population. *Scientific Reports*, *9*(1), 1–7. <https://doi.org/10.1038/s41598-019-44486-8>
- Jiang, S., Liu, H., & Li, C. (2021). Dietary Regulation of Oxidative Stress in Chronic Metabolic Diseases. *Foods*, *10*(8), 1854. <https://doi.org/10.3390/FOODS10081854>

- Koliaki, C., Dalamaga, M., & Liatis, S. (2023). Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten? *Current Obesity Reports*, 12(4), 514–527. <https://doi.org/10.1007/S13679-023-00527-Y/FIGURES/2>
- Korivi, M., & Liu, B. R. (2021). New Strategies from Natural Materials to Fight against Diet-induced Metabolic Disorders (Part - II). *Current Pharmaceutical Design*, 27(6), 761–762. <https://doi.org/10.2174/138161282706210222144912>
- Lean, M. E. J., Astrup, A., & Roberts, S. B. (2018). Making progress on the global crisis of obesity and weight management. *BMJ*, 361. <https://doi.org/10.1136/BMJ.K2538>
- Long, Y., Paengkoum, S., Lu, S., Niu, X., Thongpea, S., Taethaisong, N., Han, Y., & Paengkoum, P. (2024). Physicochemical properties, mechanism of action of lycopene and its application in poultry and ruminant production. *Frontiers in Veterinary Science*, 11, 1364589. <https://doi.org/10.3389/FVETS.2024.1364589/BIBTEX>
- Lovre, D., & Mauvais-Jarvis, F. (2015). Trends in Prevalence of the Metabolic Syndrome. *JAMA*, 314(9), 950. <https://doi.org/10.1001/JAMA.2015.8625>
- Ma, W., Zhu, H., Yu, X., Zhai, X., Li, S., Huang, N., Liu, K., Shirai, K., Sheerah, H. A., & Cao, J. (2023). Association between android fat mass, gynoid fat mass and cardiovascular and all-cause mortality in adults: NHANES 2003–2007. *Frontiers in Cardiovascular Medicine*, 10, 1055223. <https://doi.org/10.3389/FCVM.2023.1055223>
- Ma, X., Nan, F., Liang, H., Shu, P., Fan, X., Song, X., Hou, Y., & Zhang, D. (2022). Excessive intake of sugar: An accomplice of inflammation. *Frontiers in Immunology*, 13, 988481. <https://doi.org/10.3389/FIMMU.2022.988481/BIBTEX>
- Mensah, M. L. K., Komlaga, G., Forkuo, A. D., Caleb Firemong, Anning, A. K., Dickson, R. A., (2019). Toxicity and Safety Implications of Herbal Medicines Used in Africa. *Herbal Medicine*, 63(3), 1992-0849. <https://doi.org/10.5772/INTECHOPEN.72437>
- Merino, B., Fernández-Díaz, C. M., Cózar-Castellano, I., & Perdomo, G. (2020). Intestinal Fructose and Glucose Metabolism in Health and Disease. *Nutrients*, 12(1), 94. <https://doi.org/10.3390/NU12010094>

- Mwanza, J., Telukdarie, A., & Igusa, T. (2023). Impact of industry 4.0 on healthcare systems of low- and middle- income countries: a systematic review. *Health and Technology, 13*(1), 35–52. <https://doi.org/10.1007/S12553-022-00714-2/TABLES/3>
- Nakagawa, T., & Kang, D. H. (2021). Fructose in the kidney: from physiology to pathology. *Kidney Research and Clinical Practice, 40*(4), 527. <https://doi.org/10.23876/J.KRCP.21.138>
- Nguyen, T. N., Yusuf, S., & Chow, C. K. (2022). Availability and Affordability of Medicines for Diabetes and Cardiovascular Disease across Countries: Information Learned from the Prospective Urban Rural Epidemiological Study. *Diabetology, 3*(1), 236–245. <https://doi.org/10.3390/DIABETOLOGY3010014>
- Noubiap, J. J., Nansseu, J. R., Lontchi-Yimagou, E., Nkeck, J. R., Nyaga, U. F., Ngouo, A. T., Tounouga, D. N., Tianyi, F. L., Foka, A. J., Ndoadoumgué, A. L., & Bigna, J. J. (2022). Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. *The Lancet. Child & Adolescent Health, 6*(3), 158–170. [https://doi.org/10.1016/S2352-4642\(21\)00374-6](https://doi.org/10.1016/S2352-4642(21)00374-6)
- Nyirenda, K. K., & Kumwenda, F. D. (2023). Health Benefits and Toxicity Potential of Phytochemical Food Additives. *Health Risks of Food Additives - Recent Developments and Trends in Food Sector*. <https://doi.org/10.5772/intechopen.109251>
- Pathak, M., & Sagar, N. A. (2023). Influence of Thermal Treatments, Extraction Methods, and Storage Conditions on Lycopene Content of Foods. *Journal of Food Quality, 2023*(1), 6632637. <https://doi.org/10.1155/2023/6632637>
- Paul, R., Mazumder, M. K., Nath, J., Deb, S., Paul, S., Bhattacharya, P., & Borah, A. (2020). Lycopene - A pleiotropic neuroprotective nutraceutical: Deciphering its therapeutic potentials in broad spectrum neurological disorders. *Neurochemistry International, 140*, 104823. <https://doi.org/10.1016/J.NEUINT.2020.104823>
- Pereira, R. M., Botezelli, J. D., da Cruz Rodrigues, K. C., Mekary, R. A., Cintra, D. E., Pauli, J. R., da Silva, A. S. R., Ropelle, E. R., & de Moura, L. P. (2017). Fructose Consumption in the Development of Obesity and the Effects of Different Protocols of Physical Exercise on the Hepatic Metabolism. *Nutrients, 9*(4), 405. <https://doi.org/10.3390/NU9040405>

- Philips, C. A., & Theruvath, A. H. (2024). A comprehensive review on the hepatotoxicity of herbs used in the Indian (Ayush) systems of alternative medicine. *Medicine*, *103*(16), E37903. <https://doi.org/10.1097/MD.00000000000037903>
- Pluta, W., Dudzińska, W., & Lubkowska, A. (2022). Metabolic Obesity in People with Normal Body Weight (MONW)—Review of Diagnostic Criteria. *International Journal of Environmental Research and Public Health*, *19*(2), 624. <https://doi.org/10.3390/IJERPH19020624>
- Pulungan, A. B., Puteri, H. A., Ratnasari, A. F., Hoey, H., Utari, A., Darendeliler, F., Al-Zoubi, B., Joel, D., Valiulis, A., Cabana, J., Hasanoglu, E., Thacker, N., & Farmer, M. (2024). Childhood Obesity as a Global Problem: a Cross-sectional Survey on Global Awareness and National Program Implementation. *Journal of Clinical Research in Pediatric Endocrinology*, *16*(1), 31. <https://doi.org/10.4274/JCRPE.GALENOS.2023.2023-7-5>
- Qi, S. S., Shao, M. L., Sun, Z., Chen, S. M., Hu, Y. J., Wang, H. T., Wei, T. K., Li, X. S., & Zheng, H. X. (2021). Lycopene ameliorates diabetic osteoporosis via anti-inflammatory, anti-oxidation, and increasing Osteoprotegerin/RANKL expression ratio. *Journal of Functional Foods*, *83*, 104539. <https://doi.org/10.1016/J.JFF.2021.104539>
- Queiroz, L. A. D., Assis, J. B., Guimarães, J. P. T., Sousa, E. S. A., Milhomem, A. C., Sunahara, K. K. S., Sá-Nunes, A., & Martins, J. O. (2021). Endangered Lymphocytes: The Effects of Alloxan and Streptozotocin on Immune Cells in Type 1 Induced Diabetes. *Mediators of Inflammation*, *2021*(1), 9940009. <https://doi.org/10.1155/2021/9940009>
- Rehman, H. ur, Ullah, K., Rasool, A., Manzoor, R., Yuan, Y., Tareen, A. M., Kaleem, I., Riaz, N., Hameed, S., & Bashir, S. (2023). Comparative impact of streptozotocin on altering normal glucose homeostasis in diabetic rats compared to normoglycemic rats. *Scientific Reports*, *13*(1), 1–6. <https://doi.org/10.1038/s41598-023-29445-8>
- Rhee, E. J. (2022). The Influence of Obesity and Metabolic Health on Vascular Health. *Endocrinology and Metabolism*, *37*(1), 1–8. <https://doi.org/10.3803/ENM.2022.101>
- Rus, M., Crisan, S., Andronie-Cioara, F. L., Indries, M., Marian, P., Pobirci, O. L., & Ardelean, A. I. (2023). Prevalence and Risk Factors of Metabolic Syndrome: A Prospective Study on Cardiovascular Health. *Medicina*, *59*(10), 1711. <https://doi.org/10.3390/MEDICINA59101711>

- Sahin, K., Orhan, C., Sahin, N., & Kucuk, O. (2019). Anticancer Properties of Lycopene. *Reference Series in Phytochemistry*, 935–969. https://doi.org/10.1007/978-3-319-78030-6_88
- Saklayen, M. G. (2018). The Global Epidemic of the Metabolic Syndrome. *Current Hypertension Reports*, 20(2), 1-8. <https://doi.org/10.1007/S11906-018-0812-Z>
- Sánchez-Terrón, G., Martínez, R., Ruiz, J., Luna, C., & Estévez, M. (2023). Impact of Sustained Fructose Consumption on Gastrointestinal Function and Health in Wistar Rats: Glycooxidative Stress, Impaired Protein Digestion, and Shifted Fecal Microbiota. *Journal of Agricultural and Food Chemistry*, 71(43), 16270–16285. https://doi.org/10.1021/ACS.JAFC.3C04515/ASSET/IMAGES/LARGE/JF3C04515_0006.JPEG
- Sasongko, H., Nurrochmad, A., Rohman, A., & Nugroho, A. E. (2022). Characteristic of Streptozotocin-Nicotinamide-Induced Inflammation in A Rat Model of Diabetes-Associated Renal Injury. *Open Access Macedonian Journal of Medical Sciences*, 10(T8), 16–22. <https://doi.org/10.3889/oamjms.2022.9460>
- Sharif, H., Sheikh, S. S., Seemi, T., Naeem, H., Khan, U., & Jan, S. S. (2024). Metabolic syndrome and obesity among marginalised school-going adolescents in Karachi, Pakistan: a cross-sectional study. *The Lancet Regional Health - Southeast Asia*, 21, 100354. <https://doi.org/10.1016/j.lansea.2024.100354>
- Song, X., Sun, J., Liu, H., Mushtaq, A., Huang, Z., Li, D., Zhang, L., & Chen, F. (2024). Lycopene Alleviates Endoplasmic Reticulum Stress in Steatohepatitis through Inhibition of the ASK1-JNK Signaling Pathway. *Journal of Agricultural and Food Chemistry*, 72(14), 7832–7844. https://doi.org/10.1021/ACS.JAFC.3C08108/SUPPL_FILE/JF3C08108_SI_001.PDF
- Swarup, S., Ahmed, I., Grigorova, Y., & Zeltser, R. (2024). Metabolic Syndrome. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK459248/>
- Tamimi, L. N., Ahmad, M. N., & Qinna, N. A. (2021). Fructose-Induced Insulin Resistance: Prospective Biochemical Mechanisms. *Jordan Journal of Agricultural Sciences*, 17(4), 441–453. <https://doi.org/10.35516/JJAS.V17I4.96>
- Tan, R., Dong, H., Chen, Z., Jin, M., Yin, J., Li, H., Shi, D., Shao, Y., Wang, H., Chen, T., Yang, D., & Li, J. (2021). Intestinal Microbiota Mediates High-Fructose and High-Fat Diets to Induce Chronic

- Intestinal Inflammation. *Frontiers in Cellular and Infection Microbiology*, *11*, 654074. <https://doi.org/10.3389/FCIMB.2021.654074/BIBTEX>
- Tangvarasittichai, S. (2015). Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. *World Journal of Diabetes*, *6*(3), 456. <https://doi.org/10.4239/WJD.V6.I3.456>
- Taskinen, M. R., Packard, C. J., & Borén, J. (2019). Dietary Fructose and the Metabolic Syndrome. *Nutrients*, *11*(9), 1987. <https://doi.org/10.3390/NU11091987>
- Theodoridis, S., Drakou, E. G., Hickler, T., Thines, M., & Nogues-Bravo, D. (2023). Evaluating natural medicinal resources and their exposure to global change. *The Lancet Planetary Health*, *7*(2), e155–e163. [https://doi.org/10.1016/S2542-5196\(22\)00317-5](https://doi.org/10.1016/S2542-5196(22)00317-5)
- Vona, R., Pallotta, L., Cappelletti, M., Severi, C., & Matarrese, P. (2021). The Impact of Oxidative Stress in Human Pathology: Focus on Gastrointestinal Disorders. *Antioxidants*, *10*(2), 201. <https://doi.org/10.3390/ANTIOX10020201>
- Wang, Y., Yang, P., Yan, Z., Liu, Z., Ma, Q., Zhang, Z., Wang, Y., & Su, Y. (2021). The Relationship between Erythrocytes and Diabetes Mellitus. *Journal of Diabetes Research*, *2021*(1), 6656062. <https://doi.org/10.1155/2021/6656062>
- Xia, B., Dai, X., Shi, H., Yin, J., Xu, T., Liu, T., Yue, G., Guo, H., Liang, R., Liu, Y., Gao, J., Wang, X., Chen, X., Tang, J., Wang, L., Zhu, R., & Zhang, D. (2024). Lycopene Promotes Osteogenesis and Reduces Adipogenesis through Regulating FoxO1/PPAR γ Signaling in Ovariectomized Rats and Bone Marrow Mesenchymal Stem Cells. *Nutrients*, *16*(10), 1443. <https://doi.org/10.3390/NU16101443>
- Zhang, D. M., Jiao, R. Q., & Kong, L. D. (2017). High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. *Nutrients*, *9*(4), 335. <https://doi.org/10.3390/NU9040335>
- Zhou, L. Y., Deng, M. Q., Zhang, Q., & Xiao, X. H. (2020). Early-life nutrition and metabolic disorders in later life: a new perspective on energy metabolism. *Chinese Medical Journal*, *133*(16), 1961. <https://doi.org/10.1097/CM9.0000000000000976>

CHAPTER TWO: LITERATURE REVIEW

Preview

This chapter is divided into two sections. The first section serves as an introduction to the literature review, focusing on metabolic syndrome (MetS). This section specifically addresses the description, key components, diagnostic criteria, underlying pathophysiology, treatment strategies and associated health risks of MetS. The second section is made up of my published review article, titled “*Lycopene: A Potent Antioxidant with Multiple Health Benefits.*” This published article has been incorporated into this chapter since it contains a detailed review of the nature, sources, biological activities, therapeutic and prophylactic potential and pertinent *in vitro* and *in vivo* research on lycopene. It must be noted that lycopene is the phytochemical used as the experimental intervention to assess its protective effects against dietary fructose-induced metabolic ill-health in growing Wistar rats fed a fructose-infused drinking solution in a model mimicking growing children fed an obesogenic diet.

2.0 Introduction

Metabolic syndrome (MetS) refers to a cluster of related metabolic disturbances that notably increase the likelihood of developing cardiovascular disease, T2DM, and other metabolic health complications (Rus et al., 2023). It is diagnosed when individuals present with at least three out of five specific conditions: hypertension, central obesity, insulin resistance, hypertriglyceridemia, and low levels of high-density lipoprotein (HDL) cholesterol (Kao & Huang, 2021). Genetic predispositions, environmental conditions, , and lifestyle choices, such as unhealthy diets and lack of physical activity, play a crucial role in the onset of MetS (Kang et al., 2021; Chomiuk et al., 2024). Insulin resistance, which impairs cellular responsiveness to insulin, serves as a central feature of MetS and a key factor in its progression (Nolan & Prentki, 2019). Additionally, chronic inflammation and oxidative stress actively contribute to both the development and worsening of MetS (Weinberg Sibony et al., 2024). MetS is a growing public health concern, with its prevalence rising globally due to increasing prevalence of obesity and sedentary lifestyles (Jemal et al., 2023). Early detection and lifestyle interventions, such as dietary modifications and regular exercise, are essential to mitigate MetS' associated health risks (Oppert et al., 2021).

2.1 Metabolic syndrome: a historical perspective

The concept of metabolic syndrome has evolved over several decades (Mendrick et al., 2018). In 1923, Swedish physician Eskil Kylin first documented the co-occurrence of hypertension, hyperglycaemia and gout (Kylin, 1923). Later, in 1947, Jean Vague identified central obesity as a key factor associated with metabolic disturbances, noting its link to cardiovascular diseases (Vague, 1947). Gerald Reaven coined the term "Syndrome X," in 1988, emphasising insulin resistance as the syndrome's core characteristic and its contribution to a heightened risk of cardiovascular disease (CVD) and T2DM (Reaven, 1988).

Over time, MetS' description was expanded to include dyslipidaemia, in the form of elevated plasma triglycerides, reduced HDL cholesterol levels and hypertension (Alberti et al., 2009). This broader definition provided a more comprehensive understanding of MetS enabled and enables clinicians and researchers to better identify individuals at risk and implement targeted interventions (Agabiti et al., 2023). As the criteria evolved, the World Health Organisation (WHO), the International Diabetes Federation (IDF), and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), proposed diagnostic guidelines to standardise

the identification (Jha et al., 2023; Russell et al., 2024). These guidelines underscored the syndrome’s multifactorial nature and its increasing prevalence, driven by the global rise in obesity and sedentary lifestyles (Koliaki et al., 2023). Table 2.1 outlines the diagnostic criteria for MetS as defined by various organisations.

Table 2. 1: Diagnostic criteria for metabolic syndrome across different organisation

Parameter/criteria	Harmonized criteria-2009	IDF-2005	NCEP ATP III-2001
Criteria for diagnosing MeTs	Any 3 of the following:	Abdominal obesity along with any other 2	Any 3 of the following:
Waist circumference (cm)			
Men	≥ 90 cm	≥ 90 cm	≥ 102 cm
Women	≥ 80 cm	≥ 80 cm	≥ 88 cm
HDL-C			
Men < 40	< 1.03 mmol/L	< 1.03 mmol/L	< 1.03 mmol/L
Women < 50	< 1.30 mmol/L	< 1.30 mmol/L	< 1.30 mmol/L
Blood pressure (mmHg)	130/85 mmHg	130/85 mmHg	130/85 mm/Hg
Fasting blood glucose	5.6 mmol/L	5.6 mmol/L	6.1 mmol/L
Triglyceride	≥ 1.70 mmol/L (150 mg/dL)	≥ 1.70 mmol/L (150 mg/dL)	≥ 1.70 mmol/L (150 mg/dL)

Adapted from Russell et al. (2024); IDF: International Diabetes Federation, NCEP ATP: National Cholesterol Education Program Adult Treatment Panel, HDL-C: High-density lipoprotein cholesterol.

2.2 Metabolic syndrome trends

MetS represents a growing global health issue. Its increasing incidence is primarily linked to the rising rates of obesity, physical inactivity, and the persistent consumption of unhealthy diets

(Castro-Barquero et al., 2020). It affects approximately 20 to 25% of adults worldwide, with notable regional variations (Bhalwar, 2020). MetS prevalence is 16.1% in Africa, 21.3% in Asia, 37.1% in the United States of America, 10.5% in Europe, and exceeds 21.5% in mainland China (Ye et al., 2023). Urbanised and industrialised regions report higher prevalence rates due to lifestyle shifts and dietary changes (Nsabimana et al., 2024). Age and gender are key factors, as the prevalence of MetS generally increases with age and differs between sexes, influenced by population demographics and lifestyle factors (Jiang et al., 2018). Women often experience higher prevalence rates than men, particularly after menopause, due to hormonal changes that promote central obesity and increase the risk of metabolic complications (Opoku et al., 2023; Raman et al., 2023). Older adults exhibit higher MetS prevalence compared to younger individuals, as age-related changes, including increased insulin resistance, central adiposity, and declining physical activity contribute to its development (Chang & Halter, 2003; Palmer & Jensen, 2022). Alarmingly, MetS is emerging among children and adolescents, posing long-term health risks (Kelishadi et al., 2016). Recent reports show that approximately 3% of children aged 6 to 12 years and 5% of adolescents aged 13 to 18 years globally are affected by MetS (Noubiap et al., 2022). This early onset of MetS highlights the need for proactive measures to target the lifestyle factors driving the increasing prevalence of MetS in younger populations (Pacheco et al., 2019).

2.3 Components of metabolic syndrome

2.3.1 Central obesity

Central obesity, marked by excess abdominal and visceral fat, is a critical feature of MetS and a significant indicator of metabolic health risks (Paley & Johnson, 2018). The increasing global prevalence of obesity highlights its growing impact on public health (Tiwari & Balasundaram, 2023). Globally, 1.9 billion adults are overweight, with 650 million are classified as having obesity (Haase et al., 2020). Projections indicate that by 2025, 2.7 billion adults will be overweight, with more than 1 billion classified as obese (Boutari & Mantzoros, 2022).

Between 1980 and 2019, global obesity incidence rose significantly, with the prevalence of obesity in men growing from 3.2% to 12.2%, and in women from 6% to 15.7% (Boutari & Mantzoros, 2022). Projections suggest that by 2030, 1 billion individuals globally, with one in five women and one in seven men, will be affected by obesity (Ahmed & Konje, 2023). Additionally, it is projected

that by 2025, 206 million children and adolescents aged 5 to 19 will be affected, with this number expected to increase to 254 million by 2030 (Jebeile et al., 2022).

Understanding the distinction between general and central obesity, as well as their measurement, is crucial in addressing the growing MetS epidemic (Safaei et al., 2021). General obesity refers to the overall accumulation of body fat and is commonly assessed through body mass index (BMI) (Freisling et al., 2017). In contrast, central obesity is measured using waist circumference (WC) or waist-to-hip ratio (WHR), which specifically reflect fat distribution in the abdominal region (Molla et al., 2020). Central obesity is particularly harmful to metabolic health, as it is closely linked to insulin resistance, dyslipidaemia, hypertension, and inflammation, all hallmark features of MetS (Fahed et al., 2022; Molla et al., 2020). Additionally, central obesity is a key risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD), a condition characterised by fat accumulation in the liver, which often coexists with MetS and exacerbates metabolic dysfunction (Ding et al., 2023). Central obesity develops from an imbalance between caloric intake and energy expenditure and is further influenced by genetic predisposition, hormonal regulation, and environmental factors (Romieu et al., 2017; Mazza et al., 2024). This condition is primarily driven by accumulation of visceral adipose tissue (VAT), which surrounds internal organs in the abdominal cavity (Yamamoto et al., 2020). Unlike subcutaneous fat, VAT is metabolically active and secretes a variety of bioactive adipokines (Clemente-Suárez et al., 2023). These adipokines include leptin, adiponectin, resistin, and the pro-inflammatory cytokines tumour necrosis factor alpha (TNF- α), interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and visfatin (Clemente-Suárez et al., 2023). Impaired adipokine secretion from VAT is a key factor in the development of MetS, as it promotes systemic inflammation, insulin resistance, and atherogenesis (Lau et al., 2017).

2.3.2 Insulin resistance

Insulin resistance develops when the body's cells exhibit reduced responsiveness to insulin, the hormone responsible for regulating glucose metabolism (Ormazabal et al., 2018). Normally, insulin facilitates glucose uptake into myocytes, adipocytes and hepatocyte, maintaining healthy blood glucose concentration (Chadt & Al-Hasani, 2020). In insulin resistance this process falters as cells fails to effectively absorb glucose, while the liver produces excess glucose, resulting in hyperglycaemia, a hallmark of T2DM (Dandona et al., 2017). Insulin resistance also reduces

glycogenesis, limiting the ability of hepatocytes and muscle cells to store glucose as glycogen; further contributing to hyperglycaemia (Rahman et al., 2021). Concurrently, altered fat metabolism increases the release of free fatty acids from adipose tissue and promotes lipid buildup in the liver and muscles, contributing to obesity and dyslipidaemia (Giudetti, 2023). This imbalance stimulates excess lipogenesis and disrupts cellular homeostasis, which triggers oxidative stress (Yoon et al., 2021). The process generates an excessive amount of ROS that damage cellular structures and worsen insulin signalling (Bhatti et al., 2022). Chronic low-grade inflammation, often triggered by adipose tissue in obesity exacerbates these effects by releasing pro-inflammatory cytokines, TNF- α and IL-6 that disrupt insulin function and amplify metabolic dysfunction (Rehman & Akash, 2016).

2.3.3 Dyslipidaemia

Dyslipidaemia occurs in two forms: primary and secondary. Primary dyslipidaemia results from inherited genetic mutations that interfere with lipid metabolism, while secondary dyslipidaemia arises from lifestyle choices or underlying medical conditions that impact lipid concentrations (Jacobsen et al., 2024). Elevated blood cholesterol affects 39% of the global adult population, with women experiencing a slightly higher prevalence at 40% compared to 37% in men (Ghazwani et al., 2023). Over the past 30 years, the global prevalence of dyslipidaemia has risen rapidly (Pirillo et al., 2021), significantly contributing to disease burden in both developed and developing countries (Nandasena et al., 2023).

Dyslipidaemia results from abnormal lipid concentration in the blood, marked by increased LDL-cholesterol and triglycerides, along with reduced HDL-cholesterol concentrations (Eslami & Shidfar, 2019). Dyslipidaemia contributes significantly to the onset of CVD, such as atherosclerosis and coronary artery disease (Jacobsen et al., 2024). This abnormal lipid concentration in the blood is closely linked to insulin resistance and central obesity, both of which worsen the lipid profile (Malik et al., 2019). In patients with dyslipidaemia, the accumulation of LDL-cholesterol in blood vessel walls leads to plaque formation, narrowing the arteries and heightening the risk of heart attacks, strokes, and other metabolic complications (Das & Ingole, 2023). Additionally, dyslipidaemia leads to lower-than-normal plasma HDL-cholesterol levels, which impairs the transport of excess cholesterol from periphery tissues to the liver for excretion, thereby reducing protection against cardiovascular diseases (Ahmed et al., 2016). Elevated plasma

triglyceride concentrations further aggravate cardiovascular risk (Lee et al., 2017) because the liver's impaired ability to process and clear these fats in insulin-resistant individuals contributes to high lipid concentrations (Heeren & Scheja, 2021).

2.4 Complications of metabolic syndrome

2.4.1 Metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver condition characterised by the accumulation of fat in the liver, exceeding 5% of its weight, in the absence of substantial alcohol intake (Gerges et al., 2021). It (MASLD) is increasingly recognised as hepatic manifestation of MetS and a global public health concern (Mitrovic et al., 2022). The prevalence of MASLD has increased considerably, reflecting the growing rates of obesity, insulin resistance and T2DM (Vetrano et al., 2023). Approximately 38% of people worldwide are affected by MASLD, with regional variations influenced by genetic, lifestyle, and metabolic factors (Wong et al., 2023). MASLD includes a range of conditions, from simple metabolic dysfunction-associated fatty liver, (MAFL), which is simple steatosis, to metabolic dysfunction-associated steatohepatitis (MASH), which manifests with hepatic inflammation and damage (Zhang et al., 2019). Over time, MASH can progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma, significantly increasing morbidity and mortality (Boldys & Buldak, 2024). The progression from benign steatosis to MASH is influenced by “second hit” mechanism, such as increased oxidative stress, the breakdown of lipid, and the activation of inflammatory cytokine, all of which contribute to the worsening of liver damage (Myint et al., 2023).

2.4.1.1 MASLD pathophysiology in metabolic syndrome

Components of MetS, especially insulin resistance and central obesity, are key contributors to the development of MASLD (Reccia et al., 2017). Insulin resistance disrupts normal lipid metabolism, leading to increased hepatic free fatty acids uptake and upregulation of *de novo* hepatic lipogenesis (Smith et al., 2020). These processes contribute to triglycerides accumulation in hepatocytes, a hallmark of MASLD (Smith et al., 2020). Concurrently, impaired VLDL secretion and reduced fatty acid β -oxidation exacerbate hepatic lipid overload (Bhatt & Smith, 2015). Adipose tissue dysfunction in MetS further aggravates MASLD by releasing the pro-inflammatory cytokines TNF- α and IL-6, which mediate hepatic inflammation and fibrosis (Basil et al., 2024).

Additionally, increased lipid metabolism generates excessive ROS causing oxidative stress-mediated cell organelles damage and mitochondrial dysfunction resulting in hepatocyte injury and liver disease progression (Shi et al., 2021).

2.4.1.2 Clinical implications

MASLD is strongly associated with an increased CVD risk, a leading cause of death in patients with this condition (Targher et al., 2020). Furthermore, MASLD exacerbates insulin resistance, creating a bidirectional relationship with T2DM (Caussy et al., 2021). Patients with MASLD are also at higher risk for chronic kidney disease (CKD), emphasising the clinical implications of this condition (Heda et al., 2021). MASLD diagnosis involves a combination of clinical evaluation, imaging techniques (ultrasonography or transient elastography), and the exclusion of other diseases (Ajmera & Loomba, 2021; Selvaraj et al., 2021). Liver biopsy is considered the gold standard for differentiating MASH from simple steatosis and evaluating fibrosis severity, but due to its invasive nature, it is not typically performed on a routine basis (Berger et al., 2019).

2.4.1.3 Management strategies

A healthy, low-calorie diet combined with regular physical activity forms the cornerstone foundation of lifestyle modifications designed to reduce hepatic fat content and improve insulin sensitivity (Ali et al., 2024). These foundational strategies are pivotal in the management of MASLD (Keating et al., 2024). A 7 to 10% reduction in body weight has been demonstrated to markedly decrease liver fat content, alleviate MASH, and lessen fibrosis and inflammation (Brunner et al., 2019). Pharmacological options, though limited, offer additional support. The insulin-sensitising agents; pioglitazone and GLP-1 receptor agonists, have shown promise in enhancing liver outcomes (Gastaldelli et al., 2021; Liu, 2024). Fenofibrate, a PPAR- α agonist, is extensively used to treat dyslipidaemia and lowers plasma LDL-cholesterol and triglyceride concentrations (Kumar Dan et al., 2022) and it has also shown potential to attenuate hepatic inflammation thus improve liver health in patients with MASLD (Mahmoudi et al., 2021).

2.4.2 Type 2 diabetes mellitus

T2DM is a long-term metabolic condition characterised by insulin resistance and impaired glucose homeostasis (Goyal et al., 2023). It is strongly associated with central obesity, as visceral fat secretes pro-inflammatory cytokines that exacerbate insulin resistance (Wondmkun, 2020). Dyslipidaemia which is marked by higher plasma triglycerides and lower HDL cholesterol levels,

commonly coexists with the condition thus heightening cardiovascular diseases risk (Strikić et al., 2023). T2DM significantly contributes to MASLD development by promoting hepatic fat accumulation through hyperglycaemia (Targher et al., 2021). The disease's progression increases the risk of the associate complications: neuropathy, retinopathy and kidney disease (Alweendo et al., 2023). Lifestyle interventions, such as adopting a healthy balanced diet and staying physically active through regular exercise, are essential for managing this metabolic disease (Galaviz et al., 2015). Pharmacological agents including metformin, GLP-1 receptor agonists, and SGLT2 inhibitors used to treat T2DM enhance insulin sensitivity and regulate blood glucose concentration (Gastaldelli et al., 2021; Liu, 2024). Early diagnosis and proactive management remain crucial to preventing disease progression and associated complications (Antar et al., 2023).

2.4.3 Chronic kidney disease

Kidney disease, a growing global health concern, is characterised by the gradual decline in kidney function (Géza Pethő et al., 2024). It often results from risk factors such as high blood pressure, diabetes, and excessive body weight, which are hallmarks of metabolic dysfunction that contributes to renal vasculature and nephron damage (Zoccali et al., 2023). Chronic kidney disease progresses silently, with patients frequently unaware of declining function until later stages (Wolpert et al., 2023). Early intervention and management, including controlling blood pressure and blood glucose concentration, can slow disease progression, especially in individuals with MetS (Shubrook et al., 2022). In advanced stages, dialysis or kidney transplantation may be necessary. Preventive measures, which include lifestyle modifications, are essential for reducing the global burden of kidney disease (Okpechi et al., 2024).

2.4.4 Cardiovascular diseases

Cardiovascular diseases remain the leading cause of death worldwide, creating substantial health and economic challenges (Amini et al., 2021). Atherosclerosis, driven by lipid accumulation and chronic inflammation, is the primary mechanism in CVD development (Malekmohammad et al., 2021). Insulin resistance and hypertension, which co-exist with MetS, intensify endothelial dysfunction, accelerating disease progression (Petrie et al., 2018). Obesity, poor dietary habits, and physical inactivity significantly contribute to increased CVD prevalence (Wang et al., 2024). Dyslipidaemia, characterised by elevated plasma LDL-cholesterol and triglycerides concentrations, further promotes atherogenesis (Xiao et al., 2016). Lifestyle modifications,

including consumption of a balanced diet and regular exercise in combination with targeted pharmacological therapies, slow disease progression (Kaminsky et al., 2022). Early diagnosis and proactive management are vital to reducing CVD-related morbidity and mortality (Almansouri et al., 2024).

2.4.5 Bone disorders and osteoporosis

Bone health is vital for overall well-being. The skeletal system provides structural support and protects vital organs (Wilson-Barnes et al., 2022). Osteoporosis, characterised by weakened bones and increased fracture risk, often results from an imbalance between bone resorption and formation (Pouresmaeili et al., 2018). Advancing age, hormonal changes, physical inactivity, and inadequate intake of calcium and vitamin D contribute to the development of osteoporosis (Voulgaridou et al., 2023; Smit et al., 2024). Metabolic dysfunction, insulin resistance and chronic inflammation associated with MetS, have been linked to impaired bone remodelling and increased osteoporosis risk (Martiniakova et al., 2024). The condition is more prevalent in postmenopausal women, due to reduced estrogen levels (Charde et al., 2023). Early detection through bone mineral density tests and lifestyle changes, including weight-bearing exercise and proper nutrition are essential for maintaining bone health (Rondanelli et al., 2022).

2.4.6 Haematological changes

Haematological changes reflect the systemic impacts of metabolic dysfunction on metabolic health (Williams et al., 2023). Insulin resistance and inflammation have been reported to alter red and white blood cell indices, increasing oxidative stress and vascular damage (Szalai et al., 2023; Bambo et al., 2024). Metabolic syndrome has been shown to heighten platelets activation, increasing the risk of thrombosis (Barale & Russo, 2020). Monitoring haematological parameters provides early insight into metabolic derangements. Addressing metabolic risk factors through lifestyle modification can improve haematological profiles and reduce associated health risks (Essawi et al., 2023).

2.5 Metabolic programming

Metabolic programming describes how early-life environmental factors, including nutrition, hormonal signals, and stressors, shape long-term metabolic health and disease risk (Brasiel et al., 2020). Prenatal and early postnatal periods are critical windows during which metabolic pathways

are established, and disruptions during this time of developmental plasticity can have lasting effects (Daoust et al., 2021). Poor maternal nutrition, overnutrition, or exposure to stress during pregnancy can alter fetal development, leading to changes in insulin sensitivity, adiposity, and energy balance (Şanlı & Kabaran, 2019). These changes are mediated through epigenetic processes like DNA methylation and histone modification, which influence gene expression without altering the genetic code (Aboud et al., 2023).

Maternal obesity and gestational diabetes have been shown to increase the offspring's susceptibility to metabolic disorders and diseases including obesity, T2DM, and cardiovascular diseases (Ormazabal et al., 2022). Similarly, early-life exposure to high-fat or high-fructose diets can program pathways that predispose individuals to metabolic derangements in adulthood (Zheng et al., 2016; Block & El-Osta, 2017). Interventions during this critical developmental period, for instance through balanced maternal diets, breastfeeding, and appropriate post-weaning nutrition can mitigate adverse outcomes and promote healthier metabolic profiles (Martín-Rodríguez et al., 2022). Understanding metabolic programming underscores the need for preventive strategies targeting early developmental stages to curb the intergenerational transmission of metabolic dysfunction (Hsu et al., 2021).

2.6 Experimental models of metabolic programming

Various experimental models, among many chemical, genetic, and diet-induced approaches, are employed to investigate metabolic programming (Wong et al., 2016). These models offer crucial insights into how early-life environmental factors shape long-term metabolic health and contribute to disease susceptibility (Zhou et al., 2020) and or resistance.

2.6.1 Chemical intervention models

Chemically induced models of metabolic programming use chemical agents to alter physiological processes, mimicking the impact of environmental exposures on metabolism (Vatashchuk et al., 2022; La Merrill et al., 2024). These models allow researchers to investigate how early-life chemical exposures influence long-term metabolic outcomes and are widely used to study disorders like obesity, diabetes, and cardiovascular diseases (Sargis et al., 2019). Chemical agents, including toxins and endocrine disruptors, are applied to induce metabolic changes, enabling the assessment of their impact on gene expression and organ function (Hamid et al., 2021). For

instance, streptozotocin and alloxan are frequently used to induce diabetes in animal models by damaging pancreatic β -cells (Fajarwati et al., 2023; Ghasemi & Jeddi, 2023). While chemically induced models can replicate specific aspects of the pathophysiology of diet-induced metabolic disorders, their mechanisms differ. Diet-induced models rely on prolonged exposure (intake and or administration) to dietary insult(s) to trigger metabolic changes (Zhao et al., 2022), whereas chemically induced models rapidly induce specific conditions including impaired insulin sensitivity, diabetes mellitus, or liver dysfunction (Athmuri & Shiekh, 2023). However, chemically induced models do not fully capture the multifactorial nature of diet-induced pathophysiology, which involves the complex interplay of genetics, diet, and the environment (Flessa et al., 2022). Despite these limitations, chemically induced models remain valuable for exploring specific metabolic pathways and disease mechanisms (Wu & Yan, 2015; Murakami et al., 2022), even though they may not comprehensively reflect the broader spectrum of diet-induced metabolic diseases (Wong et al., 2016).

2.6.2 Genetic models

Genetically induced metabolic programming involves modifying the genome to examine its impact on metabolic pathways and long-term health outcomes (Abraham et al., 2023). Genetic modifications, for example, gene knockouts or overexpression, to induce specific metabolic alterations are used (Lee et al., 2020; Eisenhut et al., 2024). An interesting example is the ob/ob mouse model, which is leptin deficient, is widely used to study obesity and metabolic disorders, while the db/db mouse model, which lacks leptin receptors, is employed to explore diabetes-related pathologies (Frühbeck et al., 2017; Fuchs et al., 2018). These models allow researchers to explore how genetic factors contribute to metabolic diseases like obesity, diabetes, and cardiovascular disorders (Górczyńska-Kosiorz et al., 2024). By altering specific genes, scientists can observe changes in metabolic pathways, helping to pinpoint genetic predispositions to these conditions (Li et al., 2020). Genetically induced models provide insights into the molecular mechanisms underlying metabolic diseases and offer potential targets for therapeutic interventions (Sulaiman, 2024).

2.6.3 Diet-based models

Dietary interventions during critical developmental periods alter metabolism through diet-induced metabolic programming (Bonet et al., 2024). These models highlight the impact of early-life nutrition on future health, particularly in increasing the risk of obesity, diabetes, and heart disease (Rajamoorthi et al., 2022). Adjusting macronutrient composition or calorie intake replicates the effects of poor or excessive diets in humans and animal research models (Crean et al., 2024). High fructose significantly impacts metabolism, leading to insulin resistance, obesity and liver dysfunction, which mirror metabolic disturbances observed in human conditions (Dornas et al., 2015). Diet high in fat, cholesterol, and carbohydrates further disrupt metabolic pathways contributing to similar metabolic alterations (Franco-Juárez et al., 2021; Sacks & Andraski, 2021). This programming highlights how excessive intake, particularly of fructose, drives long-term health complication such as obesity and T2DM (Taskinen et al., 2019).

2.7 High fructose diets and their role in metabolic syndrome pathogenesis

Fructose, a monosaccharides present in various fruits, vegetables, and honey, has become a significant focus in metabolic health research (Agarwal et al., 2024). Over the past few decades, its consumption has risen dramatically, largely due to its inclusion in processed foods and sweetened beverages in form of high-fructose corn syrup (Malik & Hu, 2015). This increased dietary intake has raised concern about its impact on health, particularly in contributing to the development of MetS (Khitan & Kim, 2013). Different mechanisms have been suggested to elucidate the pathogenesis of fructose-induced metabolic derangements, all linked to the unique way fructose is metabolised in the liver and other tissues (Herman & Birnbaum, 2021).

The liver primarily metabolises fructose, following a unique pathway that bypasses key regulatory steps of glycolysis (Feinman & Fine, 2013). Upon entering hepatocytes, fructose undergoes rapid phosphorylation by fructokinase, converting it into fructose-1-phosphate, a process that requires ATP (Dholariya & Orrick, 2022). This unregulated pathway drives an excess flow of substrates into lipogenesis, leading to increased triglyceride synthesis and promotes hepatic fat accumulation (Geidl-Flueck & Gerber, 2023). Fructose metabolism, in contrast to glucose, does not trigger substantial insulin release and does not depend on insulin for cellular absorption (Softic et al., 2017), as it is transported into cells via glucose transporter 5 (GLUT5), whereas glucose uptake is

regulated by insulin through GLUT4 (Chadt & Al-Hasani, 2020). This allows fructose to bypass the usual energy regulation mechanisms, contributing to metabolic dysregulation (Lodge et al., 2024). Additionally, excessive fructose intake promotes the production of uric acid as a byproduct, which induces oxidative stress and inflammation (Baharuddin, 2024). Furthermore, fructose disrupts lipid profiles by stimulating the secretion of VLDLs, exacerbating systemic insulin resistance (Zhang et al., 2017).

Although the liver serves as the main organ for fructose metabolism, other tissues also contribute to its metabolic effects (Tesz & Bence, 2020). In the kidneys, fructose metabolism generates uric acid locally, exacerbating oxidative stress and potentially causing kidney damage (Jung et al., 2020). In adipose tissue, it stimulates lipogenesis, enhancing fat storage (Azevedo-Martins et al., 2024). In the small intestine, fructose is partially metabolised to glucose and lactate before releasing it into the bloodstream, where it contributes to systemic metabolic effects (Jang et al., 2018). Beyond its metabolic effects on various tissues, fructose disrupts satiety and energy regulation by reducing leptin production and impairing appetite control (Johnson et al., 2023). This disruption interferes with normal weight regulation, promoting overeating and increased caloric intake (Johnson et al., 2023). Excessive fructose intake also activates the brain's reward pathways, further encouraging overeating (Luo et al., 2015). These combined effects significantly contribute to the development of obesity, MASLD, and other components of MetS (Lara-Romero & Romero-Gómez, 2024). Recent studies underscore fructose's role in promoting inflammation and oxidative stress, which amplify metabolic dysfunction (Cheng et al., 2022; Baharuddin, 2024). Upon metabolism, fructose triggers the production of pro-inflammatory mediators and increases oxidative stress, both of which disrupt normal cellular functions (Gomez-Pinilla et al., 2021). This creates a vicious cycle, where inflammation and oxidative stress perpetuate metabolic disturbances particularly insulin resistance and hepatic fat accumulation (Onyango, 2022). These mechanisms feed into one another, amplifying their negative impact and accelerating the progression of metabolic syndrome (Masenga et al., 2023). The severity of these effects varies, depending on the dose and duration of fructose exposure, as well as factors such as age, sex, genetic predisposition and baseline metabolic health (Ismaiel & Dumitrascu, 2020; Aoun et al., 2022; Mcvicker et al., 2024; Fadhul et al., 2025). Individuals with pre-existing metabolic conditions, for example, obesity

or glucose intolerance, display a more pronounced and accelerated development of metabolic dysfunction (Piché et al., 2020).

Recognising fructose as a major contributor to metabolic disturbances is crucial for addressing MetS (Hannou et al., 2018). While naturally occurring fructose in whole fruits poses minimal risk due to the presence of fibre and other nutrients (Dreher, 2018), excessive fructose intake from processed foods remains a significant concern (Barreto et al., 2022). Therefore, identifying therapeutic and prophylactic interventions with minimal side effects is essential to address diet-induced metabolic disorders, including MetS. A deeper understanding of fructose's role can lead to targeted strategies that prevent or reverse MetS and its associated comorbidities.

2.8 Management strategies for metabolic disorders

Management strategies for metabolic disorders focus on addressing the underlying causes, improving lifestyle factors like diet and exercise, and incorporating pharmacological interventions to prevent complications and promote overall health (Martemucci et al., 2024).

2.8.1 Lifestyle interventions

The high prevalence of metabolic disorders, observed in both adults, children and adolescents, is strongly linked to the overconsumption of calorie-dense foods combined with a sedentary lifestyle (Ruiz et al., 2019; Almoraie et al., 2021). Lifestyle interventions address these challenges by focusing on diet, physical activity, and behavioural changes (Katangwe-Chigamba et al., 2024). Adopting a balanced, nutrient-rich diet that limits processed foods and added sugars, promotes a healthy metabolism and supports weight management across all age groups (Cena & Calder, 2020). Regular physical activity improves insulin sensitivity, lowers blood pressure, and enhances cardiovascular health (Nystoriak & Bhatnagar, 2018). Behavioural modification including stress reduction techniques and adequate sleep are essential for optimal metabolic function (Portell et al., 2023; Mukherjee et al., 2024). These interventions not only prevent the onset of metabolic disorders but also reduce complications in individuals already affected (Kim et al., 2021). Incorporating lifestyle changes into daily routines promotes sustainable improvement by enhancing metabolic health and preventing the progression of associated diseases over time (Dyer, 2023).

2.8.2 Conventional pharmacological treatment

Pharmacological treatments for MetS target various components of the condition: insulin resistance, dyslipidaemia, hypertension, and inflammation (Swarup et al., 2024). Commonly used conventional pharmacological agents, include statins, which lower cholesterol concentrations and reduce cardiovascular risk (Sizar et al., 2024), and metformin, which enhances insulin sensitivity and regulate blood glucose concentrations (Horakova et al., 2019). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are frequently recommended for managing hypertension and provide extra protective to the kidneys (Chen et al., 2024). In this context, fenofibrate emerge as a targeted treatment for managing dyslipidaemia, a hallmark of MetS (Deerochanawong et al., 2024).

Fenofibrate stimulates peroxisome proliferator-activated receptor alpha (PPAR- α), which boosts lipid metabolism and leads to a significant decrease in plasma triglycerides concentrations (Zhang et al., 2022). It also increases HDL-cholesterol and lowers LDL-cholesterol concentrations, thereby improving the overall lipid profile (Kim et al., 2019). Additionally, fenofibrate mitigates hepatic fat accretion, alleviating MASLD, a common comorbidity of MetS (Esler & Bence, 2019). Beyond lipid regulation, it demonstrates anti-inflammatory effects by influencing cytokine production and reducing oxidative stress, which together help mitigate cardiovascular risks and improve metabolic health (Jin et al., 2023). However, its use is associated with adverse effects, including liver cell damage, gastrointestinal discomfort, and muscle-related complications, including myopathy (Duan et al., 2018; Zhou et al., 2020; Mahmoudi et al., 2022). Pharmacological agents, including fenofibrate, are effective in managing metabolic syndrome; however, they are often costly, associated with side effects, and may be inaccessible to low-income populations (Kim et al., 2024; Li et al., 2024). These limitations underscore the importance of exploring alternative, long-term prophylactic interventions to prevent diet-induced metabolic derangements effectively.

2.8.3 Phytotherapy

Phytotherapy, the use of plant-derived medicines, has become an increasingly popular approach to managing MetS (Faris Abdulghani et al., 2024). Many medicinal plants contain bioactive compounds that can regulate lipid metabolism, reduce oxidative stress, and enhance insulin

sensitivity (Wang et al., 2020; Ansari et al., 2023; Huang et al., 2024). These plant-based interventions often come with fewer side effects compared to synthetic pharmacological agents, making them an attractive alternative for long-term disease management (Rahman et al., 2022). Additionally, they are generally more affordable and widely accessible, further contributing to their appeal in diverse populations (Eshete & Molla, 2021). One such plant-derived compound is lycopene, a potent antioxidant found in tomatoes and other red fruits (Ramírez et al., 2022). Lycopene has shown promise in improving metabolic health by reducing inflammation, regulating lipids, and enhancing insulin sensitivity (Saeed et al., 2020; Kulawik et al., 2024). As a result, it represents a valuable phytotherapeutic option in the prevention and management of MetS.

The next section, following the references contains the published review article on lycopene, which was the compound used in this study.

2.9 References

- Aboud, N. M. Al., Tupper, C., & Jialal, I. (2023). Genetics, Epigenetic Mechanism. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK532999/>
- Abraham, M. J., El Sherbini, A., El-Diasty, M., Askari, S., & Szewczuk, M. R. (2023). Restoring Epigenetic Reprogramming with Diet and Exercise to Improve Health-Related Metabolic Diseases. *Biomolecules*, *13*(2), 318. <https://doi.org/10.3390/BIOM13020318>
- Agabiti Rosei, C., Del Pinto, R., Grassi, G., Muiesan, M. L., & Ferri, C. (2023). Prevalence of Cardiovascular Risk Factors and Related Medical and Lifestyle Interventions Among Italian Cardiovascular Specialists: A Proof-of-Concept Study. *High Blood Pressure and Cardiovascular Prevention*, *30*(3), 255–264. <https://doi.org/10.1007/S40292-023-00578-1/TABLES/3>
- Agarwal, V., Das, S., Kapoor, N., Prusty, B., & Das, B. (2024). Dietary Fructose: A Literature Review of Current Evidence and Implications on Metabolic Health. *Cureus*, *16*(11), e74143. <https://doi.org/10.7759/CUREUS.74143>
- Ahmed, B., & Konje, J. C. (2023). The epidemiology of obesity in reproduction. *Best Practice & Research Clinical Obstetrics & Gynaecology*, *89*, 102342. <https://doi.org/10.1016/J.BPOBGYN.2023.102342>
- Ahmed, H. M., Miller, M., Nasir, K., McEvoy, J. W., Herrington, D., Blumenthal, R. S., & Blaha, M. J. (2016). Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results from the Multi-Ethnic Study of Atherosclerosis. *American Journal of Epidemiology*, *183*(10), 875–883. <https://doi.org/10.1093/AJE/KWV305>
- Ajmera, V., & Loomba, R. (2021). Imaging biomarkers of NAFLD, NASH, and fibrosis. *Molecular Metabolism*, *50*, 101167. <https://doi.org/10.1016/J.MOLMET.2021.101167>
- Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleman, J. I., Donato, K. A., Fruchart, J. C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international

association for the study of obesity. *Circulation*, *120*(16), 1640–1645.

<https://doi.org/10.1161/CIRCULATIONAHA.109.192644/ASSET/10AEA2ED-046A-401E-A614-D7CF312AD0FD/ASSETS/GRAPHIC/18FF1.JPEG>

Ali, H., Shahzil, M., Moond, V., Shahzad, M., Thandavaram, A., Sehar, A., Waseem, H., Siddiqui, T., Dahiya, D. S., Patel, P., & Tillmann, H. (2024). Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice. *Journal of Personalized Medicine*, *14*(1), 61.

<https://doi.org/10.3390/JPM14010061>

Almansouri, N. E., Awe, M., Rajavelu, S., Jahnavi, K., Shastry, R., Hasan, A., Hasan, H., Lakkimsetti, M., AlAbbasi, R. K., Gutiérrez, B. C., & Haider, A. (2024). Early Diagnosis of Cardiovascular Diseases in the Era of Artificial Intelligence: An In-Depth Review. *Cureus*, *16*(3), e55869.

<https://doi.org/10.7759/CUREUS.55869>

Almoraie, N. M., Saqaan, R., Alharthi, R., Alamoudi, A., Badh, L., & Shatwan, I. M. (2021). Snacking patterns throughout the life span: potential implications on health. *Nutrition Research*, *91*, 81–94.

<https://doi.org/10.1016/J.NUTRES.2021.05.001>

Alweendo, S. N., Arokoyo, D. S., Gemechu, D. B., Brooks, N. L., & Aboua, Y. G. (2023). Prevalence of dyslipidaemia among diabetic patients at the Namibia Institute of Pathology, Windhoek. *Scientific African*, *20*, e01693. <https://doi.org/10.1016/J.SCIAF.2023.E01693>

Amini, M., Zayeri, F., & Salehi, M. (2021). Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. *BMC Public Health*, *21*(1), 1–12. <https://doi.org/10.1186/S12889-021-10429-0/TABLES/3>

Ansari, P., Samia, J. F., Khan, J. T., Rafi, M. R., Rahman, M. S., Rahman, A. B., Abdel-Wahab, Y. H. A., & Seidel, V. (2023). Protective Effects of Medicinal Plant-Based Foods against Diabetes: A Review on Pharmacology, Phytochemistry, and Molecular Mechanisms. *Nutrients*, *15*(14), 3266. <https://doi.org/10.3390/NU15143266>

Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023). Diabetes mellitus: Classification, mediators, and

- complications; A gate to identify potential targets for the development of new effective treatments. *Biomedicine & Pharmacotherapy*, *168*, 115734. <https://doi.org/10.1016/J.BIOPHA.2023.115734>
- Aoun, R., Chokor, F. A. Z., Taktouk, M., Nasrallah, M., Ismaeel, H., Tamim, H., & Nasreddine, L. (2022). Dietary fructose and its association with the metabolic syndrome in Lebanese healthy adults: a cross-sectional study. *Diabetology and Metabolic Syndrome*, *14*(1), 1–14. <https://doi.org/10.1186/S13098-022-00800-5/TABLES/5>
- Athmuri, D. N., & Shiekh, P. A. (2023). Experimental diabetic animal models to study diabetes and diabetic complications. *MethodsX*, *11*, 102474. <https://doi.org/10.1016/J.MEX.2023.102474>
- Azevedo-Martins, A. K., Santos, M. P., Abayomi, J., Ferreira, N. J. R., & Evangelista, F. S. (2024). The Impact of Excessive Fructose Intake on Adipose Tissue and the Development of Childhood Obesity. *Nutrients*, *16*(7), 939. <https://doi.org/10.3390/NU16070939>
- Baharuddin, B. (2024). The Impact of Fructose Consumption on Human Health: Effects on Obesity, Hyperglycemia, Diabetes, Uric Acid, and Oxidative Stress With a Focus on the Liver. *Cureus*, *16*(9), e70095. <https://doi.org/10.7759/CUREUS.70095>
- Bambo, G. M., Asmelash, D., Alemayehu, E., Gedefie, A., Duguma, T., & Kebede, S. S. (2024). Changes in selected hematological parameters in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. *Frontiers in Medicine*, *11*, 1294290. <https://doi.org/10.3389/FMED.2024.1294290/BIBTEX>
- Barale, C., & Russo, I. (2020). Influence of Cardiometabolic Risk Factors on Platelet Function. *International Journal of Molecular Sciences*, *21*(2), 623. <https://doi.org/10.3390/IJMS21020623>
- Barreto, J. R. P. D. S., Assis, A. M. D. O., De Santana, M. L. P., Pitangueira, J. C. D., Cunha, C. D. M., & Costa, P. R. D. F. (2022). Influence of sugar consumption from foods with different degrees of processing on anthropometric indicators of children and adolescents after 18 months of follow-up. *British Journal of Nutrition*, *128*(11), 2267–2277. <https://doi.org/10.1017/S0007114522000411>
- Basil, B., Myke-Mbata, B. K., Eze, O. E., & Akubue, A. U. (2024). From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions. *Clinical Diabetes and Endocrinology*, *10*(1), 1–19. <https://doi.org/10.1186/S40842-024-00187-4>

- Berger, D., Desai, V., & Janardhan, S. (2019). Con: Liver Biopsy Remains the Gold Standard to Evaluate Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Clinical Liver Disease*, 13(4), 114. <https://doi.org/10.1002/CLD.740>
- Bhalwar, R. (2020). Metabolic syndrome: The Indian public health perspective. *Medical Journal, Armed Forces India*, 76(1), 8. <https://doi.org/10.1016/J.MJAFI.2019.12.001>
- Bhatt, H. B., & Smith, R. J. (2015). Fatty liver disease in diabetes mellitus. *Hepatobiliary Surgery and Nutrition*, 4(2), 101. <https://doi.org/10.3978/J.ISSN.2304-3881.2015.01.03>
- Bhatti, J. S., Sehrawat, A., Mishra, J., Sidhu, I. S., Navik, U., Khullar, N., Kumar, S., Bhatti, G. K., & Reddy, P. H. (2022). Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. *Free Radical Biology and Medicine*, 184, 114–134. <https://doi.org/10.1016/J.FREERADBIOMED.2022.03.019>
- Block, T., & El-Osta, A. (2017). Epigenetic programming, early life nutrition and the risk of metabolic disease. *Atherosclerosis*, 266, 31–40. <https://doi.org/10.1016/J.ATHEROSCLEROSIS.2017.09.003>
- Boldys, A., & Buldak, L. (2024). Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration. *World Journal of Gastroenterology*, 30(18), 2387. <https://doi.org/10.3748/WJG.V30.I18.2387>
- Bonet, M. L., Ribot, J., Sánchez, J., Palou, A., & Picó, C. (2024). Early Life Programming of Adipose Tissue Remodeling and Browning Capacity by Micronutrients and Bioactive Compounds as a Potential Anti-Obesity Strategy. *Cells*, 13(10), 870. <https://doi.org/10.3390/CELLS13100870>
- Boutari, C., & Mantzoros, C. S. (2022). A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. *Metabolism*, 133, 155217. <https://doi.org/10.1016/J.METABOL.2022.155217>
- Brasiel, P. G. de A., Luquetti, S. C. P. D., Brasiel, P. G. de A., & Luquetti, S. C. P. D. (2020). Metabolic Programming and Nutrition. *New Insights Into Metabolic Syndrome*. <https://doi.org/10.5772/INTECHOPEN.92201>

- Brunner, K. T., Henneberg, C. J., Wilechansky, R. M., & Long, M. T. (2019). Nonalcoholic Fatty Liver Disease and Obesity Treatment. *Current Obesity Reports*, 8(3), 220. <https://doi.org/10.1007/S13679-019-00345-1>
- Castro-Barquero, S., Ruiz-León, A. M., Sierra-Pérez, M., Estruch, R., & Casas, R. (2020). Dietary Strategies for Metabolic Syndrome: A Comprehensive Review. *Nutrients*, 12(10), 2983. <https://doi.org/10.3390/NU12102983>
- Caussy, C., Aubin, A., & Loomba, R. (2021). The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. *Current Diabetes Reports*, 21(5), 15. <https://doi.org/10.1007/S11892-021-01383-7>
- Cena, H., & Calder, P. C. (2020). Defining a Healthy Diet: Evidence for the Role of Contemporary Dietary Patterns in Health and Disease. *Nutrients*, 12(2), 334. <https://doi.org/10.3390/NU12020334>
- Chadt, A., & Al-Hasani, H. (2020). Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. *Pflügers Archiv - European Journal of Physiology*, 472(9), 1273–1298. <https://doi.org/10.1007/S00424-020-02417-X>
- Chang, A. M., & Halter, J. B. (2003). Aging and insulin secretion. *American Journal of Physiology - Endocrinology and Metabolism*, 284(1 47-1). <https://doi.org/10.1152/AJPENDO.00366.2002/ASSET/IMAGES/LARGE/H10131095003.JPEG>
- Charde, S. H., Joshi, A., & Raut, J. (2023). A Comprehensive Review on Postmenopausal Osteoporosis in Women. *Cureus*, 15(11), e48582. <https://doi.org/10.7759/CUREUS.48582>
- Chen, J.-J., Lee, C.-C., Yen, C.-L., Fan, P.-C., Chan, M.-J., Tsai, T.-Y., Chen, Y.-C., Yang, C.-W., & Chang, C.-H. (2024). Impact of Different Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blocker Resumption Timing on Post Acute Kidney Injury Outcomes. *Kidney International Reports*, 9(11), 3290–3300. <https://doi.org/10.1016/J.EKIR.2024.08.027>
- Cheng, H., Zhou, J., Sun, Y., Zhan, Q., & Zhang, D. (2022). High fructose diet: A risk factor for immune system dysregulation. *Human Immunology*, 83(6), 538–546. <https://doi.org/10.1016/J.HUMIMM.2022.03.007>

- Chomiuk, T., Niezgoda, N., Mamcarz, A., & Śliż, D. (2024). Physical activity in metabolic syndrome. *Frontiers in Physiology, 15*, 1365761. <https://doi.org/10.3389/FPHYS.2024.1365761/BIBTEX>
- Clemente-Suárez, V. J., Redondo-Flórez, L., Beltrán-Velasco, A. I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C. C., & Tornero-Aguilera, J. F. (2023). The Role of Adipokines in Health and Disease. *Biomedicines, 11*(5), 1290. <https://doi.org/10.3390/BIOMEDICINES11051290>
- Crean, A. J., Senior, A. M. N., Freire, T., Clark, T. D., Mackay, F., Austin, G., Pulpitel, T. J., Nobrega, M. A., Barrès, R., & Simpson, S. J. (2024). Paternal dietary macronutrient balance and energy intake drive metabolic and behavioral differences among offspring. *Nature Communications, 15*(1), 1–11. <https://doi.org/10.1038/s41467-024-46782-y>
- Dandona, P., Ghanim, H., Monte, S., & Caruana, J. (2017). Asthma in Obesity and Diabetes: Novel Mechanisms and Effects of Bariatric Surgery. *Metabolism and Pathophysiology of Bariatric Surgery: Nutrition, Procedures, Outcomes and Adverse Effects*, 33–38. <https://doi.org/10.1016/B978-0-12-804011-9.00002-9>
- Daoust, L., Choi, B. S. Y., Lacroix, S., Rodrigues Vilela, V., Varin, T. V., Dudonné, S., Pilon, G., Roy, D., Levy, E., Desjardins, Y., Chassaing, B., & Marette, A. (2021). The postnatal window is critical for the development of sex-specific metabolic and gut microbiota outcomes in offspring. *Gut Microbes, 13*(1). <https://doi.org/10.1080/19490976.2021.2004070>
- Das, P., & Ingole, N. (2023). Lipoproteins and Their Effects on the Cardiovascular System. *Cureus, 15*(11), e48865. <https://doi.org/10.7759/CUREUS.48865>
- Deerochanawong, C., Kim, S. G., & Chang, Y. C. (2024). Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review. *Diabetes & Metabolism Journal, 48*(2), 184. <https://doi.org/10.4093/DMJ.2023.0168>
- Dholariya, S. J., & Orrick, J. A. (2022). Biochemistry, Fructose Metabolism. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK576428/>
- Ding, Y., Deng, Q., Yang, M., Niu, H., Wang, Z., & Xia, S. (2023). Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment. *Diabetes, Metabolic Syndrome and Obesity, 16*, 3303. <https://doi.org/10.2147/DMSO.S431251>

- Dornas, W. C., de Lima, W. G., Pedrosa, M. L., & Silva, M. E. (2015). Health Implications of High-Fructose Intake and Current Research. *Advances in Nutrition*, 6(6), 729–737. <https://doi.org/10.3945/AN.114.008144>
- Dreher, M. L. (2018). Whole Fruits and Fruit Fiber Emerging Health Effects. *Nutrients*, 10(12), 1833. <https://doi.org/10.3390/NU10121833>
- Duan, W., Ou, X., Wang, X., Wang, Y., Zhao, X., Wang, Q., Wu, X., Zhang, W., Ma, H., You, H., & Jia, J., (2018). Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. *Revista Española de Enfermedades Digestivas*, 110(9), 557–563. <https://doi.org/10.17235/REED.2018.5533/2018>
- Dyer, K. A. (2023). Daily healthy habits to reduce stress and increase longevity. *Journal of Interprofessional Education & Practice*, 30, 100593. <https://doi.org/10.1016/J.XJEP.2022.100593>
- Eisenhut, P., Marx, N., Borsi, G., Papež, M., Ruggeri, C., Baumann, M., & Borth, N. (2024). Manipulating gene expression levels in mammalian cell factories: An outline of synthetic molecular toolboxes to achieve multiplexed control. *New Biotechnology*, 79, 1–19. <https://doi.org/10.1016/J.NBT.2023.11.003>
- Eshete, M. A., & Molla, E. L. (2021). Cultural significance of medicinal plants in healing human ailments among Guji semi-pastoralist people, Suro Barguda District, Ethiopia. *Journal of Ethnobiology and Ethnomedicine*, 17(1), 1–18. <https://doi.org/10.1186/S13002-021-00487-4/TABLES/9>
- Eslami, O., & Shidfar, F. (2019). Soy milk: A functional beverage with hypocholesterolemic effects? A systematic review of randomized controlled trials. *Complementary Therapies in Medicine*, 42, 82–88. <https://doi.org/10.1016/j.ctim.2018.11.001>
- Esler, W. P., & Bence, K. K. (2019). Metabolic Targets in Nonalcoholic Fatty Liver Disease. *Cellular and Molecular Gastroenterology and Hepatology*, 8(2), 247–267. <https://doi.org/10.1016/J.JCMGH.2019.04.007>
- Essawi, K., Dobie, G., Shaabi, M. F., Hakami, W., Saboor, M., Madkhali, A. M., Hamami, A. A. H., Allallah, W. H., Akhter, M. S., Mobarki, A. A., & Hamali, H. A. (2023). Comparative Analysis of Red Blood Cells, White Blood Cells, Platelet Count, and Indices in Type 2 Diabetes Mellitus

- Patients and Normal Controls: Association and Clinical Implications. *Diabetes, Metabolic Syndrome and Obesity*, 16, 3123. <https://doi.org/10.2147/DMSO.S422373>
- Fadhul, T., Park, S. H., Ali, H., Alsiraj, Y., Wali, J. A., Simpson, S. J., & Softic, S. (2025). Fructose-Induced Metabolic Dysfunction Is Dependent on the Baseline Diet, the Length of the Dietary Exposure, and Sex of the Mice. *Nutrients*, 17(1), 124. <https://doi.org/10.3390/NU17010124/S1>
- Fahed, G., Aoun, L., Zerdan, M. B., Allam, S., Zerdan, M. B., Bouferraa, Y., & Assi, H. I. (2022). Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. *International Journal of Molecular Sciences*, 23(2), 786. <https://doi.org/10.3390/IJMS23020786>
- Fajarwati, I., Duryadi Solihin, D., Wresdiyati, T., & Batubara, I. (2023). Self-recovery in diabetic Sprague Dawley rats induced by intraperitoneal alloxan and streptozotocin. *Heliyon*, 9, e15533. <https://doi.org/10.1016/j.heliyon.2023.e15533>
- Faris Abdulghani, M., Al-Fayyadh, S., Rastrelli, L., Mackonochie, M., & Nunez Selles, A. J. (2024). Natural products for managing metabolic syndrome: a scoping review. *Frontiers in Pharmacology*, 15, 1366946. <https://doi.org/10.3389/FPHAR.2024.1366946>
- Feinman, R. D., & Fine, E. J. (2013). Fructose in perspective. *Nutrition and Metabolism*, 10(1), 1–12. <https://doi.org/10.1186/1743-7075-10-45/FIGURES/8>
- Flessa, C. M., Nasiri-Ansari, N., Kyrou, I., Leca, B. M., Lianou, M., Chatzigeorgiou, A., Kaltsas, G., Kassi, E., & Randevara, H. S. (2022). Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research. *International Journal of Molecular Sciences*, 23(24), 15791. <https://doi.org/10.3390/IJMS232415791>
- Franco-Juárez, B., Gómez-Manzo, S., Hernández-Ochoa, B., Cárdenas-Rodríguez, N., Arreguin-Espinosa, R., de la Cruz, V. P., & Ortega-Cuellar, D. (2021). Effects of High Dietary Carbohydrate and Lipid Intake on the Lifespan of *C. elegans*. *Cells*, 10(9), 2359. <https://doi.org/10.3390/CELLS10092359>
- Freisling, H., Arnold, M., Soerjomataram, I., O'Doherty, M. G., Ordóñez-Mena, J. M., Bamia, C., Kampman, E., Leitzmann, M., Romieu, I., Kee, F., Tsilidis, K., Tjønneland, A., Trichopoulou, A., Boffetta, P., Benetou, V., Bueno-De-Mesquita, H. B., Huerta, J. M., Brenner, H., Wilsgaard, T., & Jenab, M. (2017). Comparison of general obesity and measures of body fat distribution in older

adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe. *British Journal of Cancer*, 116(11), 1486–1497.

<https://doi.org/10.1038/bjc.2017.106>

Frühbeck, G., Catalán, V., Rodríguez, A., Ramírez, B., Becerril, S., Portincasa, P., & Gómez-Ambrosi, J. (2017). Normalization of adiponectin concentrations by leptin replacement in ob/ob mice is accompanied by reductions in systemic oxidative stress and inflammation. *Scientific Reports*, 7(1), 1–12. <https://doi.org/10.1038/s41598-017-02848-0>

Fuchs, T., Loureiro, M. de P., Macedo, L. E., Nocca, D., Nedelcu, M., & Costa-Casagrande, T. A. (2018). Animal models in metabolic syndrome. *Revista Do Colegio Brasileiro de Cirurgioes*, 45(5), e1975. <https://doi.org/10.1590/0100-6991E-20181975>

Galaviz, K. I., Narayan, K. M. V., Lobelo, F., & Weber, M. B. (2015). Lifestyle and the Prevention of Type 2 Diabetes: A Status Report. *American Journal of Lifestyle Medicine*, 12(1), 4. <https://doi.org/10.1177/1559827615619159>

Gastaldelli, A., Stefan, N., & Häring, H. U. (2021). Liver-targeting drugs and their effect on blood glucose and hepatic lipids. *Diabetologia*, 64(7), 1461–1479. <https://doi.org/10.1007/S00125-021-05442-2>

Geidl-Flueck, B., & Gerber, P. A. (2023). Fructose drives de novo lipogenesis affecting metabolic health. *The Journal of Endocrinology*, 257(2), e220270. <https://doi.org/10.1530/JOE-22-0270>

Gerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El-Demerdash, E. (2021). Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. *Life Sciences*, 271, 119220. <https://doi.org/10.1016/J.LFS.2021.119220>

Géza Pethő, Á., Tapolyai, M., Csongrádi, É., & Orosz, P. (2024). Management of chronic kidney disease: The current novel and forgotten therapies. *Journal of Clinical & Translational Endocrinology*, 36, 100354. <https://doi.org/10.1016/J.JCTE.2024.100354>

Ghasemi, A., & Jeddi, S. (2023). Streptozotocin as a tool for induction of rat models of diabetes: a practical guide. *EXCLI Journal*, 22, 274. <https://doi.org/10.17179/EXCLI2022-5720>

Ghazwani, M., Mahmood, S. E., Gosadi, I. M., Bahri, A. A., Ghazwani, S. H., & Khmees, R. A. (2023). Prevalence of Dyslipidemia and Its Determinants Among the Adult Population of the

- Jazan Region. *International Journal of General Medicine*, 16, 4215–4226.
<https://doi.org/10.2147/IJGM.S429462>
- Giudetti, A. M. (2023). Editorial: Lipid metabolism in obesity. *Frontiers in Physiology*, 14, 1268288.
<https://doi.org/10.3389/FPHYS.2023.1268288>
- Gomez-Pinilla, F., Cipolat, R. P., & Royes, L. F. F. (2021). Dietary fructose as a model to explore the influence of peripheral metabolism on brain function and plasticity. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1867(5), 166036.
<https://doi.org/10.1016/J.BBADIS.2020.166036>
- Górczyńska-Kosiorz, S., Kosiorz, M., & Dzięgielewska-Gęsiak, S. (2024). Exploring the Interplay of Genetics and Nutrition in the Rising Epidemic of Obesity and Metabolic Diseases. *Nutrients*, 16(20), 3562. <https://doi.org/10.3390/NU16203562>
- Goyal, R., Singhal, M., & Jialal, I. (2023). *Type 2 Diabetes*.
<https://www.ncbi.nlm.nih.gov/books/NBK513253/>
- Haase, C. L., Eriksen, K. T., Lopes, S., Satylganova, A., Schneck, V., & McEwan, P. (2020). Body mass index and risk of obesity-related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database. *Obesity Science & Practice*, 7(2), 137.
<https://doi.org/10.1002/OSP4.474>
- Hamid, N., Junaid, M., & Pei, D. S. (2021). Combined toxicity of endocrine-disrupting chemicals: A review. *Ecotoxicology and Environmental Safety*, 215, 112136.
<https://doi.org/10.1016/J.ECOENV.2021.112136>
- Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018). Fructose metabolism and metabolic disease. *The Journal of Clinical Investigation*, 128(2), 545.
<https://doi.org/10.1172/JCI96702>
- Heda, R., Yazawa, M., Shi, M., Satapathy, S. K., Bhaskaran, M., Aloor, F. Z., & Thuluvath, P. J. (2021). Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. *World Journal of Gastroenterology*, 27(17), 1864. <https://doi.org/10.3748/WJG.V27.I17.1864>
- Heeren, J., & Scheja, L. (2021). Metabolic-associated fatty liver disease and lipoprotein metabolism. *Molecular Metabolism*, 50, 101238. <https://doi.org/10.1016/J.MOLMET.2021.101238>

- Herman, M. A., & Birnbaum, M. J. (2021). Molecular Aspects of Fructose Metabolism and Metabolic Disease. *Cell Metabolism*, 33(12), 2329. <https://doi.org/10.1016/J.CMET.2021.09.010>
- Horakova, O., Kroupova, P., Bardova, K., Buresova, J., Janovska, P., Kopecky, J., & Rossmeisl, M. (2019). Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. *Scientific Reports*, 9(1), 1–11. <https://doi.org/10.1038/s41598-019-42531-0>
- Hsu, C. N., Hou, C. Y., Hsu, W. H., & Tain, Y. L. (2021). Early-Life Origins of Metabolic Syndrome: Mechanisms and Preventive Aspects. *International Journal of Molecular Sciences*, 22(21), 11872. <https://doi.org/10.3390/IJMS222111872>
- Huang, L., Tan, L., Lv, Z., Chen, W., & Wu, J. (2024). Pharmacology of bioactive compounds from plant extracts for improving non-alcoholic fatty liver disease through endoplasmic reticulum stress modulation: A comprehensive review. *Heliyon*, 10(3), e25053. <https://doi.org/10.1016/J.HELIYON.2024.E25053>
- Ismail, A., & Dumitrascu, D. L. (2020). Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review. *European Journal of Clinical Investigation*, 50(10), e13331. <https://doi.org/10.1111/ECI.13331>
- Jacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & Mcevoy, J. W. (2024). Dyslipidemia. *Hypertension: A Companion to Braunwald's Heart Disease*, 476–488. <https://doi.org/10.1016/B978-0-323-88369-6.00042-6>
- Jang, C., Hui, S., Lu, W., Cowan, A. J., Morscher, R. J., Lee, G., Liu, W., Tesz, G. J., Birnbaum, M. J., & Rabinowitz, J. D. (2018). The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. *Cell Metabolism*, 27(2), 351. <https://doi.org/10.1016/J.CMET.2017.12.016>
- Jebeile, H., Kelly, A. S., O'Malley, G., & Baur, L. A. (2022). Obesity in children and adolescents: epidemiology, causes, assessment, and management. *The Lancet Diabetes and Endocrinology*, 10(5), 351–365. [https://doi.org/10.1016/S2213-8587\(22\)00047-X/ASSET/4D9C4B14-2E7C-4126-A6B9-3B59D1E89F93/MAIN.ASSETS/GR2.JPG](https://doi.org/10.1016/S2213-8587(22)00047-X/ASSET/4D9C4B14-2E7C-4126-A6B9-3B59D1E89F93/MAIN.ASSETS/GR2.JPG)
- Jemal, A., Girum, T., Kedir, S., Bedru, A., Mosa, H., Assfa, K., & Oumer, A. (2023). Metabolic syndrome and its predictors among adults seeking medical care: A trending public health concern. *Clinical Nutrition ESPEN*, 54, 264–270. <https://doi.org/10.1016/J.CLNESP.2023.01.034>

- Jha, B. K., Sherpa, M. L., Imran, M., Mohammed, Y., Jha, L. A., Paudel, K. R., & Jha, S. K. (2023). Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology. *Diabetology*, *4*(2), 134–159. <https://doi.org/10.3390/DIABETOLOGY4020015>
- Jiang, B., Zheng, Y., Chen, Y., Chen, Y., Li, Q., Zhu, C., Wang, N., Han, B., Zhai, H., Lin, D., & Lu, Y. (2018). Age and gender-specific distribution of metabolic syndrome components in East China: Role of hypertriglyceridemia in the SPECT-China study. *Lipids in Health and Disease*, *17*(1), 1–11. <https://doi.org/10.1186/S12944-018-0747-Z/FIGURES/2>
- Jin, L., Hua, H., Ji, Y., Jia, Z., Peng, M., & Huang, S. (2023). Anti-inflammatory role of fenofibrate in treating diseases. *Biomolecules and Biomedicine*, *23*(3), 376. <https://doi.org/10.17305/BB.2022.8534>
- Johnson, R. J., Lanasa, M. A., Sanchez-Lozada, L. G., Tolan, D., Nakagawa, T., Ishimoto, T., Andres-Hernando, A., Rodriguez-Iturbe, B., & Stenvinkel, P. (2023). The fructose survival hypothesis for obesity. *Philosophical Transactions of the Royal Society B: Biological Sciences*, *378*(1885), 20220230. <https://doi.org/10.1098/RSTB.2022.0230>
- Jung, S. W., Kim, S. M., Kim, Y. G., Lee, S. H., & Moon, J. Y. (2020). Uric acid and inflammation in kidney disease. *American Journal of Physiology - Renal Physiology*, *318*(6), F1327–F1340. <https://doi.org/10.1152/AJPRENAL.00272.2019/ASSET/IMAGES/LARGE/ZH20052090790001.JPG>
- Kaminsky, L. A., German, C., Imboden, M., Ozemek, C., Peterman, J. E., & Brubaker, P. H. (2022). The importance of healthy lifestyle behaviors in the prevention of cardiovascular disease. *Progress in Cardiovascular Diseases*, *70*, 8–15. <https://doi.org/10.1016/J.PCAD.2021.12.001>
- Kang, J. H., Kim, H., Kim, J., Seo, J. H., Cha, S., Oh, H., Kim, K., Park, S. J., Kim, E., Kong, S., Lee, J. H., Bae, J. S., Won, H. H., Joung, J. G., Yang, Y. J., Kim, J., & Park, W. Y. (2021). Interaction of genetic and environmental factors for body fat mass control: observational study for lifestyle modification and genotyping. *Scientific Reports*, *11*(1), 1–9. <https://doi.org/10.1038/s41598-021-92229-5>

- Kao, T. W., & Huang, C. C. (2021). Recent Progress in Metabolic Syndrome Research and Therapeutics. *International Journal of Molecular Sciences*, 22(13), 6862. <https://doi.org/10.3390/IJMS22136862>
- Katangwe-Chigamba, T., Kantilal, K., Hartley-Palmer, J., Salisu-Olatunji, S. O., Seeley, C., Naughton, F., & Chester, R. (2024). Diet and Physical Activity Interventions for People from Minority Ethnic Backgrounds in the UK: A Scoping Review Exploring Barriers, Enablers and Cultural Adaptations. *Journal of Racial and Ethnic Health Disparities*, 1–45. <https://doi.org/10.1007/S40615-024-02112-Y/TABLES/3>
- Keating, S. E., Chawla, Y., De, A., & George, E. S. (2024). Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective. *Hepatology International*, 18(2), 959–976. <https://doi.org/10.1007/S12072-024-10663-9>
- Kelishadi, R., Hovsepian, S., Djalalinia, S., Jamshidi, F., & Qorbani, M. (2016). A systematic review on the prevalence of metabolic syndrome in Iranian children and adolescents. *Journal of Research in Medical Sciences*, 21(6). <https://doi.org/10.4103/1735-1995.192506>
- Khitan, Z., & Kim, D. H. (2013). Fructose: A Key Factor in the Development of Metabolic Syndrome and Hypertension. *Journal of Nutrition and Metabolism*, 2013(1), 682673. <https://doi.org/10.1155/2013/682673>
- Kim, H. L., Chung, J., Kim, K. J., Kim, H. J., Seo, W. W., Jeon, K. H., Cho, I., Park, J. J., Lee, M. H., Suh, J., Lim, S. Y., Choi, S., & Kim, S. H. (2021). Lifestyle Modification in the Management of Metabolic Syndrome: Statement from Korean Society of CardioMetabolic Syndrome (KSCMS). *Korean Circulation Journal*, 52(2), 93. <https://doi.org/10.4070/KCJ.2021.0328>
- Kim, H., Lyu, J., Raja, V., & Kim, K. (2024). Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia. *Cost Effectiveness and Resource Allocation: C/E*, 22(1), 84. <https://doi.org/10.1186/S12962-024-00591-8>
- Kim, N. H., Han, K. H., Choi, J., Lee, J., & Kim, S. G. (2019). Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. *BMJ*, 366. <https://doi.org/10.1136/BMJ.L5125>

- Koliaki, C., Dalamaga, M., & Liatis, S. (2023). Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten? *Current Obesity Reports*, 12(4), 514. <https://doi.org/10.1007/S13679-023-00527-Y>
- Kulawik, A., Cielecka-Piontek, J., Czerny, B., Kamiński, A., & Zalewski, P. (2024). The Relationship Between Lycopene and Metabolic Diseases. *Nutrients*, 16(21), 3708. <https://doi.org/10.3390/NU16213708>
- Kumar Dan, A., Aamna, B., De, S., Pereira-Silva, M., Sahu, R., Cláudia Paiva-Santos, A., & Parida, S. (2022). Sericin nanoparticles: Future nanocarrier for target-specific delivery of chemotherapeutic drugs. *Journal of Molecular Liquids*, 368, 120717. <https://doi.org/10.1016/j.molliq.2022.120717>
- La Merrill, M. A., Smith, M. T., McHale, C. M., Heindel, J. J., Atlas, E., Cave, M. C., Collier, D., Guyton, K. Z., Koliwad, S., Nadal, A., Rhodes, C. J., Sargis, R. M., Zeise, L., & Blumberg, B. (2024). Consensus on the key characteristics of metabolism disruptors. *Nature Reviews Endocrinology* 2024, 1–17. <https://doi.org/10.1038/s41574-024-01059-8>
- Lara-Romero, C., & Romero-Gómez, M. (2024). Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach. *European Cardiology Review*, 19, e06. <https://doi.org/10.15420/ECR.2023.34>
- Lau, W. B., Ohashi, K., Wang, Y., Ogawa, H., Murohara, T., Ma, X. L., & Ouchi, N. (2017). Role of Adipokines in Cardiovascular Disease. *Circulation Journal: Official Journal of the Japanese Circulation Society*, 81(7), 920–928. <https://doi.org/10.1253/CIRCJ.CJ-17-0458>
- Lee, J. S., Chang, P. Y., Zhang, Y., Kizer, J. R., Best, L. G., & Howard, B. V. (2017). Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. *Diabetes Care*, 40(4), 529–537. <https://doi.org/10.2337/DC16-1958>
- Lee, W. H., Bhute, V. J., Higuchi, H., Ikeda, S., Palecek, S. P., & Ikeda, A. (2020). Metabolic alterations caused by the mutation and overexpression of the Tmem135 gene. *Experimental Biology and Medicine*, 245(17), 1571–1583. https://doi.org/10.1177/1535370220932856/ASSET/IMAGES/LARGE/10.1177_1535370220932856-FIG6.JPEG

- Li, C., Spencer, G., Husain, M. J., Nugent, R., Auzenne, D., Kostova, D., & Richter, P. (2024). Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries. *PLOS Global Public Health*, 4(2), e0002905. <https://doi.org/10.1371/JOURNAL.PGPH.0002905>
- Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020). Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. *Signal Transduction and Targeted Therapy*, 5(1), 1–23. <https://doi.org/10.1038/s41392-019-0089-y>
- Liu, Q. K. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. *Frontiers in Endocrinology*, 15, 1431292. <https://doi.org/10.3389/FENDO.2024.1431292/BIBTEX>
- Lodge, M., Dykes, R., & Kennedy, A. (2024). Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease. *Biomolecules*, 14(7), 845. <https://doi.org/10.3390/BIOM14070845>
- Luo, S., Monterosso, J. R., Sarpelleh, K., & Page, K. A. (2015). Differential effects of fructose versus glucose on brain and appetitive responses to food cues and decisions for food rewards. *Proceedings of the National Academy of Sciences of the United States of America*, 112(20), 6509–6514. <https://doi.org/10.1073/PNAS.1503358112/-/DCSUPPLEMENTAL>
- Mahmoudi, A., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2021). Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. *BioMed Research International*, 2021(1), 3654660. <https://doi.org/10.1155/2021/3654660>
- Mahmoudi, A., Jamialahmadi, T., Johnston, T. P., & Sahebkar, A. (2022). Impact of fenofibrate on NAFLD/NASH: A genetic perspective. *Drug Discovery Today*, 27(8), 2363–2372. <https://doi.org/10.1016/J.DRUDIS.2022.05.007>
- Malekmohammad, K., Bezsonov, E. E., & Rafieian-Kopaei, M. (2021). Role of Lipid Accumulation and Inflammation in Atherosclerosis: Focus on Molecular and Cellular Mechanisms. *Frontiers in Cardiovascular Medicine*, 8, 707529. <https://doi.org/10.3389/FCVM.2021.707529>
- Malik, S. U. F., Mahmud, Z., Alam, J., Islam, M. S., & Azad, A. K. (2019). Relationship among obesity, blood lipids and insulin resistance in Bangladeshi adults. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 13(1), 444–449. <https://doi.org/10.1016/J.DSX.2018.10.015>

- Malik, V. S., & Hu, F. B. (2015). Fructose and Cardiometabolic Health: What the Evidence from Sugar-Sweetened Beverages Tells Us. *Journal of the American College of Cardiology*, *66*(14), 1615. <https://doi.org/10.1016/J.JACC.2015.08.025>
- Martemucci, G., Khalil, M., Di Luca, A., Abdallah, H., & D'Alessandro, A. G. (2024). Comprehensive Strategies for Metabolic Syndrome: How Nutrition, Dietary Polyphenols, Physical Activity, and Lifestyle Modifications Address Diabesity, Cardiovascular Diseases, and Neurodegenerative Conditions. *Metabolites*, *14*(6), 327. <https://doi.org/10.3390/METABO14060327>
- Martiniakova, M., Mondockova, V., Kovacova, V., Babikova, M., Zemanova, N., Biro, R., Penzes, N., & Omelka, R. (2024). Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality. *Diabetology & Metabolic Syndrome*, *16*(1), 1–26. <https://doi.org/10.1186/S13098-024-01440-7>
- Martín-Rodríguez, A., Bustamante-Sánchez, Á., Martínez-Guardado, I., Navarro-Jiménez, E., Plata-SanJuan, E., Tornero-Aguilera, J. F., & Clemente-Suárez, V. J. (2022). Infancy Dietary Patterns, Development, and Health: An Extensive Narrative Review. *Children*, *9*(7), 1072. <https://doi.org/10.3390/CHILDREN9071072>
- Masenga, S. K., Kabwe, L. S., Chakulya, M., & Kirabo, A. (2023). Mechanisms of Oxidative Stress in Metabolic Syndrome. *International Journal of Molecular Sciences*, *24*(9), 7898. <https://doi.org/10.3390/IJMS24097898>
- Mazza, E., Troiano, E., Ferro, Y., Lisso, F., Tosi, M., Turco, E., Pujia, R., & Montalcini, T. (2024). Obesity, Dietary Patterns, and Hormonal Balance Modulation: Gender-Specific Impacts. *Nutrients*, *16*(11), 1629. <https://doi.org/10.3390/NU16111629>
- Mcvicker, B., Viswanathan, S., Lodge, M., Dykes, R., & Kennedy, A. (2024). Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease. *Biomolecules*, *14*(7), 845. <https://doi.org/10.3390/BIOM14070845>
- Mendrick, D. L., Diehl, A. M., Topor, L. S., Dietert, R. R., Will, Y., La Merrill, M. A., Bouret, S., Varma, V., Hastings, K. L., Schug, T. T., Hart, S. G. E., & Bureson, F. G. (2018). Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic. *Toxicological Sciences*, *162*(1), 36–42. <https://doi.org/10.1093/TOXSCI/KFX233>

- Mitrovic, B., Gluvic, Z. M., Obradovic, M., Radunovic, M., Rizzo, M., Banach, M., & Isenovic, E. R. (2022). Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today? *Archives of Medical Science: AMS*, *19*(4), 884.
<https://doi.org/10.5114/AOMS/150639>
- Molla, M. D., Wolde, H. F., & Atnafu, A. (2020). Magnitude of Central Obesity and its Associated Factors Among Adults in Urban Areas of Northwest Ethiopia. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, *13*, 4169. <https://doi.org/10.2147/DMSO.S279837>
- Mukherjee, U., Sehar, U., Brownell, M., & Reddy, P. H. (2024). Mechanisms, consequences and role of interventions for sleep deprivation: Focus on mild cognitive impairment and Alzheimer's disease in elderly. *Ageing Research Reviews*, *100*, 102457.
<https://doi.org/10.1016/J.ARR.2024.102457>
- Murakami, S., Funahashi, K., Tamagawa, N., Ning, M., & Ito, T. (2022). Taurine Ameliorates Streptozotocin-Induced Diabetes by Modulating Hepatic Glucose Metabolism and Oxidative Stress in Mice. *Metabolites*, *12*(6), 524. <https://doi.org/10.3390/METABO12060524>
- Myint, M., Oppedisano, F., De Giorgi, V., Kim, B. M., Marincola, F. M., Alter, H. J., & Nesci, S. (2023). Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions. *Journal of Translational Medicine*, *21*(1), 757. <https://doi.org/10.1186/S12967-023-04627-0>
- Nandasena, H. M. R. K. G., Tennakoon, T. M. S. U. B., & Ralapanawa, D. M. P. U. K. (2023). Prevalence and determinants of dyslipidemia among adults in the community: A cross-sectional study in a selected province, Sri Lanka. *Clinical Epidemiology and Global Health*, *24*, 101442.
<https://doi.org/10.1016/J.CEGH.2023.101442>
- Nolan, C. J., & Prentki, M. (2019). Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. *Diabetes and Vascular Disease Research*, *16*(2), 118–127.
https://doi.org/10.1177/1479164119827611/ASSET/IMAGES/LARGE/10.1177_1479164119827611-FIG3.JPEG
- Noubiap, J. J., Nansseu, J. R., Lontchi-Yimagou, E., Nkeck, J. R., Nyaga, U. F., Ngouo, A. T., Tounouga, D. N., Tianyi, F. L., Foka, A. J., Ndoadoumgué, A. L., & Bigna, J. J. (2022). Global, regional, and

country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. *The Lancet. Child & Adolescent Health*, 6(3), 158–170. [https://doi.org/10.1016/S2352-4642\(21\)00374-6](https://doi.org/10.1016/S2352-4642(21)00374-6)

Nsabimana, P., Sombié, O. O., Pauwels, N. S., Boynito, W. G., Tariku, E. Z., Vasanthakaalam, H., De Henauw, S., & Abbeddou, S. (2024). Association between urbanization and metabolic syndrome in low- and middle-income countries: A systematic review and meta-analysis. *Nutrition, Metabolism and Cardiovascular Diseases*, 34(2), 235–250. <https://doi.org/10.1016/J.NUMECD.2023.07.040>

Nystoriak, M. A., & Bhatnagar, A. (2018). Cardiovascular Effects and Benefits of Exercise. *Frontiers in Cardiovascular Medicine*, 5, 408204. <https://doi.org/10.3389/FCVM.2018.00135/BIBTEX>

Okpechi, I. G., Luyckx, V. A., Tungsanga, S., Ghimire, A., Jha, V., Johnson, D. W., & Bello, A. K. (2024). Global kidney health priorities—perspectives from the ISN-GKHA. *Nephrology Dialysis Transplantation*, 39(11), 1762–1771. <https://doi.org/10.1093/NDT/GFAE116>

Onyango, A. N. (2022). Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae. *Heliyon*, 8(12), e12294. <https://doi.org/10.1016/J.HELIYON.2022.E12294>

Opoku, A. A., Abushama, M., & Konje, J. C. (2023). Obesity and menopause. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 88, 102348. <https://doi.org/10.1016/J.BPOBGYN.2023.102348>

Oppert, J. M., Bellicha, A., & Ciangura, C. (2021). Physical activity in management of persons with obesity. *European Journal of Internal Medicine*, 93, 8–12. <https://doi.org/10.1016/J.EJIM.2021.04.028>

Ormazabal, V., Nair, S., Carrión, F., McIntyre, H. D., & Salomon, C. (2022). The link between gestational diabetes and cardiovascular diseases: potential role of extracellular vesicles. *Cardiovascular Diabetology*, 21(1), 1–19. <https://doi.org/10.1186/S12933-022-01597-3>

Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018). Association between insulin resistance and the development of cardiovascular disease. *Cardiovascular Diabetology*, 17(1), 1–14. <https://doi.org/10.1186/S12933-018-0762-4>

- Pacheco, L. S., Blanco, E., Burrows, R., Reyes, M., Lozoff, B., & Gahagan, S. (2019). Early Onset Obesity and Risk of Metabolic Syndrome Among Chilean Adolescents. *Preventing Chronic Disease, 14*(10). <https://doi.org/10.5888/PCD14.170132>
- Paley, C. A., & Johnson, M. I. (2018). Abdominal obesity and metabolic syndrome: exercise as medicine? *BMC Sports Science, Medicine and Rehabilitation, 10*(1), 7. <https://doi.org/10.1186/S13102-018-0097-1>
- Palmer, A. K., & Jensen, M. D. (2022). Metabolic changes in aging humans: current evidence and therapeutic strategies. *The Journal of Clinical Investigation, 132*(16), e158451. <https://doi.org/10.1172/JCI158451>
- Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *The Canadian Journal of Cardiology, 34*(5), 575. <https://doi.org/10.1016/J.CJCA.2017.12.005>
- Piché, M. E., Tchernof, A., & Després, J. P. (2020). Obesity Phenotypes, Diabetes, and cardiovascular diseases. *Circulation Research, 126*(11), 1477–1500. https://doi.org/10.1161/CIRCRESAHA.120.316101/SUPPL_FILE/RES_DESPRES_CORRECTION.PDF
- Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D., & Catapano, A. L. (2021). Global epidemiology of dyslipidaemias. *Nature Reviews. Cardiology, 18*(10), 689–700. <https://doi.org/10.1038/S41569-021-00541-4>
- Portell, A., Piasini, S., & Niec, L. N. (2023). Promoting positive behavior through healthy limit setting. *Handbook of Child and Adolescent Psychology Treatment Modules: Personalized Care in Behavior and Emotion, 275–290*. <https://doi.org/10.1016/B978-0-323-99613-6.00016-8>
- Pouresmaeili, F., Kamalidehghan, B., Kamarehei, M., & Goh, Y. M. (2018). A comprehensive overview on osteoporosis and its risk factors. *Therapeutics and Clinical Risk Management, 14*, 2029. <https://doi.org/10.2147/TCRM.S138000>
- Rahman, M. M., Dhar, P. S., Sumaia, Anika, F., Ahmed, L., Islam, M. R., Sultana, N. A., Cavalu, S., Pop, O., & Rauf, A. (2022). Exploring the plant-derived bioactive substances as antidiabetic

agent: An extensive review. *Biomedicine & Pharmacotherapy*, 152, 113217.
<https://doi.org/10.1016/J.BIOPHA.2022.113217>

Rahman, M. S., Hossain, K. S., Das, S., Kundu, S., Adegoke, E. O., Rahman, M. A., Hannan, M. A., Uddin, M. J., & Pang, M. G. (2021). Role of Insulin in Health and Disease: An Update. *International Journal of Molecular Sciences*, 22(12), 6403.
<https://doi.org/10.3390/IJMS22126403>

Rajamoorthi, A., LeDuc, C. A., & Thaker, V. V. (2022). The metabolic conditioning of obesity: A review of the pathogenesis of obesity and the epigenetic pathways that “program” obesity from conception. *Frontiers in Endocrinology*, 13, 1032491.
<https://doi.org/10.3389/FENDO.2022.1032491/BIBTEX>

Raman, V., Kose, V., Somalwar, S., Dwidmuthe, K. S., & Rao, S. (2023). Prevalence of Metabolic Syndrome and Its Association with Menopausal Symptoms in Post-Menopausal Women: A Scoping Review. *Cureus*, 15(5), e39069. <https://doi.org/10.7759/CUREUS.39069>

Ramírez, G., García, V. B., Aguilera Gutiérrez, Y., Leh, H. E., & Lee, L. K. (2022). Lycopene: A Potent Antioxidant for the Amelioration of Type II Diabetes Mellitus. *Molecules*, 27(7), 2335.
<https://doi.org/10.3390/MOLECULES27072335>

Reccia, I., Kumar, J., Akladios, C., Viridis, F., Pai, M., Habib, N., & Spalding, D. (2017). Non-alcoholic fatty liver disease: A sign of systemic disease. *Metabolism*, 72, 94–108.
<https://doi.org/10.1016/J.METABOL.2017.04.011>

Rehman, K., & Akash, M. S. H. (2016). Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? *Journal of Biomedical Science*, 23(1), 1–18.
<https://doi.org/10.1186/S12929-016-0303-Y>

Romieu, I., Dossus, L., Barquera, S., Blotière, H. M., Franks, P. W., Gunter, M., Hwalla, N., Hursting, S. D., Leitzmann, M., Margetts, B., Nishida, C., Potischman, N., Seidell, J., Stepien, M., Wang, Y., Westerterp, K., Winichagoon, P., Wiseman, M., & Willett, W. C. (2017). Energy balance and obesity: what are the main drivers? *Cancer Causes & Control*, 28(3), 247.
<https://doi.org/10.1007/S10552-017-0869-Z>

- Rondanelli, M., Faliva, M. A., Barrile, G. C., Cavioni, A., Mansueto, F., Mazzola, G., Oberto, L., Patelli, Z., Pirola, M., Tartara, A., Riva, A., Petrangolini, G., & Peroni, G. (2022). Nutrition, physical activity, and dietary supplementation to prevent bone mineral density loss: A food pyramid. *Nutrients*, *14*(1), 74. <https://doi.org/10.3390/NU14010074/S1>
- Ruiz, L. D., Zuelch, M. L., Dimitratos, S. M., & Scherr, R. E. (2019). Adolescent Obesity: Diet Quality, Psychosocial Health, and Cardiometabolic Risk Factors. *Nutrients*, *12*(1), 43. <https://doi.org/10.3390/NU12010043>
- Rus, M., Crisan, S., Andronie-Cioara, F. L., Indries, M., Marian, P., Pobirci, O. L., & Ardelean, A. I. (2023). Prevalence and Risk Factors of Metabolic Syndrome: A Prospective Study on Cardiovascular Health. *Medicina*, *59*(10), 1711. <https://doi.org/10.3390/MEDICINA59101711>
- Russell, J. B. W., Koroma, T. R., Sesay, S., Samura, S. K., Lakoh, S., Bockarie, A., Abiri, O. A., Conteh, V., Conteh, S., Smith, M., Mahdi, O. Z., & Lisk, D. R. (2024). Prevalence and correlates of metabolic syndrome among adults in Freetown, Sierra Leone: A comparative analysis of NCEP ATP III, IDF and harmonized ATP III criteria. *International Journal of Cardiology Cardiovascular Risk and Prevention*, *20*, 200236. <https://doi.org/10.1016/J.IJCRP.2024.200236>
- Sacks, F. M., & Andraski, A. B. (2021). Dietary fat and carbohydrate affect the metabolism of protein-based high-density lipoprotein subspecies. *Current Opinion in Lipidology*, *33*(1), 1. <https://doi.org/10.1097/MOL.0000000000000809>
- Saeed, N. M., Mansour, A. M., & Allam, S. (2020). Lycopene induces insulin signaling and alleviates fibrosis in experimental model of non-alcoholic fatty liver disease in rats. *PharmaNutrition*, *14*, 100225. <https://doi.org/10.1016/J.PHANU.2020.100225>
- Safaei, M., Sundararajan, E. A., Driss, M., Boulila, W., & Shapi'i, A. (2021). A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. *Computers in Biology and Medicine*, *136*, 104754. <https://doi.org/10.1016/J.COMPBIOMED.2021.104754>
- Şanlı, E., & Kabaran, S. (2019). Maternal Obesity, Maternal Overnutrition and Fetal Programming: Effects of Epigenetic Mechanisms on the Development of Metabolic Disorders. *Current Genomics*, *20*(6), 419. <https://doi.org/10.2174/1389202920666191030092225>

- Sargis, R. M., Heindel, J. J., & Padmanabhan, V. (2019). Interventions to address environmental metabolism-disrupting chemicals: Changing the narrative to empower action to restore metabolic health. *Frontiers in Endocrinology*, *10*, 33. <https://doi.org/10.3389/FENDO.2019.00033/BIBTEX>
- Selvaraj, E. A., Mózes, F. E., Jayaswal, A. N. A., Zafarmand, M. H., Vali, Y., Lee, J. A., Levick, C. K., Young, L. A. J., Palaniyappan, N., Liu, C. H., Aithal, G. P., Romero-Gómez, M., Brosnan, M. J., Tuthill, T. A., Anstee, Q. M., Neubauer, S., Harrison, S. A., Bossuyt, P. M., Pavlides, M., ... Doward, L. (2021). Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *Journal of Hepatology*, *75*(4), 770–785. <https://doi.org/10.1016/J.JHEP.2021.04.044>
- Shi, S., Wang, L., Van der Laan, L. J. W., Pan, Q., & Versteegen, M. M. A. (2021). Mitochondrial dysfunction and oxidative stress in liver transplantation and underlying diseases: new insights and therapeutics. *Transplantation*, *105*(11), 2362–2373. <https://doi.org/10.1097/TP.0000000000003691>
- Shubrook, J. H., Neumiller, J. J., & Wright, E. (2022). Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations. *Postgraduate Medicine*, *134*(4), 376–387. <https://doi.org/10.1080/00325481.2021.2009726>
- Sizar, O., Khare, S., Patel, P., & Talati, R. (2024). Statin Medications. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK430940/>
- Smit, A. E., Meijer, O. C., & Winter, E. M. (2024). The multi-faceted nature of age-associated osteoporosis. *Bone Reports*, *20*, 101750. <https://doi.org/10.1016/J.BONR.2024.101750>
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S. (2020). Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. *The Journal of Clinical Investigation*, *130*(3), 1453. <https://doi.org/10.1172/JCI134165>
- Softic, S., Gupta, M. K., Wang, G. X., Fujisaka, S., O'Neill, B. T., Rao, T. N., Willoughby, J., Harbison, C., Fitzgerald, K., Ilkayeva, O., Newgard, C. B., Cohen, D. E., & Kahn, C. R. (2017). Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. *The Journal of Clinical Investigation*, *127*(11), 4059–4074. <https://doi.org/10.1172/JCI94585>

- Strikić, D., Vujević, A., Perica, D., Leskovar, D., Paponja, K., Pećin, I., & Merćep, I. (2023). Importance of Dyslipidaemia Treatment in Individuals with Type 2 Diabetes Mellitus—A Narrative Review. *Diabetology*, 4(4), 538–552. <https://doi.org/10.3390/DIABETOLOGY4040048>
- Sulaiman, M. K. (2024). Molecular mechanisms and therapeutic potential of natural flavonoids in diabetic nephropathy: Modulation of intracellular developmental signaling pathways. *Current Research in Pharmacology and Drug Discovery*, 7, 100194. <https://doi.org/10.1016/J.CRPHAR.2024.100194>
- Swarup, S., Ahmed, I., Grigorova, Y., & Zeltser, R. (2024). Metabolic Syndrome. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK459248/>
- Szalai, Z., Berkó, A. M., Bódi, N., Hermes, E., Ferencz, Á., & Bagyánszki, M. (2023). Oxidative-Stress-Related Alterations in Metabolic Panel, Red Blood Cell Indices, and Erythrocyte Morphology in a Type 1 Diabetic Rat Model. *Applied Sciences (Switzerland)*, 13(17), 9920. <https://doi.org/10.3390/APP13179920/S1>
- Targher, G., Byrne, C. D., & Tilg, H. (2020). NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. *Gut*, 69(9), 1691–1705. <https://doi.org/10.1136/GUTJNL-2020-320622>
- Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021). The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. *Nature Reviews Gastroenterology & Hepatology*, 18(9), 599–612. <https://doi.org/10.1038/s41575-021-00448-y>
- Taskinen, M. R., Packard, C. J., & Borén, J. (2019). Dietary Fructose and the Metabolic Syndrome. *Nutrients*, 11(9), 1987. <https://doi.org/10.3390/NU11091987>
- Tesz, G. J., & Bence, K. K. (2020). Finding the Sweet Spot: Parsing Tissue-Specific Contributions of Fructose Metabolism. *Cell Metabolism*, 32(1), 6–8. <https://doi.org/10.1016/J.CMET.2020.06.009>
- Tiwari, A., & Balasundaram, P. (2023). Public Health Considerations Regarding Obesity. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK572122/>
- Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., & Sasso, F. C. (2023). Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-

- viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. *Biomedicines*, *11*(2), 468. <https://doi.org/10.3390/BIOMEDICINES11020468>
- Voulgaridou, G., Papadopoulou, S. K., Detopoulou, P., Tsoumana, D., Giaginis, C., Kondyli, F. S., Lymperaki, E., & Pritsa, A. (2023). Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs. *Diseases*, *11*(1), 29. <https://doi.org/10.3390/DISEASES11010029>
- Wang, F. X., Li, H. Y., Li, Y. Q., & Kong, L. D. (2020). Can Medicinal Plants and Bioactive Compounds Combat Lipid Peroxidation Product 4-HNE-Induced Deleterious Effects? *Biomolecules*, *10*(1), 146. <https://doi.org/10.3390/BIOM10010146>
- Wang, W., Zhou, H., Qi, S., Yang, H., & Hong, X. (2024). The association between physical activities combined with dietary habits and cardiovascular risk factors. *Heliyon*, *10*(7), e28845. <https://doi.org/10.1016/J.HELIYON.2024.E28845>
- Weinberg Sibony, R., Segev, O., Dor, S., & Raz, I. (2024). Overview of oxidative stress and inflammation in diabetes. *Journal of Diabetes*, *16*(10), e70014. <https://doi.org/10.1111/1753-0407.70014>
- Williams, A., Bissinger, R., Shamaa, H., Patel, S., Bourne, L., Artunc, F., & Qadri, S. M. (2023). Pathophysiology of Red Blood Cell Dysfunction in Diabetes and Its Complications. *Pathophysiology*, *30*(3), 327. <https://doi.org/10.3390/PATHOPHYSIOLOGY30030026>
- Wilson-Barnes, S. L., Lanham-New, S. A., & Lambert, H. (2022). Modifiable risk factors for bone health & fragility fractures. *Best Practice & Research Clinical Rheumatology*, *36*(3), 101758. <https://doi.org/10.1016/J.BERH.2022.101758>
- Wolpert, E. Z., Norman, S., Eek, D., Holmesson, C., & Fernström, A. (2023). How do patients experience chronic kidney disease? A mixed-methods study among patients in Sweden. *Journal of Public Health (Germany)*, *32*(10), 2015–2025. <https://doi.org/10.1007/S10389-023-01942-0/TABLES/6>
- Wondmkun, Y. T. (2020). Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, *13*, 3611. <https://doi.org/10.2147/DMSO.S275898>

- Wong, S. K., Chin, K. Y., Suhaimi, F. H., Fairus, A., & Ima-Nirwana, S. (2016). Animal models of metabolic syndrome: a review. *Nutrition & Metabolism*, *13*(1), 1–12.
<https://doi.org/10.1186/S12986-016-0123-9>
- Wong, V. W. S., Ekstedt, M., Wong, G. L. H., & Hagström, H. (2023). Changing epidemiology, global trends and implications for outcomes of NAFLD. *Journal of Hepatology*, *79*(3), 842–852.
<https://doi.org/10.1016/J.JHEP.2023.04.036>
- Wu, J., & Yan, L. J. (2015). Streptozotocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic β cell glucotoxicity. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, *8*, 181. <https://doi.org/10.2147/DMSO.S82272>
- Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016). Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. *Diabetes*, *65*(7), 1767–1778. <https://doi.org/10.2337/DB16-0046>
- Yamamoto, A., Kikuchi, Y., Kusakabe, T., Takano, H., Sakurai, K., Furui, S., & Oba, H. (2020). Imaging spectrum of abnormal subcutaneous and visceral fat distribution. *Insights into Imaging*, *11*(1), 1–17. <https://doi.org/10.1186/S13244-019-0833-4/FIGURES/20>
- Ye, Y., Zhou, Q., Dai, W., Peng, H., Zhou, S., Tian, H., Shen, L., & Han, H. (2023). Gender differences in metabolic syndrome and its components in southern china using a healthy lifestyle index: a cross-sectional study. *BMC Public Health*, *23*(1), 1–11. <https://doi.org/10.1186/S12889-023-15584-0/TABLES/3>
- Yoon, H., Shaw, J. L., Haigis, M. C., & Greka, A. (2021). Lipid metabolism in sickness and in health: emerging regulators of lipotoxicity. *Molecular Cell*, *81*(18), 3708.
<https://doi.org/10.1016/J.MOLCEL.2021.08.027>
- Zhang, D. M., Jiao, R. Q., & Kong, L. D. (2017). High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. *Nutrients*, *9*(4), 335.
<https://doi.org/10.3390/NU9040335>
- Zhang, H., Jiang, Z., & Zhang, L. (2019). Dual effect of T helper cell 17 (Th17) and regulatory T cell (Treg) in liver pathological process: From occurrence to end stage of disease. *International Immunopharmacology*, *69*, 50–59. <https://doi.org/10.1016/J.INTIMP.2019.01.005>

- Zhang, Y., Jia, X. Bin, Liu, Y. C., Yu, W. Q., Si, Y. H., & Guo, S. D. (2022). Fenofibrate enhances lipid deposition via modulating PPAR γ , SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet. *Frontiers in Nutrition*, *9*, 971581. <https://doi.org/10.3389/FNUT.2022.971581/BIBTEX>
- Zhao, Y., Wang, Q. Y., Zeng, L. T., Wang, J. J., Liu, Z., Fan, G. Q., Li, J., & Cai, J. P. (2022). Long-Term High-Fat High-Fructose Diet Induces Type 2 Diabetes in Rats through Oxidative Stress. *Nutrients*, *14*(11), 2181. <https://doi.org/10.3390/NU14112181/S1>
- Zheng, J., Feng, Q., Zhang, Q., Wang, T., & Xiao, X. (2016). Early Life Fructose Exposure and Its Implications for Long-Term Cardiometabolic Health in Offspring. *Nutrients*, *8*(11), 685. <https://doi.org/10.3390/NU8110685>
- Zhou, J., Li, D., & Cheng, Q. (2020). Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. *Medicine*, *99*(21), e20390. <https://doi.org/10.1097/MD.00000000000020390>
- Zhou, L. Y., Deng, M. Q., Zhang, Q., & Xiao, X. H. (2020). Early-life nutrition and metabolic disorders in later life: a new perspective on energy metabolism. *Chinese Medical Journal*, *133*(16), 1961. <https://doi.org/10.1097/CM9.0000000000000976>
- Zoccali, C., Mallamaci, F., Adamczak, M., De Oliveira, R. B., Massy, Z. A., Sarafidis, P., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., Wanner, C., Burnier, M., Vanholder, R., & Wiecek, A. (2023). Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. *Cardiovascular Research*, *119*(11), 2017–2032. <https://doi.org/10.1093/CVR/CVAD083>

2.10 Lycopene: A potent antioxidant with multiple health benefits – Published review article

Mercy Omoye Shafe, Nontobeko Myllet Gumede, Trevor Tapiwa Nyakudya,

and Eliton Chivandi

(2024)

Journal of Nutrition and Metabolism Volume 2024, Article ID 6252426, 17 pages

<https://doi.org/10.1155/2024/6252426>

2.10.1 Summary

Lycopene is a naturally occurring carotenoid predominantly found in tomatoes and tomato-based products. Like other phytochemicals, it exhibits health beneficial biological activities that can be exploited when it is used as a dietary supplement. *In vitro* and *in vivo*, lycopene has been demonstrated to mitigate oxidative stress-induced metabolic dysfunctions and diseases including inflammation, obesity, and diabetes mellitus. Lycopene has been shown to alleviate metabolic diseases that affect the bone, eye, kidney, liver, lungs, heart, and nervous system. This review presents the state of the art regarding lycopene's health benefits and its potential applications in health system delivery. Furthermore, lycopene's protective effects against toxins, safety in its use, and possible toxicity are explored.

2.10.2 Introduction

The use of medicinal plants has deep historical roots, ingrained in the traditional healing practices of diverse cultures worldwide (Petrovska, 2012). Throughout centuries, indigenous communities and ancient civilizations have harnessed the therapeutic properties of plants, passing down invaluable knowledge through generations (Rasool Hassan, 2012). Ethnomedicine, a field dedicated to studying traditional medicinal practices, has played a crucial role in documenting this wealth of wisdom. The effectiveness of ethnomedicinal plants in disease management is attributed to their constituent bioactive phytochemicals, such as carotenoids, which are known to have multiple health benefits (Upadhyay & Dixit, 2015). Lycopene, a fat-soluble carotenoid, is one of the most abundant and important carotenoids (Arballo et al., 2021). It has potent antioxidant activity (Przybylska, 2020). This carotenoid, a bioactive organic pigment, is found in pink grapefruit, papaya, guava, apricot, watermelon, and vegetables but is highly concentrated in tomatoes and tomato-derived products (Bin-Jumah et al., 2022). It has been reported to be one of the strongest antioxidants among carotenoids (Imran et al., 2020). As one of the most potent antioxidants, its capacity to neutralise singlet oxygen is double that of β -carotene, ten times greater than that of α -tocopherol, and one hundred and twenty-five times more effective than glutathione (Przybylska, 2020). Lycopene, isolated from *Lycopersicon esculentum* (tomato) in 1903, was named after the fruit from which it was isolated (Joshi et al., 2020). More than 85% of the lycopene in the diet is derived from tomatoes and tomato-based products (Joshi et al., 2020). In addition to fruits and vegetables, lycopene is also found in some food ingredients, as shown in Table 2.2

(Bramley, 2000; Shi & Le Maguer, 2000). While overall tomatoes are a good source of lycopene, research has demonstrated that different tomato and other fruit varieties have different lycopene content (Imran et al., 2020). In addition to varietal differences, the microenvironment in which the tomato and or other lycopene-containing fruit are grown, for example,

Table 2. 2: Lycopene concentration in fresh fruits and processed food products

Fruit/processed food product	Lycopene content (mg/100g)
Apricot	0.11-5.3
Fresh tomatoes	0.72-4.2
Carrot	0.65-0.78
Cooked tomatoes	3.70
Fresh tomatoes	0.72-4.2
Ketchup	9.90-13.44
Papaya	0.11-5.3
Pink grapefruit	0.35-3.36
Pink guava	5.23-5.5
Pumpkin	0.38-0.46
Rosehip	0.68-0.71
Sweet potato	0.02-0.11
Tomato paste	5.40-150
Tomato sauce	6.20
Watermelon	2.30-7.20

Source: Bramley, 2000; Shi & Le Maguer, 2000

temperature, humidity, edaphic conditions, and fruit maturity status at harvest also influence lycopene content (Grabowska et al., 2019). Where the soil microbiome has favourable microbes, a 36% increase in lycopene has been reported (Grabowska et al., 2019).

Several studies have investigated the potential of lycopene to mitigate risk factors for obesity, type 2 diabetes mellitus, and cardiovascular diseases; conditions characterised by dyslipidaemia, oxidative stress and inflammation (Świątkiewicz et al., 2023). These studies have shown that lycopene improved outcomes of these metabolic diseases (Abir et al., 2023a). Lycopene, known for its antioxidant properties, has been found to reduce oxidative stress, a significant contributor to the development of metabolic diseases (Guo et al., 2023). Additionally, it has been shown to mitigate inflammation and dyslipidaemia, thereby reducing the risk of cardiovascular diseases and insulin resistance (Rane et al., 2019; Tierney et al., 2020). Research suggests that regular consumption of lycopene as a dietary supplement can potentially remediate insensitivity to insulin, hypertension, and obesity-related metabolic complications (Mounien et al., 2019; Rejali et al., 2022).

2.10.3 Lycopene: Biochemistry and physical properties

In nature, over 750 carotenoids have been identified (Arunkumar et al., 2020). About 40 to 50 are found in the human diet, and lycopene is the sixth most common carotene in food products (Doyle, 2020; Meléndez-Martínez, 2020). Two main categories of carotenoids exist: hydrocarbon carotenoids and xanthophylls. Hydrocarbon carotenoids such as α , β -, and γ -carotene lycopene are made up of hydrogen and carbon, while xanthophylls, for example, lutein, β -cryptoxanthin, and zeaxanthin, contain oxygen along with carbon and hydrogen (Holzapfel et al., 2013; Arballo et al., 2021). Lycopene, as an aliphatic straight-chain hydrocarbon, contains two unconjugated double bonds and 11 conjugated bonds (Kumar et al., 2017). Its conjugated double bonds are subject to isomerization through heat, light, and chemical reactions (Doyle, 2020). Lycopene is found in *trans*- and *cis*-isomers, but the *cis*-isomers are better absorbed and have greater bioavailability than *trans*-lycopene (Zhu et al., 2020; Caseiro et al., 2020). *All-trans*, *5-cis*, *9-cis*, *13-cis*, and *15-cis* are the most common forms of lycopene isomers, and the *5-cis* isomer is the most stable isomer (Rao & Rao, 2007; Honda et al., 2017). The molecular structure and physical properties of lycopene are shown in Figure 2.1 (Gupta et al., 2018) and Table 2.2, respectively (Amjad et al., 2020; Joshi et al., 2020).

2.10.4 Lycopene: Absorption, transportation, and distribution

Following ingestion, lycopene released from the food matrix combines with micelles containing bile salts, cholesterol, and fatty acids (Story et al., 2010) and is then absorbed. Due to its hydrophobicity, the dissolution of lycopene within micelles in the small intestines facilitates its absorption (Przybylska, 2020) through the passive diffusion of lipids across the unstirred water layer in the enterocytes (Yeap et al., 2013). Inside the absorptive enterocyte, lycopene, together with free fatty acids, monoglycerides, and fat-soluble vitamins, is packaged into chylomicrons and released into the lymphatic system for transportation into the bloodstream and liver (Kumar et al., 2017). A fibre-rich diet has been proven to decrease the absorption of lycopene. Such fibrous diets also mediate the adsorption of lycopene, resulting in an over 40% reduction in plasma lycopene (Failla et al., 2008). Several factors, among them alcohol, smoking, gender, age, hormonal status, and other dietary elements, affect the absorption of lycopene (Caseiro et al., 2020). As healthy individuals grow older, the bioavailability of lycopene tends to decrease, possibly due to age-related structural changes in the gastrointestinal tract that result in reduced absorptive efficiency (Durairajanayagam et al., 2014). Humans absorb about 10% to 30% of dietary lycopene; the rest is excreted through faeces (Durairajanayagam et al., 2014; Joshi et al., 2020). The lycopene in heated and processed tomato products is better absorbed compared to that from fresh, unprocessed tomatoes (Doyle, 2020). Thermal exposure during cooking and processing of lycopene-containing foods breaks the food matrix and converts the natural (all-trans) lycopene structure to its *cis* geometric isomer, which is 2.5 times better absorbed from the gastrointestinal tract (Chauhan et al., 2011; Petyaev, 2022). Following its absorption from the small intestines, lycopene is distributed to the various body tissues (Durairajanayagam et al., 2014). The assimilation of lycopene by the tissues from lipoproteins is mediated by certain membrane receptors known as scavenger receptor class B type 1 (SR-B1) and cluster of differentiation 36 (CD36) (Arballo et al., 2021). In humans, the concentration of lycopene in the testes is ten times greater than that found in other tissues (Joshi et al., 2020). This high concentration in the testes is followed by its concentration in the adrenal gland, liver, prostate, breast, pancreas, skin, colon, ovary, lung, stomach, kidney, adipose tissue, and cervix (Joshi et al., 2020). However, *cis*-lycopene is mainly distributed in the liver and adipose tissue (Zhu et al., 2020). Table 2.4 illustrates the concentration of lycopene in various human tissues (Rao & Agarwal, 2000; Kaur et al., 2017). Lycopene, the primary carotenoid found in human plasma, exhibits a half-life of approximately 2 to 3 days. Its

concentration in plasma and tissues ranges between 0.2-21.4 nmol/g and 0.15-21.36 nmol/g, respectively (Rao & Agarwal, 2000; Joshi et al., 2020). In their study, Zaripheh et al. (2003) reported that in rats, lycopene was most concentrated in the liver, adipose tissue, adrenal tissue, and spleen.




Figure 2. 1 : Molecular structure of lycopene

Table 2. 3: Physical properties of lycopene

Property	Value/Normal range
Boiling point	660.9°C at 760mmHg
Crystal form	Long red needles separate from a mixture of carbon disulfide and Ethanol
Density	0.889 gm. /cm ³
Flash point	350.7°C
Main hazards	Combustible
Melting Point	172-175 °C
Molecular Weight	536.85 Da
Powder form	Dark reddish-brown
Refractive index	1.531
Solubility	Soluble in chloroform, hexane, benzene, carbon disulfide, acetone, petroleum, tetrahydrofuran, carbon disulphide, ether, and oil; Insoluble in water, ethanol, and methanol
Stability	Sensitive to light, oxygen, high temperature, acids, catalyst, and metal ions
Vapour pressure	$1.33 \cdot 10^{-16}$ mmHg (25°C)

Source: Amjad et al., 2020; Joshi et al., 2020.

Table 2. 4: Lycopene concentration in some human tissues

Tissue	Lycopene (nmol/g wet weight)
Adipose	0.2-1.3
Adrenal	1.9-21.6
Brainstem	Not detectable
Breast	0.8
Colon	0.3
Liver	1.3-5.7
Lung	0.2-0.6
Ovary	0.3
Prostate	0.8
Skin	0.4
Stomach	0.2
Testis	4.4-21.4

Source: Rao & Agarwal, 2000; Kaur et al., 2017

2.10.5 Lycopene autoxidation

Known to be thermolabile, lycopene undergoes auto-oxidation when exposed to both light and oxygen (Kumar et al., 2017). The heat, light, and oxygen-induced lycopene degradation gives rise to acetone, methyl-heptenone, laevulinic aldehyde, and glycoxal, a colourless compound that produces a grass-like smell (Kumar et al., 2017). In addition to the attractive colour of the final lycopene degradation products, their biodegradation also affects their flavour and nutritive value (Tahmasebi & Emam-Djomeh, 2021).

2.10.6 Biological activities of lycopene

The meta-analyses and clinical trials of lycopene in human studies are shown in Table 2.5 below.

Table 2. 5: Meta-Analyses and Clinical Trials of Lycopene in Human Studies

Biological effects	Mechanisms of action	References
Anticancer	Suppressed cell proliferation, induced cell cycle arrest and increased apoptosis in breast cancer cell lines.	(Gloria et al.,2014)
	Decreased insulin-like growth factor-1 (IGF-1) and increased apoptosis in prostate cancer cell.	(Tjahjodjati et al., 2020)
Cardioprotection	Enhanced endothelial function and decreased triglyceride levels in patients with ischemic heart failure.	(Karimian et al., 2022)
	Increased flow-mediated dilation and total oxidative status decreased	(Xaplanteris et al., 2012)
	Increased HDL, Paraoxonase-1 (PON-1), Lecithin cholesterol acyltransferase (LCAT), decreased serum amyloid A (SAA) and cholesteryl ester transfer protein (CETP) activities	(McEneny et al., 2022)
Antidiabetic	Reduced levels of fasting blood glucose in patients with type 2 diabetes mellitus	(Inoue et al., 2023)
	Decreased glycated haemoglobin (HbA1c) levels and fasting blood glucose concentration	(Leh et al., 2021)
Anti-inflammatory	Inhibited NF-kB and c-Jun N-terminal kinase (JNK) activation. Suppressed the expression of COX-2, iNOS, TNF- α , IL-1 β and IL-6	(Cha et al., 2017)
Antioxidant	Increased bone mineral density	(Sahni et al., 2009)
	Increased SOD, GSH-px and decreased MDA	(Xu et al., 2019)

Sperm quality enhancement and fertility promotion	Decreased lipid peroxidation and fragmentation of sperm DNA	(Ghyasvand et al., 2015)
	increased arachidonic acid to docosahexaenoic acid ratio	(Filipcikova et al., 2015)
	Reduced oxidative stress and enhanced sperm quality	(Nouri et al., 2019)
Hepatoprotection	Protection against steatosis and liver damage	(Donghia et al., 2024)
	Regulated oxidative stress and liver enzyme levels in individuals with metabolic syndrome.	(Mirahmadi et al., 2023)
Antiobesity	Decreased body weight, BMI, waist circumference, total cholesterol, and increased HDL levels	(Yao et al., 2021)
Reno-protection	Elevated levels of serum lycopene reduce the risk of mortality in individuals with CKD	(Zhong et al., 2022)
	Increased consumption of lycopene decreased the occurrence of CKD in women	(Shi et al., 2024)
Lung protection	Decreased airway neutrophil influx and decreased activity of neutrophil elastase in sputum.	(Wood et al., 2008)
	Increased SOD, CAT and decreased MDA, TNF- α , IL-1 β and IL-6 levels in chronic obstructive pulmonary disease (COPD)	(Kırkıl et al., 2012)
Neuroprotection	Elevated serum levels of lycopene are associated with a decreased risk of Alzheimer's disease (AD) mortality in adults.	(Min & Min, 2014)
	Enhanced cognitive function in middle age	(Kesse-Guyot et al., 2014)
Gastroprotection	Decreased bleeding index and reduction in the percentage of gingivitis.	(Chandra et al., 2007)
	Increased consumption of lycopene improved bowel	(Wang et al., 2023)

	function and helped prevent chronic constipation	
Osteoprotection	Stimulated WNT/ β -catenin and ERK1/2 pathways, increased the expression of RUNX2, alkaline phosphatase, and COL1A and decreased RANKL in Saos-2 cells.	(Russo et al., 2020)
	Increased total antioxidant capacity, decreased lipid peroxidation, protein oxidation and N-telopeptide of type 1 collagen	(MacKinnon et al., 2011)

2.10.6.1 Antiobesity effects

Obesity results from an excessive buildup of body fat. It has a detrimental effect on a person’s metabolic health and overall well-being (Albrahim & Robert, 2022). The development of obesity is influenced by a variety of factors with complicated origins that involve psychological, environmental, socioeconomic status, and biological components (Sommer et al., 2015; Franks and McCarthy, 2016; Zenebe & Caroline, 2018). The risk of cardiovascular diseases, cancer, depression, dyslipidaemia, type 2 diabetes mellitus, non-alcoholic fatty liver diseases (NAFLD), and hypertension is heightened in obese individuals (Brahimaj et al., 2019; Lavie et al., 2021; Lazarus & Edward, 2022; Overby & Ferguson, 2022). Obesity elevates the prevalence of oxidative stress by disrupting the balance between oxidants and antioxidant activity (Masschelin et al., 2020), which leads to the presence of “unpaired mitochondria” (individual mitochondria within a cell that have not fused or aligned with others to form interconnected networks) and an upsurge in reactive oxygen species (Israel et al., 2021). Consequently, the normal functioning of adipose tissue is disrupted, resulting in an increased production of adipocytokines and a reduction in adiponectin levels, which contribute to the occurrence of metabolic syndrome (Hasan et al., 2018; Naomi et al., 2023). Numerous studies have reported on the health-beneficial antioxidant activity of lycopene. In male Wistar rats exposed to a high-fat diet for 12 weeks, supplementation with lycopene at 25 mg/kg body weight for a period of 4 weeks was shown to reduce plasma interleukin 6 (IL-6), tumour necrosis factor alpha (TNF- α), leptin, very low-density lipoprotein (VLDL), low-

density lipoprotein (LDL), and total cholesterol (TC), but it elevated plasma high-density lipoprotein (HDL) levels (Baz et al., 2022). The supplemental lycopene also reduced malondialdehyde (MDA) concentration but increased hepatic superoxide dismutase (SOD) and catalase (CAT) activities in the liver tissue, demonstrating that it (lycopene) potentially is a potent antioxidant that decreases hepatic oxidative stress by increasing systemic antioxidant and enzymes activities (Baz et al., 2022). Pre- and/or post-weaning supplementing Sprague-Dawley rat pups whose dams were fed a high-fat diet with lycopene at 1% improved the offspring's brown adipose tissue (BAT) development, reduced accumulation of white adipose tissue (WAT), and enhanced serum antioxidant capacity and blood glucose homeostasis (Senkus et al., 2021). In mice fed a high-fat diet, lycopene was shown to improve glucose and lipid metabolism and decrease body weight gain by stimulating WAT browning and activating BAT through modulation of peroxisome proliferator-activated receptor gamma (PPARG) (Zhu et al., 2020). In another study, where lycopene was administered at 25 and 50 mg/kg body weight for 3 months to male Wistar rats, results showed increased HDL, improved antioxidant, and oxidant biomarkers, decreased triglycerides (TG), LDL, apolipoprotein-B (Apo-B), and β -hydroxybutyrate, but boosted hepatic PPARG levels (Albrahim & Alonazi, 2021). Furthermore, tomato oleoresin, which contains 10 mg/kg body weight of lycopene, when orally administered to male Wistar rats for 6 weeks, mediated a significant increase in the expression of messenger RNA (mRNA) of adiponectin, forkhead box 01 (Fox01), fatty acid translocase/cluster of differentiation 36 (FAT/CD36), and sirtuin 1 (SIRT1), but downregulated PPARG expression in the adipose tissue of obese rats (Luvizotto et al., 2015).

2.10.6.2 Antioxidant effects

Oxidative stress is recognised as a significant contributing factor to an increased risk of cancer, the onset and progression of various metabolic and chronic disorders (Sharifi-Rad et al., 2020). The concept of oxygen radicals has been established for the past 50 years; however, its role in the advancement of diseases was discovered in the past two decades (Liu, 2020). In several biological processes that are vital for life, free radicals play an important role, such as the destruction of intracellular bacteria by phagocytes like macrophages and granulocytes (Sharifi-Rad et al., 2020). Excessive production of reactive oxygen species (ROS) causes protein, deoxyribonucleic acid (DNA), and lipid damage (Andrés et al., 2021). Damage to these cellular molecules leads to tissue

injury and interruption of vital cellular processes (Klran et al., 2023). Consuming diets rich in antioxidants or supplementing with bioactive molecules such as vitamins, tannins, and carotenoids may offer protection against oxidative damage (Gu et al., 2008). Carotenoids like lycopene are potent antioxidants that inhibit or hinder the advancement of diverse disorders triggered by ROS (Przybylska, 2020). Carotenoid antioxidant activity has been investigated in multilamellar liposomes by measuring the inhibition of the formation of thiobarbituric acid-reactive substances. Lycopene was shown to be the most potent antioxidant in the sequence: lycopene, γ -tocopherol, astaxanthin, canthaxanthin, α -carotene, β -carotene, bixin, zeaxanthin, lutein, α -tocopherol, glutathione, cryptoxanthin, crocin, and lipoic acid (Joshi et al., 2020; Leh & Lee, 2022). Lycopene attenuates ROS effects through radical addition or adduct formation, electron transfer to the radical, and allylic hydrogen abstraction (Bin-Jumah et al., 2022), and radical addition and allylic hydrogen abstraction contribute to its antioxidant effects (Santos-Sánchez et al., 2019). Lycopene has been reported to enhance the status of enzymatic (catalase, superoxide dismutase, and peroxidase) and non-enzymatic antioxidants like vitamins C and E from their radicals by increasing the cellular antioxidant defence system (Durairajanayagam et al., 2014). In addition, lycopene acts as an antioxidant in systems that produce singlet oxygen but behaves as a pro-oxidant in systems that create peroxide (Black et al., 2020). In low doses, it acts as an antioxidant, but at high doses, it acts as a pro-oxidant (Elvira-Torales et al., 2019). Factors such as lycopene concentration, tissue oxygen tension, and interaction with other antioxidants have been reported to influence the pro-oxidant potency of lycopene (Bin-Jumah et al., 2022). In situation where there is an imbalance between antioxidant defences and ROS production, such as during inflammation or exposure to environmental toxins (Poljšak & Fink, 2014), lycopene may switch from its antioxidant role to a pro-oxidant role (Black et al., 2020). Under these conditions, lycopene radicals may contribute to oxidative stress by reacting with cellular components and promoting further ROS generation (Lucas et al., 2022). Studies have suggested that under conditions of low oxygen levels, its antioxidant properties predominate (Saini et al., 2020; Varela et al., 2022).

2.10.6.3 Hypocholesterolaemic effects

An imbalance in the level of cholesterol in the body results in a lipid disorder known as hypercholesterolemia, a notable risk factor for atherosclerosis and related conditions such as coronary and cerebrovascular diseases (Gidding & Allen, 2019; Vaduganathan et al., 2022).

Several animal and human trials have investigated the association between lycopene and cholesterol. Male broiler chickens fed a standard grower diet supplemented with lycopene at 100 mg/kg body weight for three weeks had significantly reduced serum total cholesterol, triglyceride, very low-density lipoprotein, and increased high-density lipoprotein content compared with counterparts fed the control diet (Mezbani et al., 2019). In apolipoprotein E knockout mice fed a high-fat diet and lycopene supplementation at 60 mg/kg body weight daily for fourteen weeks, the administered lycopene significantly decreased both total cholesterol and triglycerides, beginning from the sixth week to the end of the experiment (Kim et al., 2022). Similarly, male Wistar rats given a high-fat diet and 50 mg/kg body weight of lycopene daily for three months had significant reductions in plasma total cholesterol, triglycerides, and low-density lipoprotein levels but increased high-density lipoprotein cholesterol compared to the group given a high-cholesterol diet (Albrahim, 2022). The reported cholesterol-lowering effects of lycopene are attributed to reduced cholesterol synthesis through the inhibition of the expression and activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and the modulation of LDL receptor activity (Palozza et al., 2012). The findings obtained from human studies have been inconsistent. In a systematic review and meta-analysis of 12 and 11 trial arms consisting of 781 and 854 participants, respectively, supplementation of lycopene significantly increased HDL-cholesterol levels when compared to the control group; however, no significant difference was observed in the triglyceride levels (Inoue et al., 2021). The conflicting findings observed from human studies could be attributed to the differences in study design, characteristics of the populations under investigation, and the source and dose of lycopene utilised (Tierney et al., 2020; Rattanavipanon et al., 2021).

2.10.6.4 Hepatoprotection

In a healthy human adult, the liver weighs approximately 1.5kg and is the largest gland and visceral organ (Beyoğlu & Idle, 2020). It plays a vital role in metabolic processes such as bile production, digestion, detoxification of xenobiotics, metabolism of lipids, proteins, carbohydrates, immune regulation, and storage of vitamins (Kalra et al., 2022; Mohammed, 2022). Among the major causes of global mortality is liver disease (Seto & Mandell, 2021). Liver diseases may be caused by several factors; viral infections, ischemia, alcohol-induced damage, autoimmune diseases, and genetic defects such as alpha-1 antitrypsin deficiency, hereditary hemochromatosis, citrin deficiency, hereditary fructose intolerance, cystic fibrosis, cholesteryl ester storage disease, type

IV glycogen storage disease, and Wilson disease (Scorza et al., 2014; Kong et al., 2019; Bouche-careilh, 2020). Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease (Pouwels et al., 2022). Globally, the prevalence of NAFLD is about 25%, 13%, 23%, and 32% in Africa, Europe, and the Middle East, respectively (Maurice & Manousou, 2018). This disease is characterised by the accumulation of macrovesicular steatosis in $\geq 5\%$ of hepatocytes without secondary causes such as alcohol intake, drugs, or liver diseases (Maurice & Manousou, 2018; Spiers et al., 2022). Patients with type 2 diabetes, dyslipidaemia and obesity are at increased risk of developing NAFLD (Han et al., 2023). Recent studies have shown that consumption of carotenoids such as lycopene can remarkably reduce the chances of developing liver diseases such as NAFLD (Elvira-Torales et al., 2019). In their study, Li et al. (2018), using beta-carotene-15,15'-oxygenase and beta-carotene-9',10'-oxygenase double knockout mice, the oral administration of lycopene at 2.3 mg/g for 24 weeks resulted in significantly decreased severity of hepatic steatosis and triglyceride levels but significantly increased sirtuin 1 and fatty acid oxidation compared to control counterparts fed a high-fat diet. Furthermore, lycopene mediated a decrease in inflammation. In a tramadol-induced hepatotoxicity rat model, supplemental lycopene at 15 mg/kg body weight for 15 days mitigated the hepatotoxicity by increasing antioxidant activity, reducing fatty acid breakdown and necrosis, lipid peroxidation, inhibiting DNA fragmentation, and apoptosis (Sadek et al., 2018) (Kadry et al., 2018). Lycopene administered at 5, 10, and 20 mg/kg body weight for 6 weeks in a rat model of NAFLD was shown to mediate hepatoprotective effects, as seen with reduced activities of aspartate transaminase and alanine transaminase and concomitant reductions in malondialdehyde, free fatty acids, and LDL cholesterol concentrations (Jiang et al., 2016). These findings were associated with elevated hepatic superoxide dismutase and glutathione concentrations, but with reduced cytochrome P450 2E1 and tumour necrosis factor-alpha expression and decreased hepatic fat (Jiang et al., 2016). The above-mentioned experimental studies provide a clear insight that the administration of lycopene not only inhibits ROS but also improves the activity of antioxidant enzymes, thereby providing beneficial effects against NAFLD.

2.10.6.5 Renoprotection

Chronic kidney diseases (CKD) have become a global public health issue, affecting more than 200 million people worldwide (Gori et al., 2021). Chronic kidney disease is a common term used to describe different disorders that permanently affect the structure and function of the kidneys for

over a period of three months (Santos-Araújo et al., 2023). This can be diagnosed when the abnormalities in kidney or glomerular filtration rate are lower than 60 ml/min/1.73m² and albuminuria is characterised by an albumin to creatinine ratio above 30 mg/g (Jankowski et al., 2021). Patients with CKD are more prone to developing end-stage renal disease, a condition that requires expensive management by either dialysis or kidney transplantation (Hasan et al., 2018). Patients suffering from CKD commonly display a high incidence of arrhythmias, venous thromboembolism, heart failure, and ischemic heart disease, which significantly increase mortality (Virani et al., 2020; Warrens et al., 2022). The increase in the prevalence of cardiovascular disease (CVD) in CKD patients is associated with oxidative stress, chronic inflammation, and vascular endothelial dysfunction (Ravarotto et al., 2018). These three factors create an intricate cycle, resulting in pathological variations and playing a crucial role in the initiation and progression of CVD in CKD patients (Akchurin, 2015; Rapa et al., 2019). Among these factors, oxidative stress is a key mediator in the intricate pathways linked to the progression of CKD (Rapa et al., 2019). As a result, the utilisation of antioxidant therapy is one of the significant approaches to averting and mitigating the advancement of CKD (Zhong et al., 2022). Lycopene is a potent antioxidant and an efficient free radical scavenger that has been investigated and shown to protect the kidney against chemically induced damage (El-Karm, 2019; Bedir et al., 2021). In female Wistar rats fed a high-fat diet, the supplementation of 200 ml of lycopene extract twice a week for 8 weeks significantly reduced plasma creatinine, urea, serum angiotensin-converting enzymes, renal tissue malondialdehyde, and C-reactive protein levels but increased total protein and tissue antioxidant enzyme levels (Khan et al., 2016). Shams et al. (2015) observed that lycopene protected against the advancement of diabetic nephropathy and improved renal function by inhibiting the advanced glycation product and its receptors (AGE-RAGE) pathway. Lycopene has been shown to inhibit LDL-cholesterol peroxidation, which can damage the kidneys (Zhong et al., 2022). Furthermore, supplemental lycopene was shown to decrease MDA, RAGE, and TNF- α levels in the kidneys of male Wistar rats fed a high fat diet for 6 weeks (Pierine et al., 2014), and similarly, lycopene orally administered at 25 and 50 mg/kg body weight daily for 3 months protected the kidneys of male Wistar rats fed a high fat diet by inhibiting the expression of nuclear factor kappa B, interleukin 1 beta, tumour necrosis factor alpha, decreasing oxidative stress, increasing nuclear factor erythroid 2-related factor 2, and stimulating B-cell lymphoma 2, hence shielding kidney tissue against damages (Albrahim & Robert, 2022).

2.10.5.6 Osteoprotection

Oxidative stress caused by reactive oxygen species influences the activity of both osteoclasts and osteoblasts (Antioksidan et al., 2017). This is thought to impact the pathogenesis of skeletal system disorders, including osteoporosis, the most common skeletal metabolic disease (Mehta et al., 2018). Osteoporosis often develops in older adults and is characterised by an alteration of the bone microarchitecture, typified by a decline in bone mineral density, which contributes to an elevated risk of fractures (Erdayanti et al., 2022). Such bone fractures notably occur at the distal forearm, vertebral column, and proximal femur (Cauley et al., 2014). Complications associated with osteoporosis, particularly hip fractures, result in a mortality rate that is four times higher in the global adult population (Erdayanti et al., 2022). Despite its preponderance in the elderly, osteoporosis has been shown to impact individuals of various age groups, but postmenopausal women are at high risk (Shaki et al., 2021; Bhatnagar & Kekatpure, 2022), due to a decrease in estrogen production which results in increased oxidative stress and osteoclast-induced bone resorption (Shihab et al., 2018). Studies have shown that children born to parents with a history of osteoporosis and fractures are more prone to the development of osteoporosis (Walallawita et al., 2020). In addition to genetic predisposition, poor nutrition, excessive alcohol consumption, smoking, caffeine intake, and medication side effects, for example, glucocorticoids can cause the development of osteoporosis (Tu et al., 2018; Godos et al., 2022; Muñoz-garach & Garc, 2020; Wang et al., 2022). Lycopene has been shown to have an advantageous effect on skeletal health (Xu et al., 2017). It has been shown to play a vital role in protecting postmenopausal women from experiencing bone loss by upregulating alkaline phosphatase, type 1A collagen, runt-related transcription factor 2, triggering the activation of the wntless-related integration site/beta-catenin and extracellular signal-regulated kinase 1/2 pathways, and downregulating receptor activator of nuclear factor kappa-B ligand (Transl et al., 2020). In mice fed a high-fat diet, supplemental lycopene at 15 mg/kg body weight for 10 weeks increased serum levels of total antioxidant capacity (T-AOC), SOD, and reduced the levels of MDA and AGEs, RAGE, and NF-kB expressions in the tibias and femurs (Xia et al., 2022). In male albino rats, orally administered lycopene at 30 mg/kg body weight once daily over an 8-week period mitigated glucocorticoid-induced osteoporosis (Mityas et al., 2019), and in diabetic male rats, lycopene suppressed bone resorption, enhanced osteoprotegerin and RANKL expression ratios by preventing oxidative

damage and reducing inflammation (Shan et al., 2021). These research findings demonstrate that lycopene has osteoprotective properties.

2.10.6.7 Anti-inflammatory effects

Inflammation is an immune response mechanism that is triggered when exposed to various harmful stimuli, such as damaged cells, microorganisms, poisonous and allergenic substances (Chen et al., 2018). It serves as a crucial stage in the process of tissue regeneration, repair, and remodelling, as well as the restoration of tissue haemostasis in impaired areas (Greten et al., 2020). Inflammatory mediators include the cytokines interleukin (IL)-1, IL-5, IL-6, IL-12, IL-1 β , TNF- α , and interferon γ (Molnar et al., 2021), and chemokines like IL-8, monocyte chemoattractant protein 1, cyclooxygenase, vascular cell adhesion molecule 1, matrix metalloproteinase, free radicals, growth factors, and prostaglandins serve as regulatory mediators in the process of inflammation (Fernandes et al., 2015). On stimulation, these mediators activate endothelial cells, causing increased vascular permeability and the deployment of neutrophils, eosinophils, monocytes, and mast cells to the injury site, which helps eliminate the harmful agents and facilitate the healing process (Khan et al., 2021). However, inflammation is known to contribute to the development and progression of various diseases, including but not limited to CKD, cancer, diabetes mellitus, cardiovascular disease, NAFLD, obesity, asthma, rheumatoid arthritis, osteoporosis, autoimmune, and neurodegenerative disorders (Zhong & Shi, 2019; Franceschi et al., 2020; Agca et al., 2022). The consumption of natural antioxidants for maintaining human health has become popular, especially in developed nations (Karaköy et al., 2022). In a study using female Wistar rats, lycopene was shown to alleviate palmitic acid-induced neuro-inflammation by reducing oxidative stress and inhibiting the toll-like receptor 4 (TLR4) and nuclear factor kappa-B p65 (NF- κ B p65) signalling pathways (Ugbaja et al., 2021). Lycopene supplementation mitigated metalaxyl-induced liver damage in male albino rats by restoring antioxidant status, improving liver function, and alleviating liver injury-associated complications (Hassan et al., 2018). In lycopene-treated endothelial cells, lycopene inhibited the activation of TNF- α but enhanced the expression of heme oxygenase-1 (HO-1) through the upregulation of nuclear factor erythroid 2-related factor 2 signalling pathways (Yang et al., 2017). Another experimental study reported that in male albino rats, orally administered lycopene at 10 mg/kg body weight for 21 days effectively protected the colon epithelial mucosa against acetic acid-induced colitis and oxidative injury (Hussein et al.,

2020). In C57BL/6 mice chronically exposed to cigarette smoke for 60 days, lycopene was shown to restore redox status and mitigate hepatic inflammation (Fonseca et al., 2021). In addition, Li et al. (2023) reported that lycopene mitigated the dysregulation of lipid metabolism and the inflammatory response induced by lipopolysaccharide in the rat testes. Thus, evidence is plentiful demonstrating the anti-inflammatory effects of lycopene both *in vitro* and *in vivo*.

2.10.6.8 Antidiabetic effects

Diabetes mellitus (DM) causes hyperglycaemia and, if inadequately managed, can result in damage to the heart, eyes, and kidneys (Saeedi et al., 2019). The global prevalence of diabetes is approximately 9.3%, which corresponds to about 463 million individuals. However, it is predicted to rise by 25% in 2030 and 51% in 2045 (Arroo & Brunelle, 2023). Diabetes mellitus is classified into three major types: type 1 (insulin-dependent), type 2 (non-insulin-dependent), and gestational diabetes mellitus (Sakran et al., 2022). Among these, type 2 diabetes mellitus predominates and accounts for about 90% of all cases worldwide (Saeedi et al., 2019).

Scientific evidence shows that lycopene can potentially be used to prevent and treat diabetes mellitus (Zhu et al., 2020). In streptozotocin-induced diabetes model, dietary fortification with lycopene mediated increased serum insulin concentrations, decreased urine and blood sugar concentrations, and reduced diabetes-induced pancreatic injury (Ozmen et al., 2016). In diabetic Wistar rats, orally administered lycopene at 40 mg/kg body weight significantly decreased serum MDA, cortisol, and blood glucose concentration but increased SOD, CAT, and glutathione peroxidase (GSH-Px) activities at 10, 20, and 40 mg/kg body weight (Eze et al., 2018). Furthermore, supplemental lycopene was shown to attenuate renal damage in diabetic rats (Xie et al., 2022). In STZ-induced diabetic rats, at 4 mg/kg body weight, lycopene ameliorated B-cell lymphoma-extra-large and B-cell lymphoma 2 (Bcl-2) concentrations and reduced the expression of Bcl-2-associated X protein (BAX) in the hippocampus (Soleymaninejad et al., 2017). Interestingly, orally administered lycopene was shown to increase SOD and GSH-Px activities and lower MDA concentrations in rat pancreatic tissue (Yin et al., 2019), but it mediated increased plasma insulin concentrations and reduced blood and liver lipid content, fasting blood glucose and glycosylated haemoglobin concentration, and homeostatic model assessment for insulin resistance in diabetic rats (Yin et al., 2019).

2.10.6.9 Anticancer effects

Cancer is a major global health challenge and is the second primary reason for mortality in the United States (Siegel et al., 2022). The ingestion of tomatoes and tomato-based products has been associated with a reduced occurrence of different types of cancer (Xu et al., 2021). *In vivo* and *in vitro* research has demonstrated that lycopene hinders the growth and multiplication of prostate cancer cells, inhibits the cell cycle, and induces apoptosis (Mirahmadi et al., 2020). Dietary supplementation with lycopene mitigated the growth of breast cancer cells by suppressing the activity of the insulin-like growth factor 1 receptor (IGF-1R) signalling pathway (Khan et al., 2021). While research shows that the consumption of a lycopene-rich diet could be beneficial in reducing the risk of pancreatic cancer (Mehta et al., 2018). In a rat model, the consumption of lycopene was shown to reduce the progression and proliferation of ovarian cancer (Holzapfel et al., 2017), and in human studies, cisplatin-based chemotherapy in combination with lycopene supplementation enhanced cervical cancer treatment (Aktepe et al., 2021). Furthermore, in animal models of hepatocellular carcinoma, administered lycopene suppressed the onset and development of cancer (Mekuria et al., 2020). In human colorectal adenocarcinoma cell line, treatment with lycopene was shown to exhibit genotoxicity, anti-proliferative, and apoptotic effects (Ataseven & Joha, 2023), a demonstration of its anticancer effects.

2.10.6.10 Gastroprotection

The incidence of peptic ulcer disease (PUD) has substantially increased, affecting approximately 5 to 10 percent of the general population (Abbasi-Kangevari et al., 2022). The corrosive effects of acid and pepsin on the gastro-duodenal mucosa cause peptic ulceration through exposure of the mucosa's lining to gastric acid and digestive enzyme actions (Tarasconi et al., 2020). Peptic ulcer disease is primarily caused by the extensive use of nonsteroidal anti-inflammatory drugs (NSAIDs) and *Helicobacter pylori* infection (Irshad et al., 2023). Other contributing factors include surgery, severe illness, burns, Zollinger-Ellison syndrome, excessive alcohol intake, smoking, psychological and physical stress (Lee et al., 2017; Asali et al., 2018; Yim et al., 2021). The excessive production of ROS is the major factor in stress-induced ulcers (Kumar et al., 2021). Thus, the utilisation of strong antioxidants may be beneficial in the management of ulcers (Zhang et al., 2020). In male Albino rats, lycopene administered at 200 mg/kg body weight for 10 days was shown to protect against ethanol-induced mucosa injury (Al-Razzuqi et al., 2018). In their

study, Chen et al. (2021) found that supplemental lycopene at 10, 50, 100, and 150 mg/kg body weight reduced gastric juice secretion in adult male Kunming mice when compared to the gastric injury control group. However, at high doses (150 mg/kg body weight), lycopene exacerbated absolute ethanol-induced acute gastric mucosal injury. In addition to mediating for protection against alcohol-induced gastrointestinal tract mucosal injury, lycopene has been shown to suppress gastric acid secretion and combat infection by *Helicobacter pylori* (Antioksidan et al., 2017).

2.10.6.11 Neuroprotection

Neurodegenerative diseases (NDs) are characterised by gradual loss of neurons and are associated with the formation of protein aggregates (Lamprey et al., 2022). These diseases are considered a major medical challenge as it affects millions of patients globally (Cho et al., 2018). Alzheimer's, Parkinson's, Huntington's, prion and motor-neuro diseases, amyotrophic lateral sclerosis, spinocerebellar ataxia, and spinal muscular atrophy are common NDs (Lamprey et al., 2022; Duggirala et al., 2023; Dutta et al., 2023). Despite age being the leading factor in the onset of all neurodegenerative disorders, recent discoveries indicate that the combination of a person's genetic makeup and environmental influences can contribute to an elevated risk of developing NDs (Liu et al., 2022). Regardless of the various factors causing these NDs, a key feature common to all is the onset and development of neuronal cell death (Fricker et al., 2018). The progression of NDs is characterised by increased ROS production, which causes oxidative stress (Olufunmilayo et al., 2023). Administered lycopene has been shown to attenuate memory loss due to age, cognitive impairments, neuronal damage, and synaptic dysfunctions in the brain (Zhao et al., 2018). Additionally, lycopene was observed to mitigate age-related oxidative stress by suppressing lipid peroxidation and enhancing GSH, SOD, and CAT activities (Zhao et al., 2018). Dietary fortification with lycopene was demonstrated to decrease age-related neuroinflammation by attenuating microgliosis and combating inflammation (Zhao et al., 2018). Furthermore, lycopene mediated the reduction in the accumulation of amyloid beta 1-42 in the brains of aged CD-1 mice (Zhao et al., 2018) and when used as a supplement, it upregulated the mitogen-activated protein kinase (MARK)/extracellular signal-regulated kinase (ERK) signalling pathway, inhibited oxidative stress and neuronal apoptosis, and protected against bisphenol-induced neurotoxicity in the hippocampi of adult male rats (EL Morsy & Ahmed, 2020). It was also shown to decrease palmitic acid-induced brain oxidative stress and neuroinflammation and to inhibit the Toll-like

receptor 4 (TLR4)/nuclear factor kappa-light chain enhancer of activated B cells p65 (NF-kB-p65) pathway in female rats (Ugbaja et al., 2021). In mice with Alzheimer's disease induced by β amyloid, lycopene reduced oxidative stress, decreased neuronal loss, improved synaptic plasticity, and inhibited neuroinflammation (Guo et al., 2023).

2.10.6.12 Cardioprotection

Globally, cardiovascular diseases (CVDs) stand at the forefront as the leading cause of human mortality (Tierney et al., 2020). Studies have shown that in 2019, CVDs caused 17.8 million fatalities, and this trend is projected to increase by 2030 to 23 million (Przybylska & Tokarczyk, 2022). Several epidemiological studies have confirmed the significance of lycopene in preventing CVDs (Cheng et al., 2019). For instance, lycopene supplementation has been shown to reduce C-reactive protein levels, interleukin-6, pulse wave velocity, blood pressure, intercellular adhesion molecule 1 and enhance vascular health through flow mediated dilation of the endothelium (Cheng et al., 2017). Lycopene supplementation at a dosage of 5 mg/kg body weight for 21 days was shown to confer protection against atrazine-induced cardiotoxicity in mice (Lin et al., 2016). In Brown-Norway/Lewis rat model, lycopene treatment was demonstrated to have the potential to mitigate vascular arteriosclerosis in allograft transplantation by inhibiting Rho-associated kinases and by regulating the expression of nitric oxide/cyclic guanosine monophosphate signalling pathways (He et al., 2016), which indicates that lycopene has the potential to alleviate vascular arteriosclerosis. In another study, lycopene administered for 4 weeks at 10 mg/kg body weight reduced inflammation and apoptosis during post-myocardial infarction remodelling by suppressing the NF-KB signalling pathway in mice (He et al., 2015). Additionally, supplemental lycopene improves endothelial function in individuals suffering from CVDs (Gajendragadkar et al., 2014).

2.10.6.13 Lung protection

In male C57BL/6 mice, dietary lycopene supplementation at 25 or 50 mg/kg body weight mitigated cigarette smoke-induced pulmonary emphysema (Campos et al., 2019). Literature shows that lycopene or matrine treatment alone offered minimal protection against lipopolysaccharide-induced acute lung injury in mice, but when co-administered, significant mitigatory effects were observed (Li et al., 2019). These results indicate that lycopene and matrine in combination may

function as an alternative to glucocorticoid therapy in treating acute lung injury (Li et al., 2019). In a study conducted by Mustra et al. (2021), supplemental lycopene at 90 mg/kg body weight for 22 weeks effectively suppressed tobacco carcinogen/cigarette smoke (NNK/CS)-induced emphysema, chronic bronchitis, and preneoplastic lesions. Furthermore, dietary lycopene significantly decreased NNK/CS-induced buildup of total cholesterol and upregulated mRNA expression of peroxisome proliferator-activated receptor alpha (PPAR α), ATP-binding cassette (ABC) transporters ABCA1 and ABCG1, and liver X receptor alpha (LXR α) in the lungs of ferret model. These findings suggest that lycopene could act as a preventative agent against the adverse effects of tobacco smoke on lung health and lipid metabolism.

2.10.6.14 Sperm quality enhancement and fertility promotion

Infertility is a prevalent health problem that affects roughly 48 million couples and 186 million individuals globally (Ombelet, 2020). ROS-induced oxidative stress is a primary contributor to various reproductive complications (Ojo et al., 2023). In varicocele-induced rats, supplemental lycopene was shown to protect sperm against DNA damage by mediating upregulation of antioxidant responses that quenched ROS, which manifested with improved sperm viability, Johnson's score, membrane integrity, and the expression of B-cell lymphoma 2-associated X-protein (BAX) (Babaei et al., 2022). Similarly, in men with oligozoospermia, supplemental lycopene for 12 weeks at 25 mg/kg body weight attenuated oxidative stress and improved sperm quality (Nouri et al., 2019). In their study, Yamamoto et al. (2017) observed that the consumption of tomato juice with 30 mg of lycopene for a duration of 12 weeks increased plasma lycopene concentration and sperm motility and decreased the white blood cell count in the seminal plasma of the tomato juice group compared to the control group of infertile men. Dietary supplementation with lycopene at 20 mg per day for 3 months prior to the scheduled *in vitro* fertilization (IVF) treatment increased the arachidonic acid to docosahexaenoic acid ratio in the seminal fluid and resulted in 7 natural pregnancies in addition to 15 pregnancies following the IVF procedure (Filipcikova et al., 2015). In methotrexate-induced ovarian damage, pretreatment with lycopene at 5 mg/kg body weight for 5 days prevented infertility and was shown to mediate increased GSH activity as well as decreased MDA and myeloperoxidase concentrations (Turkler et al., 2020). These findings suggest that lycopene alleviates imbalances in polyunsaturated fatty acids and can serve as a preventive agent against infertility.

2.10.6.15 Protection of skin health

The skin, constituting approximately 15% of the total body weight (Doyle, 2020), plays a vital role in preventing excessive water loss from the body and maintaining the body temperature within an optimal range (Osilla et al., 2022). It provides protection against toxic substances, free radicals, physical damage, and ultraviolet radiation (Balić & Mokos, 2019). The latter causes the development of skin conditions and diseases through sunburn, photoaging, and excessive ROS production within the skin, which damages DNA and causes skin cancer (Brand et al., 2018; Balić & Mokos, 2019; Mogavero et al., 2021). Lycopene is extensively used as an ingredient in cosmetic products due to its demonstrated ability to protect the skin from aging and photodamage (Mogavero et al., 2021). Anbualakan et al. (2023) showed that lycopene can prevent and/or treat sunburn and photoaging and that it could potentially be effective against UV-induced skin cancers. As a dietary supplement, lycopene has been demonstrated to improve skin appearance and pigmentation and mitigate erythema (Zhang et al., 2023).

2.10.6.16 Protective effect on vision

Age-related ophthalmic conditions, inclusive of macular degeneration, glaucoma, cataracts, and diabetic retinopathy, are key contributors to gradual and permanent vision loss (Abu-Amero et al., 2016). In diabetic patients, serum lycopene concentration has been observed to be lower than normal (Li et al., 2018). Importantly, due to its consistently lower levels in diabetics, it has been suggested that serum lycopene concentration might serve as a diagnostic tool for diabetic retinopathy (Li et al., 2018). Using ARPE-19 cells derived from human retinal pigment epithelium, Goug et al. (2017) demonstrated that lycopene suppressed growth of human RPE cells against oxidative stress-induced cell loss findings which suggests that it (lycopene) may protect against RPE proliferative disease and old-age related macular degeneration. Oxidative stress and inflammation have been shown to be associated with the pathogenesis of eye-related conditions (Dammak et al., 2023). As a dietary supplement, lycopene has been proven to mitigate the risk of developing eye diseases associated with old age (Jiang et al., 2019). This could be due to its demonstrated ability to prevent cataract formation both *in vitro* and *in vivo* (Mehta et al., 2018).

2.10.7 Lycopene: Protective effects against toxins

Toxins are natural and harmful chemical substances that adversely impact health (Rameshrad et al., 2017). They cause specific organ toxicity, for example, skin, eye, kidney, liver, blood, cardiovascular, respiratory, reproductive, endocrine, immune, and nervous system damage (Rameshrad et al., 2017; Briffa et al., 2020). Through their actions, toxins disrupt homeostasis, alter gene expression, and cancer-related metabolic signalling pathways (Hedayati et al., 2019). Research has demonstrated that lycopene as a dietary supplement effectively mitigates the deleterious effects of myco-, bacterial and chemical toxins (Liu & Chen, 2016; El-karim, 2019; Karaca et al., 2019; Wan et al., 2022), fungicides (Macar et al., 2023), pesticides (Ahmed, 2015), herbicides (Zhu et al., 2022), and fluoride (Li et al., 2017). It is hypothesised that lycopene mediates protection against toxins through its potent antioxidant, chelating, and antiapoptotic properties (Hedayati et al., 2019).

2.10.8 Lycopene: Safety and potential toxicity

There is no specified daily prescription for dietary lycopene intake, but epidemiological studies have recommended an intake of 2 to 20 mg daily of lycopene (Saini et al., 2020). It has been shown that consumption of up to 100 mg of lycopene daily does not elicit adverse outcomes (Przybylska, 2020). In a toxicological study conducted on rats, feeding a diet fortified with lycopene at 1% (w/w) did not elicit any side effects (Jonker et al., 2003). Similarly, using lycopene at 200 mg/kg body weight per day as a dietary supplement has also been shown not to negatively impact animals (Gupta et al., 2003). Generally, it is asserted that lycopene can be used as a safe dietary supplement during pregnancy and lactation (Hanson et al., 2018). Although in pregnant women, high dietary intake of lycopene has been shown to mitigate the risk of developing preeclampsia (Kang et al., 2022). Imran et al. (2020) reported that excessive chronic consumption of tomato juice, a rich source of lycopene, caused lycopopenia. Findings from both animal and human studies suggest that although lycopene could generally be used as a safe dietary supplement, some caution must be exercised against excessive intake.

2.10.9 Conclusion

The extensive studies carried out on lycopene highlight its exceptional potential to promote overall health and well-being. Its varied spectrum of benefits places it as a potent natural compound which

can contribute to the promotion of health either as a prophylactic and ore therapeutic agent against metabolic diseases. In order to fully exploit its potential and increase its utility in health delivery, it is crucial to undertake additional research to comprehensively elucidate the health beneficial mechanisms underlying lycopene's medicinal properties. Furthermore, in order to enjoy optimal utility from the use of lycopene, there is need to evaluate and recommend effective dosages for efficacy and prevention of possible side effects of abnormally high doses.

2.10.10 References

- Abbasi-Kangevari, M., Ahmadi, N., Fattahi, N., Rezaei, N., Malekpour, M. R., Ghamari, S. H., Moghaddam, S. S., Azadnajafabad, S., Esfahani, Z., Kolahi, A. A., Roshani, S., Rezazadeh-Khadem, S., Gorgani, F., Naleini, S. N., Naderimagham, S., Larijani, B., & Farzadfar, F. (2022). Quality of care of peptic ulcer disease worldwide: A systematic analysis for the global burden of disease study 1990-2019. *PLoS ONE*, *17* (8), 1–15. <https://doi.org/10.1371/journal.pone.0271284>
- Abir, M. H., Mahamud, A. G. M. S. U., Tonny, S. H., Anu, M. S., Hossain, K. H. S., Protic, I. A., Khan, M. S. U., Baroi, A., Moni, A., & Uddin, M. J. (2023). Pharmacological potentials of lycopene against aging and aging-related disorders: A review. *Food Science & Nutrition*, *11*(10), 5701–5735. <https://doi.org/10.1002/FSN3.3523>
- Abu-Amero, K. K., Kondkar, A. A., & Chalam, K. V. (2016). Resveratrol and Ophthalmic Diseases. *Nutrients* 2016, Vol. 8, Page 200, 8(4), 200. <https://doi.org/10.3390/NU8040200>
- Agca, R., Smulders, Y., & Nurmohamed, M. (2022). *Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice*, *108*(1), 73–79. <https://doi.org/10.1136/heartjnl-2019-316378>
- Ahmed, T. A. I. (2015). Protective role of lycopene and vitamin E against diazinon-induced biochemical changes in *Oreochromis niloticus*. *African Journal of Environmental Science and Technology*, *9*(6), 557–565. <https://doi.org/10.5897/AJEST2014.1853>
- Akchurin, O. M., & Kaskel, F. (2015). Update on Inflammation in Chronic Kidney Disease. *Blood purification*, *39*(1-3), 84–92. <https://doi.org/10.1159/000368940>
- Aktepe, O. H., Şahin, T. K., Güner, G., Arik, Z., & Yalçın, Ş. (2021). Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor-kappa b (Nf-κb) pathway. *Turkish Journal of Medical Sciences*, *51*(1), 368–374. <https://doi.org/10.3906/sag-2005-413>
- Albrahim, T. (2022). Lycopene Modulates Oxidative Stress and Inflammation in Hypercholesterolemic Rats. *Pharmaceuticals*, *15*(11). <https://doi.org/10.3390/ph15111420>
- Albrahim, T., & Alonazi, M. A. (2021). Biomedicine & Pharmacotherapy Lycopene corrects metabolic syndrome and liver injury induced by high fat diet in obese rats through antioxidant,

anti-inflammatory, antifibrotic pathways. *Biomedicine & Pharmacotherapy*, *141*, 111831.
<https://doi.org/10.1016/j.biopha.2021.111831>

Albrahim, T., & Robert, A. A. (2022). Lycopene Effects on Metabolic Syndrome and Kidney Injury in Rats Fed a High-Fat Diet: An Experimental Study. *Acs Omega*, *7*(35), 30930-30938.
<https://doi.org/10.1021/acsomega.2c02796>

Al-Razzuqi, R. A. M., Abu-Rageef, A. R., Mehasin, W. S., & Al-Razzuqi, T. R. A. M. (2018). Evaluation of gastroprotective effect of Vanadyl sulfate and Lycopene on rat model with ethanol-induced gastric mucosal lesions. *Biomedical and Pharmacology Journal*, *11*(3), 1291–1294.
<https://doi.org/10.13005/bpj/1490>

Amjad, M., Hussain, S., & Rehman Khan, A. (2020). Development and Validation of HPLC assay of Lycopene in Different Matrices. *World Journal of Applied Chemistry*, *5*(2), 26.
<https://doi.org/10.11648/j.wjac.20200502.13>

Anbualakan, K., Tajul Urus, N. Q., Makpol, S., Jamil, A., Mohd Ramli, E. S., Md Pauzi, S. H., & Muhammad, N. (2023). A Scoping Review on the Effects of Carotenoids and Flavonoids on Skin Damage Due to Ultraviolet Radiation. *Nutrients*, *15*(1), 1–17. <https://doi.org/10.3390/nu15010092>

Andrés Juan, C., Manuel Pérez de la Lastra, J., Plou, F. J., Pérez-Lebeña, E., & Reinbothe, S. (2021). Molecular Sciences the Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies. *Int. J. Mol. Sci*, *22*, 4642. <https://doi.org/10.3390/ijms>

Antioksidan, L., İnsan, O., & Faydah, S. (2017). *Lycopene: Is it Beneficial to Human Health as an Antioxidant?* *14*(3), 311–318. <https://doi.org/10.4274/tjps.43043>

Arballo, J., Amengual, J., & Erdman, J. W. (2021). Lycopene: A critical review of digestion, absorption, metabolism, and excretion. *Antioxidants*, *10*(3), 1–16. <https://doi.org/10.3390/antiox10030342>

Arroo, R., & Brunelle, D. (2023). *The protective effects of flavonoids and carotenoids against diabetic complications — A review of in vivo evidence.* *March*. <https://doi.org/10.3389/fnut.2023.1020950>

Arunkumar, R., Gorusupudi, A., & Bernstein, P. S. (2020). The macular carotenoids: A biochemical overview. In *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, *1865*(11), 158617. <https://doi.org/10.1016/j.bbalip.2020.158617>

- Asali, M., A., Alghamdi, M. A., Fallatah, S. A., Alholaily, W. A., Aldandan, R. G., Alnosair, A. H., AlKhars, A. A., Alreheli, M. F., Almohaini, M. O., & Alharbi, R. A. (2018). Risk factors leading to peptic ulcer disease: systematic review in literature. *International Journal Of Community Medicine And Public Health*, *5*(10), 4617. <https://doi.org/10.18203/2394-6040.ijcmph20183869>
- Ataseven, D., & Joha, Z. (2023). Anticancer activity of lycopene in HT-29 colon cancer cell line. *Medical Oncology*, *40*(5), 127. <https://doi.org/10.21203/rs.3.rs-2566457/v1>
- Babaei, A., Asadpour, R., Mansouri, K., Sabrivand, A., & Kazemi-Darabadi, S. (2022). Lycopene improves testicular damage and sperm quality in experimentally induced varicocele: Relationship with apoptosis, hypoxia, and hyperthermia. *Food Science & Nutrition*, *10*(5), 1469–1480. <https://doi.org/10.1002/FSN3.2762>
- Balić, A., & Mokos, M. (2019). Do we utilize our knowledge of the skin protective effects of carotenoids enough? *Antioxidants*, *8*(8), 1–19. <https://doi.org/10.3390/antiox8080259>
- Baz, L., Algarni, S., Al-thepyani, M., & Aldairi, A., & Gashian, H. (2022). Lycopene Improves Metabolic Disorders and Liver Injury Induced by a Hight-Fat Diet in Obese Rats. *Molecules*, *27*(22), 7736. <https://doi: 10.3390/molecules27227736>
- Bedir, F., Kocaturk, H., Turangezli, O., Sener, E., Akyuz, S., Ozgeris, F. B., Dabanlioglu, B., Suleyman, H., Altuner, D., & Suleyman, B. (2021). The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats. *Brazilian Journal of Medical and Biological Research*, *54*(8), e10660. <https://doi: 10.1590/1414-431X2020e10660>
- Beyoğlu, D., & Idle, J. R. (2020). Metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy. *Metabolites*, *10*(2). <https://doi.org/10.3390/metabo10020050>
- Bhatnagar, A., & Kekatpure, A. L. (2022). Postmenopausal Osteoporosis: A Literature Review. *Cureus*, *14*(9). <https://doi.org/10.7759/cureus.29367>
- Bin-Jumah, M. N., Nadeem, M. S., Gilani, S. J., Mubeen, B., Ullah, I., Alzarea, S. I., Ghoneim, M. M., Alshehri, S., Al-Abbasi, F. A., & Kazmi, I. (2022). Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases. *Antioxidants*, *11*(2), 232. <https://doi.org/10.3390/antiox11020232>

- Black, H. S., Boehm, F., Edge, R., & Truscott, T. G. (2020). The benefits and risks of certain dietary carotenoids that exhibit both anti-and pro-oxidative mechanisms—A comprehensive review. *Antioxidants*, 9(3), 264. <https://doi.org/10.3390/antiox9030264>
- Bouche-careilh, M. (2020). Alpha-1 antitrypsin deficiency-mediated liver toxicity: Why do some patients do poorly? what do we know so far? *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation*, 7(3), 172–181. <https://doi.org/10.15326/jcopdf.7.3.2019.0148>
- Brahimaj, A., Rivadeneira, F., Muka, T., Sijbrands, E. J. G., & Franco, O. H. (2019). Novel metabolic indices and incident type 2 diabetes among women and men: the Rotterdam Study. *Diabetologia*, 62, 1581–1590. <https://doi.org/10.1007/s00125-019-4921-2>
- Bramley, P. M. (2000). Is lycopene beneficial to human health? *Phytochemistry*, 54(3), 233–236. [https://doi.org/10.1016/S0031-9422\(00\)00103-5](https://doi.org/10.1016/S0031-9422(00)00103-5)
- Brand, R. M., Wipf, P., Durham, A., Epperly, M. W., Greenberger, J. S., & Faló, L. D. (2018). Targeting mitochondrial oxidative stress to mitigate UV-induced skin damage. *Frontiers in Pharmacology*, 9, 358464. <https://doi.org/10.3389/FPHAR.2018.00920/BIBTEX>
- Briffa, J., Sinagra, E., & Blundell, R. (2020). Heavy metal pollution in the environment and their toxicological effects on humans. *Heliyon*, 6(9), e04691. <https://doi.org/10.1016/J.HELIYON.2020.E04691>
- Campos, K. K. D., de Oliveira Ramos, C., Martins, T. L., Costa, G. de P., Talvani, A., Garcia, C. C. M., Oliveira, L. A. M., Cangussú, S. D., Costa, D. C., & Bezerra, F. S. (2019). Lycopene mitigates pulmonary emphysema induced by cigarette smoke in a murine model. *The Journal of Nutritional Biochemistry*, 65, 93–100. <https://doi.org/10.1016/J.JNUTBIO.2018.12.008>
- Caseiro, M., Ascenso, A., Costa, A., Creagh-Flynn, J., Johnson, M., & Simões, S. (2020). Lycopene in human health. *LWT*, 127, 109323. <https://doi.org/10.1016/J.LWT.2020.109323>
- Cauley, J. A., Chalhoub, D., Kassem, A. M., & Fuleihan, G. E. (2014). in osteoporotic fractures. *Nature Publishing Group*, 10(6), 338–351. <https://doi.org/10.1038/nrendo.2014.51>
- Cha, J. H., Kim, W. K., Ha, A. W., Kim, M. H., & Chang, M. J. (2017). Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells. *Nutrition Research and Practice*, 11(2), 90. <https://doi.org/10.4162/NRP.2017.11.2.90>

- Chandra, R. V., Prabhuji, M. L. V., Roopa, D. A., Ravirajan, S., & Kishore, H. C. (2007). Efficacy of lycopene in the treatment of gingivitis: a randomised, placebo-controlled clinical trial. *Oral Health & Preventive Dentistry*, 5(4), 327–336. <https://doi.org/10.3290/J.OHPD.A12803>
- Chauhan, K., Sharma, S., Agarwal, N., & Chauhan, B. (2011). Lycopene of tomato fame: its role in health and disease. In *International Journal of Pharmaceutical Sciences Review and Research*, 10(1), 99-115.
- Chen, L., Deng, H., Cui, H., Fang, J., & Zuo, Z. (2018). *Inflammatory responses and inflammation-associated diseases in organs*. 9(6), 7204–7218.
- Chen, X., Zhao, Y., Liu, K., Li, Z., Tan, X., Wang, Y., Gao, N., Liu, C., Fang, X., & Wang, Y. (2021). Lycopene Aggravates Acute Gastric Injury Induced by Ethanol. *Frontiers in Nutrition*, 8, 1–13. <https://doi.org/10.3389/fnut.2021.697879>
- Cheng, H. M., Koutsidis, G., Lodge, J. K., Ashor, A. W., Siervo, M., & Lara, J. (2019). Lycopene and tomato and risk of cardiovascular diseases: A systematic review and meta-analysis of epidemiological evidence. *Critical Reviews in Food Science and Nutrition*, 59(1), 141–158. <https://doi.org/10.1080/10408398.2017.1362630>
- Cheng, H. M., Koutsidis, G., Lodge, J. K., Ashor, A., Siervo, M., & Lara, J. (2017). Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis. *Atherosclerosis*, 257, 100–108. <https://doi.org/10.1016/J.ATHEROSCLEROSIS.2017.01.009>
- Cho, K. S., Shin, M., Kim, S., & Lee, S. B. (2018). Recent advances in studies on the therapeutic potential of dietary carotenoids in neurodegenerative diseases. *Oxidative Medicine and Cellular Longevity*, 2018(1), 4120458. <https://doi.org/10.1155/2018/4120458>
- Dammak, A., Pastrana, C., Martin-Gil, A., Carpena-Torres, C., Peral Cerda, A., Simovart, M., Alarma, P., Huete-Toral, F., & Carracedo, G. (2023). Oxidative Stress in the Anterior Ocular Diseases: Diagnostic and Treatment. *Biomedicines*, 11(2), 292. <https://doi.org/10.3390/BIOMEDICINES11020292>
- Donghia, R., Campanella, A., Bonfiglio, C., Cuccaro, F., Tatoli, R., & Giannelli, G. (2024). Protective Role of Lycopene in Subjects with Liver Disease: NUTRIHEP Study. *Nutrients*, 16(4), 562. <https://doi.org/10.3390/NU16040562>

- Doyle, L. M. (2020). Lycopene: Implications for Human Health—A Review. *Advances in Food Technology and Nutrition Sciences – Open Journal*, 6(1), 1–12. <https://doi.org/10.17140/AFTNSOJ-6-163>
- Duggirala, N., Ngo, K. J., Pagnoni, S. M., Rosa, A. L., & Fogel, B. L. (2023). Spinocerebellar ataxia type 14 (SCA14) in an Argentinian family: a case report. *Journal of Medical Case Reports*, 17(1), 1–6. <https://doi.org/10.1186/s13256-023-03897-y>
- Durairajanayagam, D., Agarwal, A., Ong, C., & Prashast, P. (2014). Lycopene and male infertility. *Asian Journal of Andrology*, 16(3), 420–425. <https://doi.org/10.4103/1008-682X.126384>
- Dutta, S., Sklerov, M., Teunissen, C. E., & Bitan, G. (2023). Editorial: Trends in biomarkers for neurodegenerative diseases: Current research and future perspectives. *Frontiers in Aging Neuroscience*, 15, 1153932. <https://doi.org/10.3389/fnagi.2023.1153932>
- El Morsy, E. M., & Ahmed, M. A. E. (2020). Protective effects of lycopene on hippocampal neurotoxicity and memory impairment induced by bisphenol A in rats. *Human and Experimental Toxicology*, 39(8), 1066–1078. <https://doi.org/10.1177/0960327120909882>
- El-karim, D. R. S. G. (2019). Presumptive Ameliorative Effect of Lycopene on Lead-induced Nephrotoxicity in Males Wistar Rats *Journal of Advanced Veterinary Research*, 9(3), 91–96.
- Elvira-Torales, L. I., García-Alonso, J., & Periago-Castón, M. J. (2019). Nutritional importance of carotenoids and their effect on liver health: A review. *Antioxidants*, 8(7), 229. <https://doi.org/10.3390/antiox8070229>
- Erdayanti, F. Y., Atmaka, D. R., & Kagawa, M. (2022). The potential of phytochemicals lycopene in prevention of bone loss due to decreased estrogen hormone in humans and experimental animals. *Media Gizi Indonesia* 17(2), 191–203.
- Eze, E. D., Afodun, A. M., Sulaiman, S. O., Ponsiano, N., Ezekiel, I., Adams, M. D., Okpanachi, A. O., & Rabi, M. (2018). *Lycopene attenuates diabetes-induced oxidative stress in Wistar rats*. 9, 11–19. <https://doi.org/10.5897/JDE2018.0118>
- Failla, M. L., Chitchumroonchokchai, C., & Ishida, B. K. (2008). In vitro micellarization and intestinal cell uptake of cis isomers of lycopene exceed those of all-trans lycopene. *Journal of Nutrition*, 138(3), 482–486. <https://doi.org/10.1093/JN/138.3.482>

- Fernandes, J. V., Ney, R., & Cobucci, O. (2015). The Role of the Mediators of Inflammation in Cancer Development, Pathology and Oncology Research, *21*, 527–534. <https://doi.org/10.1007/s12253-015-9913-z>
- Filipcikova, R., Oborna, I., Brezinova, J., Novotny, J., Wojewodka, G., De Sanctis, J. B., Radova, L., Hajduch, M., & Radzioch, D. (2015). Lycopene improves the distorted ratio between AA/DHA in the seminal plasma of infertile males and increases the likelihood of successful pregnancy. *Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia*, *159*(1), 77–82. <https://doi.org/10.5507/BP.2013.007>
- Fonseca, D., Rocha, A., Machado-junior, P. A., Beatriz, A., Souza, F., Castro, T. D. F., Costa, G. D. P., Talvani, A., Bezerra, F. S., & Cangussú, S. D. (2021). Lycopene Ameliorates Liver Inflammation and Redox Status in Mice Exposed to Long-Term Cigarette Smoke. *BioMed Research International*, *2021*(1), 7101313.
- Franceschi, C., Ferrucci, L., Gilroy, D. W., Fasano, A., & Gary, W. (2020). *span*. *25*(12), 1822–1832. <https://doi.org/10.1038/s41591-019-0675-0>.Chronic
- Franks, PW and McCarthy, M. (2016). posing the exposures responsible for type 2 diabetes and obesity. *Science*, *6308*(354), 69–73.
- Fricker, M., Tolkovsky, A. M., Borutaite, V., Coleman, M., & Brown, G. C. (2018). Neuronal Cell Death. *Physiological Reviews*, *98*(2), 813. <https://doi.org/10.1152/PHYSREV.00011.2017>
- Gajendragadkar, P. R., Hubsch, A., Mäki-Petäjä, K. M., Serg, M., Wilkinson, I. B., & Cheriyan, J. (2014). Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. *PloS One*, *9*(6), e99070. <https://doi.org/10.1371/JOURNAL.PONE.0099070>
- Ghyasvand, T., Goodarzi, M. T., Amiri, I., Karimi, J., & Ghorbani, M. (2015). Serum levels of lycopene, beta-carotene, and retinol and their correlation with sperm DNA damage in normospermic and infertile men. *International Journal of Reproductive Biomedicine*, *13*(12), 787. <https://doi.org/10.29252/ijrm.13.12.787>

- Gidding, S. S., & Allen, N. B. (2019). Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem. *Journal of the American Heart Association*, 8(11), 1–3. <https://doi.org/10.1161/JAHA.119.012924>
- Gloria, N. F., Nathalia, S., Camila, B., Felipe L. O., Radovan B., and Anderson J. T. (2014). Lycopene and Beta-carotene induce cell-cycle arrest and apoptosis in Human breast cancer cell lines. *Anticancer Research*, 34(3), 1377–1386.
- Godos, J., Giampieri, F., Chisari, E., Micek, A., Paladino, N., Forbes-hern, T. Y., Quiles, J. L., Battino, M., Vignera, S. La, Musumeci, G., & Grosso, G. (2022). Alcohol Consumption, Bone Mineral Density, and Risk of Osteoporotic Fractures: A Dose – Response Meta-Analysis. *International Journal of Environmental Research and Public Health*, 19(3), 1515. [https://doi: 10.3390/ijerph19031515](https://doi.org/10.3390/ijerph19031515)
- Gong, X., Draper, C. S., Allison, G. S., Marisiddaiah, R., & Rubin, L. P. (2017). Effects of the macular carotenoid lutein in human retinal pigment epithelial cells. *Antioxidants*, 6(4),100. <https://doi.org/10.3390/antiox6040100>
- Gori, P., Patel, A., Solanki, N., Shah, U., Patel, V., Patel, S., Gori, P., Patel, A., Solanki, N., Shah, U., Patel, V., & Patel, S. (2021). Protective effects of lycopene against adenine-induced chronic renal failure in rats. *Indian Journal of Physiology and Pharmacology*, 65(2), 74–85. https://doi.org/10.25259/IJPP_188_2020
- Grabowska, M., Wawrzyniak, D., Rolle, K., Chomczyński, P., Oziewicz, S., Jurga, S., & Barciszewski, J. (2019). Let food be your medicine: nutraceutical properties of lycopene. *Food & Function*, 10(6), 3090-3102. <https://doi.org/10.1039/c9fo00580c>
- Greten, F. R., Grivennikov, S. I., Therapy, E., Program, C., & Chase, F. (2020). *HHS Public Access*. 51(1), 27–41. <https://doi.org/10.1016/j.immuni.2019.06.025>.Inflammation
- Gu, Y., Singh, A., Bose, S., & Singh, N. (2008). Pathogenic mutations in the glycosylphosphatidylinositol signal peptide of PrP modulate its topology in neuroblastoma cells. *Molecular and Cellular Neurosciences*, 37(4), 647. <https://doi.org/10.1016/J.MCN.2007.08.018>

- Guo, W., Huang, D., & Li, S. (2023). Lycopene alleviates oxidative stress-induced cell injury in human vascular endothelial cells by encouraging the SIRT1/Nrf2/HO-1 pathway. *Clinical and Experimental Hypertension*, 45(1), 2205051. <https://doi.org/10.1080/10641963.2023.2205051>
- Guo, Y., Fan, Z., Zhao, S., Yu, W., Hou, X., Nie, S., Xu, S., Zhao, C., Han, J., & Liu, X. (2023). Brain-targeted lycopene-loaded microemulsion modulates neuroinflammation, oxidative stress, apoptosis and synaptic plasticity in β -amyloid-induced Alzheimer's disease mice. *Neurological Research*, 45(8), 753-764. <https://doi.org/10.1080/01616412.2023.2203615>
- Gupta, M., Panizai, M., Farooq Tareen, M., Ortega-Martinez, S., Doreulee, N., & Andrew, M. (2018). An Overview on Novel Antioxidant and Anti-Cancer Properties of Lycopene: A Comprehensive Review. *GMJ Medicine*, 2(1), 45–50. <https://doi.org/10.22034/GMJM.2018.02.45>
- Gupta, S. K., Trivedi, D., Srivastava, S., Joshi, S., Halder, N., & Verma, S. D. (2003). Lycopene attenuates oxidative stress induced experimental cataract development: An in vitro and in vivo study. *Nutrition*, 19(9), 794–799. [https://doi.org/10.1016/S0899-9007\(03\)00140-0](https://doi.org/10.1016/S0899-9007(03)00140-0)
- Han, S. K., Baik, S. K., & Kim, M. Y. (2023). *Non-alcoholic fatty liver disease: Definition and subtypes*. *Clinical and molecular hepatology*, 29(Suppl), S5–S16. <https://doi.org/10.3350/cmh.2022.0424>.
- Hanson, C., Lyden, E., Furtado, J., Van Ormer, M., White, K., Overby, N., & Anderson-Berry, A. (2018). Serum Lycopene Concentrations and Associations with Clinical Outcomes in a Cohort of Maternal-Infant Dyads. *Nutrients*, 10(2), 204. <https://doi.org/10.3390/NU10020204>
- Hasan, M., Sutradhar, I., Gupta, R. Das, & Sarker, M. (2018). Prevalence of chronic kidney disease in South Asia: a systematic review. *BMC nephrology*, 19, 1–12. <https://doi.org/10.1186/s12882-018-1072-5>.
- Hassan, M. F., Hussein, S. A., Senosi, Y. El, Mansour, M. K., & Amin, A. (2018). *The Role of Lycopene as Antioxidant and Anti-inflammatory in Protection of Oxidative Stress Induced by Metalaxyl*. 3(1), 26–36. <https://doi.org/10.15436/2575-808X.18.1890>
- He, Q., Zhou, W., Xiong, C., Tan, G., & Chen, M. (2015). Lycopene attenuates inflammation and apoptosis in post-myocardial infarction remodeling by inhibiting the nuclear factor- κ B signaling pathway. *Molecular Medicine Reports*, 11(1), 374–378. <https://doi.org/10.3892/MMR.2014.2676>

- He, Y., Xia, P., Jin, H., Zhang, Y., Chen, B., & Xu, Z. (2016). Lycopene ameliorates transplant arteriosclerosis in vascular allograft transplantation by regulating the NO/cGMP pathways and rho-associated kinases expression. *Oxidative Medicine and Cellular Longevity*, 2016(1), 3128280. <https://doi.org/10.1155/2016/3128280>
- Hedayati, N., Naeini, M. B., Nezami, A., Hosseinzadeh, H., Wallace Hayes, A., Hosseini, S., Imenshahidi, M., & Karimi, G. (2019). Protective effect of lycopene against chemical and natural toxins: A review. *BioFactors*, 45(1), 5–23. <https://doi.org/10.1002/BIOF.1458>
- Holzapfel, N. P., Holzapfel, B. M., Champ, S., Feldthusen, J., Clements, J., & Hutmacher, D. W. (2013). The Potential Role of Lycopene for the Prevention and Therapy of Prostate Cancer: From Molecular Mechanisms to Clinical Evidence. *Int. J. Mol. Sci*, 14, 14620–14646. <https://doi.org/10.3390/ijms140714620>
- Holzapfel, N. P., Shokoohmand, A., Wagner, F., Landgraf, M., Champ, S., Holzapfel, B. M., Clements, J. A., Hutmacher, D. W., & Loessner, D. (2017). Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load. *American Journal of Cancer Research*, 7(6), 1322.
- Honda, M., Kudo, T., Kuwa, T., Higashiura, T., Fukaya, T., Inoue, Y., Kitamura, C., & Takehara, M. (2017). Isolation and spectral characterization of thermally generated multi-Z-isomers of lycopene and the theoretically preferred pathway to di-Z-isomers. *Bioscience, Biotechnology and Biochemistry*, 81(2), 365–371. https://doi.org/10.1080/09168451.2016.1249454/SUPPL_FILE/TBBB_A_1249454_SM8465.PDF
- Hussein, S. A., Senosi, Y. A. El, & Hashem, H. M. (2020). *Lycopene mitigates experimental colitis in rats via inhibiting oxidative stress- mediated inflammation and apoptosis*. 39, 16–21.
- Imran, M., Ghorat, F., Ul-haq, I., Ur-rehman, H., Aslam, F., Heydari, M., Shariati, M. A., Okuskhanova, E., Yessimbekov, Z., Thiruvengadam, M., Hashempur, M. H., & Rebezov, M. (2020). Lycopene as a natural antioxidant used to prevent human health disorders. In *Antioxidants*, 9(8), 1–27. <https://doi.org/10.3390/antiox9080706>

- Inoue, T., Yoshida, K., Sasaki, E., Aizawa, K., & Kamioka, H. (2023). Effect of Lycopene Intake on the Fasting Blood Glucose Level: A Systematic Review with Meta-Analysis. *Nutrients*, *15*(1), 122. <https://doi.org/10.3390/NU15010122/S1>
- Inoue, T., Yoshida, K., Sasaki, E., Aizawa, K., & Kamioka, H. (2021). Effects of lycopene intake on HDL-cholesterol and triglyceride levels: A systematic review with meta-analysis. *Journal of Food Science*, *86*(8), 3285–3302. <https://doi.org/10.1111/1750-3841.15833>
- Irshad, Z., Khan, M. S., Kamran, ., Sohail, M., Fahim, M., Naeem, S., Rashid, S. U., & Gillani, S. R. (2023). Role of Helicobacter Pylori Infection and Nonsteroidal Anti-Inflammatory Drug Use in Bleeding Peptic Ulcers. *Pakistan Journal of Health Sciences*, 147–151. <https://doi.org/10.54393/PJHS.V4I03.555>
- Israel, P., Castrej, V., Manzano-pech, L., & Guarner-lans, V. (2021). Oxidative Stress, Plant Natural Antioxidants, and Obesity. *International Journal of Molecular Sciences*, *22*(4), 1786. <https://doi.org/10.3390/ijms22041786>
- Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021). Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options. *Circulation*, *143*(11), 1157–1172.
- Jiang, H., Yin, Y., Wu, C. R., Liu, Y., Guo, F., Li, M., & Ma, L. (2019). Dietary vitamin and carotenoid intake and risk of age-related cataract. *The American Journal of Clinical Nutrition*, *109*(1), 43–54. <https://doi.org/10.1093/AJCN/NQY270>
- Jiang, W., Guo, M., & Hai, X. (2016). *Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat*. *22*(46), 10180–10188. <https://doi.org/10.3748/wjg.v22.i46.10180>
- Jonker, D., Kuper, C. F., Fraile, N., Estrella, A., & Rodríguez Otero, C. (2003). Ninety-day oral toxicity study of lycopene from *Blakeslea trispora* in rats. *Regulatory Toxicology and Pharmacology*, *37*(3), 396–406. [https://doi.org/10.1016/S0273-2300\(03\)00013-8](https://doi.org/10.1016/S0273-2300(03)00013-8)
- Joshi, B., Kar, S. K., Yadav, P. K., Yadav, S., Shrestha, L., & Bera, T. K. (2020). Therapeutic and medicinal uses of lycopene: a systematic review. *International Journal of Research in Medical Sciences*, *8*(3), 1195. <https://doi.org/10.18203/2320-6012.ijrms20200804>

- Kadry, M.S., Mohamed, A.L., Tarek, K.A., Sherif, M.N., & El-Sayed, Y. (2018). The molecular and biochemical insight view of lycopene in ameliorating tramadol-induced liver toxicity in a rat model: implication of oxidative stress, apoptosis, and MAPK signaling pathways *Environmental science and pollution research international*, 25(33,) 33119-33130
- Kalra, A., Yetiskul, E., Wehrle, C. J., & Tuma, F. (2022). Physiology, Liver. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK535438/>
- Kang, T., Liu, Y., Chen, X., Huang, X., Cao, Y., Dou, W., Duan, D., Bo, Y., Traore, S. S., Zhao, X., Fu, W., Zeng, F., Liu, J., & Lyu, Q. (2022). Dietary carotenoid intake and risk of developing preeclampsia: a hospital-based case–control study. *BMC Pregnancy and Childbirth*, 22(1), 1–13. <https://doi.org/10.1186/S12884-022-04737-5/TABLES/5>
- Karaca, A., Yilmaz, S., Kaya, E., & Altun, S. (2019). The effect of lycopene on hepatotoxicity of aflatoxin B1 in rats. *Archives of Physiology and Biochemistry*, 127(5), 429–436. <https://doi.org/10.1080/13813455.2019.1648516>
- Karaköy, Z., Cadirci, E., & Dincer, B. (2022). A New Target in Inflammatory Diseases: Lycopene. *Eurasian Journal of Medicine*, 54(1), S23-S28. <https://doi.org/10.5152/eurasianjmed.2022.22303>
- Karimian, B., Soleimani, A., Mohammadsharifi, G., Heshmat-Ghahdarjani, K., Rejali, L., Shafie, D., Amerizadeh, A., & Sadeghi, M. (2022). Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients with Ischemic Heart Failure: A Randomized Clinical Trial. *Cardiology Research and Practice*, 2022(1), 2610145. <https://doi.org/10.1155/2022/2610145>
- Kaur, G., Sandal, A., & Singh Dhillon, N. (2017.). *Lycopene and human health-A review*. *Agricultural Reviews*. 38(4), 282-289. <https://doi.org/10.18805/ag.R-1741>.
- Kesse-Guyot, E., Andreeva, V. A., Ducros, V., Jeandel, C., Julia, C., Hercberg, S., & Galan, P. (2014). Carotenoid-rich dietary patterns during midlife and subsequent cognitive function. *British Journal of Nutrition*, 111(5), 915–923. <https://doi.org/10.1017/S0007114513003188>
- Khan, N. I., Noori, S., & Mahboob, T. (2016). Efficacy of lycopene on modulation of renal antioxidant enzymes, ACE and ACE gene expression in hyperlipidaemic rats. *Journal of the*

Renin-Angiotensin-Aldosterone System, 17(3),1470320316664611.

<https://doi.org/10.1177/1470320316664611>

Khan, U. M., Sevindik, M., Zarrabi, A., Nami, M., Ozdemir, B., Kaplan, D. N., Selamoglu, Z., Hasan, M., Kumar, M., Alshehri, M. M., & Sharifi-Rad, J. (2021). Lycopene: Food Sources, Biological Activities, and Human Health Benefits. *Oxidative Medicine and Cellular Longevity* 2021(1), 2713511. <https://doi.org/10.1155/2021/2713511>

Kim, Y.-J., Kang, K. S., Cho, I.-H., Mannino, F., Pallio, G., Altavilla, D., Squadrito, F., Vermiglio, G., Bitto, A., & Irrera, N. (2022). Atherosclerosis Plaque Reduction by Lycopene Is Mediated by Increased Energy Expenditure through AMPK and PPAR α in ApoE KO Mice Fed with a High Fat Diet. *Biomolecules*, 12(7), 973. <https://doi.org/10.3390/biom12070973>

Kırkıl, G., Muz, M. H., Sancaktar, E., Kaman, D., Ahin, K., & Küçük, Ö. (2012). The effect of lycopene supplementation on chronic obstructive lung disease. *Nobel Med*, 8(3), 98–104.

Klran, T. R., Otlu, O., & Karabulut, A. B. (2023). Oxidative stress and antioxidants in health and disease. *Journal of Laboratory Medicine*, 47(1), 1–11. <https://doi.org/10.1515/labmed-2022-0108>

Kong, X., Xie, L., Zhu, H., Song, L., Xing, X., Yang, W., & Chen, X. (2019). Genotypic and phenotypic spectra of hemojuvelin mutations in primary hemochromatosis patients: A systematic review. *Orphanet Journal of Rare Diseases*, 14(1), 1–24. <https://doi.org/10.1186/s13023-019-1097-2>

Kumar, P. V. N., Elango, P., Asmathulla, S., & Kavimani, S. (2017). A systematic review on lycopene and its beneficial effects. *Biomedical and Pharmacology Journal*, 10(4), 2113–2120. <https://doi.org/10.13005/BPJ/1335>

Kumar, S., Theis, T., Tschang, M., Nagaraj, V., & Berthiaume, F. (2021). Reactive oxygen species and pressure ulcer formation after traumatic injury to spinal cord and brain. *Antioxidants*, 10(7), 1–15. <https://doi.org/10.3390/antiox10071013>

Lampthey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022). A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. *International Journal of Molecular Sciences*, 23(3), 1851. <https://doi.org/10.3390/ijms23031851>

- Lavie, C. J., Lear, S. A., & Ndumele, C. E. (2021). Obesity and cardiovascular disease: a scientific statement from American Heart Association. *Circulation*, 143(21), e984-e1010.
<https://doi.org/10.1161/CIR.0000000000000973>
- Lazarus, E., & Edward, H. (2022). Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obesity Pillars*, 3, 100026.
<https://doi.org/10.1016/j.obpill.2022.100026>
- Lee, S. P., Sung, I. K., Kim, J. H., Lee, S. Y., Park, H. S., & Shim, C. S. (2017). Risk factors for the presence of symptoms in peptic ulcer disease. *Clinical Endoscopy*, 50(6), 578–584.
<https://doi.org/10.5946/ce.2016.129>
- Leh, H. E., & Lee, L. K. (2022). Lycopene: A Potent Antioxidant for the Amelioration of Type II Diabetes Mellitus. *Molecules*, 27(7), 2335. <https://doi.org/10.3390/molecules27072335>
- Leh, H. E., Mohd Sopian, M., Abu Bakar, M. H., & Lee, L. K. (2021). The role of lycopene for the amelioration of glycaemic status and peripheral antioxidant capacity among the Type II diabetes mellitus patients: a case–control study. *Annals of Medicine*, 53(1), 1058–1064.
<https://doi.org/10.1080/07853890.2021.1943515>
- Li, W. W., Wang, T. Y., Cao, B., Liu, B., Rong, Y. M., Wang, J. J., Wei, F., Wei, L. Q., Chen, H., & Liu, Y. X. (2019). Synergistic protection of matrine and lycopene against lipopolysaccharide-induced acute lung injury in mice. *Molecular Medicine Reports*, 20(1), 455–462.
<https://doi.org/10.3892/MMR.2019.10278/HTML>
- Li, W., Jiang, B., Cao, X., Xie, Y., & Huang, T. (2017). Protective effect of lycopene on fluoride-induced ameloblasts apoptosis and dental fluorosis through oxidative stress-mediated Caspase pathways. *Chemico-Biological Interactions*, 261, 27–34. <https://doi.org/10.1016/J.CBI.2016.11.021>
- Li, Y., Zhan, M., Li, J., Zhang, W., & Shang, X. (2023). Lycopene alleviates lipopolysaccharide-induced testicular injury in rats by activating the PPAR signaling pathway to integrate lipid metabolism and the inflammatory response. *Translational Andrology and Urology*, 12(2), 271–285.
<https://doi.org/10.21037/tau-22-864>

- Li, Z. Z., Lu, X. Z., Ma, C. C., & Chen, L. (2018). Serum Lycopene Levels in Patients with Diabetic Retinopathy. *European Journal of Ophthalmology*, *20*(4), 719–723.
<https://doi.org/10.1177/112067211002000412>
- Lin, J., Li, H.-X., Xia, J., Li, X.-N., Jiang, X.-Q., Zhu, S.-Y., Ge, J., & Li, J.-L. (2016). The chemopreventive potential of lycopene against atrazine-induced cardiotoxicity: modulation of ionic homeostasis. *Scientific Reports*, *6*(1), 244855. <https://doi.org/10.1038/srep24855>
- Liu, H., Hu, Y., Zhang, Y., Zhang, H., Gao, S., Wang, L., Wang, T., Han, Z., Sun, B. liang, & Liu, G. (2022). Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy phenotype GWAX. *Alzheimer’s Research and Therapy*, *14*(1), 1–10. <https://doi.org/10.1186/s13195-022-00963-3>
- Liu, T. Y., & Chen, S. B. (2016). Sarcandra glabra combined with lycopene protect rats from lipopolysaccharide induced acute lung injury via reducing inflammatory response. *Biomedicine & Pharmacotherapy*, *84*, 34–41. <https://doi.org/10.1016/J.BIOPHA.2016.09.009>
- Liu, Z. Q. (2020). Bridging free radical chemistry with drug discovery: A promising way for finding novel drugs efficiently. *European Journal of Medicinal Chemistry*, *189*, 112020.
<https://doi.org/10.1016/J.EJMECH.2019.112020>
- Lucas, M., Freitas, M., Carvalho, F., Fernandes, E., & Ribeiro, D. (2022). Antioxidant and Pro-oxidant Activities of Carotenoids. *Plant Antioxidants and Health*, 123–148. https://doi.org/10.1007/978-3-030-78160-6_4/COVER
- Luvizotto, RAM., Nascimento, AF., Miranda, NCM and Wang XD. (2015). Lycopene-rich tomato oleoresin modulates plasma adiponectin concentration and mRNA levels of adiponectin, SIRT1, and FoxO1 in adipose tissue of obese rats. *Humam & Experimental Toxicology*, *34*(6), 612–619.
- Macar, O., Kalefetoğlu Macar, T., Çavuşoğlu, K., Yalçın, E., & Yapar, K. (2023). Lycopene: an antioxidant product reducing dithane toxicity in *Allium cepa* L. *Scientific Reports*, *13*(1), 2290. <https://doi.org/10.1038/S41598-023-29481-4>
- MacKinnon, E. S., Rao, A. V., Josse, R. G., & Rao, L. G. (2011). Supplementation with the antioxidant lycopene significantly decreases oxidative stress parameters and the bone resorption marker N-

telo peptide of type I collagen in postmenopausal women. *Osteoporosis International*, 22(4), 1091–1101. <https://doi.org/10.1007/S00198-010-1308-0>

Masschelin, P. M., Cox, A. R., Chernis, N., & Hartig, S. M. (2020). The Impact of Oxidative Stress on Adipose Tissue Energy Balance. *Frontier in Physiology*, 10, 1–8. <https://doi.org/10.3389/fphys.2019.01638>

Maurice, J., & Manousou, P. (2018). CMJv18n3-CME-Manousou.indd. *Cme Gastroenterology*, 18(3), 245–250.

McEneny, J., Henry, S. L., Woodside, J., Moir, S., Rudd, A., Vaughan, N., & Thies, F. (2022). Lycopene-rich diets modulate HDL functionality and associated inflammatory markers without affecting lipoprotein size and distribution in moderately overweight, disease-free, middle-aged adults: A randomized controlled trial. *Frontiers in Nutrition*, 9, 954593. <https://doi.org/10.3389/FNUT.2022.954593/BIBTEX>

Mehta, N., Patani, P., & Singhvi, I. (2018). A review on tomato lycopene. *International Journal of Pharmaceutical Sciences and Research*, 9(3), 916–923. [https://doi.org/10.13040/IJPSR.0975-8232.9\(3\).916-23](https://doi.org/10.13040/IJPSR.0975-8232.9(3).916-23)

Mekuria, A. N., Tura, A. K., Hagos, B., Sisay, M., Abdela, J., Mishore, K. M., & Motbaynor, B. (2020). Anti-Cancer Effects of Lycopene in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. *Frontiers in Pharmacology*, 11, 560625. <https://doi.org/10.3389/FPHAR.2020.01306/BIBTEX>

Meléndez-Martínez, A. J. (2020). An Overview of Carotenoids, Apocarotenoids, and Vitamin A in Agro-Food, Nutrition, Health, and Disease. *Molecular Nutrition and Food Research*, 63(15), 1801045. <https://doi.org/10.1002/mnfr.201801045>

Mezbani A, Kavan B P, Kiani A and Masouri B. (2019). Effect of dietary lycopene supplementation on growth performance, blood parameters and antioxidant enzymes status in broiler chickens. *Livestock Research for Rural Development*. 31(1),12. <http://www.lrrd.org/lrrd31/1/bahma31012.html>

- Min, J. Y., & Min, K. B. (2014). Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults. *Dementia and Geriatric Cognitive Disorders*, 37(3–4), 246–256. <https://doi.org/10.1159/000356486>
- Mirahmadi, M., Aghasizadeh, M., Nazifkar, F., Choubdari, M. G., Assaran-Darban, R., Tavallaie, S., Hatamzadeh, H., Ferns, G. A., Mirinezhad, M. R., Baharara, H., Hadizadeh, F., & Ghayour-Mobarhan, M. (2023). The Effects of Lycopene on Modulating Oxidative Stress and Liver Enzymes Levels in Metabolic Syndrome Patients: A Randomised Clinical Trial. *Cell Journal (Yakhteh)*, 25(12), 847. <https://doi.org/10.22074/CELLJ.2023.2006158.1353>
- Mirahmadi, M., Azimi-Hashemi, S., Saburi, E., Kamali, H., Pishbin, M., & Hadizadeh, F. (2020). Potential inhibitory effect of lycopene on prostate cancer. *Biomedicine & Pharmacotherapy*, 129, 110459. <https://doi.org/10.1016/J.BIOPHA.2020.110459>
- Mityas, G. S., Tawfik, S. M., El-bakery, N. A., & Salah, E. F. (2019). Histological Study of the Possible Protective Effect of Lycopene on Glucocorticoid-Induced Osteoporosis in Adult Male Albino Rat. *The Medical Journal of Cairo University*, 87(3), 2121–2134.
- Mogavero, M. P., DelRosso, L. M., Fanfulla, F., Bruni, O., & Ferri, R. (2021). Sleep disorders and cancer: State of the art and future perspectives. *Sleep Medicine Reviews*, 56, 101409. <https://doi.org/10.1016/j.smr.2020.101409>
- Mohammed K. H. (2022). Liver Structure, Function and its Interrelationships with Other Organs: A Review. *International Journal Dental and Medical Sciences Research*, 4(1), 88–92. <https://doi.org/10.35629/5252-04018892>
- Molnar, V., Matiši, V., Kodvanj, I., Bjelica, R., Jele, Ž., Hudetz, D., Vrdoljak, T., Vidovi, D., Rod, E., Cukelj, F., Starešini, M., & Bori, I. (2021). Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis. *International Journal of Molecular Sciences*, 22(17), 9208. <https://doi.org/10.3390/ijms22179208>
- Mounien, L., Tourniaire, F., & Landrier, J. F. (2019). Anti-Obesity Effect of Carotenoids: Direct Impact on Adipose Tissue and Adipose Tissue-Driven Indirect Effects. *Nutrients*, 11(7), 1562. <https://doi.org/10.3390/NU11071562>

- Muñoz-garach, A., & Garc, B. (2020). Nutrients and Dietary Patterns Related to osteoporosis. *Nutrients*, 12(7), 1986. <https://doi.org/10.3390/nu12071986>
- Mustra R. J., Liu, C., Veeramachaneni, S., Wu, D., Paul, L., Ausman, L. M., & Wang, X. D. (2021). Dietary lycopene attenuates cigarette smoke-promoted nonalcoholic steatohepatitis by preventing suppression of antioxidant enzymes in ferrets. *Journal of Nutritional Biochemistry*, 91, 108596. <https://doi.org/10.1016/j.jnutbio.2021.108596>
- Naomi, R., Teoh, S. H., Embong, H., Balan, S. S., Othman, F., Bahari, H., & Yazid, M. D. (2023). The Role of Oxidative Stress and Inflammation in Obesity and Its Impact on Cognitive Impairments-a narrative review. *Antioxidants*, 12(5), 1071. <https://doi.org/10.3390/antiox12051071>
- Nouri, M., Amani, R., Nasr-Esfahani, M., & Tarrahi, M. J. (2019). The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. *Phytotherapy Research*, 33(12), 3203–3211. <https://doi.org/10.1002/PTR.6493>
- Ojo, O. A., Nwafor-Ezeh, P. I., Rotimi, D. E., Iyobhebhe, M., Ogunlakin, A. D., & Ojo, A. B. (2023). Apoptosis, inflammation, and oxidative stress in infertility: A mini review. *Toxicology Reports*, 10, 448–462. <https://doi.org/10.1016/J.TOXREP.2023.04.006>
- Olufunmilayo, E. O., Gerke-Duncan, M. B., & Holsinger, R. M. D. (2023). Oxidative Stress and Antioxidants in Neurodegenerative Disorders. *Antioxidants*, 12(2), 1–30. <https://doi.org/10.3390/antiox12020517>
- Ombelet, W. (2020). WHO fact sheet on infertility gives hope to millions of infertile couples worldwide. *Facts, Views & Vision in ObGyn*, 12(4), 249–251.
- Osilla, E. V., Marsidi, J. L., & Sharma, S. (2022). Physiology, Temperature Regulation. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK507838/>
- Overby, H. B., & Ferguson, J. F. (2022). Gut microbiota-derived short-chain fatty acids facilitate microbiota: host cross talk and modulate obesity and hypertension, *Current Hypertension Reports*, 23(2), 8. <https://doi.org/10.1007/s11906-020-01125-2>.
- Ozmen, O., Topsakal, S., Aydogan, A., & Dincoglu, D. (2016). Effects of Caffeine and Lycopene in Experimentally Induced Diabetes Mellitus. *Pancreas*, 45(0192), 579–583.

- Palozza, P., Catalano, A., Simone, R. E., Mele, M. C., & Cittadini, A. (2012). Effect of Lycopene and Tomato Products on Cholesterol Metabolism. *Annals of Nutrition and Metabolism*, 61(2), 126–134. <https://doi.org/10.1159/000342077>
- Petrovska, B. B. (2012). Historical review of medicinal plants' usage. *Pharmacognosy Reviews*, 6(11), 1. <https://doi.org/10.4103/0973-7847.95849>
- Petyaev, I. M. (2022). Carotenoids in Thermal Adaptation of Plants and Animals. IntechOpen. <https://doi.org/10.5772/INTECHOPEN.104537>
- Pierine, D. T., Navarro, M. E. L., Minatel, I. O., Luvizotto, R. A. M., Nascimento, A. F., Ferreira, A. L. A., Yeum, K., & Corrêa, C. R. (2014). Lycopene supplementation reduces TNF- α via RAGE in the kidney of obese rats. *Nutrition and Diabetes*, 4(11), e142. <https://doi.org/10.1038/nutd.2014.39>
- Poljšak, B., & Fink, R. (2014). The Protective Role of Antioxidants in the Defence against ROS/RNS-Mediated Environmental Pollution. *Oxidative Medicine and Cellular Longevity*, 2014(1), 671539. <https://doi.org/10.1155/2014/671539>
- Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., & Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. *BMC Endocrine Disorders*, 22(1), 1–9. <https://doi.org/10.1186/s12902-022-00980-1>
- Przybylska, S. (2020). Lycopene – a bioactive carotenoid offering multiple health benefits: a review. In *International Journal of Food Science and Technology*, 55(1), 11–32. <https://doi.org/10.1111/ijfs.14260>
- Przybylska, S., & Tokarczyk, G. (2022). Lycopene in the Prevention of Cardiovascular Diseases. *International Journal of Molecular Sciences*, 23(4), 1957. <https://doi.org/10.3390/ijms23041957>
- Rameshrad, M., Razavi, B. M., & Hosseinzadeh, H. (2017). Protective effects of green tea and its main constituents against natural and chemical toxins: A comprehensive review. *Food and Chemical Toxicology*, 100, 115–137. <https://doi.org/10.1016/J.FCT.2016.11.035>
- Rane, B. T., Worlikar, P. S., Mulkalwar, S. A., Tilak, A. V., & Dabhade, S. A. (2019). Evaluation of the effect of lycopene on lipid profile, serum antioxidant enzymes and blood sugar level in New

- Zealand white rabbits. *International Journal of Basic & Clinical Pharmacology*, 8(3), 431–437. <https://doi.org/10.18203/2319-2003.IJBCP20190565>
- Rao, A. V., & Agarwal, S. (2000). Role of antioxidant lycopene in cancer and heart disease. *Journal of the American College of Nutrition*, 19(5), 563–569. <https://doi.org/10.1080/07315724.2000.10718953>
- Rao, A. V., & Rao, L. G. (2007). Carotenoids and human health. *Pharmacological Research*, 55(3), 207–216. <https://doi.org/10.1016/J.PHR.2007.01.012>
- Rapa, S. F., Ra, B., Iorio, D., Campiglia, P., Heidland, A., & Marzocco, S. (2019). Inflammation and Oxidative Stress in Chronic Kidney Disease — Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. *International Journal of Molecular Sciences*, 21(1), 263. <https://doi.org/10.3390/ijms21010263>.
- Rasool, H.B. A. (2012). Medicinal Plants (Importance and Uses). *Pharmaceutica Analytica Acta*, 3(10), 2153–435. <https://doi.org/10.4172/2153-2435.1000e139>
- Rattanavipanon, W., Nithiphongwarakul, C., Sirisuwansith, P., Chaiyasothi, T., Thakkinstian, A., Nathisuwan, S., & Pathomwichaiwat, T. (2021). Effect of tomato, lycopene and related products on blood pressure: A systematic review and network meta-analysis. *Phytomedicine*, 88, 153512. <https://doi.org/10.1016/J.PHYMED.2021.153512>
- Ravarotto, Verdiana, Francesca Simioni, Elisa Pagnin, P. A. D. A. C. (2018). Oxidative stress – chronic kidney disease – cardiovascular disease: A vicious circle. *Life Sciences*, 210, 125–131.
- Rejali, L., Ozumerzifon, S., Nayeri, H., & Asgary, S. (2022). Risk reduction and prevention of cardiovascular diseases: biological mechanisms of lycopene. *Bioactive Compounds in Health and Disease*, 5(10), 202–221. <https://doi.org/10.31989/bchd.v5i10.975>
- Russo, C., Ferro, Y., Maurotti, S., Salvati, M. A., Mazza, E., Pujia, R., Terracciano, R., Maggisano, G., Mare, R., Giannini, S., Romeo, S., Pujia, A., & Montalcini, T. (2020). Lycopene and bone: an in vitro investigation and a pilot prospective clinical study. *Journal of Translational Medicine*, 18(1), 43. <https://doi.org/10.1186/S12967-020-02238-7>
- Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., Shaw, J. E., & Bright, D. (2019). Global and regional diabetes

prevalence estimates for 2019 and projections for 2030 and 2045 : Results from the International Diabetes Federation Diabetes Atlas , 9th edition. *Diabetes Research and Clinical Practice*, 157, 107843. <https://doi.org/10.1016/j.diabres.2019.107843>

Sahni, S., Hannan, M. T., Blumberg, J., Cupples, L. A., Kiel, D. P., & Tucker, K. L. (2009). Inverse association of carotenoid intakes with 4-y change in bone mineral density in elderly men and women: the Framingham Osteoporosis Study. *The American Journal of Clinical Nutrition*, 89(1), 416–424. <https://doi.org/10.3945/AJCN.2008.26388>

Saini, R. K., Rengasamy, K. R. R., Mahomoodally, F. M., & Keum, Y. S. (2020). Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives. *Pharmacological Research*, 155, 104730. <https://doi.org/10.1016/J.PHR.2020.104730>

Sakran, N., Graham, Y., Pintar, T., Yang, W., Kassir, R., Willigendael, E. M., & Singhal, R. (2022). The many faces of diabetes. Is there a need for re-classification ? A narrative review. *BMC Endocrine Disorders*, 22, 1–12. <https://doi.org/10.1186/s12902-021-00927-y>

Santos-araújo, C., Mendonça, L., Carvalho, D. S., Bernardo, F., Pardal, M., Couceiro, J., Martinho, H., Gavina, C., Taveira-gomes, T., & Dinis-oliveira, R. J. (2023). Twenty years of real-world data to estimate chronic kidney disease prevalence and staging in an unselected population. *Clinical Kidney Journal*, 16(1), 111–124.

Santos-Sánchez, N. F., Salas-Coronado, R., Villanueva-Cañongo, C., Hernández-Carlos, B., Santos-Sánchez, N. F., Salas-Coronado, R., Villanueva-Cañongo, C., & Hernández-Carlos, B. (2019). Antioxidant Compounds and Their Antioxidant Mechanism. *Antioxidants*, 10, 1-29. <https://doi.org/10.5772/INTECHOPEN.85270>

Scorza, M., Elce, A., Zarrilli, F., Liguori, R., Amato, F., & Castaldo, G. (2014). Genetic Diseases That Predispose to Early Liver Cirrhosis. *International Journal of Hepatology*, 2014(1), 713754. <https://doi.org/10.1155/2014/713754>

Senkus, K. E., Zhang, Y., Wang, H., Tan, L., & Crowe-white, K. M. (2021). Lycopene supplementation of maternal and weanling high-fat diets influences adipose tissue development

and metabolic outcomes of Sprague-Dawley offspring. *Journal of nutritional science*. 10, e96.
<https://doi.org/10.1017/jns.2021.91>

Seto, W. K., & Mandell, S. M. (2021). Chronic liver disease: Global perspectives and future challenges to delivering quality health care. *PLoS ONE*, 16(1), 10–12.
<https://doi.org/10.1371/journal.pone.0243607>

Shaki, O., Rai, S. K., Gupta, T. P., Chakrabarty, B. K., & Negi, R. S. (2021). To study the awareness of osteoporosis in postmenopausal Indian women in a Northeast part of India: An evaluation of the Osteoporosis Health Belief Scale. *Journal of Family Medicine and Primary Care*, 10(5), 1950-1955. <https://doi.org/10.4103/jfmmpc.jfmmpc>

Shams, T., Khalid, Z., and Saheem, A. (2015). Lycopene powers the inhibition of glycation-induced diabetic nephropathy: a novel approach to halt the AGE-RAGE axis menace. *BioFactors*, 41(5), 372–381.

Shan, S., Li, M., Sun, Z., Min, S., Jun, Y., & Tao, H. (2021). Lycopene ameliorates diabetic osteoporosis via anti-inflammatory, anti-oxidation, and increasing Osteoprotegerin / RANKL expression ratio. *Journal of Functional Foods*, 83, 104539. <https://doi.org/10.1016/j.jff.2021.104539>

Sharifi-Rad, M., Anil Kumar, N. V., Zucca, P., Varoni, E. M., Dini, L., Panzarini, E., Rajkovic, J., Tsouh Fokou, P. V., Azzini, E., Peluso, I., Prakash Mishra, A., Nigam, M., El Rayess, Y., Beyrouthy, M. El, Polito, L., Iriti, M., Martins, N., Martorell, M., Docea, A. O., ... Sharifi-Rad, J. (2020). Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases. *Frontiers in Physiology*, 11, 1–21. <https://doi.org/10.3389/fphys.2020.00694>

Shi, J., & Le Maguer, M. (2000). Lycopene in tomatoes: Chemical and physical properties affected by food processing. *Critical Reviews in Food Science and Nutrition*, 40(1), 1–42.
<https://doi.org/10.1080/10408690091189275>

Shi, Y., Xu, Y., & Zhou, W. (2024). Dietary carotenoids intake and sex differences in relation to chronic kidney disease a cross-sectional assessment in the NHANES study. *BMC Public Health*, 24(1), 1–9. <https://doi.org/10.1186/S12889-024-17771-Z/FIGURES/2>

- Shihab, E. M., Al-abbassi, M. G., Abd, D., Wahab, A., & Ahmad, I. T. (2018). Role of Estrogen in the Oxidation Process in Postmenopausal Osteoporosis. *Journal of Global Pharma Technology*, 10(08), 80-85.
- Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. *CA: A Cancer Journal for Clinicians*, 72(1), 7–33. <https://doi.org/10.3322/CAAC.21708>
- Soleymaninejad, M., Joursaraei, S. G., Feizi, F., & Anarkooli, I. J. (2017). The Effects of Lycopene and Insulin on Histological Changes and the Expression Level of Bcl-2 Family Genes in the Hippocampus of Streptozotocin-Induced Diabetic Rats. *Journal of Diabetes Research*, 2017(1), 4650939. <https://doi.org/10.1155/2017/4650939>
- Sommer, I., Griebler, U., Mahlknecht, P., Thaler, K., Bouskill, K., & Gartlehner, G. (2015). Socioeconomic inequalities in non-communicable diseases and their risk factors : an overview of systematic reviews. *BMC Public Health*, 15, 1–12. <https://doi.org/10.1186/s12889-015-2227-y>
- Spiers, J., Brindley, J. H., Li, W., & Alazawi, W. (2022). What’s new in non-alcoholic fatty liver disease? *Frontline Gastroenterology*, 13(e1), E102–E108. <https://doi.org/10.1136/flgastro-2022-102122>
- Story, E. N., Kopec, R. E., Schwartz, S. J., & Keith Harris, G. (2010). An update on the health effects of tomato lycopene. *Annual Review of Food Science and Technology*, 1(1), 189–210. <https://doi.org/10.1146/annurev.food.102308.124120>
- Świątkiewicz, I., Wróblewski, M., Nuskiewicz, J., Sutkowy, P., Wróblewska, J., & Woźniak, A. (2023). The Role of Oxidative Stress Enhanced by Adiposity in Cardiometabolic Diseases. *International Journal of Molecular Sciences*, 24(7), 6382. <https://doi.org/10.3390/IJMS24076382>
- Tahmasebi, M., & Emam-Djomeh, Z. (2021). Lycopene degradation and color characteristics of fresh and processed tomatoes under the different drying methods: a comparative study. *Chemical Papers*, 75(7), 3617–3623. <https://doi.org/10.1007/S11696-021-01611-0>
- Tarasconi, A., Coccolini, F., Biffl, W. L., Tomasoni, M., Ansaloni, L., Picetti, E., Molfino, S., Shelat, V., Cimbanassi, S., Weber, D. G., Abu-Zidan, F. M., Campanile, F. C., Di Saverio, S., Baiocchi, G. L., Casella, C., Kelly, M. D., Kirkpatrick, A. W., Leppaniemi, A., Moore, E. E., ... Catena, F. (2020). Perforated and bleeding peptic ulcer: WSES guidelines. *World Journal of Emergency Surgery*, 15(1), 1–24. <https://doi.org/10.1186/s13017-019-0283-9>

- Tierney, A. C., Rumble, C. E., Billings, L. M., & George, E. S. (2020). Effect of Dietary and Supplemental Lycopene on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis. *Advances in Nutrition*, *11*(6), 1453. <https://doi.org/10.1093/ADVANCES/NMAA069>
- Tjahjodjati, Sugandi, S., Umbas, R., & Satari, M. (2020). The protective effect of lycopene on prostate growth inhibitory efficacy by decreasing insulin growth factor-1 in Indonesian human prostate cancer cells. *Research and Reports in Urology*, *12*, 137–143. <https://doi.org/10.2147/RRU.S232745>
- Transl, J., Russo, C., Ferro, Y., Maurotti, S., Salvati, M. A., Mazza, E., Pujia, R., Terracciano, R., Maggisano, G., Mare, R., Giannini, S., Romeo, S., & Pujia, A. (2020). Lycopene and bone: an in vitro investigation and a pilot prospective clinical study. *Journal of Translational Medicine*, *18*, 1–11. <https://doi.org/10.1186/s12967-020-02238-7>
- Tu, K. N., Lie, J. D., King, C., Wan, V., Candidate, P., Cameron, M., Candidate, P., Austel, A. G., Candidate, P., Nguyen, J. K., Candidate, P., Van, K., & Hyun, D. (2018). *Osteoporosis: A Review of Treatment Options*. *Osteoporosis: A Review of Treatment Options*, *43*(2), 92–104.
- Turkler, C., Onat, T., Yildirim, E., Kaplan, S., Yazici, G. N., Mammadov, R., & Sunar, M. (2020). An experimental study on the use of lycopene to prevent infertility due to acute oxidative ovarian damage caused by a single high dose of methotrexate. *Advances in Clinical and Experimental Medicine*, *29*(1), 5–11. <https://doi.org/10.17219/acem/111809>
- Ugbaja, R. N., James, A. S., Ugwor, E. I., Akamo, A. J., Thomas, F. C., & Kosoko, A. M. (2021). Lycopene suppresses palmitic acid-induced brain oxidative stress, hyperactivity of some neuro - signalling enzymes, and inflammation in female Wistar rat. *Scientific Reports*, *11*(1), 15038. <https://doi.org/10.1038/s41598-021-94518-5>
- Upadhyay, S., & Dixit, M. (2015). Role of polyphenols and other phytochemicals on molecular signaling. *Oxidative Medicine and Cellular Longevity*, *2015*(1), 504253. <https://doi.org/10.1155/2015/504253>
- Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022). The Global Burden of Cardiovascular Diseases and Risk. *Journal of the American College of Cardiology*, *80*(25), 2361–2371. <https://doi.org/10.1016/j.jacc.2022.11.005>

- Varela, E. L. P., Gomes, A. R. Q., da Silva Barbosa dos Santos, A., de Carvalho, E. P., Vale, V. V., & Percário, S. (2022). Potential Benefits of Lycopene Consumption: Rationale for Using It as an Adjuvant Treatment for Malaria Patients and in Several Diseases. *Nutrients*, *14*(24), 5303. <https://doi.org/10.3390/NU14245303>
- Virani SS, Alonso A, Benjamin EJ, B. M. (2020). Heart disease and stroke statistics-2020 update: a report from the American heart association. *Circulation*, *141*(9), e39–e596.
- Walallawita, U. S., Wolber, F. M., Ziv-gal, A., Kruger, M. C., & Heyes, J. A. (2020). Potential Role of Lycopene in the Prevention of Postmenopausal Bone Loss: Evidence from Molecular to Clinical Studies. *International Journal of Molecular Sciences*, *21*(19), 7119.
- Wan, X., Ji, H., Ma, H., Yang, Z., Li, N., Chen, X., Chen, Y., Yang, H., & Wang, Z. (2022). Lycopene alleviates aflatoxin B1 induced liver damage through inhibiting cytochrome 450 isozymes and improving detoxification and antioxidant systems in broiler chickens. *Italian Journal of Animal Science*, *21*(1), 31–40. <https://doi.org/10.1080/1828051X.2021.2017803>
- Wang, G., Fang, Z., & Liu, D. (2022). Association between caffeine intake and lumbar spine bone mineral density in adults aged 20 – 49: A cross-sectional study. *Frontiers in Endocrinology*, *13*, 1008275. <https://doi.org/10.3389/fendo.2022.1008275>
- Wang, J., Kong, W., Liu, M., Wang, Y., Zheng, Y., & Zhou, Y. (2023). Association between dietary carotenoids intake and chronic constipation in American men and women adults: a cross-sectional study. *BMC Public Health*, *23*(1), 1–14. <https://doi.org/10.1186/S12889-023-16367-3/FIGURES/6>
- Warrens, H., Banerjee, D., & Herzog, C. A. (2022). Cardiovascular Complications of Chronic Kidney Disease: An Introduction. *European Cardiology Review*, *17*. <https://doi.org/10.15420/ECR.2021.54>
- Wood, L. G., Garg, M. L., Powell, H., & Gibson, P. G. (2008). Lycopene-rich treatments modify noneosinophilic airway inflammation in asthma: proof of concept. *Free Radical Research*, *42*(1), 94–102. <https://doi.org/10.1080/10715760701767307>
- Xaplanteris, P., Vlachopoulos, C., Pietri, P., Terentes-Printzios, D., Kardara, D., Alexopoulos, N., Aznaouridis, K., Miliou, A., & Stefanadis, C. (2012). Tomato paste supplementation improves

endothelial dynamics and reduces plasma total oxidative status in healthy subjects. *Nutrition Research*, 32(5), 390–394. <https://doi.org/10.1016/J.NUTRES.2012.03.011>

Xia, B., Zhu, R., Zhang, H., Chen, B., Liu, Y., Dai, X., Ye, Z., Zhao, D., Mo, F., Gao, S., Wang, X., Bromme, D., Wang, L., Wang, X., & Zhang, D. (2022). Lycopene Improves Bone Quality and Regulates AGE / RAGE / NF- κ B Signaling Pathway in High-Fat Diet-Induced Obese Mice. *Oxidative Medicine and Cellular Longevity*, 2022(1), 3697067.

Xie, R., Zhang, H., Liu, X., Liu, J., & Li, Q. (2022). Extraction of lycopene from tomato pomace and its protective effects on renal injury in diabetic rats. *Food Science and Technology*, 42, e116621. <https://doi.org/10.1590/fst.116621>

Xu, J., Song, C., Song, X., Zhang, X., & Li, X. (2017). Carotenoids and risk of fracture: a meta-analysis of observational studies. *Oncotarget*, 8(2), 2391–2399. <https://doi.10.18632/oncotarget.13678>

Xu, X., Li, S., & Zhu, Y. (2021). Dietary Intake of Tomato and Lycopene and Risk of All-Cause and Cause-Specific Mortality: Results from a Prospective Study. *Frontiers in Nutrition*, 8, 684859. <https://doi.org/10.3389/FNUT.2021.684859/BIBTEX>

Xu, X., Zheng, Y., Ye, H., & Jin, L. (2019). Lycopene supplementation decreases oxidative stress in hemodialysis patients receiving intravenous iron therapy: An open-label, randomized controlled clinical trial. *European Journal of Inflammation*, 17, 2058739218822864. <https://doi.org/10.1177/2058739218822864>

Yamamoto, Y., Aizawa, K., Mieno Phd, M., Karamatsu Bsc, M., Hirano Msc, Y., Furui Msc, K., Miyashita Msc, T., Yamazaki, K., Inakuma, T., Sato, I., Suganuma, H., & Iwamoto, T. (2017). The effects of tomato juice on male infertility. *Asia Pac J Clin Nutr*, 26(1), 65–71. <https://doi.org/10.6133/apjcn.102015.17>

Yang, P., Chen, H., Huang, Y., Hsieh, C., & Wung, B. (2017). Lycopene inhibits NF- κ B activation and adhesion molecule expression through Nrf2-mediated heme oxygenase-1 in endothelial cells. *International Journal of Molecular Medicine*, 39(6), 1533–1540. <https://doi.org/10.3892/ijmm.2017.2960>

- Yao, N., Yan, S., Guo, Y., Wang, H., Li, X., Wang, L., Hu, W., Li, B., & Cui, W. (2021). The association between carotenoids and subjects with overweight or obesity: a systematic review and meta-analysis. *Food & Function*, *12*(11), 4768–4782. <https://doi.org/10.1039/D1FO00004G>
- Yeap, Y. Y., Trevaskis, N. L., & Porter, C. J. H. (2013). Lipid absorption triggers drug supersaturation at the intestinal unstirred water layer and promotes drug absorption from mixed micelles. *Pharmaceutical Research*, *30*(12), 3045–3058. <https://doi.org/10.1007/S11095-013-1104-6>
- Yim, M. H., Kim, K. H., & Lee, B. J. (2021). The number of household members as a risk factor for peptic ulcer disease. *Scientific Reports*, *11*(1), 1–10. <https://doi.org/10.1038/s41598-021-84892-5>
- Yin, Y., Zheng, Z., & Jiang, Z. (2019). Biomedicine & Pharmacotherapy Effects of lycopene on metabolism of glycolipid in type 2 diabetic rats. *Biomedicine & Pharmacotherapy*, *109*(74), 2070–2077. <https://doi.org/10.1016/j.biopha.2018.07.100>
- Zaripheh, S., Boileau, T. W. M., Lila, M. A., & Erdman, J. W. (2003). [14C]-lycopene and [14C]-labeled polar products are differentially distributed in tissues of F344 rats prefed lycopene. *The Journal of Nutrition*, *133*(12), 4189–4195. <https://doi.org/10.1093/JN/133.12.4189>
- Zenebe, S., & Caroline, L. (2018). Psychosocial Stress Over the Lifespan, Psychological Factors , and Cardiometabolic Risk in the Community. *Psychosomatic Medicine*, *80*(7), 628-639. <https://doi.10.1097/PSY.0000000000000621>
- Zhang, W., Lian, Y., Li, Q., Sun, L., Chen, R., Lai, X., Lai, Z., Yuan, E., & Sun, S. (2020). Preventative and therapeutic potential of flavonoids in peptic ulcers. *Molecules*, *25*(20), 4626. <https://doi.org/10.3390/molecules25204626>
- Zhang, X., Zhou, Q., Qi, Y., Chen, X., Deng, J., Zhang, Y., Li, R., & Fan, J. (2023). The effect of tomato and lycopene on clinical characteristics and molecular markers of UV-induced skin deterioration: A systematic review and meta-analysis of intervention trials. *Critical Reviews in Food Science and Nutrition*, *64*(18), 6198-6217. <https://doi.org/10.1080/10408398.2022.2164557>
- Zhao, B., Liu, H., Wang, J., Liu, P., Tan, X., Ren, B., Liu, Z., & Liu, X. (2018). Lycopene Supplementation Attenuates Oxidative Stress, Neuroinflammation, and Cognitive Impairment in Aged CD-1 Mice. *Journal of Agricultural and Food Chemistry*, *66*(12), 3127–3136. <https://doi.org/10.1021/ACS.JAFC.7B05770>

- Zhong, J., & Shi, G. (2019). Editorial: Regulation of Inflammation in Chronic Disease. *Frontier in Immunology*, 10, 737. <https://doi.org/10.3389/fimmu.2019.00737>
- Zhong, Q., Piao, Y., Yin, S., & Zhang, K. (2022). Association of serum lycopene concentrations with all-cause and cardiovascular mortality among individuals with chronic kidney disease: A cohort study. *Frontier in Nutrition*, 9, 1048884. <https://doi.org/10.3389/fnut.2022.1048884>
- Zhu, R., Chen, B., Bai, Y., Miao, T., Rui, L., Zhang, H., Xia, B., Li, Y., Gao, S., Wang, X. D., & Zhang, D. (2020). Lycopene in protection against obesity and diabetes: A mechanistic review. *Pharmacological Research*, 159, 104966. <https://doi.org/10.1016/J.PHRS.2020.104966>
- Zhu, S. Y., Li, X. N., Zhao, Y., Dai, X. Y., Guo, J. Y., & Li, J. L. (2022). Lycopene Ameliorate Atrazine-Induced Oxidative Damage in the B Cell Zone via Targeting the miR-27a-3p/Foxo1 Axis. *Journal of Agricultural and Food Chemistry*, 70(39), 12502–12512. https://doi.org/10.1021/ACS.JAFC.2C05103/SUPPL_FILE/JF2C05103_SI_001.PDF

**CHAPTER THREE: EFFECT OF LYCOPENE
ON GROWTH PERFORMANCE AND
GASTROINTESTINAL VISCERA
MACROMORPHOMETRY OF WISTAR RATS
FED A HIGH-FRUCTOSE DIET**

3.0 Introduction

Dietary alteration during early life can increase susceptibility to metabolic disorders or promote better health outcomes in adulthood (Reynolds et al., 2015). Metabolic syndrome, a worldwide epidemic impacting individuals of various age groups (Bitew et al., 2021), is projected to affect approximately 3.3% of children and adolescents globally (Al-Hamad & Raman, 2017). Its prevalence ranges from 0.2% to 38.9% (Al-Hamad & Raman, 2017). The heightened prevalence of metabolic disorders is linked to an upsurge in fructose consumption, among various other factors (Aoun et al., 2022). Fructose is absorbed in the small intestine and metabolised majorly by the liver, through fructolysis, glycolysis, lipogenesis and gluconeogenesis (Hannou et al., 2018).

The gastrointestinal tract (GIT) plays a vital role in the digestion and absorption of nutrients (Basile et al., 2023). Excessive dietary fructose intake has been reported to disrupt energy balance, regulation of body mass, growth, and induce changes in organ morphology, particularly in the GIT system (Guney et al., 2023). Consuming high fructose impacts gut microbiota composition, causing an increase in lipopolysaccharides production from Gram-negative bacteria (Beisner et al., 2020). This shift in microbiota alters the morphometry of the GIT viscera and accessory organs (Zhang et al., 2017). This alteration may increase the likelihood of developing metabolic disorders (Taskinen et al., 2019). High fructose intake affects bone metabolism by disrupting the absorption, reabsorption and elimination of crucial vitamins and minerals essential for promoting healthy bone growth (Kuan et al., 2018). In growing children and adolescents, a balanced diet is a necessity for proper bone growth and development and helps mitigate the risk of osteoporotic fractures in later life (Proia et al., 2021). Osteoporosis, a skeletal disorder, is marked by the reduction in bone mass, diminished bone mineral density, deterioration of microarchitectural integrity and weakened bone strength (Barnsley et al., 2021). This leads to increased fragility of bones and higher risk of fractures, particularly in the spine, hip, and humerus (Morin et al., 2014). Over 200 million individuals globally are affected by osteoporosis (Akkawi & Zmerly, 2018). Statistics indicate that vertebral or femoral fractures occur approximately every 200 seconds (De Martinis et al., 2021). It has been demonstrated that individuals with spinal cord injuries exhibit increased susceptibility to fractures in the tibia and femur (Zheng et al., 2021). Osteoporosis affects individuals across all ethnic groups and both sexes (Askari et al., 2019). Approximately 33% of women and 20% of men, usually age 50 and above will experience a fragility fracture at some point in their lifetime (Shen et al., 2022).

There is a dire need to mitigate the high fructose diet-induced alterations in growth, GIT viscera morphometry and bone development. Functional foods, which are rich in secondary plant metabolites, can be used to mitigate such diet-induced changes. Secondary plant metabolites play a key role in defending plants from herbivory, as well as from bacterial, fungal, protozoal, and viral threats (Al-Khayri et al., 2023), while also demonstrating health-promoting biological activities (Divekar et al., 2022), which can be tapped into to mitigate diet-induced metabolic derangements. Lycopene, a liposoluble carotenoid prevalent in tomatoes and watermelons, has antioxidant and anti-inflammatory activities (Rasmus & Kozłowska, 2023). In the GIT it has been shown to protect the GIT mucosae integrity leading to improved nutrient absorption (Rajput et al., 2021), bone health (Costa-Rodrigues et al., 2018), and promotion of growth (Wu et al., 2024). This study therefore evaluated the prophylactic potential of orally administered lycopene to protect against dietary fructose-induced metabolic derangements, focusing on the growth performance and gastrointestinal visceral macromorphometry in growing Wistar rats.

3.1 Materials and methods

3.1.1 Ethical approval

Approval for the study's ethical clearance was given by the Animal Ethics Screening Committee at the University of Witwatersrand (AESC 2022/03/02/C). The research protocols and procedures were thoroughly reviewed to ensure compliance with ethical standards. The research was conducted at the Wits Research Animal Facility (WRAF) in Johannesburg, South Africa and it subscribed to the ARRIVE protocol.

3.1.2 Chemicals and reagents

All chemicals and reagents used in this study were of analytical grade. Fenofibrate was obtained from Sigma-Aldrich, based in St. Louis, Missouri, USA. Fructose was purchased from Nature's Choice in Randvaal, South Africa, while lycopene was supplied by Changsha Staherb Natural Ingredient Co., Ltd (Hunan, China).

3.1.3 Animals, housing, and general care

The study involved ninety-six 21-day-old male and female Wistar rat pups. These weanling rats were selected from litters of first-time dams, with each litter containing between 8 and 12 pups. The rats were individually housed in standard Perspex cages at the Wits Research Animal Facility

(WRAF), University of the Witwatersrand, with wood shavings used as bedding, which was changed twice a week. They were kept on a 12-hour light/dark cycle, with the lights on from 7 am to 7 pm, and the room temperature was controlled at $24\pm 2^{\circ}\text{C}$. The rats had *ad libitum* access to either a standard rat chow or a 20% fructose solution, depending on their treatment group. The commercial rat feed (Pet Food Industry of Southern Africa) had the following nutritional composition: 40 g/kg fibre, 70 g/kg ash, 100 g/kg moisture, 220 g/kg protein, 50 g/kg oils and fats, 12 g/kg linoleic acid, 7.5 g/kg phosphorus, 12 g/kg calcium, 16,000 IU/kg vitamin A, 2,000 IU/kg vitamin D, and 100 g/kg vitamin E.

3.1.4 Experimental design

On postnatal day 23 (PND), after a two-day habituation period, the rats were randomly assigned to one of the following treatment groups:

group 1 (control): were given standard rat chow (SRC), plain drinking water (PDW), and a plain gelatine cube (PG).

group 2 (negative control): SRC, a 20% w/v fructose solution (FS) as drinking fluid, and PG.

group 3 (positive control): SRC, FS, and 100 mg/kg body mass per day of fenofibrate in gelatine cube (FENO).

group 4 (low dose): SRC, FS, and Lycopene at 30 mg/kg body mass per day in gelatine cube (LDLY).

group 5 (medium dose): SRC, FS, and Lycopene at 60 mg/kg body mass per day in gelatine cube (MDLY).

group 6 (high dose): SRC, FS, and Lycopene at 100 mg/kg body mass per day in gelatine cube (HDLY).

Groups 4, 5, and 6 were designed to assess the potential preventive effects of lycopene against metabolic dysfunction induced by a high-fructose diet. Each group consisted of 16 rats, with an equal number of 8 males and 8 females per group. The rats were administered to their respective treatments over a 12-week period. The fenofibrate dose (Kopf et al., 2014) and lycopene doses

(Gustin et al., 2004; Zhang et al., 2020) were selected based on previously documented studies. The gelatine cubes used to deliver fenofibrate and lycopene were prepared according to the method described by Kamerman et al. (2004), with a slight adjustment. Instead of using 16 g of brown sugar, 8 g of Selati sugar (RCL Foods and Sugar Milling Ltd, South Africa) were used, as a higher sugar concentration led to decreased intake.

3.1.5 Measurements: body mass, feed, fluid, and calorie intake

At the start of the experiment, the rats were weighed, and their weights were recorded twice weekly using a Snowrex Electronic Scale from Clover Scale (Pty) Ltd, Johannesburg. This allowed for tracking their growth performance, general health, and ensuring accurate doses of fenofibrate and lycopene during the 12-week treatment. Throughout the intervention, feed and fluid intake were monitored weekly. At the end of each week, the remaining feed and fluid were subtracted from the total amounts provided to each rat. Weekly feed and fluid consumption were then calculated as percentages of body mass, expressed as g/100g and ml/100g, respectively. Total weekly calorie intake was determined by multiplying the consumption of feed and fructose by their respective calorie values, and summing the results. The cumulative intake of feed, fluid, and calories for each experimental group was then calculated by adding up the weekly totals over the 12-week period.

3.1.6 Terminal procedures and sample collection

On postnatal day 106, the rats underwent an 11 hours overnight fast, although plain drinking water was made available to prevent dehydration. In the morning of termination (postnatal day 107), the body mass of each rat was measured using a Snowrex Electronic Scale from Clover Scale (Pty) Ltd, Johannesburg. The rats were then euthanised using an intraperitoneal injection of sodium pentobarbitone (Euthapent; Kyrion Laboratories, Johannesburg) at a dose of 200 mg/kg body mass. A midline abdominal incision was performed to extract and weigh the pancreas, liver, kidneys, stomach, caecum, small and large intestines, and visceral and epididymal fat pads (in male rats) using an electronic balance (Presica 310M, Instruments, Johannesburg, South Africa). The lengths of the small and large intestines were recorded using a ruler placed on a chilled dissection board. The left hind leg femoral attachment to the pelvis was also excised, sealed, and stored in Ziplock bags at -20°C for subsequent measurement of the long bones.

3.1.7 Measurement of bone morphometry

The femora and tibiae, which had been frozen, were removed from the freezer and left to thaw at room temperature for approximately 45 minutes. Once thawed, the bones were carefully defleshed and separated using scissors and scalpels. The bones were then placed in an oven (LABOTEC (Pty) Ltd., South Africa) set at 50°C for five days to ensure they reached constant mass. The bone masses were measured using an electronic scale (Presica 310M, Instruments, Johannesburg, South Africa). Tibia length was measured from the tibial head to the medial malleolus, while the femur

length was measured from the distal femoral articular surface to the greater trochanter, using a digital Vernier calliper (Major Tech (Pty) Ltd., KTV 150 digital calliper, Elandsfontein, South Africa).

The bone mass to length ratio was calculated using the formula: bone mass to length ratio = mass of bone (mg) / length of bone (mm), as outlined by Seedor et al. (1991).

3.1.8 Statistical analysis

The data was analysed using GraphPad Prism version 9.0 (Graph-Pad Software Inc., San Diego, USA) and presented as mean \pm standard deviation. Parametric data from multiple groups were analysed using a one-way ANOVA, while a repeated measures ANOVA was used to analyse weekly body mass, feed, fluid, and calorie intake data. Tukey's *post hoc* test was used for the mean comparison. Statistical significance was defined as $p < 0.05$.

3.2 Results

3.2.1 Body mass

Figures 3.2 and 3.3 below present the mean weekly, induction, and terminal body masses of the female and male rats, respectively. In the female rats, there were no significant differences ($p > 0.05$) observed in the mean induction, weekly body, and terminal body masses across treatment groups (Figure 3.2). Similarly, there were no significant differences ($p > 0.05$) observed in the induction body mass of the male rats (Figure 3.3). In both female and male rats, significant growth ($p < 0.00001$) was evident across the treatment groups from induction through termination (Figure 3.2 and 3.3). The mean weekly body mass of male rats fed the control diet was significantly higher ($p < 0.05$) compared to their counterparts administered medium doses of lycopene at weeks 3 and 4 and fenofibrate at weeks 10, 11, and 12 as interventions (Figure 3.3). Similarly, the terminal body mass of male rats fed the control diet was significantly higher ($p < 0.05$) compared to those fed a high fructose diet and fenofibrate as an intervention. However, the terminal body mass of male rats fed control, high fructose, and high fructose diets with low, medium, and high doses of lycopene as an intervention were similar ($p > 0.05$) (Figure 3.3).




Figure 3. 2: Weekly body masses (A) and induction and terminal body masses (B) of female Wistar rats

No significant difference ($p > 0.05$) in induction, mean weekly and terminal body mass, across treatment groups. *** $p < 0.0001$ induction compared to terminal body mass. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg/kg body mass per day (mg. $\text{kg}^{-1}\text{BM day}^{-1}$) of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 $\text{mg} \cdot \text{kg}^{-1}\text{BM day}^{-1}$ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 $\text{mg} \cdot \text{kg}^{-1}\text{BM day}^{-1}$ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 $\text{mg} \cdot \text{kg}^{-1}\text{BM day}^{-1}$ in gelatine cube. Data are expressed as mean \pm SD, $n = 8$ per treatment group.




Figure 3. 3: Weekly body masses (A) and induction and terminal body masses (B) of male Wistar rats

* $p < 0.05$ mean weekly body masses at weeks 3 (FS + LDLY), 4 (FS + MDLY), 10, 11, and 12 (FS + FENO) compared to control (PDW + PG); terminal body masses (FS + FENO) compared to control (PDW + PG) *** $p < 0.0001$ induction vs terminal. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean \pm SD, n = 8 per treatment group.

3.2.2 Feed, fluid, and calorie intake

Figures 3.4 and 3.5 below show the feed, fluid, and calories intake in female and male rats respectively. In the females, there was no significant difference ($p > 0.05$) across treatment groups in week 1, but a significant difference ($p < 0.05$) from week 2 to week 12. From week 3 through week 12, rats fed a high fructose diet, and high fructose diet with low, medium, and high doses of lycopene as an intervention had significantly ($p < 0.05$) lower weekly feed intake compared to control. In weeks 2, 3, 4, 6, 7, 8, 9, and 11 rats that had fenofibrate as an intervention had significantly ($p < 0.05$) lower weekly feed intake compared to control counterparts. From week 5 to week 11, rats administered fenofibrate had significantly ($p < 0.05$) higher weekly feed intake compared to counterparts fed the high fructose diet, and or the high fructose diet supplemented with low, medium, or high doses of lycopene (Figure 3.4A). The total feed intake (TFI) of fructose-fed rats and their counterparts fed the high fructose diet with low and medium lycopene doses as supplements was similar ($p > 0.05$). Additionally, there was no difference in TFI between rats supplemented with the low and high lycopene doses ($p > 0.05$; Figure 3.4B). There was no significant difference ($p > 0.05$) in the weekly fluid intake across treatment groups from week 1 to week 5 and week 11. However, at weeks 6 and 10, orally administered fenofibrate had significantly ($p < 0.05$) lower weekly fluid intake compared to control and low-dose lycopene, respectively. At week 12, low-dose lycopene had significantly ($p < 0.05$) higher weekly fluid intake compared to

control counterparts (Figure 3.4C). The total fluid intake of rats fed the control diet, high fructose diet and high fructose diet supplement with medium dose lycopene was similar ($p > 0.05$; Figure 3.4D). Likewise, the total fluid intake of rats fed a high fructose diet supplemented with medium and high lycopene doses were similar ($p > 0.05$; Figure 3.4D). There was no significant difference ($p > 0.05$) in the rats' total weekly calorie intake from weeks 2 to 6, weeks 8 and 11, and weeks 12. In week 1, compared to control counterparts, rats fed the high fructose diet and those fed the high fructose diet with the medium dose lycopene supplement had significantly ($p < 0.05$; Figure 3.4E) higher total weekly calories intake. In week 7, rats fed the high fructose diet with fenofibrate as an intervention had significantly higher ($p < 0.05$) total calorie intake compared to their counterparts fed the control, high fructose diet, and high fructose diet with a medium dose of lycopene, respectively. Similarly, in weeks 9 and 10, rats administered fenofibrate had significantly ($p < 0.05$) higher total weekly calorie intake compared to their counterparts fed high fructose diet, and high fructose diet supplemented with medium and high doses of lycopene (Figure 3.4E). The total calorie intake of rats fed the control diet, high fructose diet, and high fructose diet supplemented with high-dose lycopene was similar ($p > 0.05$). Similarly, fructose-fed rats and counterparts fed the high fructose diet with low, medium, and high lycopene doses as supplements were similar ($p > 0.05$). There was no difference in total calorie intake between rats supplemented with low, medium, and high lycopene doses ($p > 0.05$; Figure 3.4F).

In the male Wistar rats, there was a significant difference ($p < 0.05$) across treatment groups from week 1 to week 12. From week 1 through week 12, rats fed a high fructose diet, high fructose diet with fenofibrate, high fructose diet with low, medium, and high doses of lycopene as an intervention had significantly ($p < 0.05$) lower weekly feed intake compared to control. However, during week 2, rats fed the high fructose diet supplemented with medium lycopene doses showed a significant reduction ($p < 0.05$) in weekly feed intake compared to their control counterparts. From weeks 7 to 12, rats fed the high fructose diet with fenofibrate as an intervention had significantly higher ($p < 0.05$) weekly feed intake compared to their counterparts fed the high fructose diet with low and high doses of lycopene, respectively. However, during week 10, rats administered fenofibrate had significantly ($p < 0.05$) higher weekly feed intake compared to their counterparts fed the high fructose diet with low, medium, and high lycopene doses as supplements. In weeks 9-12, rats administered fenofibrate had significantly ($p < 0.05$) higher weekly feed intake compared to their counterparts fed a high fructose diet (Figure 3.5A). There was no difference in

the TFI between rats supplemented with the low, medium, and high lycopene doses ($p > 0.05$). Similarly, the TFI of rats fed the high fructose diet with medium and high lycopene doses was similar ($p > 0.05$; Figure 3.5B). There was no significant difference ($p > 0.05$) in the male rats' weekly fluid intake across treatment groups from week 1 to weeks 3, 5 to 7, 9, and 12. In week 4, compared to their control counterparts, rats fed the high fructose diet with medium lycopene doses as supplement had significantly ($p < 0.05$) lower weekly fluid intake. However, at weeks 10 and 11, rats fed the high fructose diet, high fructose diet with low, medium, and high lycopene doses as supplements had significantly ($p < 0.05$) higher weekly fluid intake compared to their counterparts fed the control diet. In weeks 8 and 10, rats administered fenofibrate had significantly ($p < 0.05$) lower fluid intake compared to high-dose lycopene in week 8 and compared to low- and high-dose lycopene in week 10 (Figure 3.5C). The total fluid intake of rats fed the control diet, high fructose diet and high fructose diet supplement with low dose lycopene was similar ($p > 0.05$). Similarly, the total fluid intake between rats fed high fructose diet with fenofibrate as intervention and high fructose diet supplemented with medium dose lycopene was similar (Figure 3.5D). There was no significant difference ($p > 0.05$) in the total weekly calorie intake from weeks 1 to 6, 8, 10 and 12 across treatment groups. In weeks 7, 9 and 11, rats administered fenofibrate had significantly ($p < 0.05$) higher total weekly calories intake compared to low-dose lycopene in week 7, compared to low- and medium dose lycopene in week 9 and compared to low- and high dose lycopene and high fructose diet in week 11 (Figure 3.5E). In the male Wistar rats, the total calorie intake of fructose fed rats, and their counterparts fed the high fructose diet with low and high lycopene doses as supplements was similar ($p > 0.05$). Similarly, rats administered fenofibrate were similar to the control ($p > 0.05$). Additionally, there was no difference in the total calorie intake between rats supplemented with low and high lycopene doses ($p > 0.05$; Figure 3.5F).









Figure 3. 4: Effect of lycopene on weekly feed (A), total feed (B), weekly fluid (C), total fluid (D), weekly calorie (E), and total calorie intake (F) of female Wistar rats fed a high-fructose diet.

#, α , β $p < 0.05$, * = significantly different at $p < 0.05$, *** = significantly different at $p < 0.0001$. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDL = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean \pm SD, n = 8 per treatment group.









Figure 3. 5: Effect of lycopene on weekly feed (A), total feed (B), weekly fluid (C), total fluid (D), weekly calorie (E), and total calorie intake (F) of male Wistar rats fed a high-fructose diet.

^{#, α, β} $p < 0.05$, * = significantly different at $p < 0.05$, ** = significantly different at $p < 0.001$, *** = significantly different at $p < 0.0001$. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 8 per treatment group.

3.2.3 Long bone indices

Tables 3.1 and 3.2 show the effect of lycopene on the morphometric characteristics of femur and tibia in female and male rats fed a high fructose diet. No significant differences were observed in the lengths, masses, and bone mass to length ratio of the tibiae and femora in the female rats ($p > 0.05$) across treatment groups (Table 3.1). Male Wistar rats fed a high fructose diet and fenofibrate as an intervention had significantly lower ($p < 0.05$) femora mass compared to those fed a high fructose diet with a low dose of lycopene as an intervention. However, the mean femora mass of the male rats fed the control diet, high fructose diet, and high fructose diet supplemented with low, medium, and high lycopene doses, respectively, were similar ($p > 0.05$). The mean tibia length of the male rats fed a high fructose diet with fenofibrate as an intervention was significantly shorter ($p < 0.05$) compared to that of counterparts fed the control diet and a high fructose diet in combination with either of the three lycopene doses. Nonetheless, the mean tibia length of the male rats fed the control, high fructose diet, and high fructose diet with low, medium, and high doses of lycopene as an intervention were similar ($p > 0.05$; Table 3.2).

Table 3. 1: Effect of lycopene on the lengths, masses and mass to length ratio of tibiae and femora in growing female Wistar rats fed a high-fructose diet

Parameter	PDW + PG	FS + PG	FS + FENO	FS + LDLY	FS + MDLY	FS + HDLY	Significance
Tibia							
Mass (mg)	455.00 ± 19.27 ^a	462.50 ± 19.09 ^a	462.50 ± 26.05 ^a	451.30 ± 20.31 ^a	460.50 ± 13.09 ^a	447.5 ± 26.59 ^a	ns
Length (mm)	34.98 ± 0.65 ^a	35.58 ± 1.89 ^a	34.50 ± 0.51 ^a	34.43 ± 0.60 ^a	35.37 ± 1.74 ^a	34.68 ± 0.64 ^a	ns
Mass/length ratio (mg/mm)	13.01 ± 0.58 ^a	13.09 ± 0.57 ^a	13.41 ± 0.76 ^a	13.11 ± 0.51 ^a	13.03 ± 0.69 ^a	12.89 ± 0.55 ^a	ns
Femur							
Mass (mg)	545.00 ± 31.62 ^a	548.80 ± 20.31 ^a	532.50 ± 23.75 ^a	541.30 ± 26.96 ^a	526.30 ± 48.97 ^a	535.00 ± 34.23 ^a	ns
Length (mm)	30.68 ± 0.94 ^a	30.45 ± 2.00 ^a	29.73 ± 0.53 ^a	29.97 ± 0.58 ^a	28.89 ± 2.64 ^a	30.24 ± 0.54 ^a	ns
Mass/length ratio (mg/mm)	17.75 ± 0.54 ^a	18.08 ± 1.21 ^a	17.92 ± 0.91 ^a	18.06 ± 0.91 ^a	18.22 ± 0.47 ^a	17.68 ± 0.88 ^a	ns

^aMeans within rows having the same superscripts are similar at $p > 0.05$, ns = not significant. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 8 per treatment group.

Table 3. 2: Effect of lycopene on the lengths, masses and Mass to length ratio of tibiae and femora in growing male Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Tibia							
mass (mg)	613.80 ± 35.83 ^a	605.00 ± 35.05 ^a	572.50 ± 32.84 ^a	606.30 ± 28.25 ^a	596.30 ± 28.25 ^a	597.50 ± 26.05 ^a	ns
Length (mm)	39.73 ± 0.75 ^a	39.40 ± 0.60 ^{ab}	38.47 ± 0.74 ^b	39.85 ± 0.65 ^a	39.47 ± 0.47 ^a	39.77 ± 0.61 ^a	**
Mass/length ratio (mg/mm)	15.44 ± 0.76 ^a	15.36 ± 0.87 ^a	14.89 ± 0.93 ^a	15.21 ± 0.61 ^a	15.11 ± 0.69 ^a	15.03 ± 0.63 ^a	ns
Femur							
Mass (mg)	725.00 ± 37.42 ^{ab}	710.00 ± 31.62 ^{ab}	678.80 ± 36.43 ^a	730.00 ± 27.26 ^b	718.80 ± 30.91 ^{ab}	716.30 ± 25.04 ^{ab}	*
Length (mm)	34.25 ± 0.77 ^a	34.00 ± 0.41 ^a	33.07 ± 0.79 ^a	30.18 ± 11.98 ^a	35.01 ± 0.88 ^a	34.32 ± 0.54 ^a	ns
Mass/length ratio (mg/mm)	21.16 ± 0.67 ^a	20.88 ± 0.89 ^a	20.52 ± 0.74 ^a	143.70 ± 346.00 ^a	20.53 ± 0.75 ^a	20.87 ± 0.83 ^a	ns

^{ab}Means within rows having the different superscripts differ significantly at * p < 0.05, ** p < 0.001, ns = not significant. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 8 per treatment group.

3.2.4 Visceral organ macro-morphometry

Tables 3.3 and 3.4 show the effect of lycopene on the absolute and relative masses and length (where applicable) of the small and large intestines, stomach, and caecum of female and male rats, respectively, fed a high fructose diet. There were no significant differences in viscera morphometry of female rats ($p > 0.05$) across treatment groups (Table 3.3). The male rats fed the control diet had significantly reduced ($p < 0.05$) absolute and relative stomach masses compared to their counterparts fed a high fructose diet with fenofibrate and or a high fructose diet with a medium and high dose of lycopene as interventions. However, the absolute and relative stomach masses of the rats fed the control, high fructose diet, and high fructose diet with low dose of lycopene as an intervention were similar ($p > 0.05$).

Table 3. 3: Effect of lycopene on absolute and relative masses and length of the visceral organs in growing female rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Stomach mass (g)	1.34 ± 0.12 ^a	1.36 ± 0.14 ^a	1.44 ± 0.12 ^a	1.49 ± 0.19 ^a	1.38 ± 0.20 ^a	1.34 ± 0.09 ^a	ns
Stomach (%BM)	0.64 ± 0.05 ^a	0.64 ± 0.07 ^a	0.69 ± 0.08 ^a	0.69 ± 0.08 ^a	0.64 ± 0.05 ^a	0.64 ± 0.05 ^a	ns
Caecum mass (g)	1.20 ± 0.29 ^a	0.88 ± 0.17 ^a	0.91 ± 0.29 ^a	0.80 ± 0.20 ^a	0.89 ± 0.18 ^a	1.03 ± 0.23 ^a	ns
Caecum (%BM)	0.52 ± 0.14 ^a	0.42 ± 0.08 ^a	0.44 ± 0.14 ^a	0.39 ± 0.08 ^a	0.41 ± 0.08 ^a	0.49 ± 0.12 ^a	ns
L. Intestine mass (g)	1.32 ± 0.19 ^a	1.07 ± 0.41 ^a	1.33 ± 0.19 ^a	1.24 ± 0.14 ^a	1.14 ± 0.14 ^a	1.22 ± 0.15 ^a	ns
L. Intestine (%BM)	0.63 ± 0.08 ^a	0.51 ± 0.20 ^a	0.64 ± 0.09 ^a	0.58 ± 0.07 ^a	0.53 ± 0.06 ^a	0.58 ± 0.09 ^a	ns
L. Intestine length (mm)	197.30 ± 24.18 ^a	176.30 ± 25.46 ^a	173.30 ± 69.99 ^a	183.8 ± 24.89 ^a	182.10 ± 10.58 ^a	184.40 ± 37.17 ^a	ns
S. Intestine Mass (g)	5.36 ± 0.80 ^a	5.36 ± 0.80 ^a	5.82 ± 0.69 ^a	5.90 ± 0.33 ^a	5.71 ± 1.13 ^a	5.81 ± 0.73 ^a	ns
S. Intestine (%BM)	2.55 ± 0.36 ^a	2.75 ± 0.30 ^a	2.82 ± 0.23 ^a	2.67 ± 0.59 ^a	2.70 ± 0.28 ^a	2.33 ± 0.77 ^a	ns
S. Intestine length (mm)	1023.00 ± 36.45 ^a	1018.00 ± 36.44 ^a	1068.00 ± 74.26 ^a	1059.00 ± 34.30 ^a	1026.00 ± 45.02 ^a	974.90 ± 160.40 ^a	ns

^aMeans within rows having the same superscripts are similar at $p > 0.05$, ns = not significant, L = Large, S = Small. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking

fluid + Lycopene $30 \text{ mg.kg}^{-1}\text{BM day}^{-1}$ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene $60 \text{ mg.kg}^{-1}\text{BM day}^{-1}$ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene $100 \text{ mg.kg}^{-1}\text{BM day}^{-1}$ in gelatine cube. Data are expressed as mean \pm SD, n = 8 per treatment group.

Table 3. 4 Effect of lycopene on absolute and relative masses and length of the visceral organs in growing male rats fed a high-fructose diet.

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Stomach mass (g)	1.71 ± 0.09 ^a	1.83 ± 0.36 ^{ab}	2.03 ± 0.15 ^b	1.91 ± 0.12 ^{ab}	2.00 ± 0.12 ^b	2.01 ± 0.17 ^b	*
Stomach (%BM)	0.49 ± 0.03 ^a	0.54 ± 0.11 ^{ab}	0.63 ± 0.06 ^c	0.55 ± 0.03 ^{abc}	0.59 ± 0.03 ^c	0.58 ± 0.04 ^c	***
Caecum mass (g)	1.41 ± 0.18 ^a	1.33 ± 0.33 ^a	1.28 ± 0.46 ^a	1.24 ± 0.27 ^a	1.46 ± 0.23 ^a	1.50 ± 0.31 ^a	ns
Caecum (%BM)	0.40 ± 0.05 ^a	0.38 ± 0.08 ^a	0.39 ± 0.13 ^a	0.36 ± 0.08 ^a	0.43 ± 0.06 ^a	0.44 ± 0.08 ^a	ns
L. Intestine mass (g)	1.78 ± 0.28 ^a	1.68 ± 0.16 ^a	1.72 ± 0.32 ^a	2.28 ± 1.59 ^a	1.70 ± 0.18 ^a	1.79 ± 0.13 ^a	ns
L. Intestine (%BM)	0.50 ± 0.08 ^a	0.49 ± 0.05 ^a	0.53 ± 0.08 ^a	0.67 ± 0.50 ^a	0.50 ± 0.05 ^a	0.52 ± 0.04 ^a	ns
L. Intestine length (mm)	228.10 ± 11.00 ^a	213.10 ± 17.72 ^a	222.90 ± 18.22 ^a	213.10 ± 12.23 ^a	218.80 ± 27.09 ^a	223.80 ± 8.35 ^a	ns
S. Intestine Mass (g)	7.11 ± 0.57 ^{ab}	7.69 ± 0.70 ^{ab}	8.01 ± 0.48 ^a	6.48 ± 2.18 ^b	7.60 ± 0.49 ^{ab}	8.17 ± 0.57 ^a	*
S. Intestine (%BM)	2.02 ± 0.17 ^a	2.23 ± 0.22 ^{abc}	2.48 ± 0.17 ^b	1.86 ± 0.62 ^{ac}	2.25 ± 0.16 ^{abc}	2.36 ± 0.12 ^{ab}	**
S. Intestine length (mm)	1148.00 ± 40.35 ^a	1211.00 ± 30.33 ^a	1188.00 ± 63.47 ^a	1189.00 ± 45.00 ^a	1219.00 ± 77.85 ^a	1214.00 ± 31.59 ^a	ns

^{abc}Means within rows having different superscripts differ significantly at * p < 0.05, ** p < 0.001, *** p < 0.0001, ns = not significant, L = Large, S = Small. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution

as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 8 per treatment group.

3.3 Discussion

3.3.1 Growth performance: body mass, feed and fluid intake, and calorie consumption

The study investigated the prophylactic potential of orally administered lycopene against dietary fructose-induced metabolic derangements, focusing on growth performance and gastrointestinal tract visceral macromorphometry in growing weanling Wistar rats in a model mimicking adolescents fed an obesogenic diet. The induction, mean weekly body mass, and terminal body masses of the female rats across treatment groups were similar. However, while the induction body mass of the male Wistar rats was similar across treatments, male rats fed the high fructose diet with fenofibrate and or the medium dose of lycopene had significantly lower mean weekly body masses during weeks 10 to 12 and 3 and 4, for fenofibrate and medium lycopene groups, respectively, compared to controls. These results suggest that both lycopene and fenofibrate can potentially be used to reduce body mass gain. Wang et al. (2019) noted a reduction in body mass gain in mice fed a high-fat diet with lycopene supplementation. Although the induction body masses of both the female and male rats were similar, in both sexes, the rats significantly grew across treatment groups when induction body masses were compared to terminal body masses. This suggest that the treatment protocols did not negatively affect their growth. However, in male rats fed the high fructose diet the administered fenofibrate resulted in decreased terminal body mass when compared to their control counterparts. This finding aligns with Lee et al. (2023), who reported that fenofibrate decreased the body mass, adipose tissue mass and size in ovariectomized mice fed a high-fat diet. The regulation of body mass by fenofibrate is mediated through nuclear peroxisome proliferator-activated receptor α (PPAR α), which controls the genes vital for lipid and lipoprotein metabolism by enhancing fatty acid oxidation, promoting the breakdown of triglyceride, and decreasing triglycerides synthesis and secretion (Shin et al., 2021). The terminal body masses of the rats (female and male) fed the control diet was similar to that of counterparts fed the high fructose diet and the high fructose diet with either of the lycopene doses, suggesting that dietary fructose did not mediate increased body mass gain and that both fructose and lycopene did not negatively affect growth during the 12-week intervention. These findings align with Ramos et al. (2017), who noted that feeding Wistar rats a diet supplemented with 20% fructose as drinking fluid did not alter their body mass but led to an augmentation in visceral adiposity. They suggested that the elevated adipogenic potential and relatively low energy content of fructose were accountable for the observed rise in visceral fat without a concurrent increase in body mass. It is

essential to emphasise that while body mass is a crucial marker of an animal's health, its accuracy as a gauge of growth may be compromised by the size of visceral organs, gut fill, and hydration status, thus decreasing its reliability (Borga et al., 2018; Muller et al., 2018; Ekingen et al., 2022).

This study noted a difference in the consumption of feed, fluid, and calories in the female and male rats across treatment groups. In summary, rats reared on the control diet consumed more feed, drank less plain water, and had a lower total calorie intake. Conversely, rats provided with fructose solution as the drinking fluid, drank more fluid, consumed less feed but had a higher total calorie intake. Notably, the administration of fenofibrate resulted in decreased fluid intake. In both sexes, rats fed the control diet significantly increased weekly and total feed consumption compared to their counterparts fed a high fructose diet, a high fructose diet with either fenofibrate and or lycopene as interventions. Long-term consumption of dietary fructose has been reported to decrease feed and energy intake (Smajis et al., 2020), impacting the secretion and function of appetite-regulating hormones like leptin and insulin (Capucho & Conde, 2022). This disruption may lead to irregular hunger signals and increase the risk of metabolic disorders such as obesity and T2DM (Cui et al., 2022). Rats reared on the high fructose diet with fenofibrate as an intervention had high weekly and TFI compared to counterparts fed the plain high fructose diet and as well as those fed the high fructose diet with lycopene as an intervention. This finding suggests the orally administered fenofibrate at 100 mg/kg body mass in adolescent rats fed a high fructose diet mediates increased feed intake which contradicts the observation that it (fenofibrate) decreases intake of a standard rat chow by meditating increased ketogenesis from mobilised body fat (Park et al., 2012). Based on the observation that fenofibrate decreased the body mass of fructose-fed rats compared to control, it is hypothesised that the increase in feed intake might have been a compensatory response to mitigate the fenofibrate-induced decrease in body mass. The dichotomy in these findings could have been attributed to altered metabolic pathways or hormonal responses leading to increased feed intake. Additionally, fenofibrate might have independent effects on appetite or metabolism that contribute to increased feed intake when combined with fructose. These effects could be mediated through various pathways, such as changes in gut hormone secretion or alteration in central nervous system signalling related appetite control. Male Wistar rats fed a high fructose diet had significantly higher TFI compared to their counterparts fed low, medium, and high doses of lycopene. However, in the female rats, this difference in feed

consumption was particularly evident when compared to those administered a high dose of lycopene. Additionally, female rats fed the medium dose of lycopene demonstrated significantly higher total feed intake compared to their counterparts fed the low and high doses of lycopene. Wang et al. (2019), reported that lycopene supplementation significantly inhibits the increase in body mass observed in mice fed a high fat-diet. Similar findings were reported by Zhu et al. (2020). In this current study, high-fructose diet with lycopene supplementation did not negatively affect body mass, similar to control and dietary fructose. This outcome might be attributed to the body mass changes induced by the 20% fructose, as noted in prior studies (Ramos et al., 2017). However, we did notice a decrease in feed consumption. I hypothesise that this reduction in feed intake could be linked to the influence of lycopene on metabolic processes. It's plausible that higher metabolic rates induced by lycopene (Wang, 2012), could lead to decreased feelings of hunger and, subsequently, lower feed consumption. Another explanation could be that lycopene's potential to influence appetite regulation by enhancing leptin sensitivity or reducing ghrelin secretion. Additionally, lycopene might alter taste perception or feed palatability, affecting rats' feed preferences and resulting in reduced consumption.

In this study, female rats administered fenofibrate orally at weeks 6 and 10, showed a decreased weekly fluid intake compared to control and low dose lycopene groups. Similarly, male rats on fenofibrate had reduced weekly fluid intake at week 8 compared to high-dose lycopene group, and at week 10 compared to both low and high doses of lycopene. In both sexes, the total fluid intake of the high fructose diet group was similar to control group. Female and male rats reared on the high fructose diet with fenofibrate as an intervention showed significantly lower total fluid intake compared to control group and those on a high fructose diet, with or without lycopene interventions. Fenofibrate has been shown to alter perception and reduce preference for sweet tastes in adult humans (Davis, 2020; Kochem & Breslin, 2016). Therefore, rats treated with fenofibrate may find the fructose solution less palatable, leading to reduced fluid consumption. Despite decreased fluid intake, total calorie was found to be higher in both female and male rats administered fenofibrate. This could be due to fenofibrate's effects on metabolism, as mentioned earlier. Increased fatty acid oxidation and energy expenditure may necessitate higher calorie intake to meet the body's energy demands. Interestingly, lycopene supplementation significantly increased total fluid intake, however, rats supplemented with low dose lycopene drank more fluid,

consequently had increase total fluid intake compared to either medium or high doses of lycopene. This suggest that different doses of lycopene could have varied effects on metabolic processes, such as digestion or nutrient absorption, which in turn might influence the rats' fluid patterns. Thus, it can be speculated that in the present study, lycopene supplementation, acting as an antioxidant, might interact with fructose to modulate thirst or fluid intake regulatory mechanisms. This interaction could enhance the perceived need for fluid intake, leading to increased consumption compared to rats fed a control diet, fructose alone, or fructose with fenofibrate. Moreover, it could be posited that lycopene supplementation could affect metabolic processes related to fluid regulation or thirst mechanisms in the rats. This could include an alteration in hormone levels or signalling pathways that regulate fluid balance, leading to an increase in total fluid consumption. Findings from the current study also showed that high-dose lycopene resulted in a significant increase in both total fluid and calorie intake compared to medium-dose in male Wistar rats. Conversely, in the female rats, the medium dose significantly increased total calorie intake compared to high-dose lycopene. Additionally, it was observed that in the male rats, lycopene supplementation significantly decreased total calorie intake compared to those on the control diet, while in the female rats, both low and high doses of lycopene significantly increased total calorie intake compared to their control counterparts. Furthermore, in both sexes, dietary fructose significantly increased total fluid intake compared to fenofibrate administration, although fenofibrate notably increased total calorie intake compared to dietary fructose. In the female rats, the total fluid and calorie consumption on a high fructose diet were similar to those in the control group. However, in the male rats, the total fluid intake on a high fructose diet was similar to both control and medium-dose lycopene, while the total calorie intake on fenofibrate was similar to the control group. In this study, it was noted that male rats consumed more feed and fluid, consequently resulting in a greater calorie intake than female rats. A dimorphic response has been reported in feeding, with males having higher intake than females (Maric et al., 2022). It is acknowledged that males and females have varying metabolic pathways that lead to sex-specific dietary-induced modifications (Hyer et al., 2019). Male rodents tend to be larger and heavier than females, requiring more energy to maintain their body mass (Maric et al., 2022). This larger size may contribute to their increased feed and fluid intake. Hormonal fluctuations, such as those associated with the estrous cycle in female rats, can decrease appetite and feed intake (Asarian &

Geary, 2013; Alonso-Caraballo & Ferrario, 2019). In male rats, testosterone has been linked to increased food intake and appetite regulation (Alrabadi et al., 2020).

3.3.2 Long Bone Growth

The longitudinal growth of the femora and tibia, provides a more precise measure of growth performance in growing animals than body mass (Cho et al., 2020). These antigravity bones exhibit a dose-dependent response to growth hormone (Ranke, 2021), which makes them a more reliable indicator of growth performance. Previous research has demonstrated that lycopene can prevent femora loss, increase the number osteocytes and osteoblasts in ovariectomized rats (Semeghini et al., 2022). The current study found no significant difference in femora and tibiae lengths, masses, and bone mass to length ratios across treatment groups in the female rats. This aligns with the findings of Muhammad et al. (2020), who observed no impact on these parameters in growing female Sprague Dawley rats after 10 weeks of dietary fructose and orally administered fenofibrate. This finding suggests that dietary fructose, the orally administered lycopene and fenofibrate did not negatively affect growth performance during the 12-week intervention period. However, in the male Wistar rats, supplementation of varying doses of lycopene significantly increased tibia length when compared to counterparts administered fenofibrate. Additionally, low-dose lycopene significantly increased femora mass compared to fenofibrate. These findings indicate a beneficial impact of lycopene on bone growth. The observed enhancements in tibia length and femora mass in male Wistar rats may be attributed to lycopene's antioxidant properties, which protect bone cells from oxidative damage, enhance osteoblast activity, and thereby contribute to overall bone health, by promoting bone growth and density. The sex-specific response to lycopene supplementation in terms of femora mass and tibiae length observed in this study may stem from variations in sex hormones such as testosterone and oestrogen. These hormones have different effect on bone growth and metabolism between the sexes (Emmanuelle et al., 2021). During the adolescent-to-adulthood transition, testosterone has been shown to promote linear growth (Breehl & Caban, 2023), increase bone mineral density, and enhance bone microarchitecture (Shigehara et al., 2021). Interestingly, lycopene supplementation has been reported to increase testosterone levels in varicocele-induced Sprague-Dawley rats (Antonuccio et al., 2020). These combined effects could potentially account for the observed enhancements in femora mass and tibia length in male rats.

3.3.3 Morphometry of Visceral Organs

Plant-derived bioactive chemical compounds have been demonstrated to affect visceral organ mass (Mir et al., 2019), underscoring the importance of assessing visceral mass as a tool for evaluating the impact of these compounds on overall health and metabolic function (Shaik et al., 2023). In this study, no significant difference was observed in the absolute and relative masses of the stomach, caecum, small intestine, large intestine, and the lengths of the small and large intestine of the female rats across treatment groups. These results suggest that the treatments had no discernible effect on the growth and development of the viscera. Furthermore, the findings indicate that dietary fructose, lycopene, or fenofibrate did not induce atrophy or hypertrophy of visceral organs. In the male Wistar rats, we noted a similarity in the absolute and relative masses of the caecum, and large intestine, and the length of both the small and large intestines across treatment groups. However, the rats fed a high fructose diet with fenofibrate, high fructose diet with medium and or high doses of lycopene had significantly increased absolute and relative masses of the stomach compared to their counterparts fed the control diet. Additionally, rats administered fenofibrate had a significantly heavier relative mass of stomach compared to the control group. A significant increase was observed in both the absolute and relative masses of the small intestine with the administration of fenofibrate and high-dose lycopene, compared to low-dose lycopene. Furthermore, the relative mass of the small intestine significantly increased with fenofibrate administration compared to their control counterparts. These findings suggest that fenofibrate with high fructose diet, high fructose diet with medium to high doses of lycopene may have caused hypertrophy and or hyperplasia in the cells of the stomach and small intestines. Consequently, this could have led to the observed increase in the mass of the stomach and small intestines in male rats. We therefore hypothesise that the increase in stomach and small intestine mass observed with fenofibrate administration and lycopene supplementation could be attributed to several factors: fenofibrate is known to affect lipid metabolism. It can increase fatty acid oxidation and decrease triglyceride levels, which might lead to alterations in the composition of tissues, including the stomach and small intestine. Studies have shown that both fenofibrate and lycopene possess anti-inflammatory properties. Fenofibrate has been shown to reduce inflammation in various tissues (Jin et al., 2023). Lycopene has been noted to alleviate inflammation in conditions like ulcerative colitis and Crohn's disease, which are inflammatory bowel diseases (Glabska et al., 2016; Chen et al., 2023). By reducing inflammation, lycopene and fenofibrate may prevent tissue damage and

promote the integrity of the stomach and small intestine tissues, leading to an increase in mass. Additionally, the small intestine is primarily responsible for nutrient absorption (Basile et al., 2023). Lycopene has been suggested to enhance nutrient absorption and modulate the composition and activity of the gut microbiota by improving intestinal barrier function and promoting the expression of nutrient transporters (Meng et al., 2022; Tu et al., 2023). This improved nutrient absorption and gut microbiota could contribute to improved nutrient use and assimilation in the GIT, which could translate to increased small intestine mass. I hypothesise that lycopene may promote the growth and regeneration of cells lining of the stomach and small intestine, leading to an increase in tissue mass of the male rats. In addition, hormones play a crucial role in regulating GIT function and tissue homeostasis (Norman & Henry, 2015; Farhadipour & Depoortere, 2021). Therefore, it can be speculated that lycopene may alter hormone signalling pathways involved in gastrointestinal health, thus affecting tissue growth and development. However, further research is needed to fully understand the specific mechanisms underlying this phenomenon.

3.4 Conclusion

This study found that prolonged intake of a high-fructose diet reduced total feed intake (TFI) and increased fluid consumption in both female and male rats. Supplemental lycopene similarly decreased TFI and elevated fluid intake. Female rats showed an increase in total calorie intake, while male rats had a decrease. Supplemental lycopene resulted in longer tibias, greater femoral mass, and higher absolute and relative masses of the stomach and small intestine in male rats. As a dietary supplement, lycopene may support bone growth and development, help counteract diet-induced bone mass loss, and enhance nutrient digestion and absorption in males. Nonetheless, additional research is required to clarify the underlying mechanisms responsible for these positive effects on bone and gastrointestinal health.

Having discussed the effects of supplemental lycopene on feed, fluid, calories intake, growth performance and GIT viscera morphometry in rats fed a high fructose diet, the next chapter presents a narrative on its (supplemental lycopene) potential benefits on haematology, circulating metabolic substrates, and metabolism-regulating hormones in growing Wistar rats fed a high-fructose diet.

3.5 References

- Akkawi, I., & Zmerly, H. (2018). Osteoporosis: Current Concepts. *Joints*, 6(2), 122. <https://doi.org/10.1055/S-0038-1660790>
- Al-Hamad, D., & Raman, V. (2017). Metabolic syndrome in children and adolescents. *Translational Pediatrics*, 6(4), 397. <https://doi.org/10.21037/tp.2017.10.02>
- Al-Khayri, J. M., Rashmi, R., Toppo, V., Chole, P. B., Banadka, A., Sudheer, W. N., Nagella, P., Shehata, W. F., Al-Mssallem, M. Q., Alessa, F. M., Almaghasla, M. I., & Rezk, A. A. S. (2023). Plant Secondary Metabolites: The Weapons for Biotic Stress Management. *Metabolites*, 13(6), 716. <https://doi.org/10.3390/METABO13060716>
- Alonso-Caraballo, Y., & Ferrario, C. R. (2019). Effects of the estrous cycle and ovarian hormones on cue-triggered motivation and intrinsic excitability of medium spiny neurons in the Nucleus Accumbens of female rats. *Hormones and behavior*, 116, 104583. <https://doi.org/10.1101/669804>
- Arabadi, N., Al-Rabadi, G. J., Maraqa, R., Sarayrah, H., Alzoubi, K. H., Alqudah, M., & Al-u'datt, D. G. (2020). Androgen effect on body weight and behaviour of male and female rats: novel insight on the clinical value. *Andrologia*, 52(10), e13730. <https://doi.org/10.1111/AND.13730>
- Antonuccio, P., Micali, A., Puzzolo, D., Romeo, C., Vermiglio, G., Squadrito, V., Freni, J., Pallio, G., Trichilo, V., Righi, M., Irrera, N., Altavilla, D., Squadrito, F., Marini, H. R., & Minutoli, L. (2020). Nutraceutical Effects of Lycopene in Experimental Varicocele: An “In Vivo” Model to Study Male Infertility. *Nutrients*, 12(5), 1536. <https://doi.org/10.3390/NU12051536>
- Aoun, R., Chokor, F. A. Z., Taktouk, M., Nasrallah, M., Ismaeel, H., Tamim, H., & Nasreddine, L. (2022). Dietary fructose and its association with the metabolic syndrome in Lebanese healthy adults: a cross-sectional study. *Diabetology and Metabolic Syndrome*, 14(1), 1–14. <https://doi.org/10.1186/S13098-022-00800-5/TABLES/5>
- Asarian, L., & Geary, N. (2013). Sex differences in the physiology of eating. *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology*, 305(11), R1215-R1267. <https://doi.org/10.1152/AJPREGU.00446.2012>

- Askari, M., Lotfi, M. H., Owlia, M. B., Fallahzadeh, H., & Mohammadi, M. (2019). Survey of Osteoporosis Risk Factors (Review Article). *Journal of Sabzevar University of Medical Sciences*, 25(6), 854–863. https://jsums.medsab.ac.ir/article_1148_en.html
- Barnsley, J., Buckland, G., Chan, P. E., Ong, A., Ramos, A. S., Baxter, M., Laskou, F., Dennison, E. M., Cooper, C., & Patel, H. P. (2021). Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. *Aging Clinical and Experimental Research*, 33(4), 759–773. <https://doi.org/10.1007/S40520-021-01817-Y/TABLES/2>
- Basile, E. J., Launico, M. V., & Sheer, A. J. (2023). Physiology, Nutrient Absorption. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK597379/>
- Beisner, J., Gonzalez-Granda, A., Basrai, M., Damms-Machado, A., & Bischoff, S. C. (2020). Fructose-Induced Intestinal Microbiota Shift Following Two Types of Short-Term High-Fructose Dietary Phases. *Nutrients*, 12(11), 1–21. <https://doi.org/10.3390/NU12113444>
- Bitew, Z. W., Alemu, A., Tenaw, Z., Alebel, A., Worku, T., & Ayele, E. G. (2021). Prevalence of metabolic syndrome among children and adolescents in high-income countries: A systematic review and meta-analysis of observational studies. *BioMed Research International*, 2021(1), 6661457. <https://doi.org/10.1155/2021/6661457>
- Breehl, L., & Caban, O. (2023). Physiology, Puberty. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK534827/>
- Capucho, A. M., & Conde, S. V. (2022). Impact of Sugars on Hypothalamic Satiety Pathways and Its Contribution to Dysmetabolic States. *Diabetology*, 4(1), 1–10. <https://doi.org/10.3390/DIABETOLOGY4010001>
- Chen, J., Ruan, X., Yuan, S., Deng, M., Zhang, H., Sun, J., Yu, L., Satsangi, J., Larsson, S. C., Therdoratou, E., Wang, X., & Li, X. (2023). Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study. *Aliment Pharmacol Ther*, 57, 399–408. <https://doi.org/10.1111/apt.17392>
- Cho, J. A., Baek, S. Y., Cheong, S. H., & Kim, M. R. (2020). Spirulina Enhances Bone Modeling in Growing Male Rats by Regulating Growth-Related Hormones. *Nutrients*, 12(4), 1187. <https://doi.org/10.3390/NU12041187>

- Costa-Rodrigues, J., Fernandes, M. H., Pinho, O., & Monteiro, P. R. R. (2018). Modulation of human osteoclastogenesis and osteoblastogenesis by lycopene. *The Journal of Nutritional Biochemistry*, 57, 26–34. <https://doi.org/10.1016/J.JNUTBIO.2018.03.004>
- Cui, C., Wang, C., Han, S., Yu, D., Zhu, L., & Jiang, P. (2022). Impact of a long-term high-fructose diet on systemic metabolic profiles of mice. *FASEB BioAdvances*, 4(8), 560. <https://doi.org/10.1096/FBA.2021-00152>
- Davis, T. M. E. (2020). Fenofibrate and Impaired Taste Perception in Type 2 Diabetes. *The American Journal of Case Reports*, 21, e927647-1. <https://doi.org/10.12659/AJCR.927647>
- De Martinis, M., Sirufo, M. M., Polsinelli, M., Placidi, G., Di Silvestre, D., & Ginaldi, L. (2021). Gender Differences in Osteoporosis: A Single-Center Observational Study. *The World Journal of Men's Health*, 39(4), 750–759. <https://doi.org/10.5534/WJMh.200099>
- Divekar, P. A., Narayana, S., Divekar, B. A., Kumar, R., Gadratagi, B. G., Ray, A., Singh, A. K., Rani, V., Singh, V., Singh, A. K., Kumar, A., Singh, R. P., Meena, R. S., & Behera, T. K. (2022). Plant Secondary Metabolites as Defense Tools against Herbivores for Sustainable Crop Protection. *International Journal of Molecular Sciences*, 23(5), 2690. <https://doi.org/10.3390/IJMS23052690/S1>
- Emmanuelle, N. E., Marie-Cécile, V., Florence, T., Jean-François, A., Françoise, L., Coralie, F., & Alexia, V. (2021). Critical Role of Estrogens on Bone Homeostasis in Both Male and Female: From Physiology to Medical Implications. *International Journal of Molecular Sciences*, 22(4), 1–18. <https://doi.org/10.3390/IJMS22041568>
- Farhadipour, M., & Depoortere, I. (2021). The Function of Gastrointestinal Hormones in Obesity—Implications for the Regulation of Energy Intake. *Nutrients*, 13(6), 1839. <https://doi.org/10.3390/NU13061839>
- Głąbska, D., Guzek, D., Zakrzewska, P., Włodarek, D., & Lech, G. (2016). Lycopene, Lutein and Zeaxanthin May Reduce Faecal Blood, Mucus and Pus but not Abdominal Pain in Individuals with Ulcerative Colitis. *Nutrients*, 8(10), 613. <https://doi.org/10.3390/NU8100613>

- Guney, C., Banu Bal, N., & Akar, F. (2023). The impact of dietary fructose on gut permeability, microbiota, abdominal adiposity, insulin signaling and reproductive function. *Heliyon*, *9*, e18896. <https://doi.org/10.1016/j.heliyon.2023.e18896>
- Gustin, D. M., Rodvold, K. A., Sosman, J. A., Diwadkar-Navsariwala, V., Stacewicz-Sapuntzakis, M., Viana, M., Crowell, J. A., Murray, J., Tiller, P., & Bowen, P. E. (2004). Single-Dose Pharmacokinetic Study of Lycopene Delivered in a Well-Defined Food-Based Lycopene Delivery System (Tomato Paste-Oil Mixture) in Healthy Adult Male Subjects. *Cancer Epidemiology, Biomarkers & Prevention*, *13*(5), 850–860. <https://doi.org/10.1158/1055-9965.850.13.5>
- Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018). Fructose metabolism and metabolic disease. *The Journal of Clinical Investigation*, *128*(2), 545. <https://doi.org/10.1172/JCI96702>
- Hyer, M. M., Dyer, S. K., Kloster, A., Adrees, A., Taetzsch, T., Feaster, J., Valdez, G., & Neigh, G. N. (2019). Sex modifies the consequences of extended fructose consumption on liver health, motor function, and physiological damage in rats. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, *317*(6), R903–R911. <https://doi.org/10.1152/AJPCREGU.00046.2019/ASSET/IMAGES/LARGE/ZH60111997570004.JPEG>
- Jin, L., Hua, H., Ji, Y., Jia, Z., Peng, M., & Huang, S. (2023). Anti-inflammatory role of fenofibrate in treating diseases. *Biomolecules and Biomedicine*, *23*(3), 376. <https://doi.org/10.17305/BB.2022.8534>
- Kammerman, P. R., Modisa, B. M. E., & Mphahlele, N. R. (2004). Atorvastatin, a potent HMG-CoA reductase inhibitor, is not antipyretic in rats. *Journal of Thermal Biology*, *29*(7–8), 431–435. <https://doi.org/10.1016/J.JTHERBIO.2004.08.012>
- Kochem, M., & Breslin, P. A. S. (2016). Lipid-lowering pharmaceutical clofibrate inhibits human sweet taste. *Chemical Senses*, *42*(1), 79–83. <https://doi.org/10.1093/CHEMSE/BJW104>
- Kuan Wong, S., Chin, K.-Y., Hj Suhaimi, F., Ahmad, F., Ima-Nirwana, S., Malaysia, K., Yaakob Latif, J., Tun Razak, B., Lumpur, K., & Kebangsaan Malaysia, U. (2018). Effects of metabolic syndrome

- on bone mineral density, histomorphometry and remodelling markers in male rats. *PloS One*, *13*(2), e0192416. <https://doi.org/10.1371/journal.pone.0192416>
- Maric, I., Krieger, J. P., van der Velden, P., Borchers, S., Asker, M., Vujicic, M., Wernstedt Asterholm, I., & Skibicka, K. P. (2022). Sex and Species Differences in the Development of Diet-Induced Obesity and Metabolic Disturbances in Rodents. *Frontiers in Nutrition*, *9*, 828522. <https://doi.org/10.3389/FNUT.2022.828522/FULL>
- Meng, Q., Zhang, Y., Li, J., Shi, B., Ma, Q., & Shan, A. (2022). Lycopene Affects Intestinal Barrier Function and the Gut Microbiota in Weaned Piglets via Antioxidant Signaling Regulation. *The Journal of Nutrition*, *152*(11), 2396–2408. <https://doi.org/10.1093/JN/NXAC208>
- Mir, S. A., Shah, M. A., Ganai, S. A., Ahmad, T., & Gani, M. (2019). Understanding the role of active components from plant sources in obesity management. *Journal of the Saudi Society of Agricultural Sciences*, *18*(2), 168–176. <https://doi.org/10.1016/J.JSSAS.2017.04.003>
- Morin, S. N., Lix, L. M., & Leslie, W. D. (2014). The Importance of Previous Fracture Site on Osteoporosis Diagnosis and Incident Fractures in Women. *Journal of Bone and Mineral Research*, *29*(7), 1675–1680. <https://doi.org/10.1002/JBMR.2204>
- Muhammad, N., Ibrahim, K. G., Ndhkala, A. R., & Erlwanger, K. H. (2020). Moringa oleifera Lam. prevents the development of high fructose diet-induced fatty liver. *South African Journal of Botany*, *129*, 32–39. <https://doi.org/10.1016/J.SAJB.2018.12.003>
- Norman, A. W., & Henry, H. L. (2015). Gastrointestinal Hormones. In *Hormones* (3rd ed., 141–169). Academic Press. <https://www.perlego.com/book/1834861/hormones-pdf>
- Park, M. K., Han, Y., Kim, M. S., Seo, E., Kang, S., Park, S. Y., Koh, H., Kim, D. K., & Lee, H. J. (2012). Reduction of Food Intake by Fenofibrate is Associated with Cholecystokinin Release in Long-Evans Tokushima Rats. *The Korean Journal of Physiology & Pharmacology*, *16*(3), 181. <https://doi.org/10.4196/KJPP.2012.16.3.181>
- Proia, P., Amato, A., Drid, P., Korovljev, D., Vasto, S., & Baldassano, S. (2021). The Impact of Diet and Physical Activity on Bone Health in Children and Adolescents. *Frontiers in Endocrinology*, *12*, 704647. <https://doi.org/10.3389/FENDO.2021.704647>

- Rajput, S. A., Liang, S. J., Wang, X. Q., & Yan, H. C. (2021). Lycopene Protects Intestinal Epithelium from Deoxynivalenol-Induced Oxidative Damage via Regulating Keap1/Nrf2 Signaling. *Antioxidants*, *10*(9), 1493. <https://doi.org/10.3390/ANTIOX10091493>
- Ramos, V. W., Batista, L. O., & Albuquerque, K. T. (2017). Effects of fructose consumption on food intake and biochemical and body parameters in Wistar rats. *Revista Portuguesa de Cardiologia (English Edition)*, *36*(12), 937–941. <https://doi.org/10.1016/J.REPCE.2017.04.009>
- Ranke, M. B. (2021). Short and Long-Term Effects of Growth Hormone in Children and Adolescents With GH Deficiency. *Frontiers in Endocrinology*, *12*, 720419. <https://doi.org/10.3389/FENDO.2021.720419/BIBTEX>
- Rasmus, P., & Kozłowska, E. (2023). Antioxidant and Anti-Inflammatory Effects of Carotenoids in Mood Disorders: An Overview. *Antioxidants*, *12*(3), 676. <https://doi.org/10.3390/ANTIOX12030676>
- Reynolds, C. M., Gray, C., Li, M., Segovia, S. A., & Vickers, M. H. (2015). Early Life Nutrition and Energy Balance Disorders in Offspring in Later Life. *Nutrients*, *7*(9), 8090. <https://doi.org/10.3390/NU7095384>
- Semeghini, M. S., Scalize, P. H., Coelho, M. C., Fernandes, R. R., Pitol, D. L., Tavares, M. S., de Sousa, L. G., Coppi, A. A., Siessere, S., & Bombonato-Prado, K. F. (2022). Lycopene prevents bone loss in ovariectomized rats and increases the number of osteocytes and osteoblasts. *Journal of Anatomy*, *241*(3), 729–740. <https://doi.org/10.1111/JOA.13672>
- Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., Ming, L. C., & Goh, B. H. (2023). Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management. *Frontiers in Pharmacology*, *14*, 1182937. <https://doi.org/10.3389/FPHAR.2023.1182937>
- Shen, Y., Huang, X., Wu, J., Lin, X., Zhou, X., Zhu, Z., Pan, X., Xu, J., Qiao, J., Zhang, T., Ye, L., Jiang, H., Ren, Y., & Shan, P. F. (2022). The Global Burden of Osteoporosis, Low Bone Mass, and Its Related Fracture in 204 Countries and Territories, 1990-2019. *Frontiers in Endocrinology*, *13*, 882241. <https://doi.org/10.3389/FENDO.2022.882241/FULL>

- Shigehara, K., Izumi, K., Kadono, Y., & Mizokami, A. (2021). Testosterone and Bone Health in Men: A Narrative Review. *Journal of Clinical Medicine*, *10*(3), 1–12.
<https://doi.org/10.3390/JCM10030530>
- Shin, Y., Lee, M., Lee, D., Jang, J., Shin, S. S., & Yoon, M. (2021). Fenofibrate regulates visceral obesity and nonalcoholic steatohepatitis in obese female ovariectomized c57bl/6j mice. *International Journal of Molecular Sciences*, *22*(7), 3675. <https://doi.org/10.3390/IJMS22073675/S1>
- Smajis, S., Gajdošik, M., Pflieger, L., Traussnigg, S., Kienbacher, C., Halilbasic, E., Ranzenberger-Haider, T., Stangl, A., Beiglböck, H., Wolf, P., Lamp, T., Hofer, A., Gastaldelli, A., Barbieri, C., Luger, A., Trattnig, S., Kautzky-Willer, A., Krššák, M., Trauner, M., & Krebs, M. (2020). Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. *The American Journal of Clinical Nutrition*, *111*(2), 369–377.
<https://doi.org/10.1093/AJCN/NQZ271>
- Taskinen, M. R., Packard, C. J., & Borén, J. (2019). Dietary Fructose and the Metabolic Syndrome. *Nutrients*, *11*(9), 1987. <https://doi.org/10.3390/NU11091987>
- Tu, T., Liu, H., Liu, Z., Liang, Y., Tan, C., Feng, D., & Zou, J. (2023). Amelioration of Atherosclerosis by lycopene is linked to the modulation of gut microbiota dysbiosis and related gut-heart axis activation in high-fat diet-fed ApoE^{-/-} mice. *Nutrition & Metabolism*, *20*(1), 53.
<https://doi.org/10.1186/S12986-023-00772-X>
- Wang, J., Suo, Y., Zhang, J., Zou, Q., Tan, X., Yuan, T., Liu, Z., & Liu, X. (2019). Lycopene supplementation attenuates western diet-induced body weight gain through increasing the expressions of thermogenic/mitochondrial functional genes and improving insulin resistance in the adipose tissue of obese mice. *The Journal of Nutritional Biochemistry*, *69*, 63–72.
<https://doi.org/10.1016/J.JNUTBIO.2019.03.008>
- Wang, X. D. (2012). Lycopene metabolism and its biological significance. *The American Journal of Clinical Nutrition*, *96*(5), 1214S-1222S. <https://doi.org/10.3945/AJCN.111.032359>
- Wu, H., Wang, S., Xie, J., Ji, F., Peng, W., Qian, J., Shen, Q., & Hou, G. (2024). Effects of Dietary Lycopene on the Growth Performance, Antioxidant Capacity, Meat Quality, Intestine

Histomorphology, and Cecal Microbiota in Broiler Chickens. *Animals: An Open Access Journal from MDPI*, 14(2), 203. <https://doi.org/10.3390/ANI14020203>

Zhang, D. M., Jiao, R. Q., & Kong, L. D. (2017). High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. *Nutrients*, 9(4), 335. <https://doi.org/10.3390/NU9040335>

Zhang, P., Li, J., Li, M., Sui, Y., Zhou, Y., & Sun, Y. (2020). [Effects of lycopene on metabolism of glycolipid and inflammation in non-alcoholic fatty liver disease rats]. *Wei Sheng Yan Jiu = Journal of Hygiene Research*, 49(2), 254–271. <https://doi.org/10.19813/J.CNKI.WEISHENGYANJIU.2020.02.015>

Zheng, X., Qi, Y., Zhou, H., Kang, H., Tong, Y., & Bi, L. (2021). Bone Mineral Density at the Distal Femur and Proximal Tibia and Related Factors During the First Year of Spinal Cord Injury. *International Journal of General Medicine*, 14, 1121. <https://doi.org/10.2147/IJGM.S297660>

Zhu, R., Wei, J., Liu, H., Liu, C., Wang, L., Chen, B., Li, L., Jia, Q., Tian, Y., Li, R., Zhao, D., Mo, F., Li, Y., Gao, S., Wang, X. D., & Zhang, D. (2020). Lycopene attenuates body weight gain through induction of browning via regulation of peroxisome proliferator-activated receptor γ in high-fat diet-induced obese mice. *The Journal of Nutritional Biochemistry*, 78, 108335. <https://doi.org/10.1016/J.JNUTBIO.2019.108335>

**CHAPTER FOUR: EFFECT OF LYCOPENE
ON BLOOD GLUCOSE, GLYCATED
HAEMOGLOBIN, HAEMOGLOBIN,
HAEMATOCRIT, SERUM LEPTIN
CONCENTRATION AND LIPID PROFILE IN
GROWING WISTAR RATS FED A HIGH
FRUCTOSE DIET**

4.0 Introduction

Excessive consumption of dietary fructose from childhood through adulthood can cause the emergence of metabolic conditions including dyslipidaemia, insulin resistance, obesity, and T2DM (Softic et al., 2020; Codazzi et al., 2023) which are all elements of metabolic syndrome. Metabolic syndrome has affected over a billion people globally (Mohamed et al., 2023), with its prevalence at 2.8%, 4.8% (Noubiap et al., 2022), 32.1%, and 24.7% (Nouri-Keshtkar et al., 2023) in children, adolescents, females and males, respectively. Most of the fructose consumed is metabolised by the liver (Francey et al., 2019). Unlike glucose whose metabolism is controlled by the amount of ATP produced and insulin secretion, particularly at the level of phosphofructokinase (Nakrani et al., 2023), the metabolism of fructose occurs independently of these two factors (Merino et al., 2020). Excessive fructose intake can overwhelm the liver's capacity to efficiently metabolise it, which can lead to the production of triglycerides through *de novo* lipogenesis. This dietary fructose induced *de novo* lipogenesis alters the lipid profile, increases oxidative stress and inflammation, which heightens the likelihood of developing obesity and metabolic syndrome (DiNicolantonio et al., 2018; Yu et al., 2021). In addition, excessive dietary fructose hinders the liver's ability to oxidise fatty acids and reduces the production of high-density lipoprotein cholesterol, leading to accumulation of visceral fat and an overall body mass gain (Guney et al., 2023).

Haematological abnormalities, particularly anemia, are frequently observed in individuals with metabolic syndrome, especially in those who are overweight or obese, or who have T2DM (Bekele et al., 2019; Jeong et al., 2022). Oxidative stress and inflammatory conditions, common features of metabolic syndrome, have been associated with haematological abnormalities (Bissinger et al., 2019). These abnormalities in the haematological profile increase the risk of kidney disease, cardiovascular complications, congestive heart failure, and ischemic stroke in people with metabolic syndrome (Sahay et al., 2017; Shenkut et al., 2024). Furthermore, high blood glucose and cholesterol concentrations are associated with disruptions in blood cell formation (Lee et al., 2018). Leptin, a 16-kDa polypeptide hormone primarily produced and released by white adipocytes, plays a crucial role in regulating food intake by suppressing appetite, controlling energy expenditure, and enhancing sympathetic nervous system activity (Dilworth et al., 2021). It regulates body mass and fat accumulation by activating receptors in the hypothalamus, leading to the suppression of appetite (Vilariño-García et al., 2024). Serum leptin concentrations have been shown to decrease during fasting (Fontana et al., 2023), suggesting that higher concentrations of

leptin would be associated with lower mass and vice versa (Ekmen et al., 2016). However, this is not consistently observed, especially in obese and overweight individuals who consume excessive dietary fructose (Johnson et al., 2023). In such cases, serum leptin concentrations may be more aligned with body fat due to leptin resistance (Picó et al., 2021). Elevated serum leptin negatively affects insulin secretion (Chiriaco et al., 2024), which can counteract its appetite-suppressing effects, potentially leading to weight gain over time and difficulty managing body mass (Rangareddy et al., 2023).

Metabolic disorders pose a global challenge, as the high cost of conventional synthetic medications and inadequate healthcare infrastructure, particularly in developing nations, rendering these medications out of reach for the vast majority (Yenet et al., 2023). In light of these challenges, there is a rising interest in utilising medicinal plants and naturally derived phytochemicals with a wide range of biological effects (Sezer et al., 2024). Lycopene, a fat-soluble compound present in tomatoes and watermelons, is known for its ability to combat oxidative stress and inflammation (Sharma et al., 2024). Studies have demonstrated its ability to enhance haematological parameters (Eze et al., 2019), potential in combating obesity (Zhu et al., 2020), and its hypolipidaemic and antidiabetic properties (Jin & Arroo, 2023). This study therefore investigated the potential benefits of supplemental lycopene on blood glucose, glycated haemoglobin, haemoglobin, haematocrit, serum leptin concentration, and lipid profile in growing rats fed a high fructose diet.

4.1 Materials and methods

4.1.1 Ethical approval

This is as described in chapter 3, subheading 3.1.1.

4.1.2 Chemicals and reagents

The chemicals and reagents utilised are consistent with those described in chapter 3, subheading 3.1.2.

4.1.3 Animals, housing, and general care

The management of experimental animals in this chapter is consistent with the procedures described in chapter 3, under subheading 3.1.3.

4.1.4 Experimental design

The study design is as described in chapter 3, subheading 3.1.4.

4.1.5 Terminal procedures, sample collection and measurements

On postnatal day 106, the rats were fasted overnight but were allowed access to plain drinking water to prevent dehydration. In the morning of termination (postnatal day 107), the body mass of each rat was measured using an electronic balance (Snowrex Electronic Scale, Clover Scale Pty Ltd, Johannesburg). Blood was collected via tail vein puncture (Hattori et al., 2020) to assess fasting blood glucose (FBG), triglyceride, haemoglobin, and haematocrit concentrations. FBG was measured with a Bayer Contour Plus Meter (Isando, Johannesburg, South Africa), while triglyceride concentrations were determined using an Accutrend GCT meter (Roche, Mannheim, Germany). Haemoglobin and haematocrit concentrations were measured using an Insight HCT meter (Woodley Equipment Co. Ltd., Bolton, UK).

Following this, the rats were euthanised using an intraperitoneal injection of sodium pentobarbitone at 200 mg/kg body mass (Euthapent; Kyron laboratories, Johannesburg). Blood was then obtained through cardiac puncture with 20G needles and 10ml syringes. A portion of the blood (1 ml) was transferred to EDTA K₂ blood collection tubes (BD Vacutainer Systems Bigamart, UK) and later used for the assessment of glycated haemoglobin using the A1CNow meter (PTS Diagnostics, Whitestown, USA). The remainder of the blood was placed in SST gel coated blood collection tubes (BD Vacutainer System Bigamart, UK). Subsequently, it (remainder of the blood)

was centrifuged (DLAB-DMO412S, Wolflabs Laboratory Products, Pocklington, UK) at $3000 \times g$ for 15 minutes at 20°C and the serum collected was decanted into Eppendorf microtubes (Abdos Labtech Pvt, Ltd, Utrakhand, India) and then frozen-stored at -80°C for subsequent analyses of leptin, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol (TC) concentrations.

4.1.6 Determination of serum lipoproteins, and total cholesterol

Fasting serum LDL, HDL, and TC concentrations were measured using a rat-specific enzyme-linked immunosorbent assay (ELISA) kit from Elabscience Biotechnology Inc., Houston, Texas, USA, in accordance with the manufacturer's guidelines.

4.1.7 Determination of glycated haemoglobin concentrations

Glycated haemoglobin (HbA1c) concentrations were determined from blood samples collected into EDTA K_2 blood collection tubes (BD Vacutainer Systems Bigamart, UK). An A1CNow meter (PTS Diagnostics, Whitestown, USA) was used to assess HbA1c concentrations, adhering to the manufacturer's guidelines. Briefly, a small drop of blood was pipetted onto a glass slide. It was then transferred into the collector within the shaker body where it was shaken vigorously about 6 to 8 times to mix with the reaction solution. Following this, the test cartridge was inserted into the A1CNow meter, and the blood sample was dispensed into the cartridge. The results were then displayed on the screen after 5 minutes.

4.1.8 Determination of serum leptin concentration

Serum leptin concentration was assessed using a rat-specific ELISA kit (Elabscience Biotechnology Inc., Houston, Texas, USA) based on the sandwich ELISA method. Standard solutions and diluted serum samples were added to a micro-ELISA plate, followed by the addition of a specific antibody. A biotinylated detection antibody for Rat LEP and an Avidin-Horseradish Peroxidase (HRP) conjugate were then introduced into each well, allowing leptin in the samples to bind to the antibodies. After incubation, unbound substances were removed through washing. A substrate solution was added, causing wells containing the Rat LEP HRP conjugate to turn blue. The reaction was stopped with a stop solution, resulting in a yellow color change. Optical density (OD) was measured at $450 \pm 2 \text{ nm}$ using a microplate reader (Multiskan Ascent, Lab System,

Model No. 354, Helsinki, Finland). Leptin concentrations were determined by comparing the absorbance values to a standard curve generated from known concentrations.

4.1.9 Statistical analysis

Data analysis was performed using GraphPad Prism version 9.0 (GraphPad Software Inc., San Diego, USA), and results were expressed as mean \pm standard deviation. A one-way ANOVA was used to assess parametric data across multiple groups, followed by Tukey's *post hoc* test for mean comparisons. Significance was established at $p < 0.05$.

4.2 Results

4.2.1 Haemoglobin and haematocrit concentrations

Table 4.1 show the concentrations of haemoglobin and haematocrit in female and male rats, respectively. No significant differences ($p > 0.05$) were observed in haemoglobin and haematocrit concentrations across treatment groups in both sexes.

Table 4. 1: Effect of lycopene on haemoglobin and haematocrit concentration in growing female and male Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Females							
Haemoglobin (g/dL)	17.31 ± 2.95 ^a	17.30 ± 1.50 ^a	16.13 ± 2.45 ^a	17.56 ± 3.82 ^a	17.85 ± 3.21 ^a	17.89 ± 2.68 ^a	ns
Haematocrit (%)	52 ± 8.70 ^a	52 ± 4.38 ^a	48.38 ± 7.56 ^a	52.75 ± 11.40 ^a	53.88 ± 9.60 ^a	53.5 ± 8.02 ^a	ns
Males							
Haemoglobin (g/dL)	18.55 ± 1.72 ^a	16.98 ± 2.87 ^a	17.83 ± 1.67 ^a	19.74 ± 2.26 ^a	19.06 ± 1.54 ^a	18.39 ± 2.19 ^a	ns
Haematocrit (%)	55.63 ± 5.07 ^a	46.96 ± 18.65 ^a	53.50 ± 5.10 ^a	59.50 ± 6.92 ^a	57.13 ± 4.29 ^a	55.13 ± 6.66 ^a	ns

^aMeans within rows having the same superscripts are similar at $p > 0.05$, ns = not significant. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 8 per treatment group.

4.2.2 Fasting blood glucose and glycated haemoglobin concentrations

Figures 4.1 and 4.2 show the fasting blood glucose (A) and glycated haemoglobin (B) concentrations in female and male rats, respectively. Female rats fed the high fructose diet with fenofibrate intervention exhibited significantly higher ($p < 0.05$) fasting blood glucose concentrations compared to their counterparts fed the high fructose diet with medium and high lycopene doses as supplements (Figure 4.1A). Similarly, glycated haemoglobin concentrations were significantly higher ($p < 0.05$) in female rats administered fenofibrate compared to those on the control diet (Figure 4.1B). In male rats, fasting blood glucose levels were significantly elevated ($p < 0.05$) in those fed a high-fructose diet with fenofibrate compared to those in the control group, the high-fructose group, and the high-fructose groups supplemented with low, medium, or high doses of lycopene (Figure 4.3A). However, no significant differences ($p > 0.05$) were observed in glycated haemoglobin concentrations across treatment groups in male rats (Figure 4.3B).




Figure 4. 1: Effect of lycopene on fasting blood glucose (A) and glycated haemoglobin (B) concentration in growing female Wistar rats fed a high-fructose diet.

*= significantly different at $p < 0.05$. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean \pm SD, n = 6-8 per treatment group.




Figure 4. 2: Effect of lycopene on fasting blood glucose (A) and glycated haemoglobin (B) concentration in growing male Wistar rats fed a high-fructose diet.

***= significantly different at $p < 0.001$. No significant difference ($p > 0.05$) in the glycated haemoglobin concentration across treatment groups. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean \pm SD, n = 7-8 per treatment group.

4.2.3 Lipid profile

Tables 4.2 show the effect of lycopene on lipid profiles in female and male rats fed a high fructose diet. Female rats fed the high-fructose diet with fenofibrate as an intervention exhibited significantly higher ($p < 0.05$) serum high-density lipoprotein (HDL) concentrations compared to those fed the high-fructose diet supplemented with a low dose of lycopene. However, no significant differences ($p > 0.05$) were observed in the lipid profiles of male rats across treatment groups (Table 4.2).

Table 4. 2: Effect of lycopene on lipid profile in growing female and male Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Females							
TG (mmol/L)	1.24 ± 0.28 ^a	1.49 ± 0.28 ^a	1.71 ± 0.54 ^a	1.59 ± 0.46 ^a	1.67 ± 0.38 ^a	1.41 ± 0.20 ^a	ns
LDL (µg/mL)	629.30 ± 140.50 ^a	651.00 ± 149.30 ^a	734.90 ± 299.40 ^a	446.90 ± 176.70 ^a	571.40 ± 276.80 ^a	591.00 ± 232.00 ^a	ns
HDL (ng/mL)	31386 ± 5536 ^{ab}	33943 ± 8897 ^{ab}	38597 ± 5577 ^a	26419 ± 6207 ^b	30420 ± 10269 ^{ab}	30836 ± 3659 ^{ab}	*
TC (mmol/L)	1.132 ± 0.23 ^a	1.53 ± 0.40 ^a	1.51 ± 0.40 ^a	1.32 ± 0.29 ^a	1.33 ± 0.28 ^a	1.43 ± 0.13 ^a	ns
Males							
TG (mmol/L)	1.36 ± 0.62 ^a	1.19 ± 0.14 ^a	1.57 ± 0.80 ^a	1.35 ± 0.32 ^a	1.18 ± 0.17 ^a	1.15 ± 0.10 ^a	ns
LDL (µg/mL)	574.40 ± 269.30 ^a	553.20 ± 142.60 ^a	738.40 ± 203.20 ^a	508.00 ± 86.31 ^a	536.20 ± 94.91 ^a	710.70 ± 141.70 ^a	ns
HDL (ng/mL)	22081 ± 7699 ^a	28216 ± 10721 ^a	28981 ± 3300 ^a	20604 ± 5144 ^a	24860 ± 8427 ^a	29015 ± 5309 ^a	ns
TC (mmol/L)	1.08 ± 0.15 ^a	1.25 ± 0.36 ^a	1.10 ± 0.31 ^a	0.86 ± 0.17 ^a	1.13 ± 0.48 ^a	1.42 ± 0.50 ^a	ns

^{ab}Means within rows having the different superscript differ significantly at * p < 0.05, ns = not significant. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 6-8 per treatment group.

4.2.4 Serum leptin concentration

Figures 4.3A and 4.3B show the serum concentration of leptin in female and male rats, respectively. In both sexes, the serum concentration of leptin was similar ($p > 0.05$) across treatment groups.




Figure 4. 3A: Effect of lycopene on serum leptin concentration in growing female Wistar rats fed a high-fructose diet.

No significant difference ($p > 0.05$) in the serum leptin concentration across treatment groups in the female rats. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean \pm SD, n = 6-7 per treatment group.




Figure 4. 3B: Effect of lycopene on serum leptin concentration in growing male Wistar rats fed a high-fructose diet.

No significant difference ($p > 0.05$) in the serum leptin concentration across treatment groups in the male rats. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 6-7 per treatment group.

4.3 Discussion

4.3.1 Haemoglobin and Haematocrit Concentrations

This study investigated the potential benefits of orally administered lycopene against dietary fructose-induced metabolic derangements, focusing on effects on blood glucose, haemoglobin, haematocrit and leptin concentrations and serum lipid profile in growing weanling Wistar rats in a model mimicking adolescents fed a high fructose diet. In this study, no significant differences were observed in the haemoglobin and haematocrit concentrations of the rats across treatment groups. These results suggest that the treatments did not have a detrimental effect on the haemoglobin and haematocrit levels during the 12-week intervention. Studies have shown that lycopene increased red blood cell counts, haemoglobin and haematocrit, with no effect on mean corpuscular volume, mean corpuscular haemoglobin or mean corpuscular haemoglobin concentration in streptozotocin-induced diabetic rats (Eze et al., 2019) and protected against cadmium-induced toxicity in mice (Sharma & Chowdary, 2015). Fructose's direct effects on haemoglobin and haematocrit concentration and other blood cell counts are not extensively documented. Unlike certain compounds or medications known to directly influence blood parameters, the impact of fructose on haematology appears to be more indirect and secondary to its effects on metabolism, inflammation, and oxidative stress (Bissinger et al., 2019). Kelem et al. (2023) reported that haematological abnormalities are common in individuals with type 2 diabetes mellitus who are either overweight or obese. In the current study dietary fructose did not lead to obesity, type 2 diabetes mellitus or dyslipidaemia. Therefore, I hypothesise that the effect of fructose on blood parameters may vary depending on factors such as dosage, duration of exposure, and individual metabolic and health status.

4.3.2 Glucose and Lipid Profile

In this study, female rats fed the high fructose diet with fenofibrate as an intervention showed significantly increased fasting blood glucose concentration compared to their counterparts fed the high fructose diet supplemented with medium and high doses of lycopene. Similarly, rats reared on a high-fructose diet with fenofibrate had higher glycated haemoglobin levels compared to their counterparts fed the control diet. Male Wistar rats fed the high fructose diet with fenofibrate had significantly higher fasting blood glucose concentrations compared to their counterparts fed the control diet, the high fructose diet, or the high fructose diet supplemented with low, medium, or

high doses of lycopene. However, there was no significant difference observed in the glycated haemoglobin concentration across treatment groups in the male rats. The current study found no significant difference in the triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol levels in the male rats across treatment groups. Similarly, in female Wistar rats, those fed the high fructose diet with fenofibrate as an intervention had significantly higher high-density lipoprotein compared to their counterparts fed the high fructose diet with a low lycopene dose as a supplement. These results suggest that dietary fructose did not have negative impact on metabolic markers (fasting blood glucose, HbA1c, triglycerides, LDL, HDL, and total cholesterol) levels in female and male rats. This implies that fructose consumption did not lead to adverse metabolic effects in this study. These findings align with Tillman et al. (2014), who reported that weanling c57BI/6 mice fed a 60% fructose diet showed no significant differences in body mass, plasma glucose triglycerides, and free fatty acids concentrations. Previous studies have demonstrated that long-term consumption of a high-fructose diet can lead to metabolic syndrome in adult rodents. For instance, Farag et al., (2020) found that rats fed a 60% fructose for 10 weeks exhibited signs of metabolic syndrome, such as elevated levels of fasting blood glucose, insulin, triglycerides, and total cholesterol. Koseler et al., (2018) also observed features of obesity, type 2 diabetes mellitus, hyperlipidaemia, and insulin resistance when 30% of fructose was administered for 6 weeks to adult male Wistar rats. Similarly, adult rats fed a 20% fructose diet for 12 weeks showed dyslipidaemia, insulin resistance, visceral fat accumulation and hepatomegaly (Ferreira-Santos et al., 2020). It is important to note that this study targeted adolescents, hence the use of growing weanling Wistar rats. The surge in overweight and obesity has been linked to increased consumption of sugary foods among children and adolescents (Magriplis et al., 2021). The body surface area to volume ratio is greater in young pups and growing rats than in adult rats. This can result in a faster metabolic rate and lead to the metabolism of excess fructose without exhibiting the same adverse effects seen in adult rats (Tillman et al., 2014). I hypothesise that the resistance of young growing rats to metabolic derangements caused by dietary fructose could be due to high energy demand for growth and development. This increased energy demand may help metabolise fructose more effectively, preventing the accumulation of harmful metabolic by-products. The liver plays a crucial role in metabolising fructose (Francey et al., 2019). In young growing rats, liver function may be more efficient, allowing for better clearance and utilisation of fructose compared to adult rats. Additionally, younger humans and rodents typically exhibit higher insulin

sensitivity, which helps regulate blood sugar levels more effectively (Kolb et al., 2023). This can prevent the development of hyperglycaemia associated with fructose consumption (Ehrhardt et al., 2019; Kolb et al., 2023). However, it is essential to note that excessive fructose consumption can still have detrimental effects on health over time if not properly controlled (Song et al., 2021).

Lycopene is known as a potent antioxidant (Leh & Lee, 2022). Previous studies have demonstrated that feeding a high-fat diet for 4 weeks followed by oral lycopene supplementation at 20 mg/kg body mass for 10 weeks decreased blood glucose and glycated haemoglobin levels and ameliorated lipid disorders in adult male Sprague-Dawley rats with streptozotocin-induced diabetes mellitus (Yin et al., 2019). Mulkawar et al. (2015) noted no significant difference in the fasting blood sugar levels and observed decreased lipid activity in adult male New Zealand White rabbits fed a high-fat diet supplemented with 10 mg/kg body mass of lycopene for 6 weeks. Additionally, when 300g of tomatoes were administered to 50 healthy volunteers (16 men and 34 women) daily for one month, there were no changes in their plasma triglycerides, LDL, and total cholesterol levels, but a significant increase in plasma HDL level was observed (Blum et al., 2006). The findings of this study showed that the consumption of a high-fructose diet supplemented with lycopene during the 12-week intervention neither affected blood glucose levels nor lipid profile of the rats. I hypothesise that the consumption of high fructose diet supplemented with lycopene may lack an impact on the rat's glucose and lipid profile levels. This could be due to lycopene interacting with other nutrients in the diet or with the high-fructose content in ways that did not lead to changes in glucose or lipid levels. We speculate that the rats may have had relatively healthy baseline glucose and lipid levels, making it difficult to observe significant changes with the intervention. Additionally, the 12-week duration of the intervention may have been too short to observe any meaningful changes in glucose or lipid metabolism, considering that young rats are resistant to metabolic derangements caused by dietary fructose (Tillman et al., 2014). In the present study, orally administered fenofibrate caused a significant increase in fasting blood glucose and glycated haemoglobin levels in female rats. Similarly, male rats treated with fenofibrate exhibited significantly higher fasting blood glucose concentrations. Nonetheless, it was noted that fenofibrate caused a significant increase in HDL levels in the female rats. These results suggest that orally administered fenofibrate affects glucose metabolism differently in male and female rats, indicating adverse effects on glucose regulation in both sexes, while it has a positive impact on HDL levels in the female rats. Previous studies have demonstrated that fenofibrate, when included

in the diet of female non-obese diabetic mice for 27 weeks, decreased non-fasting blood glucose and elevated fasting blood glucose levels, decreased fasting glucagon levels, and averted fasting hyperinsulinaemia (Holm et al., 2019). Liu et al. (2011) found that orally administered fenofibrate for 12 weeks decreased plasma lipid levels, showed no beneficial effects on glucose homeostasis or insulin sensitivity in obese monosodium glutamate induced male Wistar rats. In this study, insulin sensitivity was not assessed, but normal levels of circulating lipids in fructose-fed rats were observed. Given that high blood fats are linked with insulin resistance and considering that fasting blood glucose and glycated haemoglobin concentrations were normal in these rats, it suggests that the fructose-fed rats in this study may not have been insulin resistant. Fenofibrate, a hypolipidaemic peroxisome proliferator-activated receptor α (PPAR α) agonist works by reducing the production of triglycerides and increasing the levels of HDL cholesterol, often referred to as "good" cholesterol (La Fountaine et al., 2019). It is commonly prescribed to treat high levels of cholesterol and triglycerides in the blood (Lee et al., 2023). I hypothesise that fenofibrate may decrease insulin sensitivity in some rats causing their cells to take up less glucose and resulting in elevated blood glucose levels. It could also disrupt the liver's regulation of glucose production, leading to more glucose being released into the bloodstream. In addition, it may affect pancreatic function, including insulin secretion, which could further influence blood glucose levels. Fenofibrate might interfere with different pathways related to glucose metabolism, leading to irregular blood glucose levels.

4.3.3 Leptin concentration

The present study found no significant differences in the fasting serum leptin levels of the female and male rats across treatment groups. These results suggest that the treatment did not have a negative impact on fasting serum leptin concentration in the rats. Previous studies showed that a 20% fructose solution administered orally daily for 8 weeks increased plasma leptin and insulin levels, elevated serum glucose and TG levels, decreased HDL and total cholesterol levels, and showed no significant changes in LDL levels in adult male Sprague-Dawley rats (Eğritağ & Haliloğlu, 2022). Teff et al. (2004) reported that dietary fructose decreased 24-hour leptin and insulin levels, raised triglycerides, and inhibited ghrelin in women. Studies indicate that plasma leptin levels decreased during fasting or energy restriction (Mars et al., 2006), but meal consumption did not lead to an immediate increase in plasma leptin concentrations. This suggests that leptin acts as a regulator of energy balance over the medium to long term (Mendoza-Herrera

et al., 2021). Leptin secretion is controlled by the metabolism of glucose mediated by insulin. Unlike glucose, fructose does not trigger insulin secretion (Baena et al., 2016; Dilworth et al., 2021). I hypothesise that a high-fructose diet would lead to reduced leptin levels in young growing rats. However, despite the study lasting 12 weeks, no significant changes in leptin levels were observed. It is known that leptin responses to dietary changes can take weeks to become apparent. In this study, orally administered fenofibrate and lycopene did not have a negative impact on fasting serum leptin concentrations. However, Jeong et al. (2005) found that a 15% high-fat diet supplemented with fenofibrate for 14 weeks increased body mass, total cholesterol, and triglycerides in C57BL/6J female mice, but did not significantly affect the expression of leptin and TNF α genes. In their study, Nabil et al. (2020) reported that a 20% fructose solution administered for 18 weeks, with fenofibrate given from the 13th to the 18th week, resulted in decreased fasting plasma levels of leptin, TNF α , glucose, triglycerides, total cholesterol, and total lipids in male Sprague-Dawley rats. However, insulin concentrations did not differ significantly. Thus, from the current study it can be speculated that orally administered fenofibrate did not negatively affect fasting serum leptin levels, as fenofibrate primarily targets lipid metabolism and may not directly impact leptin production or secretion. Lycopene was shown to reduce the expression of leptin, resistin and interleukin-6 (IL-6) gene in epididymal adipose tissue, as well as lower plasma concentration in male Wistar rats fed a high-fat diet for 6 weeks (Luvizotto et al., 2013). I hypothesise that the lack of a significant difference in fasting serum leptin levels in lycopene-treated rats may be due to the possibility that lycopene supplementation did not exert a substantial effect on leptin levels in young growing rats during the 12-week intervention period. The young, growing rats used in the study may have different metabolic responses compared to adult rats, thereby minimizing the effects of lycopene supplementation on leptin levels. Further research is warranted to understand the dynamics of lycopene supplementation on leptin levels, considering factors such as dosage, duration, and the specific physio-metabolic conditions, for example, age, and growth stage.

4.4 Conclusion

Supplemental lycopene and dietary fructose did not negatively impact glycated haemoglobin, haemoglobin, haematocrit, blood glucose and serum leptin concentrations and lipid profile in young growing Wistar rats. However, orally administered fenofibrate may exert sex-specific effects on glucose metabolism and lipid profiles. In female and male rats, fenofibrate caused a

notable increase in fasting blood glucose but increased glycated haemoglobin (HbA1c) and serum HDL levels in females only. While orally administered fenofibrate might improve metabolic health by mediating increased serum HDL in females, its chronic use may disrupt blood glucose homeostasis in both sexes.

Having discussed the effects of supplemental lycopene on blood glucose, glycated haemoglobin, haemoglobin, haematocrit, serum leptin concentration, and lipid profile in growing rats fed a high fructose diet, the next chapter explored the potential benefits of supplemental lycopene for kidney health in growing Wistar rats fed a high-fructose diet.

4.5 References

- Baena, M., Sangüesa, G., Dávalos, A., Latasa, M. J., Sala-Vila, A., Sánchez, R. M., Roglans, N., Laguna, J. C., & Alegret, M. (2016). Fructose, but not glucose, impairs insulin signaling in the three major insulin-sensitive tissues. *Scientific Reports*, *6*(1), 1–15.
<https://doi.org/10.1038/srep26149>
- Bekele, A., Roba, K. T., Egata, G., & Gebremichael, B. (2019). Anemia and associated factors among type-2 diabetes mellitus patients attending public hospitals in Harari Region, Eastern Ethiopia. *PloS One*, *14*(12), e0225725. <https://doi.org/10.1371/JOURNAL.PONE.0225725>
- Bissinger, R., Bhuyan, A. A. M., Qadri, S. M., & Lang, F. (2019). Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases. *The FEBS Journal*, *286*(5), 826–854.
<https://doi.org/10.1111/FEBS.14606>
- Blum A, Merei M, Karem A, Blum N, Ben-Arzi S, Wirsansky I, Khazim K. (2006). Effects of tomatoes on the lipid profile. *Clinical and Investigative Medicine*, *29*(5):298-300. PMID: 17144439
- Chiriaco, M., Nesti, L., Flyvbjerg, A., Golay, A., Nazare, J. A., Anderwald, C. H., Mitrakou, A., Bizzotto, R., Mari, A., & Natali, A. (2024). At any Level of Adiposity, Relatively Elevated Leptin Concentrations Are Associated with Decreased Insulin Sensitivity. *The Journal of Clinical Endocrinology & Metabolism*, *109*(2), 461–470. <https://doi.org/10.1210/CLINEM/DGAD505>
- Codazzi, V., Frontino, G., Galimberti, L., Giustina, A., & Petrelli, A. (2023). Mechanisms and risk factors of metabolic syndrome in children and adolescents. *Endocrine*, *84*(1), 16–28.
<https://doi.org/10.1007/S12020-023-03642-X>
- Dilworth, L., Facey, A., & Omoruyi, F. (2021). Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. *International Journal of Molecular Sciences* *2021*, Vol. 22, Page 7644, *22*(14), 7644. <https://doi.org/10.3390/IJMS22147644>
- DiNicolantonio, J. J., Mehta, V., Onkaramurthy, N., & O’Keefe, J. H. (2018). Fructose-induced inflammation and increased cortisol: A new mechanism for how sugar induces visceral adiposity. *Progress in Cardiovascular Diseases*, *61*(1), 3–9. <https://doi.org/10.1016/J.PCAD.2017.12.001>
- Ehrhardt, N., Cui, J., Dagdeviren, S., Saengnipanthkul, S., Goodridge, H. S., Kim, J. K., Lantier, L., Guo, X., Chen, Y. D. I., Raffel, L. J., Buchanan, T. A., Hsueh, W. A., Rotter, J. I., Goodarzi, M. O.,

- & Péterfy, M. (2019). Adiposity-Independent Effects of Aging on Insulin Sensitivity and Clearance in Mice and Humans. *Obesity*, 27(3), 434. <https://doi.org/10.1002/OBY.22418>
- Ekmen, N., Helvacı, A., Gunaldi, M., Sasani, H., & Yildirmak, S. T. (2016). Leptin as an important link between obesity and cardiovascular risk factors in men with acute myocardial infarction. *Indian Heart Journal*, 68(2), 132. <https://doi.org/10.1016/J.IHJ.2015.07.032>
- Eze, E. D., Afodun, A. M., Kasolo, J., & Kasozi, K. I. (2019). Lycopene improves on basic hematological and immunological parameters in diabetes mellitus. *BMC Research Notes*, 12, 1-6. <https://doi.org/10.1186/S13104-019-4841-8>
- Farag, M. M., Ashour, E. H., & El-Hadidy, W. F. (2020). Amelioration of High Fructose Diet-Induced Insulin Resistance, Hyperuricemia, and Liver Oxidative Stress by Combined Use of Selective Agonists of PPAR- α and PPAR- γ in Rats. *Dubai Medical Journal*, 3(2), 76–86. <https://doi.org/10.1159/000506899>
- Ferreira-Santos, P., Aparicio, R., Carrón, R., Montero, M. J., & Sevilla, M. Á. (2020). Lycopene-supplemented diet ameliorates metabolic syndrome induced by fructose in rats. *Journal of Functional Foods*, 73, 104098. <https://doi.org/10.1016/J.JFF.2020.104098>
- Fontana, A., Vieira, J. G., Vianna, J. M., Bichowska, M., Krzysztofik, M., Wilk, M., & Reis, V. M. (2023). Reduction of leptin levels during acute exercise is dependent on fasting but not on caloric restriction during chronic exercise: A systematic review and meta-analysis. *PLOS ONE*, 18(11), e0288730. <https://doi.org/10.1371/JOURNAL.PONE.0288730>
- Francey, C., Cros, J., Rosset, R., Crézé, C., Rey, V., Stefanoni, N., Schneiter, P., Tappy, L., & Seyssel, K. (2019). The extra-splanchnic fructose escape after ingestion of a fructose-glucose drink: An exploratory study in healthy humans using a dual fructose isotope method. *Clinical Nutrition ESPEN*, 29, 125–132. <https://doi.org/10.1016/J.CLNESP.2018.11.008>
- Guney, C., Banu Bal, N., & Akar, F. (2023). The impact of dietary fructose on gut permeability, microbiota, abdominal adiposity, insulin signaling and reproductive function. *Heliyon*, 9, e18896. <https://doi.org/10.1016/j.heliyon.2023.e18896>

- Hattori, N., Takumi, A., Saito, K., & Saito, Y. (2020). Effects of serial cervical or tail blood sampling on toxicity and toxicokinetic evaluation in rats. *The Journal of Toxicological Sciences*, 45(10), 599–609. <https://doi.org/10.2131/JTS.45.599>
- Holm, L. J., Haupt-Jorgensen, M., Giacobini, J. D., Hasselby, J. P., Bilgin, M., & Buschard, K. (2019). Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice. *Diabetologia*, 62(12), 2262. <https://doi.org/10.1007/S00125-019-04973-Z>
- Jeong, J., Cho, Y., Cho, I. Y., & Ahn, J. (2022). Association between Obesity and Anemia in a Nationally Representative Sample of South Korean Adolescents: A Cross-Sectional Study. *Healthcare*, 10(6), 1055. <https://doi.org/10.3390/HEALTHCARE10061055>
- Jin, Y., & Arroo, R. (2023). The protective effects of flavonoids and carotenoids against diabetic complications—A review of in vivo evidence. *Frontiers in Nutrition*, 10, 1020950. <https://doi.org/10.3389/FNUT.2023.1020950/BIBTEX>
- Johnson, R. J., Lanaspá, M. A., Sanchez-Lozada, L. G., Tolan, D., Nakagawa, T., Ishimoto, T., Andres-Hernando, A., Rodriguez-Iturbe, B., & Stenvinkel, P. (2023). The fructose survival hypothesis for obesity. *Philosophical Transactions of the Royal Society B*, 378(1885), 20220230. <https://doi.org/10.1098/RSTB.2022.0230>
- Kelem, A., Shiferaw, E., & Adane, T. (2023). Hematological abnormalities and associated factors among metabolic syndrome patients at the University of Gondar comprehensive specialized hospital, Northwest Ethiopia. *PLOS ONE*, 18(5), e0286163. <https://doi.org/10.1371/JOURNAL.PONE.0286163>
- Kolb, H., Kempf, K., & Martin, S. (2023). Insulin and aging – a disappointing relationship. *Frontiers in Endocrinology*, 14, 1261298. <https://doi.org/10.3389/FENDO.2023.1261298>
- Köseler, E., Kızıltan, G., Türker, P. F., Saka, M., Ok, M. A., Bacanlı, D., Aydos, T. R., Bayraktar, N., & Özdemir, H. (2018). The effects of glucose and fructose on body weight and some biochemical parameters in rats. *Progress in Nutrition*, 20(1), 46–51. <https://doi.org/10.23751/pn.v20i1.5956>
- La Fontaine, M. F., Cirigliaro, C. M., Hobson, J. C., Lombard, A. T., Specht, A. F., Dyson-Hudson, T. A., Kirshblum, S. C., & Bauman, W. A. (2019). A Four Month Randomized Controlled Trial on

the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury. *Scientific Reports*, 9(1), 1–9. <https://doi.org/10.1038/s41598-019-53753-7>

Lee, J., Jeon, S., Lee, M., & Yoon, M. (2023). Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice. *Nutrition & Diabetes*, 13(1), 1–9. <https://doi.org/10.1038/s41387-023-00249-z>

Lee, J. M., Govindarajah, V., Goddard, B., Hinge, A., Muench, D. E., Filippi, M. D., Aronow, B., Cancelas, J. A., Salomonis, N., Grimes, H. L., & Reynaud, D. (2018). Obesity alters the long-term fitness of the hematopoietic stem cell compartment through modulation of Gfi1 expression. *The Journal of Experimental Medicine*, 215(2), 627. <https://doi.org/10.1084/JEM.20170690>

Leh, H. E., & Lee, L. K. (2022). Lycopene: A Potent Antioxidant for the Amelioration of Type II Diabetes Mellitus. *Molecules*, 27(7), 2335. <https://doi.org/10.3390/MOLECULES27072335>

Liu, S. nan, Liu, Q., Li, L. yi, Huan, Y., Sun, S. juan, & Shen, Z. fang. (2011). Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: Is that a latent disadvantage? *Journal of Translational Medicine*, 9(1), 176. <https://doi.org/10.1186/1479-5876-9-176>

Luvizotto, R. D. A. M., Nascimento, A. F., Imaizumi, E., Pierine, D. T., Conde, S. J., Correa, C. R., Yeum, K. J., & Ferreira, A. L. A. (2013). Lycopene supplementation modulates plasma concentrations and epididymal adipose tissue mRNA of leptin, resistin and IL-6 in diet-induced obese rats. *British Journal of Nutrition*, 110(10), 1803–1809. <https://doi.org/10.1017/S0007114513001256>

Magriplis, E., Michas, G., Petridi, E., Chrousos, G. P., Roma, E., Benetou, V., Cholopoulos, N., Michas, R., Panagiotakos, D., & Zampelas, A. (2021). Dietary sugar intake and its association with obesity in children and adolescents. *Children*, 8(8), 676. <https://doi.org/10.3390/CHILDREN8080676/S1>

Mars, M., De Graaf, C., De Groot, C. P. G. M., Van Rossum, C. T. M., & Kok, F. J. (2006). Fasting leptin and appetite responses induced by a 4-day 65%-energy-restricted diet. *International Journal of Obesity*, 30(1), 122–128. <https://doi.org/10.1038/SJ.IJO.0803070>

- Mendoza-Herrera, K., Florio, A. A., Moore, M., Marrero, A., Tamez, M., Bhupathiraju, S. N., & Mattei, J. (2021). The Leptin System and Diet: A Mini Review of the Current Evidence. In *Frontiers in Endocrinology*, 12, 749050. <https://doi.org/10.3389/fendo.2021.749050>
- Merino, B., Fernández-Díaz, C. M., Cózar-Castellano, I., & Perdomo, G. (2020). Intestinal Fructose and Glucose Metabolism in Health and Disease. *Nutrients*, 12(1), 94. <https://doi.org/10.3390/NU12010094>
- Mohamed, S. M., Shalaby, M. A., El-Shiekh, R. A., El-Banna, H. A., Emam, S. R., & Bakr, A. F. (2023). Metabolic syndrome: risk factors, diagnosis, pathogenesis, and management with natural approaches. *Food Chemistry Advances*, 3, 100335. <https://doi.org/10.1016/J.FOCHA.2023.100335>
- Mulkalwar, S., Rane, B., Munjal, N., Golande, P., & Behera, L. (2015). To evaluate and compare the hypoglycemic, antioxidant and hypolipidemic effect of lycopene with atorvastatin in hyperlipidemic New Zealand white rabbits. *International Journal of Basic & Clinical Pharmacology*, 4(1), 148. <https://doi.org/10.5455/2319-2003.ijbcp20150229>
- Nakrani, M. N., Wineland, R. H., & Anjum, F. (2023). Physiology, Glucose Metabolism. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK560599/>
- Noubiap, J. J., Nansseu, J. R., Lontchi-Yimagou, E., Nkeck, J. R., Nyaga, U. F., Ngouo, A. T., Tounouga, D. N., Tianyi, F. L., Foka, A. J., Ndoadoumgue, A. L., & Bigna, J. J. (2022). Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. *The Lancet Child & Adolescent Health*, 6(3), 158–170. [https://doi.org/10.1016/S2352-4642\(21\)00374-6](https://doi.org/10.1016/S2352-4642(21)00374-6)
- Nouri-Keshtkar, M., Shojaei Shahrokhbabadi, M., Ghaehri, A., Hosseini, R., Ketabi, H., Farjam, M., Chen, D. G., Rezaeian, M., Homayounfar, R., Tahamtani, Y., & Totonchi, M. (2023). Role of gender in explaining metabolic syndrome risk factors in an Iranian rural population using structural equation modelling. *Scientific Reports*, 13(1), 1–12. <https://doi.org/10.1038/s41598-023-40485-y>
- Picó, C., Palou, M., Pomar, C. A., Rodríguez, A. M., & Palou, A. (2021). Leptin as a key regulator of the adipose organ. *Reviews in Endocrine and Metabolic Disorders*, 23(1), 13–30. <https://doi.org/10.1007/S11154-021-09687-5>

- Rangareddy, H., Venkatapathappa, P., Mandalaneni, K., Srinivasaiah, A., Bourne-Yearwood, K., Rangareddy, H., Venkatapathappa, P., Mandalaneni, K., Srinivasaiah, A., & Bourne-Yearwood, K. (2023). Leptin and Obesity: Understanding the Impact on Dyslipidemia. *Body Mass Index - Overweight, Normal Weight, Underweight*. IntechOpen.
<https://doi.org/10.5772/INTECHOPEN.112499>
- Sezer, F., Deniz, S., Sevim, D., Chaachouay, N., & Zidane, L. (2024). Plant-Derived Natural Products: A Source for Drug Discovery and Development. *Drugs and Drug Candidates*, 3(1), 184–207.
<https://doi.org/10.3390/DDC3010011>
- Sharma, I., Khare, N., Rai, A., Sharma, I., Khare, N., & Rai, A. (2024). *Carotenoids: Sources, Bioavailability and Their Role in Human Nutrition*. IntechOpen.
<https://doi.org/10.5772/INTECHOPEN.113012>
- Sharma, S., & Chowdary, P. (2015). Protective Role of Lycopene against Cadmium Induced Haematological Changes in Swiss Albino Mice. *Asian Journal of Biomedical and Pharmaceutical Sciences*, 5(49), 17. <https://doi.org/10.15272/AJBPS.V5I49.742>
- Shenkut, M., Urgessa, F., Alemu, R., & Abebe, B. (2024). Assessment of the hematological profile of children with chronic kidney disease on follow-up at St. Paul's Hospital Millennium Medical College and Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia. *BMC Nephrology*, 25(1), 1–8. <https://doi.org/10.1186/S12882-024-03464-7/TABLES/7>
- Song, G., Qi, W., Wang, Y., Pang, S., & Li, Y. (2021). The metabolic effect of fructose on normal rats in a mild dose with glucose and saccharose as control. *Food & Nutrition Research*, 65, 5589.
<https://doi.org/10.29219/FNR.V65.5589>
- Teff, K. L., Elliott, S. S., Tschöp, M., Kieffer, T. J., Rader, D., Heiman, M., Townsend, R. R., Keim, N. L., D'Alessio, D., & Havel, P. J. (2004). Dietary Fructose Reduces Circulating Insulin and Leptin, Attenuates Postprandial Suppression of Ghrelin, and Increases Triglycerides in Women. *The Journal of Clinical Endocrinology & Metabolism*, 89(6), 2963–2972.
<https://doi.org/10.1210/JC.2003-031855>

- Tillman, E. J., Morgan, D. A., Rahmouni, K., & Swoap, S. J. (2014). Three Months of High-Fructose Feeding Fails to Induce Excessive Weight Gain or Leptin Resistance in Mice. *PLOS ONE*, *9*(9), e107206. <https://doi.org/10.1371/JOURNAL.PONE.0107206>
- Vilariño-García, T., Polonio-González, M. L., Pérez-Pérez, A., Ribalta, J., Arrieta, F., Aguilar, M., Obaya, J. C., Gimeno-Orna, J. A., Iglesias, P., Navarro, J., Durán, S., Pedro-Botet, J., & Sánchez-Margalet, V. (2024). Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes. *International Journal of Molecular Sciences*, *25*(4), 2338. <https://doi.org/10.3390/IJMS25042338>
- Yenet, A., Nibret, G., & Tegegne, B. A. (2023). Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review. *ClinicoEconomics and Outcomes Research*, *15*, 443-458. <https://doi.org/10.2147/CEOR.S413546>
- Yin, Y., Zheng, Z., & Jiang, Z. (2019). Effects of lycopene on metabolism of glycolipid in type 2 diabetic rats. *Biomedicine & Pharmacotherapy*, *109*, 2070–2077. <https://doi.org/10.1016/J.BIOPHA.2018.07.100>
- Yu, S., Li, C., Ji, G., & Zhang, L. (2021). The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease. *Frontiers in Pharmacology*, *12*, 783393. <https://doi.org/10.3389/FPHAR.2021.783393>
- Zhu, R., Chen, B., Bai, Y., Miao, T., Rui, L., Zhang, H., Xia, B., Li, Y., Gao, S., Wang, X. D., & Zhang, D. (2020). Lycopene in protection against obesity and diabetes: A mechanistic review. *Pharmacological Research*, *159*, 104966. <https://doi.org/10.1016/J.PHR.2020.104966>

**CHAPTER FIVE: EFFECT OF LYCOPENE ON
KIDNEY HEALTH IN GROWING WISTAR
RATS FED A HIGH FRUCTOSE DIET**

5.0 Introduction

Chronic kidney disease (CKD) has become one of the foremost causes of death globally (Kovesdy, 2022). This condition gradually impairs kidney function over a period of three months or more (Ammirati, 2020), posing significant health challenges and burdens for both individuals and healthcare systems (Lameire et al., 2021). It is estimated that around 850 million people worldwide are affected by CKD, with a substantial number residing in low- and middle-income countries (Jager et al., 2019). Many of these individuals do not have access to diagnosis, prevention, or treatment for the condition (Jager et al., 2019). By the year 2040, CKD is expected to rank as the fifth leading cause of death worldwide (Foreman et al., 2018). The growing prevalence of CKD cases is driven by various factors, including the global increase in diabetes, hypertension, chronic inflammation, obesity, dyslipidaemia, proteinuria, aging, high serum uric acid levels, genetic predispositions, socioeconomic and ethnic influences and dietary factors such as high salt intake (Xie et al., 2023; Jairoun et al., 2024; Mallamaci & Tripepi, 2024). All these factors are significant risk contributors to CKD, which, without proper management, can advance to end-stage renal disease (ESRD), which often requires dialysis or a kidney transplant for survival (Liu et al., 2023).

High fructose consumption and sedentary lifestyles contribute to CKD (Xu et al., 2021). Fructose is metabolised in the kidney, although the majority of fructose metabolism occurs in the liver (Dholariya & Orrick, 2022). The kidneys are involved in fructose metabolism through the enzyme fructokinase, which converts fructose to fructose-1-phosphate (Dholariya & Orrick, 2022). Under normal physiological conditions, fructose is metabolised into glucose in the proximal tubular epithelial cells of the kidneys (Faivre et al., 2021). However, prolonged exposure to high dietary fructose levels can trigger fructolysis, causing substantial ATP depletion and inflammation that ultimately lead to injury to the renal tubules (Nakagawa et al., 2020). This metabolic process can impact kidney function, especially in people with diabetes mellitus or metabolic syndrome, where excessive fructose consumption may cause kidney damage or exacerbate existing kidney conditions (DiNicolantonio et al., 2016; Nakagawa & Kang, 2021).

Surrogate markers like serum creatinine, albumin levels, and blood urea nitrogen (BUN) are commonly used to evaluate kidney function and monitor CKD progression (Gounden et al., 2023). However, the glomerular filtration rate (GFR) remains the gold standard for assessing kidney function, offering a thorough evaluation of kidney health (Farrell & Vassalotti, 2024). In contrast,

neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) provide early detection and specific insights into acute kidney injury by detecting proteins released from injured kidney cells, indicating early renal tubular damage and injury (Westhoff et al., 2017; Treacy et al., 2019). Nonetheless, kidney biopsies and histology provide the most accurate and detailed information about kidney structure and specific disease processes, serving as the gold standard for assessment (Madrazo-Ibarra & Vaitla, 2023; Schnuelle, 2023). This evaluation includes a thorough examination of histopathological features and morphometric changes, such as variations in glomerular tufts, urinary spaces, renal corpuscle areas, and both proximal and distal convoluted tubules (Abd-Eldayem et al., 2024).

Lifestyle adjustments and the use of synthetic medications can reduce the risk and advancement of diet-related kidney disease (Alkhatib et al., 2023). However, synthetic medications do not completely cure the disease and can have adverse side effects (Alhassani et al., 2021). Additionally, the cost of treating advanced stages of kidney disease with dialysis and kidney transplants places a substantial strain on both patients and the healthcare system (Himmelfarb et al., 2020). In response to these challenges, there is growing interest in the use of crude plant extracts and phytochemicals derived from medicinal plants which exhibit health benefitting biological effects (Misra et al., 2024). Lycopene, a naturally occurring carotenoid abundant in red fruits and vegetables possesses antioxidant and anti-inflammatory properties (Sharma et al., 2024). It has been shown to mitigate oxidative stress-induced kidney damage in rats treated with isoniazid and rifampicin (Bedir et al., 2021). Furthermore, the carotenoid has been demonstrated to reduce serum levels of creatinine and BUN in rats with adenine-induced chronic renal failure (Gori et al., 2021) and to decrease KIM-1 and NGAL concentration in rats with diclofenac-induced acute kidney injury (Rasheed et al., 2020). Majority of the research on the efficacy of lycopene have evaluated its potential therapeutic value and its prophylactic potential. Hence this study evaluated the potential of orally administered lycopene to protect kidney health in Wistar rats fed a high fructose diet focusing specifically on kidney macro- and micromorphometry as well as on serum biomarkers reflecting kidney function.

5.1 Materials and methods

5.1.1 Ethical approval

This is as detailed in chapter 3, under subheading 3.1.1.

5.1.2 Chemicals and reagents

The chemicals and reagents utilised are consistent with those detailed in chapter 3, under subheading 3.1.2.

5.1.3 Animals, housing, and general care

The management of experimental animals in this chapter is consistent with the same procedures outlined in chapter 3, under subheading 3.1.3

5.1.4 Experimental design

The study design is as detailed in chapter 3, under subheading 3.1.4.

5.1.5 Terminal procedures, sample collection, and measurements

Following the 12-week intervention period, the rats were fasted overnight but with access to plain drinking water to prevent dehydration. The terminal body mass of each rat was measured using an electronic balance [Snowrex Electronic Scale from Clover Scale (Pty) Ltd, Johannesburg]. The rats were subsequently euthanised using an intraperitoneal injection of sodium pentobarbitone administered at a dose of 200 mg/kg body mass (Euthapent; Kyron laboratories, Johannesburg). Blood samples were obtained through cardiac puncture using 20G needles and 10ml syringes into SST gel-coated blood collection tubes (BD Vacutainer System Bigamart, UK). The blood was then centrifuged (DLAB-DMO412S, Wolflabs Laboratory Products, Pocklington, UK) at $3000 \times g$ for 15 minutes at $-20\text{ }^{\circ}\text{C}$. The serum collected was decanted into Eppendorf microtubes (Abdos Labtech Pvt, Ltd, Uttarakhand, India) and frozen-stored at $-80\text{ }^{\circ}\text{C}$ pending assay for serum creatinine, blood urea nitrogen (BUN), BUN/creatinine ratio, KIM-1, and NGAL concentrations. After blood collection, a midline incision was performed in the abdomen of each rat, and kidneys were carefully removed and weighed using an electronic balance (Presica 310M, Instruments, Johannesburg, South Africa). The left kidney was fixed in 10% phosphate-buffered formalin for histological analysis. The mass of both kidneys relative to body mass (%BM) was then calculated as described by Muhammad et al. (2022) using the formula:

$$\text{Relative kidney mass} = \frac{\text{Mass of kidney (g)}}{\text{Terminal body mass (g)}} \times 100$$

5.1.6 Determination of kidney function and injury biomarkers

Serum creatinine, BUN, and BUN/creatinine ratio concentrations were measured using a Noahcali-100 automatic LOCMEDT biochemistry analyser (Tianjin LOCMEDT Technologies Co., Ltd., China). Following the manufacturer's guidelines, 120 µl of serum was added to the reagent disc containing lyophilised beads, which was then loaded into the Noahcali-100 analyser. Results were generated within 8-12 minutes. Serum concentrations of KIM-1, and NGAL were determined using a rat-specific Enzyme-Linked Immunosorbent Assay (ELISA) kits from Elabscience Biotechnology Inc., Houston, Texas, USA, following the manufacturer's instructions.

5.1.7 Determination of kidney micromorphometry

The kidney samples preserved in 10% phosphate-buffered formalin were processed using an automatic tissue processor (Micro STP 120, Thermo Fisher Scientific, Waltham, USA) before being embedded in paraffin wax. Sections of 3 µm thickness were cut using a rotary microtome (Leica Biosystems, Buffalo Grove, USA) and mounted onto glass slides. Paraffin was removed from sections using xylene, and the tissues were rehydrated by passing through a series of progressively decreasing alcohol concentrations. The sections were then stained with haematoxylin and eosin. Following staining, the sections were dehydrated by passing through a series of increasing alcohol concentrations. The sections were then cleared in xylene to make the tissue transparent. A coverslip was placed over each tissue section using a mounting medium. The slides were examined under a light microscope and images were taken from various fields using a high definition ICC50W digital camera (Leica Biosystems, Germany) connected to a Leica DM750 microscope (Leica Biosystems, Germany). The images were assessed with the groups blinded to prevent bias. Measurements were obtained using ImageJ software for precise image analysis and quantification. The urinary space area, as well as the epithelial areas of the proximal and distal convoluted tubules, were determined using the following formulas:

(a) Urinary space area (µm²) = Renal corpuscular area (µm²) – Glomerular tuft area (µm²)

(b) Proximal convoluted tubules epithelial area (μm^2) = Proximal convoluted tubules outer area (μm^2) – Proximal convoluted tubules inner area (μm^2)

(c) Distal convoluted tubules epithelial area (μm^2) = Distal convoluted tubules outer area (μm^2) – Distal convoluted tubules inner area (μm^2)

5.1.8 Statistical analysis

GraphPad Prism version 9.0 (GraphPad Software Inc., San Diego, USA) was employed for data analysis, and results were presented as mean \pm standard deviation. A one-way ANOVA assessed parametric data across multiple groups, followed by *Tukey's post hoc* test to compare differences between means. A p-value of less than 0.05 was considered statistically significant.

5.2 Results

5.2.1 Kidney mass

Table 5.1 show the effect of lycopene on the absolute and relative kidney masses of female and male Wistar rats. In females, no significant differences ($p > 0.05$) were observed in either absolute or relative kidney masses across treatment groups. In males, although no significant differences ($p > 0.05$) were found in absolute kidney mass across the groups, rats fed a high-fructose diet with fenofibrate intervention had significantly higher ($p < 0.05$) relative kidney masses compared to those fed the control diet or the high-fructose diet with any of the lycopene supplementation.

Table 5. 1: Effect of lycopene on absolute and relative kidney masses in growing female and male Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Females							
Kidney (g)	1.50 ± 0.13 ^a	1.43 ± 0.38 ^a	1.66 ± 0.12 ^a	1.53 ± 0.07 ^a	1.58 ± 0.11 ^a	1.45 ± 0.09 ^a	ns
Kidney (%BM)	0.71 ± 0.05 ^a	0.68 ± 0.18 ^a	0.80 ± 0.04 ^a	0.71 ± 0.04 ^a	0.73 ± 0.05 ^a	0.69 ± 0.02 ^a	ns
Males							
Kidney (g)	2.45 ± 0.19 ^a	2.43 ± 0.15 ^a	2.58 ± 0.20 ^a	2.36 ± 0.11 ^a	2.33 ± 0.10 ^a	2.28 ± 0.48 ^a	ns
Kidney (%BM)	0.69 ± 0.04 ^a	0.70 ± 0.04 ^{ab}	0.80 ± 0.03 ^b	0.68 ± 0.02 ^a	0.69 ± 0.02 ^a	0.65 ± 0.13 ^a	*

^{ab}Means within rows having different superscripts differ significantly at * $p < 0.05$, ns = not significant. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. % BM = Percentage body mass (relative to body mass). Data are expressed as mean ± SD, n = 8 per treatment group.

5.2.2 Serum biomarker concentrations

Table 5.2 shows the serum concentrations of BUN, creatinine, BUN/creatinine ratio, KIM-1, and NGAL in the rats. No significant differences ($p > 0.05$) were detected in the concentrations of these biomarkers across treatment groups in both sexes.

Table 5. 2: Effect of lycopene on serum concentrations of creatinine, BUN, BUN/creatinine ratio, KIM-1 and NGAL in growing female and male Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Females							
BUN (mg/dL)	19.14 ± 2.85 ^a	19.94 ± 3.63 ^a	19.14 ± 2.45 ^a	20.64 ± 2.33 ^a	18.38 ± 3.41 ^a	20.40 ± 2.03 ^a	ns
Creatinine (mg/dL)	0.34 ± 0.04 ^a	0.31 ± 0.06 ^a	0.33 ± 0.04 ^a	0.33 ± 0.03 ^a	0.32 ± 0.07 ^a	0.32 ± 0.03 ^a	ns
BUN/creatinine ratio	55.99 ± 6.44 ^a	65.01 ± 6.01 ^a	60.20 ± 12.40 ^a	62.56 ± 7.13 ^a	59.36 ± 15.96 ^a	64.48 ± 8.031 ^a	ns
KIM-1 (ng/mL)	1.52 ± 0.47 ^a	1.86 ± 0.10 ^a	2.19 ± 0.59 ^a	1.07 ± 0.68 ^a	1.57 ± 1.12 ^a	1.82 ± 0.73 ^a	ns
NGAL (pg/mL)	32466 ± 16756 ^a	55094 ± 29085 ^a	63863 ± 21220 ^a	38193 ± 15550 ^a	55944 ± 42247 ^a	60882 ± 25192 ^a	ns
Males							
BUN (mg/dL)	23.67 ± 1.27 ^a	23.72 ± 11.66 ^a	20.73 ± 1.91 ^a	21.20 ± 3.13 ^a	22.55 ± 2.07 ^a	26.19 ± 3.47 ^a	ns
Creatinine (mg/d/L)	0.35 ± 0.03 ^a	0.33 ± 0.05 ^a	0.31 ± 0.03 ^a	0.29 ± 0.06 ^a	0.29 ± 0.04 ^a	0.35 ± 0.03 ^a	ns
BUN/creatinine ratio	67.81 ± 7.76 ^a	78.18 ± 48.03 ^a	67.62 ± 3.80 ^a	74.14 ± 16.17 ^a	78.54 ± 8.52 ^a	74.88 ± 12.16 ^a	ns
KIM-1 (ng/mL)	0.88 ± 0.52 ^a	1.78 ± 1.25 ^a	1.39 ± 0.52 ^a	0.54 ± 0.58 ^a	1.60 ± 1.12 ^a	1.23 ± 0.55 ^a	ns
NGAL (pg/mL)	32916 ± 16570 ^a	55491 ± 47379 ^a	49216 ± 19611 ^a	22840 ± 15022 ^a	66128 ± 34323 ^a	74428 ± 47699 ^a	ns

^aMeans within rows having the same superscripts are similar at $p > 0.05$, ns = not significant, BUN = Blood urea nitrogen, KIM-1 = Kidney injury molecule 1, NGAL = Neutrophil gelatinase-associated lipocalin. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS +

HDLY = 20% w/v fructose solution as drinking fluid + Lycopene $100 \text{ mg} \cdot \text{kg}^{-1} \text{BM day}^{-1}$ in gelatine cube. Data are expressed as mean \pm SD, n = 5-7 per treatment group.

5.2.3 Kidney histomorphology

Tables 5.3 and 5.4 show the kidney morphometry of the female and male rats respectively. Figures 5.1 and 5.2 represent the kidney histology (H and E staining, 40x magnification) in female and male rats respectively fed a high fructose diet. No significant differences ($p > 0.05$) were observed in the corpuscular area, glomerular tuft area, or the outer, inner, and epithelial areas of the proximal convoluted tubules across treatment groups in the female rats (Table 5.3 and Figure 5.1). Female rats fed the control diet had a significantly larger urinary space area ($p < 0.05$; Table 5.3) compared to those on the high fructose diet supplemented with a low lycopene dose. Similarly, female rats fed the high fructose diet supplemented with a medium dose of lycopene had significantly increased urinary space area ($p < 0.05$) compared to those administered fenofibrate and counterparts whose diets were fortified with low and high lycopene doses. Female rats fed the high fructose diet with fenofibrate intervention had significantly larger ($p < 0.05$) outer, inner, and epithelial areas of the distal convoluted tubules compared to those on the high fructose diet supplemented with a high dose of lycopene. Furthermore, female rats fed the control diet had significantly larger renal distal convoluted tubule outer area ($p < 0.05$; Table 5.3) compared to counterparts fed the high fructose diet supplemented with low, medium, or high doses of lycopene. Female rats fed the control diet had significantly larger renal distal convoluted tubule inner areas ($p < 0.05$) compared to the high fructose diet fed and lycopene-supplemented counterparts. Additionally, the renal distal convoluted tubule epithelial area was significantly larger ($p < 0.05$) in control rats compared to high-dose lycopene-supplemented counterparts (Table 5.3 and Figure 5.1).

Table 5. 3: Effect of lycopene on kidney morphometry in growing female Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Corpuscular area (μm^2)	5213 \pm 1884 ^a	4932 \pm 1393 ^a	4364 \pm 809 ^a	4650 \pm 983 ^a	4958 \pm 1846 ^a	4460 \pm 925 ^a	ns
Glomerular tuft area (μm^2)	4351 \pm 1387 ^a	4206 \pm 1174 ^a	3761 \pm 735 ^a	4108 \pm 1000 ^a	3943 \pm 1435 ^a	3802 \pm 780 ^a	ns
Urinary space area (μm^2)	862. \pm 608 ^{ac}	727 \pm 434 ^{dc}	603 \pm 283 ^{dc}	542 \pm 425 ^d	1015 \pm 541 ^{ab}	658 \pm 465 ^{cd}	*
PCT outer area (μm^2)	950 \pm 256 ^a	979 \pm 299 ^a	1038 \pm 278 ^a	1003 \pm 264 ^a	1031 \pm 208 ^a	1112 \pm 454 ^a	ns
PCT inner area (μm^2)	299 \pm 123 ^a	306 \pm 148 ^a	283 \pm 117 ^a	307 \pm 151 ^a	336 \pm 99 ^a	355 \pm 195 ^a	ns
PCT epithelial area (μm^2)	651 \pm 163 ^a	674 \pm 173 ^a	755 \pm 182 ^a	696 \pm 140 ^a	695 \pm 135 ^a	757 \pm 277 ^a	ns
DCT outer area (μm^2)	953 \pm 505 ^a	794 \pm 331 ^{ab}	919 \pm 444 ^{ac}	698 \pm 280 ^{bc}	703 \pm 248 ^{bc}	622 \pm 199 ^b	*
DCT inner area (μm^2)	236 \pm 239 ^a	133 \pm 70 ^{bc}	208 \pm 170 ^{ab}	134 \pm 79 ^{bc}	130 \pm 68 ^{bc}	111 \pm 53 ^c	*
DCT epithelial area (μm^2)	717 \pm 380 ^a	661 \pm 294 ^{ab}	712 \pm 302 ^a	565 \pm 227 ^{ab}	574 \pm 221 ^{ab}	511 \pm 167 ^b	*

^{abcd}Means within rows having different superscripts differ significantly at * $p < 0.05$, ns = not significant. PCT = Proximal convoluted tubule, DCT = Distal convoluted tubule. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution

as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 4 per treatment group.

Male Wistar rats fed the control diet had significantly larger renal corpuscular and urinary space areas ($p < 0.05$) compared to those fed the high fructose diet supplemented with a medium lycopene dose (Table 5.4). Male rats fed the high fructose diet had significantly larger renal urinary space areas ($p < 0.05$) compared to their lycopene supplemented counterparts. Similarly, the renal urinary space areas of males administered fenofibrate were significantly larger ($p < 0.05$) compared to those males supplemented with a medium lycopene dose. Additionally, the distal convoluted tubule epithelial area of the rats was significantly larger ($p < 0.05$) in the fenofibrate administered rats compared to control, high fructose diet fed and low and high lycopene supplemented counterparts. Furthermore, male rats administered fenofibrate had a significantly larger ($p < 0.05$) distal convoluted tubule outer area compared to the high fructose diet-fed and high-dose lycopene-supplemented counterparts. Male rats supplemented with a medium lycopene dose showed a significant increase ($p < 0.05$) in the proximal convoluted inner area compared to those administered fenofibrate. No significant differences ($p > 0.05$) were observed in the glomerular tuft, outer and epithelial areas of the proximal tubules, or the inner area of the distal tubules across male treatment groups (Table 5.4, Figure 5.2). Additionally, no evidence of histological tubular damage was detected in either sex (Figures 5.1 or 5.2).

Table 5. 4: Effect of lycopene on kidney morphometry in growing male Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS + FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Corpuscular area (μm^2)	6820 \pm 2256 ^a	6358 \pm 2233 ^{ab}	6024 \pm 1989 ^{ab}	5879 \pm 1534 ^{ab}	5435 \pm 1298 ^b	5847 \pm 1070 ^{ab}	*
Glomerular tuft area (μm^2)	5644 \pm 1827 ^a	4976 \pm 1641 ^a	4804 \pm 1600 ^a	5032 \pm 1257 ^a	4795 \pm 1235 ^a	4978 \pm 870 ^a	ns
Urinary space Area (μm^2)	1176 \pm 649 ^{ac}	1382 \pm 808 ^a	1219 \pm 597 ^{ac}	847 \pm 622 ^{bc}	640 \pm 357 ^b	869 \pm 588 ^{bc}	*
PCT outer area (μm^2)	1511 \pm 487 ^a	1489 \pm 419 ^a	1635 \pm 457 ^a	1524 \pm 499 ^a	1827 \pm 740 ^a	1557 \pm 548 ^a	ns
PCT inner area (μm^2)	521 \pm 251 ^{ab}	528 \pm 240 ^{ab}	495 \pm 194 ^a	555 \pm 241 ^{ab}	676 \pm 363 ^b	593 \pm 259 ^{ab}	*
PCT epithelial area (μm^2)	990 \pm 275 ^a	961 \pm 244 ^a	1140 \pm 292 ^a	969 \pm 289 ^a	1151 \pm 415 ^a	964 \pm 335 ^a	ns
DCT outer area (μm^2)	1010 \pm 484 ^{ab}	920 \pm 407 ^a	1305 \pm 651 ^b	995 \pm 503 ^{ab}	1045 \pm 511 ^{ab}	901 \pm 415 ^{ac}	*
DCT inner area (μm^2)	190 \pm 147 ^a	186 \pm 82 ^a	189 \pm 74 ^a	192 \pm 120 ^a	191 \pm 134 ^a	177 \pm 126 ^a	ns
DCT epithelial area (μm^2)	819 \pm 395 ^a	734 \pm 359 ^a	1116 \pm 593 ^b	803 \pm 414 ^a	854 \pm 391 ^{ab}	723 \pm 344 ^a	*

^{abc}Means within rows having different superscripts differ significantly at * p < 0.05, ns = not significant. PCT = Proximal convoluted tubule, DCT = Distal convoluted tubule. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution

as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 4 per treatment group.




Figure 5. 1 Representative photomicrographs illustrating the effect of lycopene on kidney histology (H&E staining, 40x magnification, scale bar = 50 μm) in growing female Wistar rats fed a high-fructose diet.

CA = corpuscular area; GTA = glomerular tuft area; USA = urinary space area; PCTOA = proximal convoluted tubules outer area; PCTIA = proximal convoluted tubules inner area; PCTEA = proximal convoluted tubules epithelial area; DCTOA = distal convoluted tubules outer area; DCTIA = distal convoluted tubules inner area; DCTEA = distal convoluted tubules epithelial area. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube.




Figure 5. 2: Representative photomicrographs illustrating the effect of lycopene on kidney histology (H&E staining, 40x magnification, scale bar = 50 μm) in growing male Wistar rats fed a high-fructose diet.

CA = corpuscular area; GTA = glomerular tuft area; USA = urinary space area; PCTOA = proximal convoluted tubules outer area; PCTIA = proximal convoluted tubules inner area; PCTEA = proximal convoluted tubules epithelial area; DCTOA = distal convoluted tubules outer area; DCTIA = distal convoluted tubules inner area; DCTEA = distal convoluted tubules epithelial area. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube.

5.3 Discussion

5.3.1 Kidney masses

This study evaluated the prophylactic potential of orally administered lycopene against possible dietary fructose-induced kidney derangements in growing weanling Wistar rats in a model mimicking human adolescents fed a high fructose diet. Findings showed no significant differences in the kidney masses (absolute and relative to body weight) of female rats and the absolute kidney mass of male rats across treatment groups. However, male Wistar rats fed a high fructose diet with fenofibrate intervention had significantly heavier relative kidney mass compared to those fed the control diet or the high fructose diet supplemented with lycopene. These results suggest that dietary fructose and lycopene neither compromised nor increased kidney mass in both female and male rats. However, treatment with fenofibrate caused an increase in the kidney mass in male rats through either hypertrophy and or hyperplasia. This increase may reflect structural adaptations in renal tubules. Histological analysis from the present study revealed a reduction in the inner area of the proximal convoluted tubule (PCT), alongside an increase in the outer and epithelial areas of the distal convoluted tubules (DCT). These findings suggest a compensatory response, possibly linked to altered renal workload or PPAR- α -mediated changes in tubular morphology (Kikuchi et al., 2023). Previous studies have also associated fenofibrate with glomerular and tubular modifications, which could contribute to overall increase in kidney mass (Li et al., 2021; Kikuchi et al., 2023). High dietary fructose intake has been associated with the development of metabolic syndrome, obesity, hypertension, and insulin resistance (Giussani et al., 2022). All these metabolic conditions can lead to kidney hypertrophy (Kotsis et al., 2021). However, young rats have been shown to exhibit resistance to metabolic derangements caused by dietary fructose (Tillman et al., 2014), which may explain the absence of significant changes in kidney masses during the 12-week intervention period. Lycopene is renowned for its potent antioxidant and anti-inflammatory properties (Long et al., 2024), which can protect kidney tissues from oxidative stress and damage (Bedir et al., 2021), potentially counteracting any negative effects of fructose (Ferreira-Santos et al., 2020), thereby helping to maintain kidney mass and function (Abir et al., 2023). Previous studies demonstrated that fenofibrate administered orally for 12 weeks to male mice on a high-fat diet reduced glomerular and tubulointerstitial damage caused by lipotoxicity (Tanaka et al., 2011). According to Yaribeygi et al. (2018), an 8-week oral administration of fenofibrate enhanced renal function by reducing oxidative stress, alleviating inflammation, and preventing apoptosis in

streptozotocin-induced diabetic male Wistar rats. Additionally, a high dose of fenofibrate administered to male Wistar-Han rats for 30 days was shown to activate multiple cellular stress pathways in the kidneys of aged rats (Wrońska et al., 2024). I hypothesise that the sexually dimorphic effect in the increased relative kidney mass with fenofibrate could be due to hormonal and metabolic differences between males and females. In males, testosterone may enhance kidney hypertrophy through interactions with androgen receptors, while differences in metabolism and pharmacokinetics may also account for the distinct responses seen in both sexes (Harvey & Alvarez De La Rosa, 2024; Steiger et al., 2024). In addition, fenofibrate can induce different levels of inflammation or cellular stress in male compared to female rats, potentially leading to increased cellular hypertrophy or hyperplasia in males.

5.3.2 Renal function and injury biomarkers

The present study found no significant differences in fasting serum concentrations of BUN, creatinine, BUN/creatinine ratio, KIM-1 and NGAL in female and male rats across treatment groups. These results suggest that dietary fructose, fenofibrate and lycopene did not negatively affect renal function, as reflected by these biomarkers. While BUN and creatinine concentrations and BUN/creatinine ratio are important indicators of kidney function, the lack of significant changes suggests that these treatments (fructose, fenofibrate and lycopene) did not induce adverse effects on kidney health in young growing rats. BUN reflects the concentration of urea nitrogen in the blood, a byproduct of protein metabolism, produced in the liver and excreted by the kidneys (Jiang et al., 2017). Creatinine, a waste product of muscle metabolism, is a sensitive indicator of glomerular filtration efficiency (Brodsky et al., 2021). The BUN/creatinine ratio is commonly used to differentiate between prerenal and intrinsic renal conditions (Sancho-Martínez et al., 2023). Elevations in these markers are indicative of impaired kidney function (Al Jameil, 2019; Brookes & Power, 2022). High fructose intake has been associated with elevated plasma concentrations of BUN and creatinine (Monteiro et al., 2023), likely due to its role in inducing oxidative stress, promoting uric acid production, and impairing renal perfusion and glomerular filtration (Yokota et al., 2018; Hu et al., 2023; Du et al., 2024). Flisiński et al. (2021) reported no significant changes in serum concentrations of BUN or creatinine clearance in male Wistar rats fed 10% or 60% fructose diets for 8 weeks, while creatinine concentrations remained unchanged only in the 10% fructose group. Similarly, in the present study, serum concentrations of BUN and creatinine and BUN/creatinine ratio remained unaffected in growing Wistar rats fed a 20% fructose solution for

12 weeks. Studies in humans have demonstrated that fenofibrate increases serum concentrations of BUN and creatinine, although these levels generally return to normal once the drug is discontinued (McQuade et al., 2008; Park et al., 2017; Emami et al., 2020). Wrońska et al. (2024) also found that fenofibrate treatment elevated serum creatinine and BUN concentrations in adult male Wistar-Han rats, compared to younger rats. Researchers believe that these changes result from altered renal haemodynamics or mild renal impairment, which are usually reversed after discontinuation of the drug (McQuade et al., 2008; Attridge et al., 2012; Park et al., 2017). However, the degree and reversibility of these effects may vary, depending on factors such as age, dosage, treatment duration, and baseline renal health (Emami et al., 2020; Wrońska et al., 2024). Interestingly, some studies have suggested that fenofibrate might exert protective effects under certain conditions. For instance, in models of kidney injury or metabolic disorders, fenofibrate has been shown to reduce oxidative stress, inflammation, and lipid accumulation, as well as serum creatinine and BUN concentrations, which may mitigate renal damage (Kadian et al., 2013; Balakumar et al., 2014; Chakkarwar & Kawtikwar, 2021; Feng et al., 2021). These dual effects highlight the complexity of fenofibrate's impact on renal physiology and suggest that outcomes may depend on the experimental context (Kostapanos et al., 2013; Med et al., 2018). Lycopene has demonstrated protective effects by reducing serum concentrations of urea, creatinine, uric acid, and KIM-1, alleviating renal function decline associated with 5-fluorouracil induced nephrotoxicity in male rats (Albadrani et al., 2024). Similarly, lycopene has been reported to lower plasma creatinine and urea concentrations in adult female Wistar rats fed a high-fat diet for 8 weeks (Khan et al., 2016). These findings underscore the relevance of early biomarkers like KIM-1 and NGAL, which are recognised in both serum and urine for their high sensitivity and specificity in detecting renal tubular injury and damage (Treacy et al., 2019). High fructose consumption has been reported to cause renal tubular damage (Flisiński et al., 2021), which can result in increased concentrations of KIM-1 and NGAL (Juett et al., 2021). Although dietary fructose did not significantly increase serum KIM-1 and NGAL concentrations to indicate renal tubular injury in this study, it elevated serum KIM-1 concentrations compared to the respective control groups. In female rats, fructose increased KIM-1 concentrations by 22.4%, though this was not statistically significant and was attenuated by supplemental lycopene at low (42.5%), medium (15.6%), and high (2.2%) doses. Similarly, in male rats, fructose caused a 102.3% increase in KIM-1 concentrations compared to control, suggesting potential biological relevance despite the lack of

statistical significance and a tendency towards increased risk of renal tubular injury. Supplemental lycopene mitigated this increase by 69.7%, 10.1%, and 30.9% at low, medium, and high doses, respectively. Additionally, high-fructose diet caused a non-statistically significant increase in serum NGAL concentrations compared to controls in both sexes. In females, dietary fructose increased serum NGAL concentrations by 70%. Supplemental lycopene reduced this increase by 30.7% at low doses but increased it by 1.5% and 10.5% at medium and high doses, respectively. In males, fructose elevated serum NGAL concentrations by 69%. Lycopene reduced this increase by 58.8% at low doses, while medium and high doses increased serum NGAL concentrations by 19.2% and 34.1%, respectively. These findings point to a biological significance, suggesting that while fructose induces an increase in serum NGAL concentrations, supplemental lycopene modulates this effect differently across doses. Lycopene is widely recognised for its potent antioxidant and anti-inflammatory properties (Shinkre et al., 2024), offering protective effects against kidney damage in various models of renal injury (Shalaby & El Shaer, 2019; Adikwu et al., 2021; Xie et al., 2022). Its ability to neutralise free radicals and reduce oxidative stress plays a crucial role in maintaining kidney health (Stojiljkovic et al., 2018). However, while lycopene acts as an antioxidant at low doses, very high doses have been shown to exhibit pro-oxidant behaviour, potentially inducing mild cellular stress (Elvira-Torales et al., 2019). The observed non-significant increase in NGAL levels might reflect this complex dynamic rather than indicating pathological kidney damage. Further investigation is needed to elucidate these effects and establish the optimal dosage for therapeutic benefits.

As a PPAR α agonist, fenofibrate primarily functions to lower lipid levels (Jin et al., 2023). It alleviates oxidative stress, reduces apoptotic and inflammatory markers, and decreases KIM-1 and NGAL concentrations in male Wistar rats with vancomycin-induced nephrotoxicity (El-Shoura et al., 2024). Additionally, fenofibrate significantly attenuates high-fat diet induced upregulation of KIM-1 and NGAL mRNA expression in the kidneys, as well as the urinary excretion of these markers, in C57BL/6J male mice fed a high-fat diet for 12 weeks (Sohn et al., 2017). However, in certain conditions such as high-dose treatment or ageing, fenofibrate has also been shown to activate cellular stress pathways, potentially increasing these markers (Wrońska et al., 2024). In the present study, fenofibrate did not cause renal tubular damage, and consequently, no adverse effects were seen in KIM-1 and NGAL concentrations in female and male rats (Table 5.2). Lycopene has potent antioxidant and anti-inflammatory activities (Khongthaw et al., 2022).

Supplementing male Wistar rats on a high-fat diet with 50 mg/kg body mass of lycopene for three months prevented renal damage and led to reductions in creatinine, urea, and NGAL levels (Albrahim & Robert, 2022). Similarly, Rasheed et al. (2020) reported a notable decrease in serum concentrations of creatinine, urea, KIM-1, and NGAL and an increase in the estimated glomerular filtration rate following the administration of 5 mg/kg/day of lycopene for 10 days to male Sprague-Dawley rats with diclofenac-induced acute kidney injury. In the present study, young, growing Wistar rats did not exhibit significant changes in concentrations of BUN and creatinine concentrations, or the BUN/creatinine ratio across treatment groups. Although serum KIM-1 and NGAL concentrations showed slight increases in fructose-treated rats compared to the control group, these changes were not significant, suggesting that no substantial renal injury or oxidative stress occurred. The heightened resilience of young rats to metabolic and oxidative stress, coupled with their adaptable renal systems, likely contributed to these consistent findings across all renal markers.

5.3.3 Kidney histomorphometry

Kidney biopsies and histological analysis offer the most precise and comprehensive insights into kidney structure and specific disease mechanisms, making them the gold standard for evaluation of kidney health (Schnuelle, 2023). In this study, the long-term consumption of a high-fructose diet resulted in sex-specific responses in the kidneys of rats. In females, supplementation with low and high doses of lycopene as well as treatment with fenofibrate reduced urinary space area compared to medium-dose lycopene. Conversely, in males, the high-fructose diet resulted in a significant increase in urinary space area compared to lycopene-treated groups, but this increase was not significant when compared to the control group. Supplemental lycopene at low, medium, and high doses effectively mitigated the fructose-induced urinary space enlargement, reducing it by 39%, 54%, and 37.1%, respectively. Additionally, dietary fortification with the medium-dose lycopene decreased urinary space area in male rats compared to control and fenofibrate treated counterparts (Figures 5.1 and 5.2). An enlarged urinary space area may reflect swelling of the renal interstitium or damage to the tubular or glomerular structures, leading to a disruption in the kidney's normal architecture (Tobar et al., 2013). The findings of the current study suggest that dietary fructose contribute to renal changes in male rats, as indicated by the non-statistically significant but biologically significant increase in urinary space area pointing to potential biological effects. However, supplemental lycopene at various doses significantly reduced urinary

space area, suggesting a protective role against fructose-induced renal enlargement. Medium-dose supplemental lycopene reduced the renal corpuscular area in males compared to the control but with no effect in the glomerular tuft area. However, no treatment regime induced differences were observed in either the renal corpuscular or glomerular tuft areas in female rats. This finding suggests that lycopene can reduce the size of the glomeruli or the overall filtration area in male rats. A reduction in the renal corpuscular area indicates a normalisation or decrease in hypertrophy, which is potential beneficial. An increase in renal corpuscular area is associated with glomerular hypertrophy (Kataoka et al., 2020), which can result from diabetes mellitus, hypertension and/or chronic kidney disease (Poloni & Rotta, 2022). Glomeruli enlargement often indicates stress on the kidneys which can lead to further damage and decreased kidney function over time (Kataoka et al., 2023). Findings from the current study show that dietary fructose did not cause significant difference in the inner, outer, or epithelial areas of the distal convoluted tubule (DCT) in either female or male rats compared to their control counterparts. However supplemental lycopene significantly reduced these areas in females compared to the control group, suggesting a potential protective effect. In contrast, fenofibrate increased these areas compared to high-dose lycopene. Similarly, in males, orally administered fenofibrate increased the outer area of the DCT compared to the high-fructose diet and high-dose lycopene and increased the epithelial area of the DCT compared to the control, high-fructose diet, and low- and high-dose lycopene, with no significant change observed in the inner area (Tables 5.3 and 5.4, respectively). These findings suggests that dietary fructose did not negatively affect DCT areas in either female or male rats. Lycopene may help counteract the enlargement of DCT areas induced by fenofibrate. High fructose intake has been shown to induce renal damage in renal corpuscles, distal tubules, and the interstitium when a 25% fructose diet was fed to adult male Wistar rats for 8 weeks (Elsisy et al., 2021). Thus, it can be hypothesised that a high-fructose diet may not significantly affect DCT areas in young, growing rats, as they may exhibit reduced susceptibility to fructose-induced metabolic and structural changes in kidney function. This could be attributed to their active growth phase, higher metabolic demands, or compensatory renal mechanisms (Kolb et al., 2023). Lycopene has been shown to preserve kidney structure and improve renal function markers in male Sprague Dawley rats treated with adenine for 30 days (Gori et al., 2021). Conversely, orally administered fenofibrate for 6 weeks has been demonstrated to induce inflammation, necrosis, fibrosis, and oxidative stress, leading to detrimental alterations in the kidney's structure and function in adult male albino rats

(Med et al., 2018). These changes included damage to both the proximal and distal convoluted tubules, with observations of dilated bowman's capsule, disrupted tubular lumina, loss of cellular differentiation, and increased interstitial infiltration (Med et al., 2018). The DCT plays a crucial role in maintaining homeostasis: it reabsorbs sodium and calcium to maintain electrolyte balance, regulates pH, and controls blood pressure and fluid levels (Subramanya & Ellison, 2014; Franken et al., 2021; Shrimanker & Bhattarai, 2023). Studies have shown that excessive enlargement of the DCT areas lead to hypertension, hypercalcaemia and hypokalaemia due to increased reabsorption of sodium, calcium, and excessive potassium, respectively (Purbhoo, 2020; Pearce et al., 2022). In contrast, a substantial reduction in DCT areas decreases reabsorption, causing sodium and water loss, which may result in low sodium levels, hypotension, and hypocalcaemia (Purbhoo, 2020; Zieg et al., 2024). This study also that found dietary fructose did not significantly affect the proximal convoluted tubule (PCT) in both sexes across treatment groups. Orally administered fenofibrate reduced the inner area of the PCT compared to medium-dose lycopene in male rats, with no significant changes observed in the outer or epithelial areas. In female rats, no significant changes were noted in the outer, inner, or epithelial areas of the PCT (Tables 5.3 and 5.4, respectively). These results suggest that dietary fructose, orally administered lycopene, and fenofibrate did not negatively affect the inner, outer, or epithelial areas of the PCT in female rats over the 12-week intervention period. In contrast, fenofibrate had a selective impact on the inner area of the PCT in male Wistar rats, with no significant effects observed in other areas. These findings imply that fenofibrate's effects are specific to certain aspects of kidney tubule structure and may be influenced by sex. A reduction in the inner area of the PCT generally leads to impaired reabsorption, potential fluid and electrolyte imbalances, and may signal kidney dysfunction (Dalal et al., 2023). Conversely, an increase in the inner area of the PCT can enhance reabsorption efficiency as part of an adaptive response, though excessive enlargement may indicate pathological changes (Chevalier, 2016). Research has shown that fenofibrate protects proximal tubular cells from apoptosis caused by albumin-bound fatty acids by activating NF- κ B in human kidney-2 (HK-2) cells (Zuo et al., 2015). The reduction in the inner area of the PCT observed in male rats with fenofibrate highlights potential sex-specific renal responses. While Zuo et al. (2015) reported protective effects of fenofibrate on proximal tubular cells, the current findings suggest its impact may vary based on sex or physiological context. Further research is needed to determine whether these structural changes reflect adaptive responses or early markers of dysfunction, with particular

emphasis on their effects on electrolyte balance and fluid regulation. Investigating the specific mechanisms of action of both fenofibrate and lycopene is essential for understanding their impact on kidney tubules and overall renal health.

5.4 Conclusion

The consumption of a high-fructose diet and fenofibrate in male rats resulted in increased urinary space area, highlighting a sex-specific response. Lycopene demonstrated protective effects by preventing potential diet induced enlargement of the urinary space and distal convoluted tubule. While caution is advised with fenofibrate use, as it might cause kidney damage, lycopene holds promise as a dietary supplement for improving kidney health and function.

Having discussed the effects of supplemental lycopene on kidney masses, serum BUN, creatinine, KIM-1, NGAL concentrations and BUN/creatinine ratio and renal histomorphometry in growing rats fed a high fructose diet, the next chapter investigated the potential benefits of supplemental lycopene on liver health in growing Wistar rats fed a high-fructose diet.

5.5 References

- Abd-Eldayem, A. M., Makram, S. M., Messiha, B. A. S., Abd-Elhafeez, H. H., & Abdel-Reheim, M. A. (2024). Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF- α , NF- κ B, and Bax. *Scientific Reports*, *14*(1), 7434. <https://doi.org/10.1038/S41598-024-57300-X>
- Abir, M. H., Mahamud, A. G. M. S. U., Tonny, S. H., Anu, M. S., Hossain, K. H. S., Protic, I. A., Khan, M. S. U., Baroi, A., Moni, A., & Uddin, M. J. (2023). Pharmacological potentials of lycopene against aging and aging-related disorders: A review. *Food Science & Nutrition*, *11*(10), 5701–5735. <https://doi.org/10.1002/FSN3.3523>
- Al Jameil, N. (2019). Assessment of Blood Urea Nitrogen (BUN) and Creatinine As Biochemical Markers in Chronic Kidney Disease and End Stage Renal Disease Patients Undergoing Hemodialysis. *Saudi Journal of Medicine*, *4*(2), 97-102. <https://doi.org/10.36348/sjm.2019.v04i02.004>
- Albadrani, G. M., Altyar, A. E., Kensara, O. A., Haridy, M. A. M., Sayed, A. A., Mohammedsaleh, Z. M., Al-Ghadi, M. Q., Saleem, R. M., & Abdel-Daim, M. M. (2024). Lycopene alleviates 5-fluorouracil-induced nephrotoxicity by modulating PPAR- γ , Nrf2/HO-1, and NF- κ B/TNF- α /IL-6 signals. *Renal Failure*, *46*(2), 2423843. <https://doi.org/10.1080/0886022X.2024.2423843>
- Albrahim, T., & Robert, A. A. (2022). Lycopene Effects on Metabolic Syndrome and Kidney Injury in Rats Fed a High-Fat Diet: An Experimental Study. *ACS Omega*, *7*(35), 30930-30938. <https://doi.org/10.1021/ACSOMEGA.2C02796>
- Alhassani, R. Y., Bagadood, R. M., Balubaid, R. N., Barno, H. I., Alahmadi, M. O., & Ayoub, N. A. (2021). Drug Therapies Affecting Renal Function: An Overview. *Cureus*, *13*(11), 19924. <https://doi.org/10.7759/CUREUS.19924>
- Alkhatib, L., Diaz, L. A. V., Varma, S., Chowdhary, A., Bapat, P., Pan, H., Kukreja, G., Palabindela, P., Selvam, S. A., & Kalra, K. (2023). Lifestyle Modifications and Nutritional and Therapeutic Interventions in Delaying the Progression of Chronic Kidney Disease: A Review. *Cureus*, *15*(2), e34572. <https://doi.org/10.7759/CUREUS.34572>

- Ammirati, A. L. (2020). Chronic Kidney Disease. *Revista Da Associação Médica Brasileira*, 66(1), s03–s09. <https://doi.org/10.1590/1806-9282.66.S1.3>
- Attridge, R. L., Linn, W. D., Ryan, L., Koeller, J., & Frei, C. R. (2012). Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. *Journal of Clinical Lipidology*, 6(1), 19–26. <https://doi.org/10.1016/J.JACL.2011.08.008>
- Balakumar, P., Varatharajan, R., Nyo, Y. H., Renushia, R., Raaginey, D., Oh, A. N., Akhtar, S. S., Rupeshkumar, M., Sundram, K., & Dhanaraj, S. A. (2014). Fenofibrate and dipyridamole treatments in low doses either alone or in combination blunted the development of nephropathy in diabetic rats. *Pharmacological Research*, 90, 36–47. <https://doi.org/10.1016/J.PHR.2014.08.008>
- Bedir, F., Kocaturk, H., Turangezli, O., Sener, E., Akyuz, S., Ozgeris, F. B., Dabanlioglu, B., Suleyman, H., Altuner, D., & Suleyman, B. (2021). The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats. *Brazilian Journal of Medical and Biological Research*, 54, e10660. <https://doi.org/10.1590/1414-431X2020e10660>
- Brodsky, S., Bevc, S., Jafri, L., Cusumano, A. M., Tzanno-Martins, C., & Rosa-Diez, G. J. (2021). The Glomerular Filtration Rate: From the Diagnosis of Kidney Function to a Public Health Tool. *Frontiers in Medicine*, 8, 769335. <https://doi.org/10.3389/FMED.2021.769335>
- Brookes, E. M., & Power, D. A. (2022). Elevated serum urea-to-creatinine ratio is associated with adverse inpatient clinical outcomes in non-end stage chronic kidney disease. *Scientific Reports*, 12(1), 1–10. <https://doi.org/10.1038/s41598-022-25254-7>
- Chakkarwar, V., & Kawtikwar, P. (2021). Fenofibrate Prevents nicotine-induced Acute Kidney Injury: Possible Involvement of Endothelial Nitric Oxide Synthase. *Indian Journal of Nephrology*, 31(5), 435. https://doi.org/10.4103/IJN.IJN_380_20
- Chevalier, R. L. (2016). The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. *American Journal of Physiology -Renal Physiology*, 311(1), F145. <https://doi.org/10.1152/AJPRENAL.00164.2016>
- Dalal, R., Bruss, Z. S., & Sehdev, J. S. (2023). Physiology, Renal Blood Flow and Filtration. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK482248/>

- Dholariya, S. J., & Orrick, J. A. (2022). Biochemistry, Fructose Metabolism. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK576428/>
- DiNicolantonio, J. J., Bhutani, J., & O'Keefe, J. H. (2016). Added sugars drive chronic kidney disease and its consequences: A comprehensive review. *Journal of Insulin Resistance*, *1*(1), 1-6. <https://doi.org/10.4102/JIR.V1I1.3>
- Du, L., Zong, Y., Li, H., Wang, Q., Xie, L., Yang, B., Pang, Y., Zhang, C., Zhong, Z., & Gao, J. (2024). Hyperuricemia and its related diseases: mechanisms and advances in therapy. *Signal Transduction and Targeted Therapy*, *9*(1), 1–29. <https://doi.org/10.1038/s41392-024-01916-y>
- El-Shoura, Ehab A. M., Sharkawi, Souty M. Z., Abdelzaher, Lobna A., Abdel-Wahab, Basel A., Ahmed, Yasmine H., & Abdel-Sattar, A. (2024). Reno-Protective Effect of Fenofibrate and Febuxostat Against Vancomycin-Induced Acute Renal Injury in Rats: Targeting PPAR γ /NF- κ B/COX-II and AMPK/Nrf2/HO-1 Signaling Pathways. *Immunopharmacology and Immunotoxicology*, *46*(4), 509-520. <https://doi.org/10.1080/08923973.2024.2373216>
- Elsisy, R. A., El-Magd, M. A., & Abdelkarim, M. A. (2021). High-fructose diet induces earlier and more severe kidney damage than high-fat diet on rats. *Egyptian Journal of Histology*, *44*(2), 535-544. <https://doi.org/10.21608/ejh.2020.31508.1304>
- Elvira-Torales, L. I., García-Alonso, J., & Periago-Castón, M. J. (2019). Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review. *Antioxidants*, *8*(7), 229. <https://doi.org/10.3390/ANTIOX8070229>
- Emami, F., Hariri, A., Matinfar, M., & Nematbakhsh, M. (2020). Fenofibrate-induced renal dysfunction, yes, or no? *Journal of Research in Medical Sciences*, *25*(1), 39. https://doi.org/10.4103/JRMS.JRMS_772_19
- Faivre, A., Verissimo, T., Auwerx, H., Legouis, D., & de Seigneux, S. (2021). Tubular Cell Glucose Metabolism Shift During Acute and Chronic Injuries. *Frontiers in Medicine*, *8*, 742072. <https://doi.org/10.3389/FMED.2021.742072/BIBTEX>
- Farrell, D. R., & Vassalotti, J. A. (2024). Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what? *BMC Nephrology*, *25*(1), 1–13. <https://doi.org/10.1186/S12882-024-03466-5>

- Feng, X., Gao, X., Wang, S., Huang, M., Sun, Z., Dong, H., Yu, H., & Wang, G. (2021). PPAR- α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice. *Frontiers in Medicine*, 8, 652558. <https://doi.org/10.3389/FMED.2021.652558/BIBTEX>
- Ferreira-Santos, P., Aparicio, R., Carrón, R., Montero, M. J., & Sevilla, M. Á. (2020). Lycopene-supplemented diet ameliorates metabolic syndrome induced by fructose in rats. *Journal of Functional Foods*, 73, 104098. <https://doi.org/10.1016/J.JFF.2020.104098>
- Flisiński, M., Brymora, A., Skoczylas-Makowska, N., Stefańska, A., & Manitius, J. (2021). Fructose-Rich Diet Is a Risk Factor for Metabolic Syndrome, Proximal Tubule Injury and Urolithiasis in Rats. *International Journal of Molecular Sciences*, 23(1), 203. <https://doi.org/10.3390/IJMS23010203>
- Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., Pletcher, M. A., Smith, A. E., Tang, K., Yuan, C. W., Brown, J. C., Friedman, J., He, J., Heuton, K. R., Holmberg, M., Patel, D. J., Reidy, P., Carter, A., Cercy, K., ... Murray, C. J. L. (2018). Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. *The Lancet*, 392(10159), 2052–2090. [https://doi.org/10.1016/S0140-6736\(18\)31694-5](https://doi.org/10.1016/S0140-6736(18)31694-5)
- Franken, G. A. C., Adella, A., Bindels, R. J. M., & de Baaij, J. H. F. (2021). Mechanisms coupling sodium and magnesium reabsorption in the distal convoluted tubule of the kidney. *Acta Physiologica*, 231(2), e13528. <https://doi.org/10.1111/APHA.13528>
- Giussani, M., Lieti, G., Orlando, A., Parati, G., & Genovesi, S. (2022). Fructose Intake, Hypertension and Cardiometabolic Risk Factors in Children and Adolescents: From Pathophysiology to Clinical Aspects. A Narrative Review. *Frontiers in Medicine*, 9, 792949. <https://doi.org/10.3389/FMED.2022.792949/BIBTEX>
- Gori, P., Patel, A., Solanki, N., Shah, U., Patel, V., Patel, S., Gori, P., Patel, A., Solanki, N., Shah, U., Patel, V., & Patel, S. (2021). Protective effects of lycopene against adenine-induced chronic renal failure in rats. *Indian Journal of Physiology and Pharmacology*, 65(2), 74–85. https://doi.org/10.25259/IJPP_188_2020

- Gounden, V., Bhatt, H., & Jialal, I. (2023). Renal Function Tests. *StatPearls*.
<https://www.ncbi.nlm.nih.gov/books/NBK507821/>
- Harvey, B. J., & Alvarez De La Rosa, D. (2024). Sex Differences in Kidney Health and Disease. *Nephron*, 15, 1-27. <https://doi.org/10.1159/000541352>
- Himmelfarb, J., Vanholder, R., Mehrotra, R., & Tonelli, M. (2020). The current and future landscape of dialysis. *Nature Reviews. Nephrology*, 16(10), 573. <https://doi.org/10.1038/S41581-020-0315-4>
- Jager, K. J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V., & Zoccali, C. (2019). A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. *Kidney International*, 96(5), 1048–1050. <https://doi.org/10.1016/j.kint.2019.07.012>
- Jairoun, A. A., Ping, C. C., & Ibrahim, B. (2024). Predictors of chronic kidney disease survival in type 2 diabetes: a 12-year retrospective cohort study utilizing estimated glomerular filtration rate. *Scientific Reports*, 14(1), 1–13. <https://doi.org/10.1038/s41598-024-58574-x>
- Jiang, H., Li, J., Yu, K., Yang, H., Min, X., Chen, H., & Wu, T. (2017). Associations of estimated glomerular filtration rate and blood urea nitrogen with incident coronary heart disease: the Dongfeng-Tongji Cohort Study. *Scientific Reports*, 7(1), 1–9. <https://doi.org/10.1038/s41598-017-09591-6>
- Jin, L., Hua, H., Ji, Y., Jia, Z., Peng, M., & Huang, S. (2023). Anti-inflammatory role of fenofibrate in treating diseases. *Biomolecules and Biomedicine*, 23(3), 376.
<https://doi.org/10.17305/BB.2022.8534>
- Juett, L. A., James, L. J., & Mears, S. A. (2021). Effects of Exercise on Acute Kidney Injury Biomarkers and the Potential Influence of Fluid Intake. *Annals of Nutrition and Metabolism*, 76(Suppl. 1), 53–59. <https://doi.org/10.1159/000515022>
- Kadian, S., Mahadevan, N., & Balakumar, P. (2013). Differential effects of low dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. *European Journal of Pharmacology*, 698(1–3), 388–396. <https://doi.org/10.1016/J.EJPHAR.2012.10.012>
- Kataoka, H., Nitta, K., & Hoshino, J. (2023). Glomerular hyperfiltration and hypertrophy: an evaluation of maximum values in pathological indicators to discriminate “diseased” from “normal.” *Frontiers in Medicine*, 10, 1179834. <https://doi.org/10.3389/FMED.2023.1179834/BIBTEX>

- Kataoka, H., Ohara, M., Suzuki, T., Inoue, T., Akanuma, T., Kawachi, K., Manabe, S., Ushio, Y., Kawasoe, K., Akihisa, T., Sato, M., Iwasa, N., Sawara, Y., Honda, K., Mochizuki, T., Tsuchiya, K., & Nitta, K. (2020). Time series changes in pseudo-R2 values regarding maximum glomerular diameter and the Oxford MEST-C score in patients with IgA nephropathy: A long-term follow-up study. *PLoS ONE*, *15*(5), e023288. <https://doi.org/10.1371/JOURNAL.PONE.0232885>
- Khan, N. I., Noori, S., & Mahboob, T. (2016). Efficacy of lycopene on modulation of renal antioxidant enzymes, ACE and ACE gene expression in hyperlipidaemic rats. *Journal of the Renin-Angiotensin-Aldosterone System: JRAAS*, *17*(3), 1470320316664611. <https://doi.org/10.1177/1470320316664611>
- Khongthaw, B., Dulta, K., Chauhan, P. K., Kumar, V., & Ighalo, J. O. (2022). Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19). *Inflammopharmacology*, *30*(6), 1955–1976. <https://doi.org/10.1007/S10787-022-01061-4>
- Kikuchi, H., Chou, C. L., Yang, C. R., Chen, L., Jung, H. J., Park, E., Limbutara, K., Carter, B., Yang, Z. H., Kun, J. F., Remaley, A. T., & Knepper, M. A. (2023). Signaling mechanisms in renal compensatory hypertrophy revealed by multi-omics. *Nature Communications*, *14*(1), 1–22. <https://doi.org/10.1038/s41467-023-38958-9>
- Kolb, H., Kempf, K., & Martin, S. (2023). Insulin and aging – a disappointing relationship. *Frontiers in Endocrinology*, *14*, 1261298. <https://doi.org/10.3389/FENDO.2023.1261298/BIBTEX>
- Kostapanos, M. S., Florentin, M., & Elisaf, M. S. (2013). Fenofibrate and the kidney: an overview. *European Journal of Clinical Investigation*, *43*(5), 522–531. <https://doi.org/10.1111/ECL.12068>
- Kotsis, V., Martinez, F., Trakatelli, C., & Redon, J. (2021). Impact of Obesity in Kidney Diseases. *Nutrients*, *13*(12), 4482. <https://doi.org/10.3390/NU13124482>
- Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. *Kidney International Supplements*, *12*(1), 7–11. <https://doi.org/10.1016/J.KISU.2021.11.003>
- Lameire, N. H., Levin, A., Kellum, J. A., Cheung, M., Jadoul, M., Winkelmayr, W. C., Stevens, P. E., Caskey, F. J., Farmer, C. K. T., Ferreiro Fuentes, A., Fukagawa, M., Goldstein, S. L., Igiraneza, G., Kribben, A., Lerma, E. V., Levey, A. S., Liu, K. D., Małyszko, J., Ostermann, M., ... Srisawat, N. (2021). Harmonizing acute and chronic kidney disease definition and classification: report of a

- Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney International*, 100(3), 516–526. <https://doi.org/10.1016/J.KINT.2021.06.028>
- Li, X., Sun, W., Lu, J., He, Y., Chen, Y., Ren, W., Cui, L., Liu, Z., Wang, C., Wang, X., Ma, L., Cheng, X., Han, L., Li, H., Zhang, H., Yuan, X., Ji, X., Ji, A., Merriman, T. R., & Li, C. (2021). Effects of fenofibrate therapy on renal function in primary gout patients. *Rheumatology*, 60(11), 5020–5027. <https://doi.org/10.1093/RHEUMATOLOGY/KEAB231>
- Liu, Y., He, Q., Li, Q., Tian, M., Li, X., Yao, X., He, D., & Deng, C. (2023). Global incidence and death estimates of chronic kidney disease due to hypertension from 1990 to 2019, an ecological analysis of the global burden of diseases 2019 study. *BMC Nephrology*, 24(1), 1–13. <https://doi.org/10.1186/S12882-023-03391-Z/FIGURES/6>
- Long, Y., Paengkoum, S., Lu, S., Niu, X., Thongpea, S., Taethaisong, N., Han, Y., & Paengkoum, P. (2024). Physicochemical properties, mechanism of action of lycopene and its application in poultry and ruminant production. *Frontiers in Veterinary Science*, 11, 1364589. <https://doi.org/10.3389/FVETS.2024.1364589/BIBTEX>
- Madrazo-Ibarra, A., & Vaitla, P. (2023). Histology, Nephron. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK554411/>
- Mallamaci, F., & Tripepi, G. (2024). Risk Factors of Chronic Kidney Disease Progression: Between Old and New Concepts. *Journal of Clinical Medicine*, 13(3), 678. <https://doi.org/10.3390/JCM13030678>
- McQuade, C. R., Griego, J., Anderson, J., & Pai, A. B. (2008). Elevated serum creatinine levels associated with fenofibrate therapy. *American Journal of Health-System Pharmacy*, 65(2), 138–141. <https://doi.org/10.2146/AJHP070005>
- Med, A.-A. J., Abo-Ouf, A. M., & Arafa, M. A. A. (2018). Effect of fenofibrate administration and its withdrawal on the kidneys of adult male albino rats (histological and biochemical studies). *Al-Azhar Medical Journal*, 47(4), 759–780. <https://doi.org/10.21608/0053059>
- Misra, R. C., Thimmappa, R., & Bonfill, M. (2024). Editorial: Advances in discoveries of plant phytochemicals. *Frontiers in Plant Science*, 15, 1414150. <https://doi.org/10.3389/FPLS.2024.1414150/BIBTEX>

- Monteiro, L. M., Barbosa, C. F., Lichtenecker, D. C. K., Argeri, R., & Gomes, G. N. (2023). Sex modifies the renal consequences of high fructose consumption introduced after weaning. *Frontiers in Physiology, 14*, 1090090. <https://doi.org/10.3389/fphys.2023.1090090>
- Muhammad, N., Lembede, B. W., & Erlwanger, K. H. (2022). Neonatal administration of zingerone prevents the subsequent development of high dietary fructose-induced early features of nephropathy in rats. *General Physiology and Biophysics, 41*(2), 141–150. https://doi.org/10.4149/GPB_2022008
- Nakagawa, T., Johnson, R. J., Andres-Hernando, A., Roncal-Jimenez, C., Sanchez-Lozada, L. G., Tolan, D. R., & Lanaspa, M. A. (2020). Fructose Production and Metabolism in the Kidney. *Journal of the American Society of Nephrology, 31*(5), 898-906. <https://doi.org/10.1681/ASN.2019101015>
- Nakagawa, T., & Kang, D. H. (2021). Fructose in the kidney: from physiology to pathology. *Kidney Research and Clinical Practice, 40*(4), 527–541. <https://doi.org/10.23876/J.KRCP.21.138>
- Park, G. T., Jung, M., Kim, Y., Cho, I., Won, H., Shin, S. Y., Lee, W.-S., Lee, K. J., Kim, S.-W., Kim, T. H., & Kim, C. J. (2017). Effect of Long-term Fenofibrate Therapy on Serum Creatinine and Its Reversibility in Hypertriglyceridemic Patients with Hypertension. *Journal of Lipid and Atherosclerosis, 6*(2), 89. <https://doi.org/10.12997/JLA.2017.6.2.89>
- Pearce, D., Manis, A. D., Nesterov, V., & Korbmacher, C. (2022). Regulation of distal tubule sodium transport: mechanisms and roles in homeostasis and pathophysiology. *Pflügers Archiv - European Journal of Physiology, 474*(8), 869–884. <https://doi.org/10.1007/S00424-022-02732-5>
- Poloni, J. A. T., & Rotta, L. N. (2022). Diabetic kidney disease: Pathophysiological changes and urinalysis contribution to diagnosis-a narrative review. *Journal of Laboratory and Precision Medicine, 7*. <https://doi.org/10.21037/JLPM-21-20/COIF>
- Purbhoo, K. (2020). Physiology of the distal convoluted tubule and collecting duct. *Southern African Journal of Anaesthesia and Analgesia, 26*(6), S137–S141. <https://doi.org/10.36303/sajaa.2020.26.6.s3.2559>
- Rasheed, H., Al-Naimi, M., Hussien, N., Al-Harchan, N., Al-Kuraishy, H., & Al-Gareeb, A. (2020). New insight into the effect of lycopene on the oxidative stress in acute kidney injury.

International Journal of Critical Illness and Injury Science, 10(5), S11–S16.

https://doi.org/10.4103/IJCIIS.IJCIIS_113_19

Sancho-Martínez, S. M., Casanova, A. G., Düwel, A. G., Rivero-García, K., García-Garrido, T., Morales, A. I., Martínez-Salgado, C., López-Hernández, F. J., & Fraile, P. (2023). Identification of Pre-Renal and Intrinsic Acute Kidney Injury by Anamnestic and Biochemical Criteria: Distinct Association with Urinary Injury Biomarkers. *International Journal of Molecular Sciences*, 24(3), 1826. <https://doi.org/10.3390/IJMS24031826>

Schnuelle, P. (2023). Renal Biopsy for Diagnosis in Kidney Disease: Indication, Technique, and Safety. *Journal of Clinical Medicine*, 12(19), 6424. <https://doi.org/10.3390/JCM12196424>

Shalaby, A. M., & El Shaer, D. F. (2019). Lycopene protects against renal cortical damage induced by nandrolone decanoate in adult male rats. *Annals of Anatomy - Anatomischer Anzeiger*, 224, 142–152. <https://doi.org/10.1016/J.AANAT.2019.05.003>

Sharma, I., Khare, N., Rai, A., Sharma, I., Khare, N., & Rai, A. (2024). Carotenoids: Sources, Bioavailability and Their Role in Human Nutrition. IntechOpen. <https://doi.org/10.5772/INTECHOPEN.113012>

Shinkre, R., Rodrigues, E., Naik, S., Mopkar, M., Rodricks, D., & Jain, V. K. (2024). Lycopene as a Potential Anti-inflammatory Therapeutic Agent for Temporomandibular Joint Disorders: A Narrative Review. *Journal of Pharmacy and Bioallied Sciences*, 16, S1981–S1983. https://doi.org/10.4103/JPBS.JPBS_87_24

Shrimanker, I., & Bhattarai, S. (2023). Electrolytes. *Pharmacology in Veterinary Anesthesia and Analgesia*, 362–369. <https://doi.org/10.1002/9781118975169.ch29>

Sohn, M., Kim, K., Uddin, M. J., Lee, G., Hwang, I., Kang, H., Kim, H., Lee, J. H., & Ha, H. (2017). Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of ampk autophagy. *American Journal of Physiology - Renal Physiology*, 312(2), F323–F334. <https://doi.org/10.1152/AJPRENAL.00596.2015/ASSET/IMAGES/LARGE/ZH20141680150007.JPEG>

- Steiger, S., Li, L., Bruchfeld, A., Stevens, K. I., Moran, S. M., Floege, J., Caravaca-Fontán, F., Mirioglu, S., Teng, O. Y. K., Frangou, E., & Kronbichler, A. (2024). Sex dimorphism in kidney health and disease: mechanistic insights and clinical implication. *Kidney International*, *107*(1), 51–67. <https://doi.org/10.1016/J.KINT.2024.08.038/ASSET/F23D8799-8D66-462F-902A-3AD4E86E684F/MAIN.ASSETS/GR2.JPG>
- Stojiljkovic, N., Ilic, S., Jakovljevic, V., Stojanovic, N., Stojnev, S., Kocic, H., Stojanovic, M., & Kocic, G. (2018). The Encapsulation of Lycopene in Nanoliposomes Enhances Its Protective Potential in Methotrexate-Induced Kidney Injury Model. *Oxidative Medicine and Cellular Longevity*, *2018*(1), 2627917. <https://doi.org/10.1155/2018/2627917>
- Subramanya, A. R., & Ellison, D. H. (2014). Distal Convoluted Tubule. *Clinical Journal of the American Society of Nephrology*, *9*(12), 2147-2163. <https://doi.org/10.2215/CJN.05920613>
- Tanaka, Y., Kume, S., Araki, S. I., Isshiki, K., Chin-Kanasaki, M., Sakaguchi, M., Sugimoto, T., Koya, D., Haneda, M., Kashiwagi, A., Maegawa, H., & Uzu, T. (2011). Fenofibrate, a PPAR α agonist, has renoprotective effects in mice by enhancing renal lipolysis. *Kidney International*, *79*(8), 871–882. <https://doi.org/10.1038/KI.2010.530>
- Tillman, E. J., Morgan, D. A., Rahmouni, K., & Swoap, S. J. (2014). Three Months of High-Fructose Feeding Fails to Induce Excessive Weight Gain or Leptin Resistance in Mice. *PLOS ONE*, *9*(9), e107206. <https://doi.org/10.1371/JOURNAL.PONE.0107206>
- Tobar, A., Ori, Y., Benchetrit, S., Milo, G., Herman-Edelstein, M., Zingerman, B., Lev, N., Gafer, U., & Chagnac, A. (2013). Proximal tubular hypertrophy and enlarged glomerular and proximal tubular urinary space in obese subjects with proteinuria. *PloS One*, *8*(9), e75547. <https://doi.org/10.1371/JOURNAL.PONE.0075547>
- Treacy, O., Brown, N. N., & Dimeski, G. (2019). Biochemical evaluation of kidney disease. *Translational Andrology and Urology*, *8*(Suppl 2), S214–S223. <https://doi.org/10.21037/TAU.2018.10.02>
- Wrońska, A., Kieżun, J., & Kmiec, Z. (2024). High-Dose Fenofibrate Stimulates Multiple Cellular Stress Pathways in the Kidney of Old Rats. *International Journal of Molecular Sciences*, *25*(5), 3038. <https://doi.org/10.3390/IJMS25053038/S1>

- Xie, D., Ma, T., Cui, H., Li, J., Zhang, A., Sheng, Z., & Xie, Y. (2023). Global burden and influencing factors of chronic kidney disease due to type 2 diabetes in adults aged 20–59 years, 1990–2019. *Scientific Reports*, *13*(1), 20234. <https://doi.org/10.1038/S41598-023-47091-Y>
- Xu, L., Hu, G., Qiu, J., Fan, Y., Ma, Y., Miura, T., Kohzuki, M., & Ito, O. (2021). High fructose-induced hypertension and renal damage are exaggerated in dahl salt-sensitive rats via renal renin-angiotensin system activation. *Journal of the American Heart Association*, *10*(14), 16543. https://doi.org/10.1161/JAHA.120.016543/SUPPL_FILE/JAH36414-SUP-0001-TABLES-FIGS.PDF
- Yaribeygi, H., Mohammadi, M. T., Rezaee, R., & Sahebkar, A. (2018). Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy. *Journal of Cellular Biochemistry*, *119*(9), 7458–7469. <https://doi.org/10.1002/JCB.27055>
- Zieg, J., Ghose, S., & Raina, R. (2024). Electrolyte disorders related emergencies in children. *BMC Nephrology*, *25*(1), 1–16. <https://doi.org/10.1186/S12882-024-03725-5/TABLES/11>
- Zuo, N., Zheng, X., Liu, H., & Ma, X. (2015). Original Article Fenofibrate, a PPAR α agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-kB. *International Journal of Clinical and Experimental Pathology*, *8*(9), 10653–10661. www.ijcep.com/

**CHAPTER SIX: EFFECT OF LYCOPENE ON
LIVER HEALTH IN GROWING WISTAR
RATS FED A HIGH FRUCTOSE DIET**

6.0 Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing global health concern, primarily associated with the increasing prevalence of obesity, T2DM and metabolic syndrome (Grander et al., 2023). This condition is characterised by the buildup of fat in the liver in individuals who consume little to no alcohol (Godoy-Matos et al., 2020). Histologically, MASLD includes a spectrum of liver conditions, ranging from simple steatosis (fat accumulation) to non-alcoholic steatohepatitis (NASH), which causes liver inflammation and can progress to fibrosis, cirrhosis, and liver cancer (Huby & Gautier, 2021; Allen et al., 2023). MASLD is one of the most common liver diseases worldwide (Muhamad et al., 2023), affecting about 30% of adults, with higher rates in those with metabolic disorders (Younossi et al., 2023). It impacts 80% to 90% of obese adults, 30% to 50% of those with diabetes mellitus, and over 90% of patients with hyperlipidaemia (Kudaravalli & John, 2023). In children, MASLD is present in 3% to 10% of the population, increasing to 40% to 70% in obese children (Kudaravalli & John, 2023). Projections indicate that MASLD will continue to increase and become a leading cause of liver transplantation by 2030, placing a growing financial burden on healthcare systems (Satapathy et al., 2022; Dong et al., 2024).

This alarming trend is closely linked to excessive fructose consumption, which has been strongly associated with the development of MASLD by promoting fat accumulation in the liver (Federico et al., 2021). This metabolic process primarily takes place in the liver, where fructose is converted into fatty acids, leading to hepatic steatosis, a hallmark of MASLD (Duarte et al., 2019). Over the past 40 years, fructose consumption has significantly increased in children and adults, further increasing the risk of developing MASLD (McVicker et al., 2024). Prolonged fructose metabolism in the liver depletes adenosine triphosphate (ATP), leading to elevated uric acid production (Zhang et al., 2022). The subsequent increase in plasma uric acid concentration disrupts mitochondrial function and triggers oxidative stress, leading to further damaging liver cells (Muriel et al., 2021). This worsens inflammation and fibrosis, ultimately accelerating the progression of MASLD (Ma et al., 2021). Individuals with MASLD who consume high amounts of fructose often show elevated serum markers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT), as well as increased total bilirubin (TBIL) and total bile acids (TBA) (Lee et al., 2023; Zhang et al., 2023), which are indicative of impaired liver function. Additionally, the progression of MASLD has been associated with decreased levels of plasma total

protein (TP), albumin (ALB), and increase globulin (GLOB), further highlighting liver dysfunction (Dzordzo & Andreychyn, 2022). Excessive dietary fructose intake contributes to visceral fat pad accumulation by promoting *de novo* lipogenesis in the liver, where fructose is rapidly metabolised into triglycerides (Geidi-Flueck & Gerber, 2023). These triglycerides are subsequently stored in visceral adipose tissue leading to increased visceral fat pad size and metabolic disruptions (Hernández-Díazcouder et al., 2019). In male rodents, fructose feeding increases epididymal fat pad mass, further reflecting broader metabolic changes. (Azevedo-Martins et al., 2024). Visceral fat is metabolically active; it secretes pro-inflammatory cytokines and adipokines that impair insulin signalling and fuel systemic inflammation (Azevedo-Martins et al., 2024). The combined effects of visceral and epididymal fat accumulation exacerbate these inflammatory and insulin-resistant states, creating a feedback loop that accelerates MASLD progression through heightened hepatic fat deposition and metabolic derangement (Rodrigues et al., 2021; Azevedo-Martins et al., 2024).

Currently, pharmacological agents for treating MASLD, such as metformin, fenofibrate, and N-acetylcysteine, have shown mixed results, often accompanied by side effects and limitations in addressing the full spectrum of the disease (Francque & Vonghia, 2019). These treatments can also be expensive and inaccessible to some communities, further complicating management of MASLD. This highlights the growing need to explore safer, more effective alternatives, particularly those derived from medicinal plants and phytochemicals. Lycopene, a potent antioxidant abundant in tomatoes, is widely recognised for its ability to reduce oxidative stress, lower inflammation, and inhibit hepatic fat accumulation. Its potential to target the metabolic dysfunctions underlying MASLD makes it a promising intervention that can be used to complement traditional therapies and or used as a natural prophylactic agent against lifestyle induced metabolic diseases. This study therefore evaluated the potential prophylactic benefits of supplemental lycopene to protect liver health in Wistar rats fed a high fructose diet by specifically determining effects on liver lipid content hepatic and systemic antioxidant and oxidant status, serum markers of liver function, and histomorphology.

6.1 Materials and methods

6.1.1 Ethical approval

As explained in chapter 3, under subheading 3.1.1.

6.1.2 Chemicals and reagents

The chemicals and reagents utilised are consistent with those detailed in chapter 3, under subheading 3.1.2.

6.1.3 Animals, housing, and general care

The management of experimental animals in this chapter is consistent with the procedures explained in chapter 3, under subheading 3.1.3.

6.1.4 Experimental design

As explained in chapter 3, under subheading 3.1.4.

6.1.5 Terminal procedures, sample collection and measurements

After a 12-week intervention, the rats were fasted overnight with access to plain drinking water to prevent dehydration. Their fasting terminal body mass was recorded using an electronic balance [Snowrex Electronic Scale, Clover Scale (Pty) Ltd, Johannesburg]. The rats were then euthanised via intraperitoneal injection of sodium pentobarbitone (Euthapent; Kyron Laboratories, Johannesburg) at a dose of 200 mg/kg body mass. Blood samples were collected through cardiac puncture using 20G needles and 10 ml syringes, then transferred into SST gel-coated blood collection tubes (BD Vacutainer System, Bigamart, UK). The blood was then centrifuged (DLAB-DMO412S, Wolflabs Laboratory Products, Pocklington, UK) at $3000 \times g$ for 15 minutes at 20°C. The serum collected was decanted into Eppendorf microtubes (Abdos Labtech Pvt, Ltd, Utrakhand, India) and frozen-stored at -80°C for subsequent analyses of serum markers of oxidative stress, systemic glutathione peroxidase (GPX-1) activity and liver health.

A midline abdominal incision was performed on each rat to extract and weigh the liver, visceral fat, and epididymal fat (in males) using an electronic balance (Presica 310M, Instruments, Johannesburg, South Africa). A liver sample from the medial hepatic lobe was preserved in 10% phosphate-buffered formalin for histological examination. Additionally, another liver sample was collected and stored in sealed ziplock bags at -20°C for the assessment of hepatic oxidative stress (TBARS) and antioxidant enzyme activities (GPX-1, CAT). The remaining portion of the liver was stored in a sealed ziplock bag at -20°C for hepatic lipid content analysis.

6.1.6 Determination of hepatic lipid content

The liver lipid content was measured by solvent extraction using a Soxhlet apparatus (Gebr. Rettberg GmbH, Göttingen, Germany), following the procedure outlined by the Association of Official Analytical Chemists (AOAC, 2005, method number 920.39). Briefly, the liver samples were thawed at room temperature for 30 minutes prior to the assay. Liver samples from the rats, females and males, in each group were combined to form a composite sample. Each group composite sample was then, homogenised, 2 to 3 grams from each homogenised composite sample were weighed into the thimble above the cotton wool and placed into the Soxhlet extractor chamber. An empty distillation flask was weighed, and 200 ml of petroleum ether was added into the distillation flask and placed onto the heating pad. The thermostat was set at $40 \pm 10^{\circ}\text{C}$, the cooling water supply to the condenser was turned on, and the power supply was switched on. Each subsample was extracted for 4 hours. Thereafter, the excess petroleum ether in the extracted lipid was blown off using a rotary evaporator (LabFriend PTY Ltd, Johannesburg, South Africa) at $50 \pm 10^{\circ}\text{C}$ for 5 to 10 minutes, leaving the extracted lipid in the flask. The distillation flask with the lipid was then placed in an oven (LABOTEC (Pty) Ltd., Johannesburg, South Africa) at 50°C for 30 to 45 minutes to remove any residual petroleum ether from the lipid. Finally, the flask was placed in a desiccator to cool, and the flask with the lipid was weighed again. The total liver lipid content percentage was then calculated using the formula:

$$\% \text{ lipid} = \frac{\text{Mass of flask with lipid} - \text{Mass of empty flask (g)}}{\text{Mass of the liver sample (g)}} \times 100$$

This extraction process was repeated three times for each treatment group.

6.1.7 Determination of serum and hepatic oxidative stress and antioxidant status

Fasting serum and hepatic GPX-1, hepatic CAT, and serum and hepatic TBARS were measured using a rat-specific enzyme-linked immunosorbent assay (ELISA) kit from Elabscience Biotechnology Inc., Houston, Texas, USA, following the manufacturer's guidelines.

6.1.8 Determination of serum surrogate markers for liver function

The serum activities of Alanine aminotransferase (AST), Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), and Gamma-glutamyl transferase (GGT), along with the concentrations of globulin, total protein (TP), albumin, total bilirubin (TBIL), total bile acids (TBA), and uric acid (UA), were determined using a Noahcali-100 automatic LOCMEDT biochemistry analyser (Tianjin LOCMEDT Technologies Co., Ltd., China), according to the manufacturer's instructions. Briefly, 120 µl of serum was added to the reagent disc containing lyophilised beads. The disc was then inserted into the Noahcali-100 analyser, and results were obtained after 8-12 minutes.

6.1.9 Liver histology assessment

Liver samples were fixed in 10% phosphate-buffered formalin and processed using an automatic tissue processor (Micro STP 120, Thermo Fisher, Waltham, USA). They were then embedded in paraffin wax, sectioned to a thickness of 3 µm using a rotary microtome (Leica Biosystems, Buffalo Grove, USA), and placed onto glass slides. Following paraffin removal with xylene, the sections were rehydrated, stained with haematoxylin and eosin, dehydrated, and cleared in xylene to enhance transparency. A mounting medium was used to apply coverslips. The slides were examined under a Leica DM750 microscope, with images captured via a high-definition ICC50W digital camera (Leica Biosystems, Germany). The haematoxylin and eosin-stained sections were semi-quantitatively evaluated for steatosis, lobular inflammation, and hepatocyte hypertrophy using criteria from Kleiner et al. (2005) and Liang et al. (2014). Micro- and macro-steatosis and hepatocyte hypertrophy were graded within each 40x magnification field based on the percentage of affected area: grade 0 for <5%, grade 1 for 5-33%, grade 2 for 33-66%, and grade 3 for >66% (Liang et al., 2014). Lobular inflammation was scored by counting inflammatory foci in the liver parenchyma: grade 0 for no foci, grade 1 for <2 foci, grade 2 for 2-4 foci, and grade 3 for >4 foci per field (Kleiner et al., 2005).

6.1.10 Statistical analysis

Data were analysed using GraphPad Prism version 9.0 (GraphPad Software Inc., San Diego, USA). Parametric data from multiple groups were assessed using one-way ANOVA and presented as mean ± standard deviation, with Tukey's *post-hoc* test used for mean comparison. Non-parametric data (steatosis, hypertrophy, and inflammation scores) were analysed with the Kruskal-Wallis test

(non-parametric one-way ANOVA) and presented as median \pm range, followed by Dunn's *post-hoc* test for median comparisons. Statistical significance was defined as $p < 0.05$.

6.2 Results

6.2.1 Liver, visceral fat pad, and epididymal fat pad masses

Tables 6.1 and 6.2 show the liver and visceral fat masses of the rats, as well as the epididymal fat mass of male rats. Both female and male rats fed a high fructose diet with fenofibrate intervention had significantly heavier ($p < 0.05$) liver masses (absolute and relative to body mass) compared to control, fructose-fed and lycopene-supplemented counterparts (Tables 6.1 and 6.2). Additionally, female and male rats fed the high fructose diet supplemented with a low lycopene dose had significantly heavier livers ($p < 0.05$) compared to livers of the control diet fed counterparts. Female rats on the high fructose diet had significantly higher ($p < 0.05$) relative liver masses compared to the relative liver masses from control diet fed counterparts. In males, the epididymal fat mass was similar across treatment regimes.

Table 6. 1: Effect of lycopene on absolute and relative masses of the liver and visceral fat pads of growing female Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS +FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Liver mass (g)	5.96 ± 0.35 ^a	6.69 ± 0.43 ^{ac}	9.15 ± 0.81 ^b	6.80 ± 0.60 ^c	6.63 ± 0.39 ^{ac}	6.24 ± 0.34 ^{ac}	*
Liver (% BM)	2.83 ± 0.12 ^a	3.16 ± 0.19 ^b	4.36 ± 0.31 ^c	3.16 ± 0.19 ^b	3.09 ± 0.13 ^{ab}	2.97 ± 0.12 ^{ab}	*
Visceral fat pad mass (g)	6.20 ± 1.25 ^a	7.14 ± 2.78 ^a	7.49 ± 1.63 ^a	8.33 ± 1.44 ^a	8.27 ± 1.23 ^a	6.75 ± 1.61 ^a	ns
Visceral fat pad (% BM)	2.94 ± 0.56 ^a	3.34 ± 1.18 ^a	3.55 ± 0.67 ^a	3.86 ± 0.51 ^a	3.84 ± 0.49 ^a	3.20 ± 0.71 ^a	ns

^{abc}Means within rows having the different superscript differ significantly at * $p < 0.05$, ns = not significant, $P > 0.05$. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube; % BM = Percentage body mass (relative to body mass). Data are expressed as mean ± SD, n = 8 per treatment group.

Table 6. 2: Effect of lycopene on the absolute and relative masses of the liver, visceral fat pads, and epididymal fat pads of growing male Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS +FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Liver mass (g)	10.12 ± 0.43 ^a	10.55 ± 0.69 ^{ac}	14.49 ± 0.87 ^b	11.13 ± 0.37 ^c	10.48 ± 0.55 ^{ac}	10.96 ± 0.65 ^{ac}	*
Liver (% BM)	2.88 ± 0.07 ^a	3.05 ± 0.13 ^{ac}	4.48 ± 0.41 ^b	3.21 ± 0.10 ^c	3.09 ± 0.14 ^{ac}	3.16 ± 0.09 ^{ac}	*
Visceral fat pad mass (g)	9.21 ± 1.70 ^a	8.45 ± 1.80 ^a	9.11 ± 2.20 ^a	8.50 ± 2.33 ^a	8.31 ± 1.89 ^a	9.09 ± 1.34 ^a	ns
Visceral fat pad (% BM)	2.62 ± 0.47 ^a	2.43 ± 0.38 ^a	2.79 ± 0.59 ^a	2.45 ± 0.67 ^a	2.44 ± 0.52 ^a	2.62 ± 0.38 ^a	ns
Epididymal fat pad mass (g)	3.27 ± 1.61 ^a	3.86 ± 0.97 ^a	3.55 ± 0.94 ^a	3.76 ± 1.46 ^a	3.57 ± 1.38 ^a	4.15 ± 1.33 ^a	ns
Epididymal fat pad mass (% BM)	0.92 ± 0.43 ^a	1.12 ± 0.30 ^a	1.09 ± 0.244 ^a	1.08 ± 0.40 ^a	1.05 ± 0.39 ^a	1.19 ± 0.34 ^a	ns

^{abc}Means within rows having the different superscript differ significantly at *p < 0.05, ns = not significant, P > 0.05. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube; % BM = Percentage body mass (relative to body mass). Data are expressed as mean ± SD, n = 8 per treatment group.

6.2.2 Liver lipid content

Figures 6.1A and 6.1B present the liver lipid content of female and male rats, respectively. Female rats fed the high fructose diet had significantly higher ($p < 0.05$) liver lipid content compared to fructose-fed but fenofibrate treated as well as the low- and high-dose lycopene supplements counterparts (Figure 6.1A). Similarly, male rats fed the high fructose diet showed significantly elevated ($p < 0.05$) liver lipid content compared to fructose-fed but fenofibrate treated as well as the medium- and high-dose lycopene supplements counterparts (Figure 6.1B).




Figure 6. 1A: Effect of lycopene on liver lipid content in growing female Wistar rats fed a high-fructose diet.

*= significantly different at $p < 0.05$. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDL=

20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 3 per treatment group.









Figure 6. 1B: Effect of lycopene on liver lipid content in growing male Wistar rats fed a high-fructose diet.

*= significantly different at $p < 0.05$. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDL= 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 3 per treatment group.

6.2.3 Systemic and hepatic oxidative stress and antioxidant status

Figures 6.2 and 6.3 show the effect of lycopene on serum TBARS concentration (A), and GPX-1 activity (B) and hepatic TBARS (C) concentration, GPX-1 (D), and CAT (E) activities in female, and male rats fed a high fructose-diet, respectively. Serum TBARS concentration and GPX-1 activity as well as hepatic TBARS concentration and hepatic CAT levels were similar ($p > 0.05$) in female rats across treatment groups (Figures 6.2A, B, C, and E). However, fenofibrate-treated female rats had significantly higher hepatic GPX-1 activity ($P < 0.05$) compared to control diet-fed and lycopene supplemented counterparts (Figure 6.2D). Similarly, serum TBARS and GPX-1 activity, and hepatic TBARS concentration of male rats was similar ($P > 0.05$) across treatment groups (Figures 6.3A, B, and C). However, fenofibrate-treated male rats had significantly higher hepatic GPX-1 activity ($p < 0.05$) compared to control diet-fed or low- and medium-dose lycopene-supplemented counterparts (Figure 6.3D). Additionally, fenofibrate treated and high-dose lycopene supplemented male rats had significantly higher hepatic GPX-1 activity ($p < 0.05$) compared to the control diet fed counterparts (Figure 6.3D). Male rats whose diet was supplemented with a high-dose of lycopene had significantly higher ($p < 0.05$) hepatic CAT activity compared to control, high-fructose diet fed, fenofibrate-treated and low and medium lycopene supplemented counterparts (Figure 6.3E).



PDW+PG

 FS+PG

 FS+FENO






 FS+LDLY

 FS+MDLY

 FS+HDLY

Figure 6. 2: Effect of lycopene on serum TBARS (A) concentration and GPX-1 (B) activity and hepatic TBARS (C) concentration, GPX-1 (D) and CAT (E) activities in growing female Wistar rats fed a high-fructose diet.

***= significantly different at $p < 0.0001$. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean \pm SD, n = 6-7 per treatment group.



□ PDW+PG ▨ FS+PG ▩ FS+FENO ▧ FS+LDLY ▦ FS+MDLY ▤ FS+HDLY

Figure 6. 3: Effect of lycopene on serum TBARS (A) concentration and GPX-1 (B) activity and hepatic TBARS (C) concentration, GPX-1 (D) and CAT (E) activities in growing male Wistar rats fed a high-fructose diet.

*= significantly different at $p < 0.05$, **= significantly different at $p < 0.001$. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean \pm SD, n = 6-7 per treatment group.

6.2.4 Serum markers of hepatic function

Tables 6.3 and 6.4 present the serum concentrations of surrogate markers of liver health in the rats. In female rats, serum albumin, TP, globulin, TBA, and uric acid concentrations as well as GGT, ALT, and AST activities were similar ($p > 0.05$) across treatment groups. However, the fenofibrate-treated female rats had significantly higher ALP activity ($p < 0.05$) compared to control diet-fed, high fructose diet-fed and lycopene-supplemented groups (Table 6.3). In male rats, dietary fructose caused significantly higher serum concentrations of albumin, total protein, and globulin ($p < 0.05$) compared to control diet-fed, fenofibrate-treated, or lycopene-supplemented groups. Additionally, fenofibrate-treated male rats had significantly higher ALP activity ($p < 0.05$) compared to control diet-fed, high fructose diet-fed and lycopene-supplemented groups. Furthermore, fenofibrate-treated male rats showed significantly higher serum total bile acids ($p < 0.05$) compared to the control group. Male rats fed a high fructose diet also had significantly increased serum uric acid concentrations ($p < 0.05$) compared to control counterparts. However, serum activities of GGT, ALT, AST, and total TBIL concentrations were similar ($p > 0.05$) across treatment groups in male rats (Table 6.4).

Table 6. 3: Effect of lycopene on serum markers of hepatic function in growing female Wistar rats fed a high fructose diet

Parameter	PDW +PG	FS + PG	FS +FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Albumin (g/L)	31.20±0.84 ^a	35.33±2.34 ^a	35.83±1.84 ^a	32.83±1.94 ^a	5.50±4.93 ^a	34.67±3.01 ^a	ns
Globulin (g/L)	29.40±1.52 ^a	33.50±4.32 ^a	30.00±2.53 ^a	30.67±2.81 ^a	33.50±5.47 ^a	34.83±4.40 ^a	ns
TP (g/L)	60.60±1.52 ^a	68.83±6.56 ^a	65.83±3.71 ^a	63.50±3.83 ^a	69.00±10.26 ^a	69.50±7.34 ^a	ns
TBIL (g/L)	2.80±0.84 ^a	4.50±0.55 ^{ab}	4.17±1.17 ^{ab}	5.17±1.33 ^b	5.00±1.10 ^b	4.50±0.84 ^{ab}	*
TBA (µmol/L)	29.60±9.45 ^a	33.67±9.65 ^a	32.50±5.17 ^a	29.67±4.23 ^a	33.33±6.31 ^a	31.50±4.93 ^a	ns
UA (µmol/L)	77.40±39.05 ^a	87.00±22.81 ^a	74.67±40.86 ^a	73.00±36.86 ^a	82.17±34.15 ^a	103.3±12.16 ^a	ns
GGT (U/L)	7.80±1.92 ^a	6.00±0.63 ^a	5.83±1.33 ^a	7.17±3.06 ^a	6.67±1.03 ^a	6.67±0.82 ^a	ns
ALP (U/L)	64.80±10.26 ^a	64.33±18.00 ^a	109.70±14.07 ^b	56.33±15.40 ^a	56.50±10.93 ^a	72.50±8.64 ^a	***
AST (U/L)	230.80±98.79 ^a	336.70±181.10 ^a	354.20±213.20 ^a	416.00±265.80 ^a	349.20±158.10 ^a	212.50±8.64 ^a	ns
ALT (U/L)	72.40±46.93 ^a	62.00±14.27 ^a	102.30±49.84 ^a	119.70±81.67 ^a	78.33±37.55 ^a	56.00±10.62 ^a	ns

^{ab}Means within rows having the different superscript differ significantly at * $p < 0.05$, *** $p < 0.0001$, ns = not significant, $p > 0.05$. TP = Total protein, TBIL = Total bilirubin, TBA = Total bile acids, GGT = Gamma-glutamyl transferase, ALP = Alkaline phosphatase, AST = Aspartate aminotransferase, ALT = Alanine aminotransferase, UA = Uric acid. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 6 per treatment group, except for the control group which had n = 5.

Table 6. 4: Effect of lycopene on serum markers of hepatic function in growing male Wistar rats fed a high fructose diet

Parameter	PDW +PG	FS + PG	FS +FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Albumin (g/L)	31.50±0.55 ^a	44.83±8.91 ^b	35.67±2.07 ^a	34.33±1.21 ^a	32.33±1.21 ^a	34.67±3.67 ^a	**
Globulin (g/L)	31.50±1.76 ^a	47.50±11.74 ^b	27.67±2.42 ^a	34.17±2.23 ^a	32.00±1.27 ^a	33.67±4.08 ^a	**
TP (g/L)	63.00±2.10 ^a	88.67±17.56 ^b	63.33±4.08 ^a	68.50±3.27 ^a	64.33±2.07 ^a	68.33±7.63 ^a	**
TBIL (g/L)	3.67±1.03 ^a	5.00±1.27 ^a	4.17±1.47 ^a	4.17±1.17 ^a	3.50±0.55 ^a	4.33±1.21 ^a	ns
TBA (µmol/L)	31.83±15.79 ^a	47.17±7.22 ^{ab}	52.83±11.99 ^b	36.17±10.74 ^{ab}	34.67±4.72 ^{ab}	42.00±8.17 ^{ab}	*
UA (µmol/L)	75.00±64.32 ^a	162.20±37.50 ^b	83.50±40.62 ^{ab}	121.30±68.11 ^{ab}	100.00±37.62 ^{ab}	94.50±23.05 ^{ab}	*
GGT (U/L)	5.33±0.82 ^a	7.17±0.98 ^a	5.67±0.82 ^a	13.83 ±20.20 ^a	5.50±0.55 ^a	5.83±0.92 ^a	ns
ALP (U/L)	91.17±38.09 ^a	133.50±24.09 ^a	259.70±61.48 ^b	104.80±19.42 ^a	94.67±11.08 ^a	104.70±26.55 ^a	***
AST (U/L)	310.00±223.80 ^a	438.30±300.30 ^a	270.20±71.78 ^a	398.20±178.70 ^a	284.30±83.70 ^a	314.00±97.68 ^a	ns
ALT (U/L)	319.50±390.00 ^a	159.20±98.14 ^a	82.00±20.13 ^a	147.00±68.40 ^a	104.30±28.29 ^a	108.80±54.44 ^a	ns

^{ab}Means within rows having the different superscript differ significantly at * P < 0.05, ** P < 0.001, *** P < 0.0001, ns = not significant, P > 0.05. TP = Total protein, TBIL = Total bilirubin, TBA = Total bile acids, GGT = Gamma-glutamyl transferase, ALP = Alkaline phosphatase, AST = Aspartate aminotransferase, ALT = Alanine aminotransferase, UA = Uric acid. PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 6 per treatment group.

6.2.5 Liver histomorphology

Figures 6.4 and 6.5 show liver histology photomicrographs at 40x magnification (H&E stained) for female and male rats, respectively, from each treatment group. In both female and male rats fed a high-fructose diet, there was marked fatty infiltration, including micro- and macro-vesicular steatosis (Figures 6.4 and 6.5). Lycopene supplementation and fenofibrate treatment prevented fructose-induced steatosis in both sexes. However, fenofibrate-treated rats showed increased hepatic hypertrophy, which was mitigated by supplemental lycopene (Figures 6.4 and 6.5).




Figure 6.4: Representative photomicrographs showing the effects of lycopene on liver histology in growing female Wistar rats fed a high-fructose diet (H&E staining, 40x magnification, scale bar = 50 µm).

The green arrows point to micro-steatosis, the blue arrows point to macro-steatosis, the black arrow points to hypertrophy and circle A marks foci of lobular inflammation. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube.




Figure 6.5: Representative photomicrographs showing the effects of lycopene on liver histology in growing male Wistar rats fed a high-fructose diet (H&E staining, 40x magnification, scale bar = 50 µm).

The green arrows point to micro-steatosis, the blue arrows point to macro-steatosis, the black arrow points to hypertrophy and circle A marks foci of lobular inflammation. PDW + PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube.

Tables 6.5 and 6.6 present scores for micro- and macro-steatosis, lobular inflammation, and hepatocyte hypertrophy in the treatment groups. No significant differences ($p > 0.05$) were noted in lobular inflammation scores across treatment groups for both female and male rats (Tables 6.5 and 6.6). However, in both sexes, rats fed a high-fructose diet showed significantly increased micro- and macro-steatosis ($p < 0.05$) compared to those on the control diet, fenofibrate-treated, and lycopene-supplemented counterparts. Additionally, fenofibrate-treated rats exhibited significant hypertrophy ($p < 0.05$) in both female and male groups, with no hypertrophy observed in the control, high-fructose diet, or lycopene-supplemented groups (Tables 6.5 and 6.6).

Table 6. 5: Effect of lycopene on liver steatosis, lobular inflammation, and hepatocyte hypertrophy scores in growing female Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS +FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Micro-steatosis	1 (1, 2) ^a	2 (1.3, 2) ^b	1 (1, 1) ^a	1 (0.3, 1) ^a	1 (1, 1.8) ^a	1 (0, 1) ^a	***
Macro-steatosis	0 (0, 1) ^a	2 (1.3, 2) ^b	0.5 (0, 1) ^a	0 (0, 1) ^a	1 (1, 1) ^a	0.5 (0, 1) ^a	***
Lobular inflammation	0 (0, 1) ^a	1 (0.3, 2) ^a	1 (0, 1) ^a	1 (0.3, 1.8) ^a	1 (0, 1.8) ^a	1 (0.3, 1) ^a	ns
Hepatocyte hypertrophy	0 (0, 0) ^a	0 (0, 0) ^a	1 (0, 1) ^b	0 (0, 0) ^a	0 (0, 0) ^a	0 (0, 0) ^a	**

^{ab}Means within rows having the different superscript differ significantly at ** $p < 0.001$, *** $p < 0.0001$, ns = not significant, $p > 0.05$.

PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 4 per treatment group.

Table 6. 6: Effect of lycopene on liver steatosis, lobular inflammation, and hepatocyte hypertrophy scores in growing male Wistar rats fed a high-fructose diet

Parameter	PDW +PG	FS + PG	FS +FENO	FS +LDLY	FS + MDLY	FS + HDLY	Significance
Micro-steatosis	1 (0, 1) ^a	1 (1, 2) ^b	0 (0, 1) ^a	0 (0, 1) ^a	0 (0, 1) ^a	0 (0, 0.8) ^a	***
Macro-steatosis	0 (0, 1) ^a	2 (1, 2) ^b	0 (0, 1) ^a	1 (0, 1) ^a	0 (0, 1) ^a	0 (0, 0) ^a	***
Lobular inflammation	1 (0, 1) ^a	1 (0, 2) ^a	1 (0, 1.8) ^a	0 (0, 1) ^a	1 (0, 2) ^a	1 (0, 1) ^a	ns
Hepatocyte hypertrophy	0 (0, 0) ^a	0 (0, 0) ^a	1 (0, 1) ^b	0 (0, 0) ^a	0 (0, 0) ^a	0 (0, 0) ^a	**

^{ab}Means within rows having the different superscript differ significantly at ** $p < 0.001$, *** $p < 0.0001$, ns = not significant, $p > 0.05$.

PDW +PG = plain drinking water + plain gelatine cube; FS + PG = 20% w/v fructose solution as drinking fluid + PG; FS + FENO = 20% w/v fructose solution as drinking fluid + 100 mg.kg⁻¹BM day⁻¹ of fenofibrate in gelatine cube; FS + LDLY = 20% w/v fructose solution as drinking fluid + Lycopene 30 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + MDLY = 20% w/v fructose solution as drinking fluid + Lycopene 60 mg.kg⁻¹BM day⁻¹ in gelatine cube; FS + HDLY = 20% w/v fructose solution as drinking fluid + Lycopene 100 mg.kg⁻¹BM day⁻¹ in gelatine cube. Data are expressed as mean ± SD, n = 4 per treatment group.

6.3 Discussion

This study investigated the potential of orally administered lycopene to protect against high fructose diet-induced hepatic metabolic derangements in growing weanling Wistar rats. It focused specifically on effects on hepatic fat content, oxidative stress and antioxidant enzyme activity, hepatic histomorphology and serum markers of hepatic function.

6.3.1 Abdominal fat and liver mass

No significant differences were observed in the visceral fat mass of the rats or the epididymal fat mass in males across treatment groups. Together, the results suggest that dietary fructose, the orally administered lycopene and fenofibrate did not negatively affect visceral and epididymal fat pad masses during the 12-week intervention period. This finding aligns with Ibrahim et al. (2022), who reported no impact on these parameters in growing female and male Sprague Dawley rats administered 20% fructose as drinking fluid for 9 weeks. Tillman et al. (2014) similarly found that young rat pups and growing rats demonstrate greater resistance to fructose-induced visceral adiposity compared to adult rats. Female rats fed the high fructose diet had relative heavier liver masses compared to control counterparts, suggesting sex-specific effects. Notably, fenofibrate-treated female and male rats had significantly heavier liver masses compared to control, high-fructose and lycopene-supplemented counterparts. Additionally, low-dose lycopene supplemented female and male rats had heavier liver masses compared to control counterparts. These findings suggest that, in female and male rats, fenofibrate induced hepatomegaly through either hypertrophy and or hyperplasia. The heavier liver masses observed in rats that had low dose supplemental lycopene compared to those of control counterparts might suggest that lycopene may positively influence liver growth. Collectively, these results suggest that supplemental lycopene could potentially be used to mitigate liver hypertrophy and/or hyperplasia induced by fructose and fenofibrate. Excessive fructose intake has been shown to increase liver mass through fat accumulation, enhanced lipogenesis, oxidative stress, and inflammation (García-Berumen et al., 2019; Novelle et al., 2021). Fenofibrate has been similarly associated with liver enlargement primarily through increased fatty acid metabolism, peroxisome proliferation, and mitochondrial biogenesis, which may collectively drive hypertrophy and potentially hyperplastic changes in the liver (Lakhia et al., 2018; Fan et al., 2024). Oxidative stress drives liver damage in MASLD by generating excess ROS, causing cellular damage, inflammation, mitochondrial dysfunction, and

fibrosis, leading to hepatomegaly (Smirne et al., 2022). Lycopene, with its antioxidant properties directly combats oxidative stress by neutralizing free radicals, thereby protecting liver cells from damage that can lead to inflammation, fibrosis, and liver growth (Zhao et al., 2021; Kulawik et al., 2024).

6.3.2 Hepatic lipid yield

Though not statistically significantly different, it is important to note that female and male rats fed the fructose enriched diet had 62% and 55.2%, respectively, more hepatic fat content compared to control counterparts pointing to a biologically significant increase in hepatic fat with fructose feeding. Findings from this study showed that female rats fed a high-fructose diet had significantly more hepatic lipid compared to fenofibrate treated as well as low and high dose lycopene supplemented counterparts. Furthermore, male rats fed a high-fructose diet had significantly more hepatic lipid compared to fenofibrate treated as well as medium and high dose lycopene supplemented counterparts. These findings demonstrate that dietary fructose promotes hepatic lipid accretion in growing female and male Wistar rats which (lipid accretion) might eventually cause liver diseases. In contrast, treatment with fenofibrate and fortifying a high-fructose diet with supplemental lycopene attenuated the diet-induced increase in hepatic lipid build-up. Excessive fructose intake contributes to undesirable changes in liver fat levels, that potentially lead to steatosis and other metabolic complications related to high liver lipid content (Yu et al., 2021). This lipid accumulation reflects an imbalance in hepatic lipid metabolism, with fructose promoting hepatic lipogenesis than the liver can adequately clear (Lodge et al., 2024). Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR α), significantly reduced hepatic lipid content in male C57BL/6J mice fed a high-fat diet for 14 weeks (Zhang et al., 2023). This lipid-lowering effect is attributed to fenofibrate's activation of PPAR α , which enhances fatty acid oxidation and reduces lipogenesis in the liver, ultimately decreasing lipid storage (Mahmoudi et al., 2022). Similarly, lycopene markedly lowered hepatic lipid accumulation in male C57BL/6J mice fed for 10-weeks on a high-fat and fructose-enriched diet (Wang et al., 2020). In the current study, hepatic lipid content was notably elevated in both female and male rats fed a high-fructose diet, by 62% and 55.2% respectively, when compared to controls. Supplemental lycopene attenuated this increase, with reductions in hepatic lipid accumulation of 43%, 26%, and 40% for low, medium, and high doses in females, and 29.1%, 47%, and 55.2% in males. Interestingly, supplemental lycopene showed a sex-specific response: in females, the low dose supplemental

lycopene was most effective yet in males, it induced a dose-dependent hepatic lipid reduction. These findings underscore lycopene's antioxidative and anti-inflammatory effects in reducing liver lipid accumulation by alleviating oxidative stress and inflammation, key contributors to hepatic lipid build-up (Delli Bovi et al., 2021). Thus, it could be hypothesised that the observed sex-specific response to lycopene may be influenced by hormonal and metabolic differences between males and females.

6.3.3 Oxidative stress and systemic antioxidant response

Excessive fructose intake contributes to obesity, increases ROS production, induces oxidative stress, and elevates lipid peroxidation (Hernández-Díazcouder et al., 2019). The thiobarbituric acid reactive substances (TBARS) assay measures lipid peroxidation in biological samples by detecting MDA, a key byproduct of lipid oxidation. MDA reacts with thiobarbituric acid (TBA) to form MDA-TBA₂ adducts, known as TBARS, which serve as markers of oxidative stress (Aguilar Diaz De Leon & Borges, 2020). Current study findings showed similarities in serum and hepatic TBARS concentrations and serum GPX-1 activity in the rats across treatment groups. Likewise, hepatic CAT activity was similar in females across treatment groups. Fenofibrate-treated females had significantly increased hepatic GPX-1 activity compared to control, high-fructose diet-fed, low, medium, or high lycopene-supplemented counterparts, while fenofibrate-treated males had significantly higher hepatic GPX-1 levels compared to control, low, or medium-dose lycopene-supplemented counterparts. However, the high dose lycopene supplemented males had higher hepatic GPX-1 activity compared to control males. Furthermore, the same high-dose lycopene-supplemented males also had higher hepatic CAT activity compared to control, high fructose diet-fed as well as low and medium dose lycopene supplemented counterparts. These findings demonstrate that in growing Wistar rats, chronic 12 week high-fructose diet neither causes systemic nor hepatic oxidative stress as supported by similarities in TBARS concentrations across treatment groups. Similarly, the 12-week dietary fructose insult did not activate endogenous antioxidant enzymes (GPX-1 and CAT) activity. These current study findings align with Nestorov et al. (2014), who observed that in growing male Wistar rats a 9-week insult with a 10% fructose in drinking water neither stimulated increased hepatic TBARS concentration nor increased CAT or GPX activity pointing to no effects on oxidative stress and endogenous antioxidant enzymes activities. Similar observations were noted by Glban et al. (2015) in 21-day old male Wistar rats challenged with a 60% fructose solution for a 9-week period. Studies have demonstrated that

young, growing rats exhibit better antioxidant capacity to combat oxidative stress than adult rats (Cao et al., 1996; Lee et al., 2024). This enhanced capacity may explain the lack or minimal impact of fructose on oxidative stress and the systemic antioxidant enzyme response observed in this study. At this developmental stage, young rats maintain redox balance, keep ROS levels within safe limits, and efficiently shield cells from oxidative damage (Glban et al., 2015).

In this study, orally administered fenofibrate and high-dose lycopene exerted distinct antioxidant effects in hepatic tissue as demonstrated by mediating increased GPX-1 activity in female and male rats treated with fenofibrate. The increased hepatic GPX-1 activity indicates its effectiveness in enhancing hepatic antioxidant defences across sexes. Supplemental high-dose lycopene mediated, increased GPX-1 and CAT activities in males. It can, therefore, be inferred that these findings suggest that while fenofibrate supports hepatic antioxidant capacity, particularly GPX-1, regardless of sex, the high-dose supplemental lycopene may offer additional antioxidant benefits that appear more pronounced in male rats, possibly due to sex-specific metabolic responses to lycopene at higher doses. Lycopene has been reported to increase MDA concentrations and to significantly elevate SOD, GSH, and CAT activities in human liver cells (HepG2) exposed to acrylamide- and glycidamide-induced toxicity, indicating its protective role against oxidative damage (Reshmitha & Nisha, 2021). Fenofibrate significantly lowers circulating conjugated dienes, a lipid peroxidation marker, decrease MDA concentrations, and increase GPX activity in patients with dyslipidaemia (Tkáč et al., 2006). Findings from the current study demonstrate that lycopene and fenofibrate reduce oxidative stress and boost antioxidant defences, likely through activation of enzymes like GPX-1 and CAT. However, the exact mechanisms by which they mediate these effects remain unclear and require further investigation to fully understand their potential as prophylactic and therapeutic agents, respectively.

6.3.4 Serum biomarkers of hepatic function

This study observed no significant variations in serum GGT, ALT, and AST activities of female and male rats across treatment groups. However, serum ALP activity was elevated in fenofibrate-treated female and male rats compared to their control, high fructose diet-fed, and lycopene-supplemented counterparts. These findings suggest that the treatments did not damage hepatocytes and cause leakage of ALT, AST and GGT into systemic circulation. However, the increased serum ALP activity with fenofibrate treatment suggest that it (fenofibrate) damaged cells lining the biliary

system resulting in leakage of ALP, which is found in high concentrations in cells that line the bile canaliculi and bile ducts (Reshetnyak & Maev, 2023), into systemic circulation. Current study findings demonstrate that supplemental lycopene attenuated the fenofibrate-treatment induced damage of biliary cells. Elevated activities of AST, GGT, and ALT are commonly used as markers of liver damage, particularly in hepatocytes (Krisnamurti et al., 2022; Thakur et al., 2024). Fenofibrate-induced elevation of serum ALP aligns with evidence linking its use to cholestasis and liver injury (Zubrzycki et al., 2020; Vanasco & vanSonnenberg, 2023). Beyond the hepatic effect, elevated ALP is also observed in osteomalacia, a bone metabolic condition characterised by defective mineralisation (Zhao et al., 2021; Cianferotti, 2022). This suggests that the increase in serum ALP with fenofibrate treatment may reflect impacts on both hepatic and skeletal systems. Moreso, in Chapter 3 (under subheading 3.2.3 long bone indices, pages 127-129), fenofibrate treatment was associated with femoral bone loss and reduced tibia length in males, further supporting the notion of its skeletal impact. This study reports similarities in serum albumin, total protein, globulin, total bile acids, and uric acid concentrations across treatment groups in the female rats but females that had supplemental low- and medium-dose lycopene had higher serum total bilirubin concentrations compared to controls. While there were similarities in serum total bilirubin concentration in males across treatment groups, male rats on a high fructose diet exhibited significantly elevated serum albumin, total protein, and globulin concentrations compared to the control, fenofibrate-treated, and lycopene supplemented counterparts. Both dietary fructose and fenofibrate treatment increased serum uric acid and total bile acids concentrations, respectively, in males compared to control males. The findings suggest that the treatments (dietary fructose, fenofibrate, and supplemental lycopene) elicit sex-specific responses. In female rats, these treatments did not adversely affect hepatic synthetic and excretory capacity as demonstrated by similarities serum albumin, total protein, globulin, total bile acids, and or uric acid concentrations. However, low- and medium-dose supplemental lycopene may have interfered with the liver's ability to process or excrete bilirubin. In male rats, similarities in serum total bilirubin concentrations across treatments, suggest that dietary fructose, fenofibrate, and supplemental lycopene did not impair the liver's ability to process and excrete bilirubin. Bilirubin, a byproduct of red blood cell breakdown, is primarily conjugated and excreted into bile by hepatocytes (Kumbhar et al., 2024). Elevated serum bilirubin concentrations can signal liver dysfunction or altered hepatic metabolism (Guerra Ruiz et al., 2021). It is noteworthy that some current research

contends that elevated bilirubin concentrations might play a protective role in preventing the development of diabetes mellitus and metabolic syndrome (Nikouei et al., 2024). Bilirubin, at physiological concentrations, acts as a powerful endogenous antioxidant (Jansen & Daiber, 2012). It neutralises ROS by undergoing oxidation to form biliverdin, which is converted back into bilirubin through the action of biliverdin reductase, creating a continuous antioxidative cycle (Jansen & Daiber, 2012). This recycling mechanism allows nanomolar bilirubin concentrations to protect cells against oxidants present at up to 10,000-fold excess in cell culture studies (Stocker et al., 1987). It can be hypothesised that the increased serum total bilirubin observed in female rats that had low- and medium-dose supplemental lycopene represents an adaptive response to changes in oxidative balance. As a potent antioxidant, lycopene may influence the liver's redox state, triggering mechanisms that enhance bilirubin production or recycling. This could involve shifting the oxidative-antioxidative equilibrium, prompting the liver to produce or retain more bilirubin to complement lycopene's antioxidant activity. Additionally, lycopene may upregulate enzymes such as biliverdin reductase, facilitating the conversion of biliverdin back to bilirubin and increasing circulating levels. The observed increase in serum total bilirubin concentrations in female rats may reflect a coordinated response to maintain redox homeostasis rather than a marker of dysfunction. Nevertheless, further research is needed to validate this hypothesis and determine whether the effect is protective or indicative of oxidative stress.

In the current study, a high fructose diet led to increased serum albumin, total protein, and globulin concentrations, suggesting an impact on hepatic plasma protein synthesis. Additionally, dietary fructose increased serum uric acid concentrations. Treatment with fenofibrate resulted in increased serum total bile acids concentrations, indicating potential adverse effects on liver function in male rats. Notably, the high fructose-induced increases in serum albumin, total protein, and globulin concentrations, as well as the fenofibrate-induced increase in serum total bile acids, were mitigated by supplemental lycopene, demonstrating its protective role in maintaining hepatic homeostasis. The liver serves as the primary site for plasma protein (albumin and globulin) synthesis, and it plays a pivotal role in amino acid metabolism and detoxification (Paulusma et al., 2022; Yu et al., 2022). Insulin resistance impairs these hepatic processes, disrupting the regulation of protein synthesis and degradation, processes that contribute to metabolic dysfunction (Ren et al., 2017; Ruegsegger et al., 2018). Excessive fructose intake disrupts hepatic function by promoting oxidative stress, which indirectly alters protein metabolism and plasma albumin, globulin, and

total protein concentrations (Softic et al., 2019; Duvall et al., 2023). Importantly, chronic fructose consumption contributes to insulin resistance, reduces hepatic and muscle amino acid uptake, further disrupting protein metabolism (Tappy, 2021; Zeng et al., 2024). Additionally, excessive fructose consumption has been associated with hyperuricemia (Zhang et al., 2020; Lubawy & Formanowicz, 2023). High plasma uric acid concentrations contribute to the onset of gout and renal calculi, and are widely recognised as a significant risk factor for both cardiovascular disease and metabolic syndrome (De Oliveira & Burini, 2012). Consistent with these findings, the current study findings show dietary fructose-induced increased serum uric acid concentrations in male rats by 116.3% increase compared to controls. However, this dietary fructose-induced uric acid increase was mitigated by supplemental lycopene in a dose-dependent manner, with reductions of 25.2%, 38.4%, and 41.7% for low, medium, and high doses, respectively suggesting that fortification of obesogenic diets with lycopene could potentially protect against cardiovascular and renal diseases and metabolic syndrome. Indeed, in animal and human models' lycopene has been shown to effectively reduces serum uric acid concentrations (Basuny et al., 2009; Han & Liu, 2017) which is congruent with findings from the current study. In the liver, fructose is metabolised more rapidly than glucose by unregulated fructokinase, which converts it to fructose-1-phosphate: a process that depletes ATP (Nakagawa et al., 2020). This process increases ADP concentrations, activates AMP deaminase, and breaks down purine nucleotides into uric acid, thereby increasing serum uric acid concentrations (Dewdney et al., 2020). Beyond generating uric acid as a byproduct, this pathway also contributes to metabolic disturbances and liver dysfunction (Zhang et al., 2022). Fenofibrate, known for its effectiveness in managing hyperlipidaemia (Deerochanawong et al., 2024), has been shown to increase total bile acid concentrations. Wang et al. (2023) demonstrated that male C57BL/6 mice treated with 125 mg/kg of fenofibrate daily for 3 weeks exhibited elevated serum total bile acid concentrations. Similarly, in the current study, fenofibrate-treated male rats registered a 66% increase in serum total bile acids concentration compared to the control counterparts. This increase was mitigated by supplemental lycopene, which reduced bile acid levels by 32%, 34.4%, and 21% at low, medium, and high doses, respectively. The increase in serum total bile acid concentrations observed in male Wistar rats may result from fenofibrate's activation of PPAR α , which upregulates cholesterol 7 α -hydroxylase (CYP7A1) activity; driving bile acid synthesis from cholesterol in the liver (Liu et al., 2014; Sun et al., 2024). Fenofibrate's effects on lipid metabolism may alter bile acid homeostasis by increasing synthesis and secretion

to facilitate lipid digestion and absorption (Jia et al., 2021; Ye et al., 2022). Additionally, fenofibrate may modulate the farnesoid X receptor (FXR), a key regulator of bile acid synthesis and transport, contributing to the elevated plasma bile acid concentrations (Pavlović et al., 2018). In contrast, lycopene's antioxidant properties are well-documented in mitigating oxidative stress and preserving liver function (Abdel-Rahman et al., 2018; Khan et al., 2024). When administered at 10 mg/kg orally for 18 days, lycopene reduced serum total bile acids, bilirubin concentrations, and AST, ALT, ALP, and GGT activities but increased hepatic albumin and total protein concentrations in male albino rats with ethinylestradiol-induced cholestasis (Wadie et al., 2021). These findings support lycopene's protective role against dietary fructose and/or fenofibrate-induced adverse effects on hepatic health, warranting further investigation into its underlying mechanisms.

6.3.5 Hepatic microarchitecture

Excessive intake of dietary fructose is known to contribute to the development of steatosis, metabolic dysfunction-associated steatotic liver disease (MASLD), inflammation, and hepatic hypertrophy (DiStefano & Shaibi, 2020; Li et al., 2024). In the liver, fructose metabolism bypasses key regulatory steps, leading to unregulated lipogenesis and the accumulation of triglycerides within hepatocytes, which are hallmark features of steatosis (Skenderian et al., 2020). Over time, this excessive lipid deposition may progress to MASLD, a condition closely linked to metabolic syndrome and obesity (Pereira et al., 2017). Histologically, MASLD is defined by fatty infiltration into hepatocytes, with steatosis affecting more than 5% of liver cells in histological sections (Brunt et al., 2021). In the present study, no significant differences in hepatic inflammation were observed in either female or male rats across treatment groups. However, dietary fructose notably increased both micro- and macro-vesicular steatosis in both sexes compared to rats fed the control diet, fenofibrate-treated, or supplemented with low, medium and high doses of lycopene. Additionally, orally administered fenofibrate significantly induced hepatocyte hypertrophy in female and male rats compared to control, high-fructose-fed, and lycopene-treated groups. These findings suggest that dietary fructose, supplemental lycopene, and fenofibrate did not cause hepatic inflammation during the 12-week intervention period. Similar to the current study findings, chronic fructose intake has been reported not to induce hepatic inflammation in female Sprague-Dawley rats given a 10% fructose solution as drinking fluid for seven months (Sangüesa et al., 2019). Fenofibrate and lycopene are recognised for their anti-inflammatory properties (Mahmoudi et al., 2022;

Mirahmadi et al., 2023). Although fenofibrate induced hepatocyte hypertrophy in the present study, it has been demonstrated that this increase in hepatocyte size is a physiological adaptive response associated with its lipid-lowering effects, as observed in wild-type C57BL/6 male mice (Fan et al., 2024). This hypertrophy results from fenofibrate's role as a PPAR- α agonist, which enhances fatty acid β -oxidation in peroxisomes and mitochondria, leading to increased metabolic demands on hepatocytes (Jiang & Yang, 2014). These demands necessitate a larger cell size to support elevated metabolic and biosynthetic activity (Jiang & Yang, 2014). Additionally, fenofibrate may promote protein synthesis and organelle proliferation, including an increase in peroxisomes and mitochondria, further contributing to hepatocyte enlargement (Bougarne et al., 2018). Unlike pathological hypertrophy, which is often linked to cellular damage or inflammation (Hora & Wuestefeld, 2023), the hypertrophy recorded in the current study could serve as an adaptive response. However, various factors, such as species, sex, age, and the administered fenofibrate dose can influence the extent of hepatocyte hypertrophy, highlighting its context-dependent nature (Maronpot et al., 2010). Lycopene has been reported to attenuate fructose-induced hepatic steatosis (Ferreira-Santos et al., 2020). Furthermore, lycopene has been demonstrated to prevent the progression of lipotoxicity-induced non-alcoholic steatohepatitis (NASH) by reducing oxidative stress in mice (Ni et al., 2020). In this study, while a high-fructose diet induced steatosis, lycopene effectively mitigated excessive hepatic fat accumulation.

The absence of inflammation in both male and female rats, despite the presence of steatosis in the fructose-fed group and hypertrophy in the fenofibrate-treated group, suggests that the rats in this study did not progress to advanced fatty liver disease, which is commonly marked by steatohepatitis and damage to parenchymal tissues (Peng et al., 2020).

6.4 Conclusion

Dietary fructose elicited sexually dimorphic responses in growing female and male Wistar rats. In males, fructose increased serum albumin, total protein, globulin, and uric acid levels, while no such changes were observed in females. Lycopene effectively mitigated these effects. Both sexes exhibited elevated serum alkaline phosphatase (ALP) levels following fenofibrate treatment, but lycopene protected against fructose-induced lipid accumulation and prevented liver mass increase. Fenofibrate caused hepatomegaly, while high-dose lycopene enhanced hepatic GPX-1 and CAT

activity in male rats. Additionally, fructose induced micro- and macro-vesicular steatosis in both sexes, which lycopene attenuated, while fenofibrate was associated with hepatocyte hypertrophy.

These findings underscore the protective role of lycopene against fructose- and fenofibrate-induced hepatic alterations. By mitigating lipid accumulation, oxidative stress, and steatosis, lycopene offers a promising prophylactic approach to diet-induced liver dysfunction in a sex-dependent manner, highlighting its potential to prevent diet-induced liver pathologies.

Having explored the potential benefits of supplemental lycopene in protecting liver health in Wistar rats fed a high fructose diet, with a focus on hepatic oxidant and antioxidant status, lipid content, hepatic and serum markers of liver function, and liver histomorphology in this chapter, chapter 7 summarises the study's key findings and major conclusions, highlights some of the study's limitations, and proposes recommendations for future research.

6.5 References

- Abdel-Rahman, H. G., Abdelrazek, H. M. A., Zeidan, D. W., Mohamed, R. M., & Abdelazim, A. M. (2018). Lycopene: Hepatoprotective and Antioxidant Effects toward Bisphenol A-Induced Toxicity in Female Wistar Rats. *Oxidative Medicine and Cellular Longevity*, 2018(1), 5167524. <https://doi.org/10.1155/2018/5167524>
- Aguilar Diaz De Leon, J., & Borges, C. R. (2020). Evaluation of Oxidative Stress in Biological Samples Using the Thiobarbituric Acid Reactive Substances Assay. *Journal of Visualized Experiments*, 2020(159), e61122. <https://doi.org/10.3791/61122>
- Allen, A. M., Lazarus, J. V., & Younossi, Z. M. (2023). Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties. *Journal of Hepatology*, 79(1), 200-217. <https://doi.org/10.1016/j.jhep.2023.01.026>
- Azevedo-Martins, A. K., Santos, M. P., Abayomi, J., Ferreira, N. J. R., & Evangelista, F. S. (2024). The Impact of Excessive Fructose Intake on Adipose Tissue and the Development of Childhood Obesity. *Nutrients*, 16(7), 939. <https://doi.org/10.3390/NU16070939>
- Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018). Molecular Actions of PPAR α in Lipid Metabolism and Inflammation. *Endocrine Reviews*, 39(5), 760–802. <https://doi.org/10.1210/ER.2018-00064>
- Brunt, E. M., Kleiner, D. E., Carpenter, D. H., Rinella, M., Harrison, S. A., Loomba, R., Younossi, Z., Neuschwander-Tetri, B. A., & Sanyal, A. J. (2021). NAFLD: Reporting Histologic Findings in Clinical Practice. *Hepatology*, 73(5), 2028–2038. <https://doi.org/10.1002/HEP.31599>
- Cao, G., Giovanoni, M., & Prior, R. L. (1996). Antioxidant capacity decreases during growth but not aging in rat serum and brain. *Archives of Gerontology and Geriatrics*, 22(1), 27–37. [https://doi.org/10.1016/0167-4943\(95\)00674-5](https://doi.org/10.1016/0167-4943(95)00674-5)
- Cianferotti, L. (2022). Osteomalacia Is Not a Single Disease. *International Journal of Molecular Sciences*, 23(23), 14896. <https://doi.org/10.3390/IJMS232314896>
- De Oliveira, E. P., & Burini, R. C. (2012). High plasma uric acid concentration: Causes and consequences. *Diabetology and Metabolic Syndrome*, 4(1), 1–7. <https://doi.org/10.1186/1758-5996-4-12/FIGURES/1>

- Deerochanawong, C., Kim, S. G., & Chang, Y. C. (2024). Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review. *Diabetes & Metabolism Journal*, 48(2), 184. <https://doi.org/10.4093/DMJ.2023.0168>
- Delli Bovi, A. P., Marciano, F., Mandato, C., Siano, M. A., Savoia, M., & Vajro, P. (2021). Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. *Frontiers in Medicine*, 8, 595371. <https://doi.org/10.3389/FMED.2021.595371/BIBTEX>
- Dewdney, B., Roberts, A., Qiao, L., George, J., & Hebbard, L. (2020). A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma. *Biomolecules*, 10(4), 496. <https://doi.org/10.3390/BIOM10040496>
- DiStefano, J. K., & Shaibi, G. Q. (2020). The relationship between excessive dietary fructose consumption and pediatric fatty liver disease. *Pediatric Obesity*, 16(6), e12759. <https://doi.org/10.1111/IJPO.12759>
- Dong, X., Li, J. M., Lu, X. L., Lin, X. Y., Hong, M. Z., Weng, S., & Pan, J. S. (2024). Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future. *Translational Gastroenterology and Hepatology*, 9, 33. <https://doi.org/10.21037/TGH-23-118/COIF>
- Duarte, S. M. B., Stefano, J. T., Vanni, D. S., Carrilho, F. J., & De Oliveira, C. P. M. S. (2019). Impact of current diet at the risk of non-alcoholic fatty liver disease (NAFLD). *Arquivos de Gastroenterologia*, 56(4), 431–439. <https://doi.org/10.1590/S0004-2803.201900000-67>
- Duvall, L. E., Shipman, A. R., & Shipman, K. E. (2023). Investigative algorithms for disorders affecting plasma proteins with a focus on albumin and the calculated globulin fraction: A narrative review. *Journal of Laboratory and Precision Medicine*, 8. <https://doi.org/10.21037/JLPM-23-15/COIF>
- Dzordzo, Y., & Andreychyn, S. (2022). Search for a way to improve the serum albumin binding function and the functional state of the liver when hypertension combined with non-alcoholic fatty liver disease. *Journal of Education, Health and Sport*, 12(1), 55–64. <https://doi.org/10.12775/jehs.2022.12.01.005>
- Fan, S., Gao, Y., Zhao, P., Xie, G., Zhou, Y., Yang, X., Li, X., Zhang, S., Gonzalez, F. J., Qu, A., Huang, M., & Bi, H. (2024). Fenofibrate-promoted hepatomegaly and liver regeneration are PPAR α -

dependent and partially related to the YAP pathway. *Acta Pharmaceutica Sinica. B*, 14(7), 2992. <https://doi.org/10.1016/J.APSB.2024.03.030>

Federico, A., Rosato, V., Masarone, M., Torre, P., Dallio, M., Romeo, M., & Persico, M. (2021). The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. *Nutrients*, 13(4), 1314. <https://doi.org/10.3390/NU13041314>

Ferreira-Santos, P., Aparicio, R., Carrón, R., Montero, M. J., & Sevilla, M. Á. (2020). Lycopene-supplemented diet ameliorates metabolic syndrome induced by fructose in rats. *Journal of Functional Foods*, 73, 104098. <https://doi.org/10.1016/J.JFF.2020.104098>

Francque, S., & Vonghia, L. (2019). Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. *Advances in Therapy*, 36(5), 1052. <https://doi.org/10.1007/S12325-019-00898-6>

García-Berumen, C. I., Ortiz-Avila, O., Vargas-Vargas, M. A., Del Rosario-Tamayo, B. A., Guajardo-López, C., Saavedra-Molina, A., Rodríguez-Orozco, A. R., & Cortés-Rojo, C. (2019). The severity of rat liver injury by fructose and high fat depends on the degree of respiratory dysfunction and oxidative stress induced in mitochondria. *Lipids in Health and Disease*, 18(1), 1–11. <https://doi.org/10.1186/S12944-019-1024-5/FIGURES/4>

Geidl-Flueck, B., & Gerber, P. A. (2023). Fructose drives de novo lipogenesis affecting metabolic health. *The Journal of Endocrinology*, 257(2), e220270. <https://doi.org/10.1530/JOE-22-0270>

Giban, A. M., Vasiljević, A., Veličković, N., Nikolić-Kokić, A., Blagojević, D., Matić, G., & Nestorov, J. (2015). The expression and activity of antioxidant enzymes in the liver of rats exposed to high-fructose diet in the period from weaning to adulthood. *Journal of the Science of Food and Agriculture*, 95(11), 2319–2324. <https://doi.org/10.1002/JSFA.6953>

Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020). NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. *Diabetology and Metabolic Syndrome*, 12(1), 1–20. <https://doi.org/10.1186/S13098-020-00570-Y/TABLES/5>

Grander, C., Grabherr, F., & Tilg, H. (2023). Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. *Cardiovascular Research*, 119(9), 1787. <https://doi.org/10.1093/CVR/CVAD095>

- Guerra Ruiz, A. R., Crespo, J., López Martínez, R. M., Iruzubieta, P., Casals Mercadal, G., Lalana Garcés, M., Lavin, B., & Morales Ruiz, M. (2021). Measurement and clinical usefulness of bilirubin in liver disease. *Advances in Laboratory Medicine*, 2(3), 352. <https://doi.org/10.1515/ALMED-2021-0047>
- Han, G. M., & Liu, P. (2017). Higher serum lycopene is associated with reduced prevalence of hypertension in overweight or obese adults. *European Journal of Integrative Medicine*, 13, 34–40. <https://doi.org/10.1016/J.EUJIM.2017.07.002>
- Hernández-Díazcouder, A., Romero-Nava, R., Carbó, R., Sánchez-Lozada, L. G., & Sánchez-Muñoz, F. (2019). High Fructose Intake and Adipogenesis. *International Journal of Molecular Sciences*, 20(11), 2787. <https://doi.org/10.3390/IJMS20112787>
- Hora, S., & Wuestefeld, T. (2023). Liver Injury and Regeneration: Current Understanding, New Approaches, and Future Perspectives. *Cells*, 12(17), 2129. <https://doi.org/10.3390/CELLS12172129>
- Huby, T., & Gautier, E. L. (2021). Immune cell-mediated features of non-alcoholic steatohepatitis. *Nature Reviews Immunology* 2021 22:7, 22(7), 429–443. <https://doi.org/10.1038/s41577-021-00639-3>
- Ibrahim, K. G., Chivandi, E., Nkomozepe, P., & Erlwanger, K. H. (2022). Neonatal orally administered curcumin: impact on the metabolic response and renal histology of Sprague-Dawley rats fed a high-fructose diet until adolescence. *Bulletin of the National Research Centre* 2022 46:1, 46(1), 1–13. <https://doi.org/10.1186/S42269-022-00845-6>
- Jansen, T., & Daiber, A. (2012). Direct Antioxidant Properties of Bilirubin and Biliverdin. Is there a Role for Biliverdin Reductase? *Frontiers in Pharmacology*, 3, 30. <https://doi.org/10.3389/FPHAR.2012.00030>
- Jia, X., Xu, W., Zhang, L., Li, X., Wang, R., & Wu, S. (2021). Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia. *Frontiers in Cellular and Infection Microbiology*, 11, 634780. <https://doi.org/10.3389/FCIMB.2021.634780/BIBTEX>
- Jiang, M., & Yang, N. (2014). Peroxisome Proliferators. *Encyclopedia of Toxicology: Third Edition*, 815–819. <https://doi.org/10.1016/B978-0-12-386454-3.00346-8>

- Khan, M., Gul, S., Rehman, I., Leghari, Q. ain, Badar, R., & Zille-Huma. (2024). Protective effect of lycopene against celecoxib induced fat deposition and glycogen reduction in liver cells. *Journal of Taibah University Medical Sciences*, 19(4), 856–866.
<https://doi.org/10.1016/J.JTUMED.2024.07.007>
- Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y. C., Torbenson, M. S., Unalp-Arida, A., Yeh, M., McCullough, A. J., & Sanyal, A. J. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*, 41(6), 1313–1321. <https://doi.org/10.1002/HEP.20701>
- Krisnamurti, D. G. B., Purwaningsih, E. H., Tarigan, T. J. E., Nugroho, C. M. H., Soetikno, V., & Louisa, M. (2022). Alterations of Liver Functions and Morphology in a Rat Model of Prediabetes After a Short-term Treatment of a High-fat High-glucose and Low-dose Streptozotocin. *Open Access Macedonian Journal of Medical Sciences*, 10(A), 668–674.
<https://doi.org/10.3889/OAMJMS.2022.8717>
- Kudaravalli, P., & John, S. (2023). Nonalcoholic Fatty Liver. *StatPearls*.
<https://www.ncbi.nlm.nih.gov/books/NBK541033/>
- Kulawik, A., Cielecka-Piontek, J., Czerny, B., Kamiński, A., & Zalewski, P. (2024). The Relationship Between Lycopene and Metabolic Diseases. *Nutrients*, 16(21), 3708.
<https://doi.org/10.3390/NU16213708>
- Kumbhar, S., Musale, M., & Jamsa, A. (2024). Bilirubin metabolism: delving into the cellular and molecular mechanisms to predict complications. *The Egyptian Journal of Internal Medicine*, 36(1), 1–9. <https://doi.org/10.1186/S43162-024-00298-5>
- Lakhia, R., Yheskel, M., Flaten, A., Quittner-Strom, E. B., Holland, W. L., & Patel, V. (2018). PPAR α agonist fenofibrate enhances fatty acid β -oxidation and attenuates polycystic kidney and liver disease in mice. *American Journal of Physiology - Renal Physiology*, 314(1), F122–F131.
<https://doi.org/10.1152/AJPRENAL.00352.2017/ASSET/IMAGES/LARGE/ZH20101783570006.JPGG>
- Lee, A. S., Persoff, J., & Lange, S. M. (2023). Liver Function Tests. *Mayo Clinic Medical Manual*, 373–387. <https://doi.org/10.1201/b14283-48>

- Lee, S., Itagaki, A., Satoh, A., Sugimoto, I., Saito, T., Shibukawa, Y., & Tatehana, H. (2024). Effects of psychogenic stress on oxidative stress and antioxidant capacity at different growth stages of rats: Experimental study. *PLOS ONE*, *19*(4), e0287421.
<https://doi.org/10.1371/JOURNAL.PONE.0287421>
- Li, C., Li, M., Sheng, W., Zhou, W., Zhang, Z., Ji, G., & Zhang, L. (2024). High dietary Fructose Drives Metabolic Dysfunction-Associated Steatotic Liver Disease via Activating ubiquitin-specific peptidase 2/11 β -hydroxysteroid dehydrogenase type 1 Pathway in Mice. *International Journal of Biological Sciences*, *20*(9), 3480. <https://doi.org/10.7150/IJBS.97309>
- Liang, W., Menke, A. L., Driessen, A., Koek, G. H., Lindeman, J. H., Stoop, R., Havekes, L. M., Kleemann, R., & Van Den Hoek, A. M. (2014). Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. *PloS One*, *9*(12), e115922.
<https://doi.org/10.1371/JOURNAL.PONE.0115922>
- Liu, A., Krausz, K. W., Fang, Z. Z., Brocker, C., Qu, A., & Gonzalez, F. J. (2014). Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPAR α and its relevance to hepatotoxicity. *Archives of Toxicology*, *88*(4), 983–996. <https://doi.org/10.1007/S00204-013-1188-0>
- Lodge, M., Dykes, R., & Kennedy, A. (2024). Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease. *Biomolecules*, *Page 845*, *14*(7), 845. <https://doi.org/10.3390/BIOM14070845>
- Lubawy, M., & Formanowicz, D. (2023). High-Fructose Diet–Induced Hyperuricemia Accompanying Metabolic Syndrome–Mechanisms and Dietary Therapy Proposals. *International Journal of Environmental Research and Public Health*, *20*(4), 3596.
<https://doi.org/10.3390/IJERPH20043596>
- Ma, Y., Lee, G., Heo, S. Y., & Roh, Y. S. (2021). Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. *Antioxidants*, *11*(1), 91.
<https://doi.org/10.3390/ANTIOX11010091>
- Mahmoudi, A., Moallem, S. A., Johnston, T. P., & Sahebkar, A. (2022). Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models. *PPAR Research*, *2022*(1), 5805398.
<https://doi.org/10.1155/2022/5805398>

- Maronpot, R. R., Yoshizawa, K., Nyska, A., Harada, T., Flake, G., Mueller, G., Singh, B., Ward, J. M., & Botts, S. (2010). Liver enlargement - STP regulatory policy papers: Hepatic enzyme induction: Histopathology. *Toxicologic Pathology*, 38(5), 776–795.
https://doi.org/10.1177/0192623310373778/ASSET/IMAGES/LARGE/10.1177_0192623310373778-FIG9.JPEG
- Mcvicker, B., Viswanathan, S., Lodge, M., Dykes, R., & Kennedy, A. (2024). Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease. *Biomolecules*, 14(7), 845.
<https://doi.org/10.3390/BIOM14070845>
- Mirahmadi, M., Aghasizadeh, M., Nazifkar, F., Choubdari, M. G., Assaran-Darban, R., Tavallaie, S., Hatamzadeh, H., Ferns, G. A., Mirinezhad, M. R., Baharara, H., Hadizadeh, F., & Ghayour-Mobarhan, M. (2023). The Effects of Lycopene on Modulating Oxidative Stress and Liver Enzymes Levels in Metabolic Syndrome Patients: A Randomised Clinical Trial. *Cell Journal (Yakhteh)*, 25(12), 847. <https://doi.org/10.22074/CELLJ.2023.2006158.1353>
- Muhamad, N. A., Maamor, N. H., Leman, F. N., Mohamad, Z. A., Bakon, S. K., Mutalip, M. H. A., Rosli, I. A., Aris, T., Lai, N. M., & Hassan, M. R. A. (2023). The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis. *Interactive Journal of Medical Research*, 12, e40653. <https://doi.org/10.2196/40653>
- Muriel, P., López-sánchez, P., & Ramos-tovar, E. (2021). Fructose and the Liver. *International Journal of Molecular Sciences*, 22(13), 6969. <https://doi.org/10.3390/IJMS22136969>
- Nakagawa, T., Lanaspá, M. A., Millan, I. S., Fini, M., Rivard, C. J., Sanchez-Lozada, L. G., Andres-Hernando, A., Tolan, D. R., & Johnson, R. J. (2020). Fructose contributes to the Warburg effect for cancer growth. *Cancer & Metabolism*, 8(1), 1–12. <https://doi.org/10.1186/S40170-020-00222-9>
- Nestorov, J., Glban, A. M., Mijušković, A., Nikolić-Kokić, A., Elaković, I., Veličković, N., & Matic, G. (2014). Long-term fructose-enriched diet introduced immediately after weaning does not induce oxidative stress in the rat liver. *Nutrition Research*, 34(7), 646–652.
<https://doi.org/10.1016/J.NUTRES.2014.06.006>

- Ni, Y., Zhuge, F., Nagashimada, M., Nagata, N., Xu, L., Yamamoto, S., Fuke, N., Ushida, Y., Suganuma, H., Kaneko, S., & Ota, T. (2020). Lycopene prevents the progression of lipotoxicity-induced nonalcoholic steatohepatitis by decreasing oxidative stress in mice. *Free Radical Biology & Medicine*, *152*, 571–582. <https://doi.org/10.1016/J.FREERADBIOMED.2019.11.036>
- Nikouei, M., Cheraghi, M., Ghaempanah, F., Kohneposhi, P., Saniee, N., Hemmatpour, S., & Moradi, Y. (2024). The association between bilirubin levels, and the incidence of metabolic syndrome and diabetes mellitus: a systematic review and meta-analysis of cohort studies. *Clinical Diabetes and Endocrinology*, *10*(1), 1. <https://doi.org/10.1186/S40842-023-00159-0>
- Novelle, M. G., Bravo, S. B., Deshons, M., Iglesias, C., García-Vence, M., Annells, R., da Silva Lima, N., Nogueiras, R., Fernández-Rojo, M. A., Diéguez, C., & Romero-Picó, A. (2021). Impact of liver-specific GLUT8 silencing on fructose-induced inflammation and omega oxidation. *IScience*, *24*(2), 102071. <https://doi.org/10.1016/j.isci.2021.102071>
- Paulusma, C. C., Lamers, W. H., Broer, S., & van de Graaf, S. F. J. (2022). Amino acid metabolism, transport and signalling in the liver revisited. *Biochemical Pharmacology*, *201*, 115074. <https://doi.org/10.1016/J.BCP.2022.115074>
- Pavlović, N., Goločorbin-Kon, S., Danić, M., Stanimirov, B., Al-Salami, H., Stankov, K., & Mikov, M. (2018). Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. *Frontiers in Pharmacology*, *9*, 1283. <https://doi.org/10.3389/FPHAR.2018.01283/BIBTEX>
- Peng, C., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020). Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. *Frontiers in Pharmacology*, *11*, 603926. <https://doi.org/10.3389/FPHAR.2020.603926>
- Pereira, R. M., Botezelli, J. D., da Cruz Rodrigues, K. C., Mekary, R. A., Cintra, D. E., Pauli, J. R., da Silva, A. S. R., Ropelle, E. R., & de Moura, L. P. (2017). Fructose Consumption in the Development of Obesity and the Effects of Different Protocols of Physical Exercise on the Hepatic Metabolism. *Nutrients*, *9*(4), 405. <https://doi.org/10.3390/NU9040405>

- Ren, T., Zhu, Y., Xia, X., Ding, Y., Guo, J., & Kan, J. (2017). Zanthoxylum alkylamides ameliorate protein metabolism disorder in STZ-induced diabetic rats. *Journal of Molecular Endocrinology*, 58(3), 113. <https://doi.org/10.1530/JME-16-0218>
- Reshetnyak, V. I., & Maev, I. V. (2023). Pathophysiology of biochemical signs of primary biliary cholangitis. *Open Exploration*, 2(4), 149–171. <https://doi.org/10.37349/EDD.2023.00024>
- Reshmitha, T. R., & Nisha, P. (2021). Lycopene mitigates acrylamide and glycidamide induced cellular toxicity via oxidative stress modulation in HepG2 cells. *Journal of Functional Foods*, 80, 104390. <https://doi.org/10.1016/J.JFF.2021.104390>
- Rodrigues, R. M., Guan, Y., & Gao, B. (2021). Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player. *The Journal of Clinical Investigation*, 131(20), e153640. <https://doi.org/10.1172/JCI153640>
- Rueggsegger, G. N., Creo, A. L., Cortes, T. M., Dasari, S., & Nair, K. S. (2018). Altered mitochondrial function in insulin-deficient and insulin-resistant states. *The Journal of Clinical Investigation*, 128(9), 3671–3681. <https://doi.org/10.1172/JCI120843>
- Sangüesa, G., Montañés, J. C., Baena, M., Sánchez, R. M., Roglans, N., Alegret, M., & Laguna, J. C. (2019). Chronic fructose intake does not induce liver steatosis and inflammation in female Sprague–Dawley rats, but causes hypertriglyceridemia related to decreased VLDL receptor expression. *European Journal of Nutrition*, 58(3), 1283–1297. <https://doi.org/10.1007/S00394-018-1654-9/FIGURES/7>
- Satapathy, S. K., Bernstein, D. E., & Roth, N. C. (2022). Liver transplantation in patients with non-alcoholic steatohepatitis and alcohol-related liver disease: the dust is yet to settle. *Translational Gastroenterology and Hepatology*, 7. <https://doi.org/10.21037/TGH-2020-15/COIF>
- Skenderian, S., Park, G., & Jang, C. (2020). Organismal Fructose Metabolism in Health and Non-Alcoholic Fatty Liver Disease. *Biology*, 9(11), 405. <https://doi.org/10.3390/BIOLOGY9110405>
- Smirne, C., Croce, E., Di Benedetto, D., Cantaluppi, V., Comi, C., Sainaghi, P. P., Minisini, R., Grossini, E., & Pirisi, M. (2022). Oxidative Stress in Non-Alcoholic Fatty Liver Disease. *Livers*, 2(1), 30–76. <https://doi.org/10.3390/LIVERS2010003>

- Softic, S., Meyer, J. G., Wang, G. X., Gupta, M. K., Batista, T. M., Lauritzen, H. P. M. M., Fujisaka, S., Serra, D., Herrero, L., Willoughby, J., Fitzgerald, K., Ilkayeva, O., Newgard, C. B., Gibson, B. W., Schilling, B., Cohen, D. E., & Kahn, C. R. (2019). Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins. *Cell Metabolism*, 30(4), 735-753. <https://doi.org/10.1016/J.CMET.2019.09.003>
- Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., & Ames, B. N. (1987). Bilirubin is an antioxidant of possible physiological importance. *Science*, 235(4792), 1043–1046. <https://doi.org/10.1126/SCIENCE.3029864>
- Sun, Y., Zhang, L., & Jiang, Z. (2024). The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism. *Basic & Clinical Pharmacology & Toxicology*, 134(3), 315–324. <https://doi.org/10.1111/BCPT.13971>
- Tappy, L. (2021). Metabolism of sugars: A window to the regulation of glucose and lipid homeostasis by splanchnic organs. *Clinical Nutrition*, 40(4), 1691–1698. <https://doi.org/10.1016/J.CLNU.2020.12.022>
- Thakur, S., Kumar, V., Das, R., Sharma, V., & Mehta, D. K. (2024). Biomarkers of Hepatic Toxicity: An Overview. *Current Therapeutic Research*, 100, 100737. <https://doi.org/10.1016/J.CURTHERES.2024.100737>
- Tillman, E. J., Morgan, D. A., Rahmouni, K., & Swoap, S. J. (2014). Three Months of High-Fructose Feeding Fails to Induce Excessive Weight Gain or Leptin Resistance in Mice. *PLOS ONE*, 9(9), e107206. <https://doi.org/10.1371/JOURNAL.PONE.0107206>
- Tkáč, I., Molčányiová, A., Javorský, M., & Kozárová, M. (2006). Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. *Pharmacological Research*, 53(3), 261–264. <https://doi.org/10.1016/J.PHRS.2005.12.002>
- Vanasco, A., & vanSonnenberg, E. (2023). Fibrates and Fibrate-induced Liver Injury in Primary Biliary Cholangitis. *Gene Expression*, 22(4), 321–328. <https://doi.org/10.14218/GE.2023.00015>
- Wadie, W., Mohamed, A. H., Masoud, M. A., Rizk, H. A., & Sayed, H. M. (2021). Protective impact of lycopene on ethinylestradiol-induced cholestasis in rats. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 394(3), 447–455. <https://doi.org/10.1007/S00210-020-01980-5/FIGURES/7>

- Wang, J., Geng, T., Zou, Q., Yang, N., Zhao, W., Li, Y., Tan, X., Yuan, T., Liu, X., & Liu, Z. (2020). Lycopene prevents lipid accumulation in hepatocytes by stimulating PPAR α and improving mitochondrial function. *Journal of Functional Foods*, *67*, 103857.
<https://doi.org/10.1016/J.JFF.2020.103857>
- Wang, X., Luo, J., Lu, Z., Fang, S., Sun, M., Luo, W., Shen, J., Liu, A., & Ye, H. (2023). Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design. *Frontiers in Pharmacology*, *14*, 1190458.
<https://doi.org/10.3389/FPHAR.2023.1190458/BIBTEX>
- Ye, X., Zhang, T., & Han, H. (2022). PPAR α : A potential therapeutic target of cholestasis. *Frontiers in Pharmacology*, *13*, 916866. <https://doi.org/10.3389/FPHAR.2022.916866/BIBTEX>
- Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology*, *77*(4), 1335.
<https://doi.org/10.1097/HEP.0000000000000004>
- Yu, L., Hua, Z., Luo, X., Zhao, T., & Liu, Y. (2022). Systematic interaction of plasma albumin with the efficacy of chemotherapeutic drugs. *Biochimica et Biophysica Acta - Reviews on Cancer*, *1877*(1), 188655. <https://doi.org/10.1016/j.bbcan.2021.188655>
- Yu, S., Li, C., Ji, G., & Zhang, L. (2021). The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease. *Frontiers in Pharmacology*, *12*, 783393.
<https://doi.org/10.3389/FPHAR.2021.783393/BIBTEX>
- Zeng, R. X., Xu, J. P., Zhang, Y. Z., Tan, J. W., Kong, Y. J., Zhang, M. Z., & Guo, L. H. (2024). Associations of total protein, albumin, and globulin with insulin resistance: an NHANES study. *Frontiers in Endocrinology*, *15*, 1393137.
<https://doi.org/10.3389/FENDO.2024.1393137/BIBTEX>
- Zhang, C., Li, L., Zhang, Y., & Zeng, C. (2020). Recent advances in fructose intake and risk of hyperuricemia. *Biomedicine & Pharmacotherapy*, *131*, 110795.
<https://doi.org/10.1016/J.BIOPHA.2020.110795>

- Zhang, D., Ma, Y., Liu, J., Wang, D., Geng, Z., Wen, D., Chen, H., Wang, H., Li, L., Zhu, X., Wang, X., Huang, M., Zou, C., Chen, Y., & Ma, L. (2023). Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice. *European Journal of Pharmacology*, *960*, 176159. <https://doi.org/10.1016/J.EJP HAR.2023.176159>
- Zhang, D., Wang, H., Liu, A., Wang, S., Xu, C., Lan, K., Xiang, W., Zhu, K., Xiao, Y., Fu, J., Jiang, R., Chen, W., & Ni, Y. (2023). The chronic consumption of dietary fructose promotes the gut Clostridium species imbalance and bile acid alterations in developing nonalcoholic fatty liver disease. *The Journal of Nutritional Biochemistry*, *121*, 109434. <https://doi.org/10.1016/J.JNUTBIO.2023.109434>
- Zhang, P., Sun, H., Cheng, X., Li, Y., Zhao, Y., Mei, W., Wei, X., Zhou, H., Du, Y., & Zeng, C. (2022). Dietary intake of fructose increases purine de novo synthesis: A crucial mechanism for hyperuricemia. *Frontiers in Nutrition*, *9*, 1045805. <https://doi.org/10.3389/FNUT.2022.1045805>
- Zhao, Y., Bao, R. K., Zhu, S. Y., Talukder, M., Cui, J. G., Zhang, H., Li, X. N., & Li, J. L. (2021). Lycopene prevents DEHP-induced hepatic oxidative stress damage by crosstalk between AHR–Nrf2 pathway. *Environmental Pollution*, *285*, 117080. <https://doi.org/10.1016/j.envpol.2021.117080>
- Zubrzycki, A., Wrońska, A., Kotulak-Chrząszcz, A., Wierzbicki, P. M., & Kmiec, Z. (2020). Fenofibrate impairs liver function and structure more pronounced in old than young rats. *Archives of Gerontology and Geriatrics*, *91*, 104244. <https://doi.org/10.1016/J.ARCHGER.2020.104244>

**CHAPTER SEVEN: CONCLUSIONS,
LIMITATIONS AND RECOMMENDATIONS
FOR FUTURE RESEARCH**

7.0 Introduction

This study evaluated whether orally administered lycopene could protect growing Wistar rats from metabolic derangements caused by dietary fructose, focusing specifically on its effects on:

- growth performance as determined by body mass and long bone indices and gastrointestinal macromorphometry.
- some haematology components, serum metabolic substrate, lipid profile and leptin concentration.
- kidney macro- and micro-morphometry and serum surrogate biomarkers of kidney health.
- liver macro- and micro-morphometry, liver lipid and epididymal (males) and visceral fat, hepatic oxidant and antioxidant status and serum biomarkers of liver health.

7.1 Summary of key findings, limitations, and recommendations

The 12-week chronic fructose consumption decreased total feed intake which (feed intake) was further reduced in rats supplemented with lycopene, but it increased the rats' fluid intake. Supplemental lycopene caused sex-specific effects on total calorie intake (TCI) by increasing TCI in females but decreasing it in males. Femora from male rats treated with fenofibrate were lighter compared to those of counterparts supplemented with low-dose lycopene, and their tibiae shorter compared to those fed the control diet and lycopene-supplemented counterparts. Supplemental lycopene resulted in longer tibiae compared to fenofibrate treated males and heavier femora in low dose-supplemented males compared to fenofibrate-treated counterparts. Furthermore, the medium and high dose supplemental lycopene resulted in heavier stomach masses, but low dose supplemental lycopene caused decrease intestinal mass. It can be inferred that supplemental lycopene may enhance bone growth and development, protect against diet-induced bone mass reduction, enhance gastric digestion and secretion but its low dose could negatively affect nutrient digestion and absorption in the small intestines of males. Therefore, lycopene can be used to fortify diets to support bone health and improve nutrient assimilation, especially in populations exposed to diet-induced bone loss and dietary nutrient imbalances. It is imperative, however, that further studies be conducted to clarify underlying mechanisms of the protective effects of lycopene on bone health and enhance gastric and small intestinal development. Despite its potential positive

effects on bone health and the small intestines and stomach, there is need to further explore its sex-specific effects, potential interactions with obesogenic diets and therapeutic agents including fenofibrate to optimise its utility.

Neither the 12-week fructose insult nor supplemental lycopene adversely affected haematocrit, haemoglobin, HbA1c, fasting blood glucose (FBG) and leptin concentrations and lipid profile of growing Wistar rats. However, fenofibrate produced distinct sex-specific effects on glucose metabolism and lipid profiles by increasing FBC concentrations in females and males and HbA1c in females only. Liu et al. (2011) reported that fenofibrate disrupts glucose metabolism, an observation that aligns with the current study. Importantly, in females, fenofibrate increased serum HDL concentrations, whose increased concentration positively impact cardiovascular health by mopping up cholesterol from the periphery to the liver where it is metabolised and excreted into bile (Perswani et al., 2024). Despite fenofibrate's potential cardiovascular benefits in females, its chronic use poses risks to glucose regulation in both sexes, highlighting the need for caution for long term use. It can be deduced from the study findings that in growing Wistar rats, both dietary fructose and dietary fortification with lycopene may have minimal adverse metabolic effects, if any, but use of fenofibrate can potentially benefit cardiovascular health in females by mediating increases in serum HDL concentration. However, its adverse effects on blood glucose homeostasis warrants caution. Future studies should focus on investigating the potential of lycopene to mitigate fenofibrate-induced metabolic disturbances, which could enhance its therapeutic and prophylactic applications.

Compared to control and lycopene-supplemented rats, fenofibrate-treated males had heavier relative kidney mass but had no effect of the females' kidney masses. Treatment regimens had no effect on serum KIM-1, NGAL, BUN, creatinine concentrations and the rats' BUN/creatinine ratio. Both dietary fructose and fenofibrate increased the urinary space area, enlarged the outer and epithelial areas of the distal convoluted tubule and reduced the inner area of the proximal convoluted tubule of males only indicating a sex-specific effect. In females, fenofibrate caused an enlargement of the inner, outer, and epithelial areas of the distal convoluted tubule. Supplemental lycopene mitigated the dietary fructose-induced changes, demonstrating its health benefits against high-fructose induced renal changes. It thus can be deduced that supplemental lycopene can potentially safeguard both function and structure from dietary fructose induced renal disturbances.

Although fenofibrate positively impacts the lipid profile in patients suffering with MASLD (Martin et al., 2022) and has cardiovascular protective effects in females (d'Emden et al., 2014), its chronic use must be with caution as it can induce adverse renal effects. To mitigate these risks, lycopene-rich foods such as tomatoes or dietary supplements may serve as a beneficial strategy to safeguard kidney health against fenofibrate- and diet-induced kidney alterations. Future studies should explore the molecular mechanism of lycopene's renoprotective effects, with particular focus on its mitigatory effects on increased renal urinary space enlargement and tubular changes. Optimal doses and durations of lycopene supplementation should also be evaluated to ensure its efficacy and safety as a dietary intervention for kidney health.

Regarding the current study's last objective, findings showed sex-specific metabolic responses to dietary fructose and the protective potential of lycopene. In male rats, dietary fructose caused an increase in serum concentrations of globulin, albumin, and total protein compared to the other treatment regimens, and resulted in higher serum uric acid concentration. Although it does not point to a specific condition, higher than normal blood protein concentration is indicative of chronic inflammation. Supplemental lycopene mitigated these alterations, underscoring its protective role. Fenofibrate-treated female and male rats exhibited increased serum ALP activity and hepatomegaly. Fenofibrate-induced hepatomegaly has been confirmed in previous studies (Oscarsson et al., 2018; Fan et al., 2024). Additionally, fructose-induced lipid accretion has been shown in previous research (Coronati et al., 2022). Lycopene, however, prevented fructose-induced liver mass enlargement and lipid accumulation. Notably, the high-dose supplemental lycopene significantly enhanced hepatic GPX-1 and CAT (antioxidant enzymes) activities in males, a further indication of its potential protective role via upregulation the activity of systemic antioxidant system. Additionally, the fructose-induced hepatic micro- and macro-vesicular steatosis in both sexes was attenuated by supplemental lycopene but, fenofibrate caused hepatocyte hypertrophy. These findings suggest that lycopene may be exploited to fortify diets to protect against fructose- and fenofibrate-induced liver disturbances. Future research should aim to clarify the underlying mechanism of lycopene's hepatoprotective effects, particularly its role in enhancing antioxidant defences and mitigating hepatic lipid accumulation. Molecular studies could provide deeper insights into the pathways through which lycopene prevents hepatic lipid accretion, attenuates steatosis, and counteracts oxidative stress. Further exploration of lycopene's

interactions with dietary fructose and fenofibrate across varying doses and durations will help establish its efficacy and safety in both dietary and therapeutic applications. The exclusion of a lycopene-only group from the study design restricted our ability to fully understand its broader health benefits. Future research should address this gap by incorporating a lycopene-only group to assess its protective effects across various organs and systems, contributing to its potential application for promoting overall health and wellness.

7.2 Overall conclusion

Findings from this study demonstrate that dietary fructose induced significant sex-specific metabolic and hepatic and renal macro-and micro-morphometrical changes. Supplemental lycopene effectively mitigated diet-induced hepatic lipid accumulation, and it enhanced the systematic antioxidant enzymes activity thus mitigating oxidative stress. Additionally, supplemental lycopene improved stomach and small intestine growth and development, which may contribute to more efficient nutrient digestion and absorption. It also supported long bone integrity in male rats, further underscoring its positive effects on the skeletal system. Based on these findings, supplemental lycopene demonstrates potential in mitigating high-fructose-induced metabolic disturbances in growing female and male Wistar rats, potentially contributing to sustained health advantages over time.

7.3 References

- Coronati, M., Baratta, F., Pastori, D., Ferro, D., Angelico, F., & Del Ben, M. (2022). Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. *Nutrients*, *14*(6), 1127. <https://doi.org/10.3390/NU14061127>
- d'Emden, M. C., Jenkins, A. J., Li, L., Zannino, D., Mann, K. P., Best, J. D., Stuckey, B. G. A., Park, K., Saltevo, J., & Keech, A. C. (2014). Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetologia*, *57*(11), 2296–2303. <https://doi.org/10.1007/S00125-014-3344-3/FIGURES/3>
- Fan, S., Gao, Y., Zhao, P., Xie, G., Zhou, Y., Yang, X., Li, X., Zhang, S., Gonzalez, F. J., Qu, A., Huang, M., & Bi, H. (2024). Fenofibrate-promoted hepatomegaly and liver regeneration are PPAR α -dependent and partially related to the YAP pathway. *Acta Pharmaceutica Sinica B*, *14*(7), 2992–3008. <https://doi.org/10.1016/J.APSB.2024.03.030>
- Liu, S. nan, Liu, Q., Li, L. yi, Huan, Y., Sun, S. juan, & Shen, Z. fang. (2011). Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: Is that a latent disadvantage? *Journal of Translational Medicine*, *9*(1), 1–11. <https://doi.org/10.1186/1479-5876-9-176/FIGURES/6>
- Martin, A., Lang, S., Goeser, T., Demir, M., Steffen, H. M., & Kasper, P. (2022). Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. *Current Atherosclerosis Reports*, *24*(7), 533–546. <https://doi.org/10.1007/S11883-022-01028-4/FIGURES/3>
- Oscarsson, J., Önnérhag, K., Risérus, U., Sundén, M., Johansson, L., Jansson, P. A., Moris, L., Nilsson, P. M., Eriksson, J. W., & Lind, L. (2018). Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. *Journal of Clinical Lipidology*, *12*(6), 1390–1403. <https://doi.org/10.1016/J.JACL.2018.08.003>
- Perswani, P., Ismail, S. M., Mumtaz, H., Uddin, N., Asfand, M., Khalil, A. B. Bin, Ijlal, A., Khan, S. E., Usman, M., Younas, H., & Rai, A. (2024). Rethinking HDL-C: An In-Depth Narrative

Review of Its Role in Cardiovascular Health. *Current Problems in Cardiology*, 49(2), 102152.
<https://doi.org/10.1016/J.CPCARDIOL.2023.102152>

APPENDICES

Appendix 1: Animal ethics approval certificate

ANIMALS RESEARCH ETHICS COMMITTEE (AREC)

STRICTLY CONFIDENTIAL

CLEARANCE CERTIFICATE NUMBER: 2022/03/02/C

APPLICANT: Mrs M Shafe

School: School of Physiology; Department: N/A; Location: WRAF

PROJECT TITLE: Lycopene: Protective Potential Against Diet-Induced Metabolic Derangements in Wistar Rats

Category: C; Species and Numbers involved: 48X 21 day old weaning pups, male, Wistar Rats and 48X 21 day old weaning pups, female, Wistar Rats

Approval is hereby given for the use of animals for the research project named above and described in the application reviewed by a quorate meeting of the AREC held on 29 Mar 2022. This approval remains valid until 8 May 2024 and is conditional to the following (if blank there are no special conditions):


Condition 1	Condition 2	Condition 3	Condition 4

All material changes to the approved research must be reported to the AREC before they are implemented. Failure to do so will invalidate this clearance certificate.

An annual progress report must be provided to the AREC.

The use of these animals is subject to AREC guidelines on the use and care of laboratory animals, is limited to the procedures described in the application and is subject to additional conditions listed below:

I, the Chair of the AREC (or my designated representative) am satisfied that the proposed research is ethical as judged by local law, international standards and University policy.

Signed: _____  _____ Date: 10/05/2022
(Chairperson of the AREC)

I am satisfied that the persons listed in this application are competent to perform the procedures described in the application, in the context of Section 23 (1) (c) of the veterinary and Para-veterinary Professions Act (19 of 1982).

Appendix 2: First amendment to ethics clearance

Please note that only type written applications will be accepted.

**UNIVERSITY OF THE WITWATERSRAND
ANIMAL ETHICS SCREENING COMMITTEE
MODIFICATIONS AND EXTENSIONS TO EXPERIMENTS**

- a. Name: Mercy Shafe (2404174)
 b. School and email address: School of Physiology. 2404174@students.wits.ac.za
 c. Experiment to be modified / extended **AESC NO**

Original AESC number	2022	03	02C
Other M&Es:	nil		

- d. Project Title: **Lycopene: Protective Potential Against Diet-Induced Metabolic Derangements in Wistar Rats.**

	No.	Species
e. Number and species of animals originally approved:	96	Wistar Rats (Female: 48, Male: 48)
f. Number of additional animals previously allocated on M&Es:	0	
g. Total number of animals allocated to the experiment to date:	10	
h. Number of animals used to date:	10	

- i. Specific modification / extension requested:

A new MSc Med student, Ms. Motlhale Gomotsegang (student no: 2643348; email address: 2643348@students.wits.ac.za) has registered with the School of Physiology, University of Witwatersrand, under the supervision of Prof. Eliton Chivandi (Wits) and Dr. Nontobeko Gumede (UL). Currently Ms. Gomotsegang is attached, as a co-worker, to aforementioned project. She has written and successfully presented her MSc. Medicine (Physiology) protocol with the study titled: **Effects of Lycopene on Bone, kidney, and Pancreatic Health of growing Wistar Rats fed an Obesogenic Diet.**

Ms. Gomotsegang Motlhale will conduct assays on the pancreata (fat content, lipid profile, histology, oxidant and antioxidant markers), kidneys (fat content, lipid profile, surrogate biomarkers, histology, oxidant and antioxidant markers) and bone (bone indices, bone breaking strength and histology) samples. Motlhale will also assay for serum surrogate markers (amylase and lipase) of pancreatic health and serum concentrations of hormones (osteocalcin, C-telopeptide of type I collagen and parathyroid hormone) that regulate bone health. Additionally, serum inflammatory and anti-oxidant biomarkers will also be analysed.

Motivation for modification / extension:

The animal study has just commenced and the tissues have not yet been collected. I am requesting your good office to allow Ms Motlhale Gomotsegang to use the stated tissues from the rats under my ethical clearance as this will be in conformity with the principle of the 3Rs and help reduce the number of animals (rats) by avoiding the need to repeat the study with new rats.

Date: 11/08/2022

Signature:



Recommendations

Addition of a co-worker and addition of tissue samples as stated above.

Condition: the co-worker requires to assist to the WRAF induction training.

Date: 12/08/2022

Signature: *FMichel*

Chairman, AESC

Appendix 3: Second amendment to ethics clearance

Please note that only type written applications will be accepted.

**UNIVERSITY OF THE WITWATERSRAND
ANIMAL ETHICS SCREENING COMMITTEE
MODIFICATIONS AND EXTENSIONS TO EXPERIMENTS**

- a. Name: Mercy Shafe (2404174)
 b. School and email address: School of Physiology. 2404174@students.wits.ac.za
 c. Experiment to be modified / extended AESC NO

Original AESC number	2022	03	02C
Other M&Es:	nil		

- d. Project Title: **Lycopene: Protective Potential Against Diet-Induced Metabolic Derangements in Wistar Rats.**

	No.	Species
e. Number and species of animals originally approved:	96	Wistar Rats (Female: 48, Male: 48)
f. Number of additional animals previously allocated on M&Es:	0	
g. Total number of animals allocated to the experiment to date:	75	
h. Number of animals used to date:	75	

- i. Specific modification / extension requested:

We request to add additional co-workers to the AREC approved research project titled “**Lycopene: Protective Potential Against Diet-Induced Metabolic Derangements in Wistar Rats.**” The approved Ethics clearance was given to Mrs. Mercy Shafe (Student number: 2404174; a current PhD student in the Wits School of Physiology; Animal ethical clearance certificate number 2022/03/02/C) under the supervision of Prof. Eliton Chivandi (Wits), Dr. Trevor Nyakudya (UP) and Dr. Nontobeko Gumede (UP). The animal study is currently ongoing. We request that Dr. Jaclyn Johnson and Olukemi Daramola of the Wits School of Anatomical Sciences be attached as co-workers to the aforementioned project. The requested additional co-workers and ourselves will evaluate the effect of lycopene on the hearts, testes, epididymides, ovaries and uteri in Wistar rats fed an obesogenic diet in order to optimize the utility of animal use in research and thus fulfill the requirements for the 3Rs. Histology, antioxidant and molecular assays will be measured on the said tissues in order to evaluate if lycopene protects the organs against potential high-fructose diet induced metabolic derangements and histological alterations.

Motivation for modification / extension:

The animal study is currently ongoing and the tissues have not yet been collected. I humbly request that the two be added as co-workers and collaborate with me and my supervisors and

AESC 2012 M&E

thereby following the principle of reduction by avoiding the need to repeat the study with new rats.

Date: 23/10/2022

Signature:



Addition of coworkers (Drs Johnson and Daramola - School of Anatomical Sciences).

Date: 14/12/2022

Signature: *F Michel*

Chairman, AESC

Appendix 4: Published review article (Chapter 2)

Review Article

Lycopene: A Potent Antioxidant with Multiple Health Benefits

Mercy Omoye Shafe ^{1,2}, Nontobeko Myllet Gumede,³ Trevor Tapiwa Nyakudya,³ and Eliton Chivandi¹

¹School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa

²Department of Human Physiology, Faculty of Basic Medical Sciences, College of Medicine and Allied Health Sciences, Bingham University, P.M.B. 005, New Karu, Nasarawa 961002, Nigeria

³Department of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa

Correspondence should be addressed to Mercy Omoye Shafe; 2404174@students.wits.ac.za

Received 27 December 2023; Revised 14 May 2024; Accepted 20 May 2024

Academic Editor: Toshikazu Suzuki

Copyright © 2024 Mercy Omoye Shafe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lycopene is a naturally occurring carotenoid predominantly found in tomatoes and tomato-based products. Like other phytochemicals, it exhibits health beneficial biological activities that can be exploited when it is used as a dietary supplement. *In vitro* and *in vivo*, lycopene has been demonstrated to mitigate oxidative stress-induced metabolic dysfunctions and diseases including inflammation, obesity, and diabetes mellitus. Lycopene has been shown to alleviate metabolic diseases that affect the bone, eye, kidney, liver, lungs, heart, and nervous system. This review presents the state of the art regarding lycopene's health benefits and its potential applications in health system delivery. Furthermore, lycopene's protective effects against toxins, safety in its use, and possible toxicity are explored.

1. Introduction

The use of medicinal plants has deep historical roots, ingrained in the traditional healing practices of diverse cultures worldwide [1]. Throughout centuries, indigenous communities and ancient civilizations have harnessed the therapeutic properties of plants, passing down invaluable knowledge through generations [2]. Ethnomedicine, a field dedicated to study traditional medicinal practices, has played a crucial role in documenting this wealth of wisdom. The effectiveness of ethnomedicinal plants in disease management is attributed to their constituent bioactive phytochemicals, such as carotenoids, which are known to have multiple health benefits [3]. Lycopene, a fat-soluble carotenoid, is one of the most abundant and important carotenoids [4]. It has potent antioxidant activity [5]. This carotenoid, a bioactive organic pigment, is found in pink grapefruit, papaya, guava, apricot, watermelon, and vegetables but is

highly concentrated in tomatoes and tomato-derived products [6]. It has been reported to be one of the strongest antioxidants among carotenoids [7]. As one of the most potent antioxidants, its capacity to neutralise singlet oxygen is double that of β -carotene, ten times greater than that of α -tocopherol, and one hundred and twenty-five times more effective than glutathione [5]. Lycopene, isolated from *Lycopersicon esculentum* (tomato) in 1903, was named after the fruit from which it was isolated [8]. More than 85% of the lycopene in the diet is derived from tomatoes and tomato-based products [8]. In addition to fruits and vegetables, lycopene is also found in some food ingredients, as shown in Table 1 [9, 10]. While overall tomatoes are a good source of lycopene, research has demonstrated that different tomato and other fruit varieties have different lycopene content [7]. In addition to varietal differences, the microenvironment in which the tomato and or other lycopene-containing fruit are grown, for example,

TABLE 1: Lycopene concentration in fresh fruits and processed food products.

Fruit/processed food product	Lycopene content (mg/100 g)
Apricot and fresh tomatoes	0.11–5.3
Carrot	0.65–0.78
Cooked tomatoes	3.70
Fresh tomatoes	0.72–4.2
Ketchup	9.90–13.44
Papaya	0.11–5.3
Pink grapefruit	0.35–3.36
Pink guava	5.23–5.5
Pumpkin	0.38–0.46
Rosehip	0.68–0.71
Sweet potato	0.02–0.11
Tomato paste	5.40–150
Tomato sauce	6.20
Watermelon	2.30–7.20

Source: [9, 10].

temperature, humidity, edaphic conditions, and fruit maturity status at harvest also influence lycopene content [11]. Where the soil microbiome has favourable microbes, a 36% increase in lycopene has been reported [11].

Several studies have investigated the potential of lycopene to mitigate risk factors for obesity, type 2 diabetes mellitus, and cardiovascular diseases, conditions characterised by dyslipidaemia, oxidative stress, and inflammation [12]. These studies have shown that lycopene improved outcomes of these metabolic diseases [13]. Lycopene, known for its antioxidant properties, has been found to reduce oxidative stress, a significant contributor to the development of metabolic diseases [14]. In addition, it has been shown to mitigate inflammation and dyslipidaemia, thereby reducing the risk of cardiovascular diseases and insulin resistance [15, 16]. Research suggests that regular consumption of lycopene as a dietary supplement can potentially remediate insensitivity to insulin, hypertension, and obesity-related metabolic complications [17, 18].

2. Lycopene: Biochemistry and Physical Properties

In nature, over 750 carotenoids have been identified [19]. About 40 to 50 are found in the human diet, and lycopene is the sixth most common carotene in food products [20, 21]. Two main categories of carotenoids exist: hydrocarbon carotenoids and xanthophylls. Hydrocarbon carotenoids such as α -, β -, and γ -carotene lycopene are made up of hydrogen and carbon, while xanthophylls, for example, lutein, β -cryptoxanthin, and zeaxanthin, contain oxygen along with carbon and hydrogen [4, 22]. Lycopene, as an aliphatic straight-chain hydrocarbon, contains two unconjugated double bonds and 11 conjugated bonds [23]. Its conjugated double bonds are subject to isomerization through heat, light, and chemical reactions [20]. Lycopene is found in *trans*- and *cis*-isomers, but the *cis*-isomers are better absorbed and have greater bioavailability than *trans*-lycopene [24, 25]. All-*trans*-, 5-*cis*-,

9-*cis*-, 13-*cis*-, and 15-*cis* are the most common forms of lycopene isomers, and the 5-*cis* isomer is the most stable isomer [26, 27]. The molecular structure and physical properties of lycopene are shown in Figure 1 [28] and Table 2, respectively [8, 29].

3. Lycopene: Absorption, Transportation, and Distribution

Following ingestion, lycopene released from the food matrix combines with micelles-containing bile salts, cholesterol, and fatty acids [30] and is then absorbed. Due to its hydrophobicity, the dissolution of lycopene within micelles in the small intestines facilitates its absorption [5] through the passive diffusion of lipids across the unstirred water layer in the enterocytes [31]. Inside the absorptive enterocyte, lycopene, together with free fatty acids, monoglycerides, and fat-soluble vitamins, is packaged into chylomicrons and released into the lymphatic system for transportation into the bloodstream and liver [23]. A fibre-rich diet has been proven to decrease the absorption of lycopene. Such fibrous diets also mediate the absorption of lycopene, resulting in over 40% reduction in plasma lycopene [32]. Several factors, among these, alcohol, smoking, gender, age, hormonal status, and other dietary elements, affect the absorption of lycopene [32]. As healthy individuals grow older, the bioavailability of lycopene tends to decrease, possibly due to age-related structural changes in the gastrointestinal tract that result in reduced absorptive efficiency [33]. Humans absorb about 10% to 30% of dietary lycopene; the rest is excreted through faeces [8, 33]. The lycopene in heated and processed tomato products is better absorbed compared to that from fresh, unprocessed tomatoes [20]. Thermal exposure during cooking and processing of lycopene-containing foods breaks the food matrix and converts the natural (all-*trans*) lycopene structure to its *cis* geometric isomer, which is 2.5 times better absorbed from the gastrointestinal tract [34, 35]. Following its absorption from the small intestines, lycopene is distributed to the various body tissues [33]. The assimilation of lycopene by the tissues from lipoproteins is mediated by certain membrane receptors known as scavenger receptor class B type 1 (SR-B1) and cluster of differentiation 36 (CD36) [4]. In humans, the concentration of lycopene in the testes is ten times greater than that found in other tissues [8]. This high concentration in the testes is followed by its concentration in the adrenal gland, liver, prostate, breast, pancreas, skin, colon, ovary, lung, stomach, kidney, adipose tissue, and cervix [8]. However, *cis*-lycopene is mainly distributed in the liver and adipose tissue [24]. Table 3 illustrates the concentration of lycopene in various human tissues [36, 37]. Lycopene, the primary carotenoid found in human plasma, exhibits a half-life of approximately 2 to 3 days. Its concentration in plasma and tissues ranges between 0.2–21.4 nmol/g and 0.15–21.36 nmol/g, respectively [8, 36]. In their study, Zaripheh et al. [38] reported that in rats, lycopene was most concentrated in the liver, adipose tissue, adrenal tissue, and spleen.




FIGURE 1: Molecular structure of lycopene.

TABLE 2: Physical properties of lycopene.

Property	Value/normal range
Boiling point	660.9°C at 760 mmHg
Crystal form	Long red needles separate from a mixture of carbon disulfide and ethanol
Density	0.889 gm/cm ³
Flash point	350.7°C
Main hazards	Combustible
Melting point	172–175°C
Molecular weight	536.85 Da
Powder form	Dark reddish-brown
Refractive index	1.531
Solubility	Soluble in chloroform, hexane, benzene, carbon disulfide, acetone, petroleum, tetrahydrofuran, carbon disulfide, ether, and oil; insoluble in water, ethanol, and methanol
Stability	Sensitive to light, oxygen, high temperature, acids, catalyst, and metal ions
Vapour pressure	1.33·10 ⁻¹⁶ mmHg (25°C)

Source: [8, 29].

TABLE 3: Lycopene concentration in some human tissues.

Tissue	Lycopene (nmol/g wet weight)
Adipose	0.2–1.3
Adrenal	1.9–21.6
Brainstem	Non detectable
Breast	0.8
Colon	0.3
Liver	1.3–5.7
Lung	0.2–0.6
Ovary	0.3
Prostate	0.8
Skin	0.4
Stomach	0.2
Testis	4.4–21.4

Source: [36, 37].

4. Lycopene Autoxidation

Known to be thermolabile, lycopene undergoes autoxidation when exposed to both light and oxygen [23]. The heat-, light-, and oxygen-induced lycopene degradation gives rise to acetone, methyl-heptenone, laevulinic aldehyde, and glyoxal, a colourless compound that produces a grass-like smell [23]. In addition to the attractive colour of the final lycopene degradation products, their biodegradation also affects their flavour and nutritive value [39].

5. Biological Activities of Lycopene

The meta-analyses and clinical trials of lycopene in human studies are shown in Table 4.

5.1. Antiobesity Effects. Obesity results from an excessive buildup of body fat. It has a detrimental effect on a person's metabolic health and overall well-being [66]. The development of obesity is influenced by a variety of factors with complicated origins that involve psychological, environmental, socioeconomic status, and biological components [67–69]. The risk of cardiovascular diseases, cancer, depression, dyslipidaemia, type 2 diabetes mellitus, non-alcoholic fatty liver diseases (NAFLD), and hypertension is heightened in obese individuals [70–73]. Obesity elevates the prevalence of oxidative stress by disrupting the balance between oxidants and antioxidant activity [74], which leads to the presence of “unpaired mitochondria” (individual mitochondria within a cell that have not fused or aligned with others to form interconnected networks) and an upsurge in reactive oxygen species [75]. Consequently, the normal functioning of the adipose tissue is disrupted, resulting in an increased production of adipocytokines and a reduction in adiponectin levels, which contribute to the occurrence of metabolic syndrome [76, 77]. Numerous studies have reported on the health beneficial antioxidant activity of lycopene. In male Wistar rats exposed to a high-fat diet for 12 weeks, supplementation with lycopene at 25 mg/kg body weight for a period of 4 weeks was shown to reduce plasma interleukin 6 (IL-6), tumour necrosis factor alpha (TNF- α), leptin, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and total cholesterol (TC), but it elevated plasma high-density lipoprotein (HDL) levels [78]. The supplemental lycopene also reduced malondialdehyde (MDA) concentration but increased hepatic superoxide dismutase (SOD) and catalase (CAT) activities in the liver tissue, demonstrating that it (lycopene) potentially is a potent antioxidant that decreases hepatic oxidative stress by increasing systemic antioxidant and enzyme activities [78]. Pre- and/or postweaning supplementing Sprague–Dawley rat pups whose dams were fed a high-fat diet with lycopene at 1% improved the offspring's brown adipose tissue (BAT) development, reduced accumulation of white adipose tissue (WAT), and enhanced serum antioxidant capacity and blood glucose homeostasis [79]. In mice fed a high-fat diet, lycopene was shown to improve glucose and lipid metabolism and decrease body weight gain by stimulating WAT browning and activating BAT through modulation of peroxisome proliferator-activated receptor gamma (PPARG) [24]. In another study, where lycopene was administered at 25 and 50 mg/kg body weight for 3 months to male Wistar rats, results showed increased HDL, improved antioxidant, and oxidant biomarkers, decreased triglycerides (TG), LDL, apolipoprotein-B (Apo-B), and β -hydroxybutyrate, but boosted hepatic PPARG levels [80]. Furthermore, tomato oleoresin, which contains 10 mg/kg body weight of lycopene, when orally administered to male Wistar rats for 6 weeks, mediated a significant increase in the expression of

TABLE 4: Meta-analyses and clinical trials of lycopene in human studies.

Biological effects	Mechanisms of action	References
Anticancer	Suppressed cell proliferation, induced cell cycle arrest, and increased apoptosis in breast cancer cell lines	[40]
	Decreased insulin-like growth factor-1 (IGF-1) and increased apoptosis in prostate cancer cell	[41]
Cardioprotection	Enhanced endothelial function and decreased triglyceride levels in patients with ischemic heart failure	[42]
	Increased flow-mediated dilation and total oxidative status decreased	[43]
	Increased HDL, paraoxonase-1 (PON-1), lecithin cholesterol acyltransferase (LCAT), decreased serum amyloid A (SAA), and cholesteryl ester transfer protein (CETP) activities	[44]
Antidiabetic	Reduced levels of fasting blood glucose in patients with type 2 diabetes mellitus Decreased glycated haemoglobin (HbA1c) levels and fasting blood glucose concentration	[45] [46]
Anti-inflammatory	Inhibited NF- κ B and c-Jun N-terminal kinase (JNK) activation. Suppressed the expression of COX-2, iNOS, TNF- α , IL-1 β , and IL-6	[47]
Antioxidant	Increased bone mineral density Increased SOD, GSH-px, and decreased MDA	[48] [49]
Sperm quality enhancement and fertility promotion	Decreased lipid peroxidation and fragmentation of sperm DNA	[50]
	Increased arachidonic acid to docosahexaenoic acid ratio	[51]
	Reduced oxidative stress and enhanced sperm quality	[52]
Hepatoprotection	Protection against steatosis and liver damage Regulated oxidative stress and liver enzyme levels in individuals with metabolic syndrome	[53] [54]
Antiobesity	Decreased body weight, BMI, waist circumference, total cholesterol, and increased HDL levels	[55]
Renoprotection	Elevated levels of serum lycopene reduce the risk of mortality in individuals with CKD	[56]
	Increased consumption of lycopene decreased the occurrence of CKD in women	[57]
Lung protection	Decreased airway neutrophil influx and decreased activity of neutrophil elastase in sputum	[58]
	Increased SOD and CAT and decreased MDA, TNF- α , IL-1 β , and IL-6 levels in chronic obstructive pulmonary disease (COPD)	[59]
Neuroprotection	Elevated serum levels of lycopene are associated with a decreased risk of Alzheimer's disease (AD) mortality in adults	[60]
	Enhanced cognitive function in middle age	[61]
Gastroprotection	Decreased bleeding index and reduction in the percentage of gingivitis	[62]
	Increased consumption of lycopene improved bowel function and helped prevent chronic constipation	[63]
Osteoprotection	Stimulated WNT/ β -catenin and ERK1/2 pathways, increased the expression of RUNX2, alkaline phosphatase, and COL1A, and decreased RANKL in Saos-2 cells	[64]
	Increased total antioxidant capacity, decreased lipid peroxidation, protein oxidation, and N-telopeptide of type 1 collagen	[65]

messenger RNA (mRNA) of adiponectin, forkhead box 01 (FoxO1), fatty acid translocase/cluster of differentiation 36 (FAT/CD36), and sirtuin 1 (SIRT1), but downregulated PPAR γ expression in the adipose tissue of obese rats [81].

5.2. Antioxidant Effects. Oxidative stress is recognised as a significant contributing factor to an increased risk of cancer, the onset and progression of various metabolic and chronic disorders [82]. The concept of oxygen radicals has been established for the past 50 years; however, its role in the advancement of diseases was discovered in the past two decades [83]. In several biological processes that are vital for life, free radicals play an important role, such as the destruction of intracellular bacteria by phagocytes such as macrophages and granulocytes [82]. Excessive production of reactive oxygen species (ROS) causes protein, deoxyribonucleic acid (DNA), and lipid damage [84]. Damage to these cellular molecules leads to tissue injury and interruption in vital cellular processes [85]. Consuming diets rich in antioxidants or supplementing with bioactive molecules such as vitamins, tannins, and carotenoids may offer protection against oxidative damage [86]. Carotenoids such as lycopene are potent antioxidants that inhibit or hinder the advancement of diverse disorders triggered by ROS [5]. Carotenoid antioxidant activity has been investigated in multilamellar liposomes by measuring the inhibition of the formation of thio-barbituric acid-reactive substances. Lycopene was shown to be the most potent antioxidant in the sequence: lycopene, γ -tocopherol, astaxanthin, canthaxanthin, α -carotene, β -carotene, bixin, zeaxanthin, lutein, α -tocopherol, glutathione, cryptoxanthin, crocin, and lipoic acid [8, 87]. Lycopene attenuates ROS effects through radical addition or adduct formation, electron transfer to the radical, and allylic hydrogen abstraction [6], and radical addition and allylic hydrogen abstraction contribute to its antioxidant effects [88]. Lycopene has been reported to enhance the status of enzymatic (catalase, superoxide dismutase, and peroxidase) and nonenzymatic antioxidants such as vitamins C and E from their radicals by increasing the cellular antioxidant defence system [33]. In addition, lycopene acts as an antioxidant in systems that produce singlet oxygen but behaves as a pro-oxidant in systems that create peroxide [89]. In low doses, it acts as an antioxidant, but at high doses, it acts as a pro-oxidant [90]. Factors such as lycopene concentration, tissue oxygen tension, and interaction with other antioxidants have been reported to influence the pro-oxidant potency of lycopene [6]. In situation where there is an imbalance between antioxidant defences and ROS production, such as during inflammation or exposure to environmental toxins [91], lycopene may switch from its antioxidant role to a pro-oxidant role [89]. Under these conditions, lycopene radicals may contribute to oxidative stress by reacting with cellular components and promoting further ROS generation [92]. Studies have suggested that under conditions of low oxygen levels, its antioxidant properties predominate [93, 94].

5.3. Hypocholesterolaemic Effects. An imbalance in the level of cholesterol in the body results in a lipid disorder known as hypercholesterolemia, a notable risk factor for atherosclerosis and related conditions such as coronary and cerebrovascular diseases [95, 96]. Several animal and human trials have investigated the association between lycopene and cholesterol. Male broiler chickens fed a standard grower diet supplemented with lycopene at 100 mg/kg body weight for 3 weeks had significantly reduced serum total cholesterol, triglyceride, very low-density lipoprotein, and increased high-density lipoprotein content compared to counterparts fed the control diet [97]. In apolipoprotein E knockout mice fed a high-fat diet and lycopene supplementation at 60 mg/kg body weight daily for 14 weeks, the administered lycopene significantly decreased both total cholesterol and triglycerides, beginning from the sixth week to the end of the experiment [98]. Similarly, male Wistar rats given a high-fat diet and 50 mg/kg body weight of lycopene daily for 3 months had significant reductions in plasma total cholesterol, triglycerides, and low-density lipoprotein levels but increased high-density lipoprotein cholesterol compared to the group given a high-cholesterol diet [99]. The reported cholesterol-lowering effects of lycopene are attributed to reduce cholesterol synthesis through the inhibition of the expression and activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and the modulation of LDL receptor activity [100]. The findings obtained from human studies have been inconsistent. In a systematic review and meta-analysis of 12 and 11 trial arms consisting of 781 and 854 participants, respectively, supplementation of lycopene significantly increased HDL-cholesterol levels when compared to the control group; however, no significant difference was observed in the triglyceride levels [101]. The conflicting findings observed from human studies could be attributed to the differences in the study design, characteristics of the populations under investigation, and the source and dose of lycopene utilised [16, 102].

5.4. Hepatoprotection. In a healthy human adult, the liver weighs approximately 1.5 kg and is the largest gland and visceral organ [103]. It plays a vital role in metabolic processes such as bile production, digestion, detoxification of xenobiotics, metabolism of lipids, proteins, carbohydrates, immune regulation, and storage of vitamins [104, 105]. Among the major causes of global mortality is liver disease [106]. Liver diseases may be caused by several factors, viral infections, ischemia, alcohol-induced damage, autoimmune diseases, and genetic defects such as alpha-1 antitrypsin deficiency, hereditary hemochromatosis, citrin deficiency, hereditary fructose intolerance, cystic fibrosis, cholesteryl ester storage disease, type IV glycogen storage disease, and Wilson disease [107–109]. Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease [110]. Globally, the prevalence of NAFLD is about 25%, in Africa, it is 13% while in Europe, the rate is 23% and the highest at 32% in the Middle East [111]. This disease is characterised by the accumulation of macrovesicular steatosis in $\geq 5\%$ of hepatocytes without secondary causes such as alcohol intake, drugs,

or liver diseases [111, 112]. Patients with type 2 diabetes, dyslipidaemia, and obesity are at increased risk of developing NAFLD [113]. Recent studies have shown that consumption of carotenoids such as lycopene can remarkably reduce the chances of developing liver diseases such as NAFLD [90]. In their study, Li et al. [114], using beta-carotene-15,15'-oxygenase and beta-carotene-9',10'-oxygenase double knockout mice, the oral administration of lycopene at 2.3 mg/g for 24 weeks resulted in significantly decreased severity of hepatic steatosis and triglyceride levels but significantly increased sirtuin 1 and fatty acid oxidation compared to control counterparts fed a high-fat diet. Furthermore, lycopene mediated a decrease in inflammation. In a tramadol-induced hepatotoxicity rat model, supplemental lycopene at 15 mg/kg body weight for 15 days mitigated the hepatotoxicity by increasing antioxidant activity, reducing fatty acid breakdown and necrosis, lipid peroxidation, inhibiting DNA fragmentation, and apoptosis [115]. Lycopene administered at 5, 10, and 20 mg/kg body weight for 6 weeks in a rat model of NAFLD was shown to mediate hepatoprotective effects, as seen with reduced activities of aspartate transaminase and alanine transaminase and concomitant reductions in malondialdehyde, free fatty acids, and LDL-cholesterol concentrations [116]. These findings were associated with elevated hepatic superoxide dismutase and glutathione concentrations, but with reduced cytochrome P450 2E1 and tumour necrosis factor-alpha expression and decreased hepatic fat [116]. The abovementioned experimental studies provide a clear insight that the administration of lycopene not only inhibits ROS but also improves the activity of antioxidant enzymes, thereby providing beneficial effects against NAFLD.

5.5. Renoprotection. Chronic kidney diseases (CKD) have become a global public health issue, affecting more than 200 million people worldwide [117]. Chronic kidney disease is a common term used to describe different disorders that permanently affect the structure and function of the kidneys for over a period of 3 months [118]. This can be diagnosed when the abnormalities in the kidney or glomerular filtration rate are lower than 60 ml/min/1.73 m² and albuminuria is characterised by an albumin to creatinine ratio above 30 mg/g [119]. Patients with CKD are more prone to develop end-stage renal disease, a condition that requires expensive management by either dialysis or kidney transplantation [76]. Patients suffering from CKD commonly display a high incidence of arrhythmias, venous thromboembolism, heart failure, and ischemic heart disease, which significantly increases mortality [120, 121]. The increase in the prevalence of cardiovascular disease (CVD) in CKD patients is associated with oxidative stress, chronic inflammation, and vascular endothelial dysfunction [122]. These three factors create an intricate cycle, resulting in pathological variations and playing a crucial role in the initiation and progression of CVD in CKD patients [123, 124]. Among these factors, oxidative stress is a key mediator in the intricate pathways linked to the progression of CKD [124]. As a result, the utilisation of antioxidant therapy is one of the significant

approaches to avert and mitigate the advancement of CKD [56]. Lycopene is a potent antioxidant and an efficient free radical scavenger that has been investigated and shown to protect the kidney against chemically induced damage [125, 126]. In female Wistar rats fed a high-fat diet, the supplementation of 200 ml of lycopene extract twice a week for 8 weeks significantly reduced plasma creatinine, urea, serum angiotensin-converting enzymes, renal tissue malondialdehyde, and C-reactive protein levels but increased total protein and tissue antioxidant enzyme levels [127]. Tabrez et al. [128] observed that lycopene protected against the advancement of diabetic nephropathy and improved renal function by inhibiting the advanced glycation product and its receptors' (AGE-RAGE) pathway. Lycopene has shown to inhibit LDL-cholesterol peroxidation, which can damage the kidneys [56]. Furthermore, supplemental lycopene has shown to decrease MDA, RAGE, and TNF- α levels in the kidneys of male Wistar rats fed a high-fat diet for 6 weeks [129], and similarly, lycopene orally administered at 25 and 50 mg/kg body weight daily for 3 months protected the kidneys of male Wistar rats fed a high-fat diet by inhibiting the expression of nuclear factor kappa-B, interleukin 1 beta, tumour necrosis factor alpha, decreasing oxidative stress, increasing nuclear factor erythroid 2-related factor 2, and stimulating B-cell lymphoma 2, hence shielding the kidney tissue against damages [66].

5.6. Osteoprotection. Oxidative stress caused by reactive oxygen species influences the activity of both osteoclasts and osteoblasts [130]. This is thought to impact the pathogenesis of skeletal system disorders, including osteoporosis, the most common skeletal metabolic disease [131]. Osteoporosis often develops in older adults and is characterised by an alteration of the bone microarchitecture, typified by a decline in bone mineral density, which contributes to an elevated risk of fractures [132]. Such bone fractures notably occur at the distal forearm, vertebral column, and proximal femur [133]. Complications associated with osteoporosis, particularly hip fractures, result in a mortality rate that is 4 times higher in the global adult population [132]. Despite its preponderance in the elderly, osteoporosis has shown to impact individuals of various age groups, but postmenopausal women are at high risk [134, 135] due to a decrease in estrogen production which results in increased oxidative stress and osteoclast-induced bone resorption [136]. Studies have shown that children born to parents with a history of osteoporosis and fractures are more prone to the development of osteoporosis [137]. In addition to genetic predisposition, poor nutrition, excessive alcohol consumption, smoking, caffeine intake, and medication side effects, for example, glucocorticoids, can cause the development of osteoporosis [138–141]. Lycopene has shown to have an advantageous effect on the skeletal health [142]. It has shown to play a vital role in protecting postmenopausal women from experiencing bone loss by upregulating alkaline phosphatase, type 1A collagen, runt-related transcription factor 2, triggering the activation of the wingless-related integration site/beta-catenin and extracellular signal-regulated kinase 1/2 pathways, and downregulating receptor activator

of nuclear factor kappa-B ligand [143]. In mice fed a high-fat diet, supplemental lycopene at 15 mg/kg body weight for 10 weeks increased serum levels of total antioxidant capacity (T-AOC), SOD, and reduced the levels of MDA and AGEs, RAGE, and NF- κ B expressions in the tibias and femurs [144]. In male albino rats, orally administered lycopene at 30 mg/kg body weight once daily over an 8-week period mitigated glucocorticoid-induced osteoporosis [145], and in diabetic male rats, lycopene suppressed bone resorption, enhanced osteoprotegerin and RANKL expression ratios by preventing oxidative damage and reducing inflammation [146]. These research findings demonstrate that lycopene has osteoprotective properties.

5.7. Anti-Inflammatory Effects. Inflammation is an immune response mechanism that is triggered when exposed to various harmful stimuli, such as damaged cells, microorganisms, poisonous, and allergenic substances [147]. It serves as a crucial stage in the process of tissue regeneration, repair, and remodelling, as well as the restoration of tissue haemostasis in impaired areas [148]. Inflammatory mediators include the cytokines interleukin (IL)-1, IL-5, IL-6, IL-12, IL-1 β , TNF- α , and interferon γ [149], and chemokines such as IL-8, monocyte chemoattractant protein 1, cyclooxygenase, vascular cell adhesion molecule 1, matrix metalloproteinase, free radicals, growth factors, and prostaglandins serve as regulatory mediators in the process of inflammation [150]. On stimulation, these mediators activate endothelial cells, causing increased vascular permeability and the deployment of neutrophils, eosinophils, monocytes, and mast cells to the injury site, which helps eliminate the harmful agents and facilitate the healing process [151]. However, inflammation is known to contribute to the development and progression of various diseases, including but not limited to CKD, cancer, diabetes mellitus, cardiovascular disease, NAFLD, obesity, asthma, rheumatoid arthritis, osteoporosis, autoimmune, and neurodegenerative disorders [152–154]. The consumption of natural antioxidants for maintaining human health has become popular, especially in developed nations [155]. In a study using female Wistar rats, lycopene was shown to alleviate palmitic acid-induced neuroinflammation by reducing oxidative stress and inhibiting the toll-like receptor 4 (TLR4) and nuclear factor kappa-B p65 (NF- κ B p65) signalling pathways [156]. Lycopene supplementation mitigated metalaxyl-induced liver damage in male albino rats by restoring antioxidant status, improving liver function, and alleviating liver injury-associated complications [157]. In lycopene-treated endothelial cells, lycopene inhibited the activation of TNF- α but enhanced the expression of heme oxygenase-1 (HO-1) through the upregulation of nuclear factor erythroid 2-related factor 2 signalling pathways [158]. Another experimental study reported that in male albino rats, orally administered lycopene at 10 mg/kg body weight for 21 days effectively protected the colon epithelial mucosa against acetic acid-induced colitis and oxidative injury [159]. In C57BL/6 mice chronically exposed to cigarette smoke for 60 days, lycopene has shown to restore redox status and

mitigate hepatic inflammation [160]. In addition, Li et al. [161] reported that lycopene mitigated the dysregulation of lipid metabolism and the inflammatory response induced by lipopolysaccharide in the rat testes. Thus, evidence is plentiful demonstrating the anti-inflammatory effects of lycopene both *in vitro* and *in vivo*.

5.8. Antidiabetic Effects. Diabetes mellitus (DM) causes hyperglycaemia and, if inadequately managed, can result in damage to the heart, eyes, and kidneys [162]. The global prevalence of diabetes is approximately 9.3%, which corresponds to about 463 million individuals. However, it is predicted to rise by 25% in 2030 and 51% in 2045 [163]. Diabetes mellitus is classified into three major types: type 1 (insulin-dependent), type 2 (noninsulin-dependent), and gestational diabetes mellitus [164]. Among these, type 2 diabetes mellitus predominates and accounts for about 90% in all cases worldwide [162].

Scientific evidence shows that lycopene can potentially be used to prevent and treat diabetes mellitus [24]. In streptozotocin-induced diabetes model, dietary fortification with lycopene mediated increased serum insulin concentrations, decreased urine and blood sugar concentrations, and reduced diabetes-induced pancreatic injury [165]. In diabetic Wistar rats, orally administered lycopene at 40 mg/kg body weight significantly decreased serum MDA, cortisol, and blood glucose concentration but increased SOD, CAT, and glutathione peroxidase (GSH-Px) activities at 10, 20, and 40 mg/kg body weight [166]. Furthermore, supplemental lycopene has shown to attenuate renal damage in diabetic rats [167]. In STZ-induced diabetic rats, at 4 mg/kg body weight, lycopene ameliorated B-cell lymphoma-extra-large, and B-cell lymphoma 2 (Bcl-2) concentrations and reduce the expression of Bcl-2-associated X-protein (BAX) in the hippocampus [168]. Interestingly, orally administered lycopene has shown to increase SOD and GSH-Px activities and lower MDA concentrations in rat pancreatic tissue [169], but it mediated increased plasma insulin concentrations and reduced blood and liver lipid content, fasting blood glucose and glycosylated haemoglobin concentration, and homeostatic model assessment for insulin resistance in diabetic rats [169].

5.9. Anticancer Effects. Cancer is a major global health challenge and is the second primary reason for mortality in the United States [170]. The ingestion of tomatoes and tomato-based products has been associated with a reduced occurrence of different types of cancer [171]. *In vivo* and *in vitro* research has demonstrated that lycopene hinders the growth and multiplication of prostate cancer cells, inhibits the cell cycle, and induces apoptosis [172]. Dietary supplementation with lycopene mitigated the growth of breast cancer cells by suppressing the activity of the insulin-like growth factor 1 receptor (IGF-1R) signalling pathway [151]. While research shows that the consumption of a lycopene-rich diet could be beneficial in reducing the risk of pancreatic cancer [131]. In a rat model, the consumption of lycopene has shown to reduce the progression and proliferation of

ovarian cancer [173], and in human studies, cisplatin-based chemotherapy in combination with lycopene supplementation enhanced cervical cancer treatment [174]. Furthermore, in animal models of hepatocellular carcinoma, administered lycopene suppressed the onset and development of cancer [175]. In human colorectal adenocarcinoma cell line, treatment with lycopene has shown to exhibit genotoxicity, antiproliferative, and apoptotic effects [176], a demonstration of its anticancer effects.

5.10. Gastroprotection. The incidence of peptic ulcer disease (PUD) has substantially increased, affecting approximately 5 to 10 percent of the general population [177]. The corrosive effects of acid and pepsin on the gastroduodenal mucosa cause peptic ulceration through exposure of the mucosa's lining to gastric acid and digestive enzyme actions [178]. Peptic ulcer disease is primarily caused by the extensive use of nonsteroidal anti-inflammatory drugs (NSAIDs) and *Helicobacter pylori* infection [179]. Other contributing factors include surgery, severe illness, burns, Zollinger–Ellison syndrome, excessive alcohol intake, smoking, and psychological and physical stress [180–182]. The excessive production of ROS is the major factor in stress-induced ulcers [183]. Thus, the utilisation of strong antioxidants may be beneficial in the management of ulcers [184]. In male Albino rats, lycopene administered at 200 mg/kg body weight for 10 days has shown to protect against ethanol-induced mucosal injury [185]. In their study, Chen et al. [186] found that supplemental lycopene at 10, 50, 100, and 150 mg/kg body weight reduced gastric juice secretion in adult male Kunming mice when compared to the gastric injury control group. However, at high doses (150 mg/kg body weight), lycopene exacerbated absolute ethanol-induced acute gastric mucosal injury. In addition to mediating for protection against alcohol-induced gastrointestinal tract mucosal injury, lycopene has shown to suppress gastric acid secretion and combat infection by *Helicobacter pylori* [130].

5.11. Neuroprotection. Neurodegenerative diseases (NDs) are characterised by gradual loss of neurons and are associated with the formation of protein aggregates [187]. These diseases are considered a major medical challenge as it affects millions of patients globally [188]. Alzheimer's, Parkinson's, Huntington's, prion and motor-neural diseases, amyotrophic lateral sclerosis, spinocerebellar ataxia, and spinal muscular atrophy are common NDs [187, 189, 190]. Despite age being the leading factor in the onset of all neurodegenerative disorders, recent discoveries indicate that the combination of a person's genetic makeup and environmental influences can contribute to an elevated risk of developing NDs [191]. Regardless of the various factors causing these NDs, a key feature common to all is the onset and development of neuronal cell death [192]. The progression of NDs is characterised by increased ROS production, which causes oxidative stress [193]. Administered lycopene has shown to attenuate memory loss due to age, cognitive impairments, neuronal damage, and synaptic dysfunctions in the brain [194]. In addition, lycopene was

observed to mitigate age-related oxidative stress by suppressing lipid peroxidation and enhancing GSH, SOD, and CAT activities [194]. Dietary fortification with lycopene was demonstrated to decrease age-related neuroinflammation by attenuating microgliosis and combating inflammation [194]. Furthermore, lycopene mediated the reduction in the accumulation of amyloid beta 1–42 in the brains of aged CD-1 mice [194] and when used as a supplement, it upregulated the mitogen-activated protein kinase (MARK)/extracellular signal-regulated kinase (ERK) signalling pathway, inhibited oxidative stress and neuronal apoptosis, and protected against bisphenol-induced neurotoxicity in the hippocampi of adult male rats [195]. It has also shown to decrease palmitic acid-induced brain oxidative stress and neuroinflammation and to inhibit the toll-like receptor 4 (TLR4)/nuclear factor kappa-light chain enhancer of activated B cells p65 (NF- κ B-p65) pathway in female rats [156]. In mice with Alzheimer's disease induced by β amyloid, lycopene reduced oxidative stress, decreased neuronal loss, improved synaptic plasticity, and inhibited neuroinflammation [196].

5.12. Cardioprotection. Globally, cardiovascular diseases (CVDs) stand at the forefront as the leading cause of human mortality [16]. Studies have shown that in 2019, CVDs caused 17.8 million fatalities, and this trend is projected to increase by 2030 to 23 million [197]. Several epidemiological studies have confirmed the significance of lycopene in preventing CVDs [198]. For instance, lycopene supplementation has shown to reduce C-reactive protein levels, interleukin-6, pulse wave velocity, blood pressure, and intercellular adhesion molecule 1 and enhance vascular health through flow-mediated dilation of the endothelium [199]. Lycopene supplementation at a dosage of 5 mg/kg body weight for 21 days has shown to confer protection against atrazine-induced cardiotoxicity in mice [200]. In Brown–Norway/Lewis rat model, lycopene treatment was demonstrated to have the potential to mitigate vascular arteriosclerosis in allograft transplantation by inhibiting Rho-associated kinases and by regulating the expression of nitric oxide/cyclic guanosine monophosphate signalling pathways [201], which indicates that lycopene has the potential to alleviate vascular arteriosclerosis. In another study, lycopene administered for 4 weeks at 10 mg/kg body weight reduced inflammation and apoptosis during postmyocardial infarction remodelling by suppressing the NF- κ B signalling pathway in mice [202]. In addition, supplemental lycopene improves endothelial function in individuals suffering from CVDs [203].

5.13. Lung Protection. In male C57BL/6 mice, dietary lycopene supplementation at 25 or 50 mg/kg body weight mitigated cigarette smoke-induced pulmonary emphysema [204]. The literature shows that lycopene or matrine treatment alone offered minimal protection against lipopolysaccharide-induced acute lung injury in mice, but when coadministered, significant mitigatory effects were observed [205]. These results indicate that lycopene and matrine in combination may function as an alternative to

glucocorticoid therapy in treating acute lung injury [205]. In a study conducted by Mustra Rakic et al. [206], supplemental lycopene at 90 mg/kg body weight for 22 weeks effectively suppressed tobacco carcinogen/cigarette smoke (NNK/CS)-induced emphysema, chronic bronchitis, and preneoplastic lesions. Furthermore, dietary lycopene significantly decreased NNK/CS-induced buildup of total cholesterol and upregulated mRNA expression of peroxisome proliferator-activated receptor alpha (PPAR α), ATP-binding cassette (ABC) transporters ABCA1 and ABCG1, and liver X receptor alpha (LXR α) in the lungs of the ferret model. These findings suggest that lycopene could act as a preventative agent against the adverse effects of tobacco smoke on lung health and lipid metabolism.

5.14. Sperm Quality Enhancement and Fertility Promotion.

Infertility is a prevalent health problem that affects roughly 48 million couples and 186 million individuals globally [207]. ROS-induced oxidative stress is a primary contributor to various reproductive complications [208]. In varicocele-induced rats, supplemental lycopene has shown to protect sperm against DNA damage by mediating upregulation of antioxidant responses that quenched ROS, which manifested with improved sperm viability, Johnson's score, membrane integrity, and the expression of B-cell lymphoma 2-associated X-protein (BAX) [209]. Similarly, in men with oligozoospermia, supplemental lycopene for 12 weeks at 25 mg/kg body weight attenuated oxidative stress and improved sperm quality [52]. In their study, Yamamoto et al. [210] observed that the consumption of tomato juice with 30 mg of lycopene for a duration of 12 weeks increased plasma lycopene concentration and sperm motility and decreased the white blood cell count in the seminal plasma of the tomato juice group compared to the control group of infertile men. Dietary supplementation with lycopene at 20 mg per day for 3 months prior to the scheduled *in vitro* fertilization (IVF) treatment increased the arachidonic acid to docosahexaenoic acid ratio in the seminal fluid and resulted in 7 natural pregnancies in addition to 15 pregnancies following the IVF procedure [51]. In methotrexate-induced ovarian damage, pretreatment with lycopene at 5 mg/kg body weight for 5 days prevented infertility and has shown to mediate increased GSH activity as well as decreased MDA and myeloperoxidase concentrations [211]. These findings suggest that lycopene alleviates imbalances in polyunsaturated fatty acids and can serve as a preventive agent against infertility.

5.15. *Protection of Skin Health.* The skin, constituting approximately 15% of the total body weight [20], plays a vital role in preventing excessive water loss from the body and maintaining the body temperature within an optimal range [212]. It provides protection against toxic substances, free radicals, physical damage, and ultraviolet radiation [213]. The latter causes the development of skin conditions and diseases through sunburn, photoaging, and excessive ROS production within the skin, which damages DNA and causes skin cancer [213–215]. Lycopene is extensively used as an

ingredient in cosmetic products due to its demonstrated ability to protect the skin from aging and photodamage [215]. Anbualakan et al. [216] showed that lycopene can prevent and/or treat sunburn and photoaging and that it could potentially be effective against UV-induced skin cancers. As a dietary supplement, lycopene has been demonstrated to improve skin appearance and pigmentation and mitigate erythema [217].

5.16. *Protective Effect on Vision.* Age-related ophthalmic conditions, inclusive of macular degeneration, glaucoma, cataracts, and diabetic retinopathy, are key contributors to gradual and permanent vision loss [218]. In diabetic patients, serum lycopene concentration has been observed to be lower than normal [114]. Importantly, due to its consistent lower levels in diabetics, it has been suggested that serum lycopene concentration might serve as a diagnostic tool for diabetic retinopathy [114]. Using ARPE-19 cells derived from human retinal pigment epithelium, Gong et al. [219] demonstrated that lycopene suppressed growth of human RPE cells against oxidative stress-induced cell loss findings which suggests that it (lycopene) may protect against RPE proliferative disease and old-age related macular degeneration. Oxidative stress and inflammation have been shown to be associated with the pathogenesis of eye-related conditions [220]. As a dietary supplement, lycopene has been proven to mitigate the risk of developing eye diseases associated with old age [221]. This could be due to its demonstrated ability to prevent cataract formation both *in vitro* and *in vivo* [131].

6. Lycopene: Protective Effects against Toxins

Toxins are natural and harmful chemical substances that adversely impact health [222]. They cause specific organ toxicity, for example, skin, eye, kidney, liver, blood, cardiovascular, respiratory, reproductive, endocrine, immune, and nervous system damage [222, 223]. Through their actions, toxins disrupt homeostasis, alter gene expression, and cancer-related metabolic signalling pathways [224]. Research has demonstrated that lycopene as a dietary supplement effectively mitigates the deleterious effects of myco-, bacterial, and chemical toxins [225] [125, 226, 227], fungicides [228], pesticides [229], herbicides [230], and fluoride [231]. It is hypothesised that lycopene mediates protection against toxins through its potent antioxidant, chelating, and antiapoptotic properties [224].

7. Lycopene: Safety and Potential Toxicity

There is no specified daily prescription for dietary lycopene intake, but epidemiological studies have recommended an intake of 2 to 20 mg daily of lycopene [93]. It has shown that consumption of up to 100 mg of lycopene daily does not elicit adverse outcomes [5]. In a toxicological study conducted on rats, feeding a diet fortified with lycopene at 1% (w/w) did not elicit any side effects [232]. Similarly, using lycopene at 200 mg/kg body weight per day as a dietary supplement has also been shown not to negatively impact animals [233]. Generally, it is asserted that lycopene can be

used as a safe dietary supplement during pregnancy and lactation [234]. Although in pregnant women, high dietary intake of lycopene has shown to mitigate the risk of developing preeclampsia [235]. Imran et al. [7] reported that excessive chronic consumption of tomato juice, a rich source of lycopene, caused lycopenemia. Findings from both animal and human studies suggest that although lycopene could generally be used as a safe dietary supplement, some caution must be exercised against excessive intake.

8. Conclusion

The extensive studies carried out on lycopene highlight its exceptional potential to promote overall health and well-being. Its varied spectrum of benefits places it as a potent natural compound which can contribute to the promotion of health either as a prophylactic or ore therapeutic agent against metabolic diseases. In order to fully exploit its potential and increase its utility in health delivery, it is crucial to undertake additional research to comprehensively elucidate the health beneficial mechanisms underlying lycopene's medicinal properties. Furthermore, in order to enjoy optimal utility from the use of lycopene, there is a need to evaluate and recommend effective dosages for efficacy and prevention of possible side effects of abnormally high doses.

Data Availability

The data that support this systematic review come from studies and datasets that were previously reported and cited in this article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was funded by the Faculty Research Committee grant, Faculty of Health Sciences, University of the Witwatersrand, South Africa.

References

- [1] B. B. Petrovska, "Historical review of medicinal plants' usage," *Pharmacognosy Reviews*, vol. 6, no. 11, p. 1, 2012.
- [2] B. A. Rasool Hassan, "Medicinal plants (importance and uses)," *Pharmaceutica Analytica Acta*, vol. 03, no. 10, 2012.
- [3] S. Upadhyay and M. Dixit, "Role of polyphenols and other phytochemicals on molecular signaling," *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 504253, 15 pages, 2015.
- [4] J. Arballo, J. Amengual, and J. W. Erdman, "Lycopene: a critical review of digestion, absorption, metabolism, and excretion," *Antioxidants*, vol. 10, no. 3, pp. 342–416, 2021.
- [5] S. Przybylska, "Lycopene – a bioactive carotenoid offering multiple health benefits: a review," *International Journal of Food Science and Technology*, vol. 55, no. 1, pp. 11–32, 2020.
- [6] M. N. Bin-Jumah, M. S. Nadeem, S. J. Gilani et al., "Lycopene: a natural arsenal in the war against oxidative stress and cardiovascular diseases," *Antioxidants*, vol. 11, no. 2, p. 232, 2022.
- [7] M. Imran, F. Ghorat, I. Ul-haq et al., "Lycopene as a natural antioxidant used to prevent human health disorders," *Antioxidants*, vol. 9, no. 8, pp. 706–727, 2020.
- [8] B. Joshi, S. K. Kar, P. K. Yadav, S. Yadav, L. Shrestha, and T. K. Bera, "Therapeutic and medicinal uses of lycopene: a systematic review," *International Journal of Research in Medical Sciences*, vol. 8, no. 3, p. 1195, 2020.
- [9] P. M. Bramley, "Is lycopene beneficial to human health?" *Phytochemistry*, vol. 54, no. 3, pp. 233–236, 2000.
- [10] J. Shi and M. L. Maguer, "Lycopene in tomatoes: chemical and physical properties affected by food processing," *Critical Reviews in Food Science and Nutrition*, vol. 40, no. 1, pp. 1–42, 2000.
- [11] M. Grabowska, D. Wawrzyniak, K. Rolle et al., "Let food be your medicine: nutraceutical properties of lycopene," *Food and Function*, vol. 10, no. 6, pp. 3090–3102, 2019.
- [12] I. Świątkiewicz, M. Wróblewski, J. Nuzkiewicz, P. Sutkowy, J. Wróblewska, and A. Woźniak, "The role of oxidative stress enhanced by adiposity in cardiometabolic diseases," *International Journal of Molecular Sciences*, vol. 24, no. 7, p. 6382, 2023.
- [13] M. H. Abir, A. G. M. S. U. Mahamud, S. H. Tonny et al., "Pharmacological potentials of lycopene against aging and aging-related disorders: a review," *Food Science and Nutrition*, vol. 11, no. 10, pp. 5701–5735, 2023.
- [14] W. Guo, D. Huang, and S. Li, "Lycopene alleviates oxidative stress-induced cell injury in human vascular endothelial cells by encouraging the SIRT1/Nrf2/HO-1 pathway," *Clinical and Experimental Hypertension*, vol. 45, no. 1, Article ID 2205051, 2023.
- [15] B. T. Rane, P. S. Worlikar, S. A. Mulkalwar, A. V. Tilak, and S. A. Dabhade, "Evaluation of the effect of lycopene on lipid profile, serum antioxidant enzymes and blood sugar level in New Zealand white rabbits," *International Journal of Basic and Clinical Pharmacology*, vol. 8, no. 3, pp. 431–437, 2019.
- [16] A. C. Tierney, C. E. Rumble, L. M. Billings, and E. S. George, "Effect of dietary and supplemental lycopene on cardiovascular risk factors: a systematic review and meta-analysis," *Advances in Nutrition*, vol. 11, no. 6, pp. 1453–1488, 2020.
- [17] L. Mounien, F. Tourniaire, and J. F. Landrier, "Anti-obesity effect of carotenoids: direct impact on adipose tissue and adipose tissue-driven indirect effects," *Nutrients*, vol. 11, no. 7, p. 1562, 2019.
- [18] L. Rejali, S. Ozumerzifon, H. Nayeri, and S. Asgary, "Risk reduction and prevention of cardiovascular diseases: biological mechanisms of lycopene," *Bioactive Compounds in Health and Disease*, vol. 5, no. 10, pp. 202–221, 2022.
- [19] R. Arunkumar, A. Gorusupudi, and P. S. Bernstein, "The macular carotenoids: a biochemical overview," *Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids*, vol. 1865, no. 11, Article ID 158617, 2020.
- [20] L. M. Doyle, "Lycopene: implications for human health—A review," *Advances in Food Technology and Nutritional Sciences- Open Journal*, vol. 6, no. 1, pp. 1–12, 2020.
- [21] A. J. Meléndez-Martínez, "An overview of carotenoids, apocarotenoids, and vitamin A in agro-food, nutrition, health, and disease," *Molecular Nutrition and Food Research*, vol. 63, no. 15, Article ID e1801045, 2019.
- [22] N. P. Holzapfel, B. M. Holzapfel, S. Champ, J. Feldthusen, J. Clements, and D. W. Huttmacher, "The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence,"

- International Journal of Molecular Sciences*, vol. 14, no. 7, pp. 14620–14646, 2013.
- [23] V. Naveen Kumar P, P. Elango, S. Asmathulla, and S. Kavimani, “A systematic review on lycopene and its beneficial effects,” *Biomedical and Pharmacology Journal*, vol. 10, no. 4, pp. 2113–2120, 2017.
- [24] R. Zhu, B. Chen, Y. Bai et al., “Lycopene in protection against obesity and diabetes: a mechanistic review,” *Pharmacological Research*, vol. 159, Article ID 104966, 2020.
- [25] M. Caseiro, A. Ascenso, A. Costa, J. Creagh-Flynn, M. Johnson, and S. Simões, “Lycopene in human health,” *Lebensmittel-Wissenschaft und-Technologie*, vol. 127, Article ID 109323, 2020.
- [26] A. V. Rao and L. G. Rao, “Carotenoids and human health,” *Pharmacological Research*, vol. 55, no. 3, pp. 207–216, 2007.
- [27] M. Honda, T. Kudo, T. Kuwa et al., “Isolation and spectral characterization of thermally generated multi-Z-isomers of lycopene and the theoretically preferred pathway to di-Z-isomers,” *Bioscience Biotechnology and Biochemistry*, vol. 81, no. 2, pp. 365–371, 2017.
- [28] M. Gupta, M. Panizai, M. F. Tareen, S. Ortega-Martinez, N. Doreulee, and M. Andrew, “An overview on novel antioxidant and anti-cancer properties of lycopene: a comprehensive review,” *GMJ Medicine*, vol. 2, no. 1, pp. 45–50, 2018.
- [29] M. Amjad, S. Hussain, and A. Rehman Khan, “Development and validation of HPLC assay of lycopene in different matrices,” *World Journal of Applied Chemistry*, vol. 5, no. 2, p. 26, 2020.
- [30] E. N. Story, R. E. Kopec, S. J. Schwartz, and G. K. Harris, “An update on the health effects of tomato lycopene,” *Annual Review of Food Science and Technology*, vol. 1, no. 1, pp. 189–210, 2010.
- [31] Y. Y. Yeap, N. L. Trevasakis, and C. J. H. Porter, “Lipid absorption triggers drug supersaturation at the intestinal unstirred water layer and promotes drug absorption from mixed micelles,” *Pharmaceutical Research*, vol. 30, no. 12, pp. 3045–3058, 2013.
- [32] M. L. Failla, C. Chitchumroonchokchai, and B. K. Ishida, “In vitro micellarization and intestinal cell uptake of cis isomers of lycopene exceed those of all-trans lycopene,” *The Journal of Nutrition*, vol. 138, no. 3, pp. 482–486, 2008.
- [33] A. Agarwal, D. Durairajanayagam, C. Ong, and P. Prashast, “Lycopene and male infertility,” *Asian Journal of Andrology*, vol. 16, no. 3, pp. 420–425, 2014.
- [34] K. Chauhan, S. Sharma, N. Agarwal, and B. Chauhan, “Lycopene of tomato fame: its role in health and disease,” *International Journal of Pharmaceutical Sciences Review and Research*, vol. 10, no. 1, 2011.
- [35] I. M. Petyaev, “Carotenoids in thermal adaptation of plants and animals,” *Carotenoids- New Perspectives and Application*, 2022.
- [36] A. V. Rao and S. Agarwal, “Role of antioxidant lycopene in cancer and heart disease,” *Journal of the American College of Nutrition*, vol. 19, no. 5, pp. 563–569, 2000.
- [37] G. Kaur, A. Sandal, and N. S. Dhillon, “Lycopene and human health-A review,” *Agricultural Reviews*, vol. 38, no. 04, pp. 282–289, 2017.
- [38] S. Zaripheh, M. A. Lila, J. W. Erdman, and T. W. M. Boileau, “[14C]-lycopene and [14C]-labeled polar products are differentially distributed in tissues of F344 rats prefed lycopene,” *The Journal of Nutrition*, vol. 133, no. 12, pp. 4189–4195, 2003.
- [39] M. Tahmasebi and Z. Emam-Djomeh, “Lycopene degradation and color characteristics of fresh and processed tomatoes under the different drying methods: a comparative study,” *Chemical Papers*, vol. 75, no. 7, pp. 3617–3623, 2021.
- [40] N. F. Gloria, N. Soares, C. Brand, F. L. Oliveira, R. Borojevic, and A. J. Teodoro, “Lycopene and Beta-carotene induce cell-cycle arrest and apoptosis in Human breast cancer cell lines,” *Anticancer Research*, vol. 34, no. 3, pp. 1377–1386, 2014.
- [41] Tjahjodjati, S. Sugandi, R. Umbas, and M. Satari, “The protective effect of lycopene on prostate growth inhibitory efficacy by decreasing insulin growth factor-1 in Indonesian human prostate cancer cells,” *Research and Reports in Urology*, vol. 12, pp. 137–143, 2020.
- [42] B. Karimian, A. Soleimani, G. Mohammadsharifi et al., “Effect of lycopene supplementation on some cardiovascular risk factors and markers of endothelial function in Iranian patients with ischemic heart failure: a randomized clinical trial,” *Cardiology Research and Practice*, vol. 2022, Article ID 2610145, 7 pages, 2022.
- [43] P. Xaplanteris, C. Vlachopoulos, P. Pietri et al., “Tomato paste supplementation improves endothelial dynamics and reduces plasma total oxidative status in healthy subjects,” *Nutrition Research*, vol. 32, no. 5, pp. 390–394, 2012.
- [44] J. McEneny, S. L. Henry, J. Woodside et al., “Lycopene-rich diets modulate HDL functionality and associated inflammatory markers without affecting lipoprotein size and distribution in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial,” *Frontiers in Nutrition*, vol. 9, Article ID 954593, 2022.
- [45] T. Inoue, K. Yoshida, E. Sasaki, K. Aizawa, and H. Kamioka, “Effect of lycopene intake on the fasting blood glucose level: a systematic review with meta-analysis,” *Nutrients*, vol. 15, no. 1, p. 122, 2022.
- [46] H. E. Leh, M. Mohd Sopian, M. H. Abu Bakar, and L. K. Lee, “The role of lycopene for the amelioration of glycaemic status and peripheral antioxidant capacity among the Type II diabetes mellitus patients: a case-control study,” *Annals of Medicine*, vol. 53, no. 1, pp. 1060–1066, 2021.
- [47] J. H. Cha, W. K. Kim, A. W. Ha, M. H. Kim, and M. J. Chang, “Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells,” *Nutrition Research and Practice*, vol. 11, no. 2, p. 90, 2017.
- [48] S. Sahni, M. T. Hannan, J. Blumberg, L. A. Cupples, D. P. Kiel, and K. L. Tucker, “Inverse association of carotenoid intakes with 4-y change in bone mineral density in elderly men and women: the Framingham Osteoporosis Study,” *The American Journal of Clinical Nutrition*, vol. 89, no. 1, pp. 416–424, 2009.
- [49] X. Xu, Y. Zheng, H. Ye, and L. Jin, “Lycopene supplementation decreases oxidative stress in hemodialysis patients receiving intravenous iron therapy: an open-label, randomized controlled clinical trial,” *European Journal of Inflammation*, vol. 17, Article ID 205873921882286, 2019.
- [50] T. Ghyasvand, M. T. Goodarzi, I. Amiri, J. Karimi, and M. Ghorbani, “Serum levels of lycopene, beta-carotene, and retinol and their correlation with sperm DNA damage in normospermic and infertile men,” *International Journal of Reproductive Biomedicine*, vol. 13, no. 12, pp. 787–792, 2015.
- [51] R. Filipcikova, I. Oborna, J. Brezinova et al., “Lycopene improves the distorted ratio between AA/DHA in the seminal plasma of infertile males and increases the likelihood of successful pregnancy,” *Biomedical Papers*, vol. 159, no. 1, pp. 077–082, 2015.

- [52] M. Nouri, R. Amani, M. Nasr-Esfahani, and M. J. Tarrahi, "The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: a randomized, double-blind, placebo-controlled clinical trial," *Phytotherapy Research*, vol. 33, no. 12, pp. 3203–3211, 2019.
- [53] R. Donghia, A. Campanella, C. Bonfiglio, F. Cuccaro, R. Tatoli, and G. Giannelli, "Protective role of lycopene in subjects with liver disease: NUTRIHEP study," *Nutrients*, vol. 16, no. 4, p. 562, 2024.
- [54] M. Mirahmadi, M. Aghasizadeh, F. Nazifkar et al., "The effects of lycopene on modulating oxidative stress and liver enzymes levels in metabolic syndrome patients: a randomized clinical trial," *Cell Journal (Yakhteh)*, vol. 25, no. 12, pp. 847–853, 2023.
- [55] N. Yao, S. Yan, Y. Guo et al., "The association between carotenoids and subjects with overweight or obesity: a systematic review and meta-analysis," *Food and Function*, vol. 12, no. 11, pp. 4768–4782, 2021.
- [56] Q. Zhong, Y. Piao, S. Yin, and K. Zhang, "Association of serum lycopene concentrations with all-cause and cardiovascular mortality among individuals with chronic kidney disease: a cohort study," *Frontiers in Nutrition*, vol. 9, pp. 1048884–1048911, 2022.
- [57] Y. Shi, Y. Xu, and W. Zhou, "Dietary carotenoids intake and sex differences in relation to chronic kidney disease a cross-sectional assessment in the NHANES study," *BMC Public Health*, vol. 24, no. 1, pp. 293–299, 2024.
- [58] L. G. Wood, M. L. Garg, H. Powell, and P. G. Gibson, "Lycopene-rich treatments modify noneosinophilic airway inflammation in asthma: proof of concept," *Free Radical Research*, vol. 42, no. 1, pp. 94–102, 2008.
- [59] G. Kırkıl, M. H. Muz, E. Sancaktar, D. Kaman, K. Ahin, and Ö. Küçük, "The effect of lycopene supplementation on chronic obstructive lung disease," *Nobel Medical*, vol. 8, no. 3, pp. 98–104, 2012.
- [60] J. Y. Min and K. B. Min, "Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults," *Dementia and Geriatric Cognitive Disorders*, vol. 37, no. 3–4, pp. 246–256, 2014.
- [61] E. Kesse-Guyot, V. A. Andreeva, V. Ducros et al., "Carotenoid-rich dietary patterns during midlife and subsequent cognitive function," *British Journal of Nutrition*, vol. 111, no. 5, pp. 915–923, 2014.
- [62] R. V. Chandra, M. L. V. Prabhuj, D. A. Roopa, S. Ravirajan, and H. C. Kishore, "Efficacy of lycopene in the treatment of gingivitis: a randomised, placebo-controlled clinical trial," *Oral Health and Preventive Dentistry*, vol. 5, no. 4, pp. 327–336, 2007.
- [63] J. Wang, W. Kong, M. Liu, Y. Wang, Y. Zheng, and Y. Zhou, "Association between dietary carotenoids intake and chronic constipation in American men and women adults: a cross-sectional study," *BMC Public Health*, vol. 23, no. 1, pp. 1597–1614, 2023.
- [64] C. Russo, Y. Ferro, S. Maurotti et al., "Lycopene and bone: an in vitro investigation and a pilot prospective clinical study," *Journal of Translational Medicine*, vol. 18, no. 1, p. 43, 2020.
- [65] E. S. MacKinnon, A. V. Rao, R. G. Josse, and L. G. Rao, "Supplementation with the antioxidant lycopene significantly decreases oxidative stress parameters and the bone resorption marker N-telopeptide of type I collagen in postmenopausal women," *Osteoporosis International*, vol. 22, no. 4, pp. 1091–1101, 2011.
- [66] T. Albrahim and A. A. Robert, "Lycopene effects on metabolic syndrome and kidney injury in rats fed a high-fat diet: an experimental study," *ACS Omega*, vol. 7, no. 35, pp. 30930–30938, 2022.
- [67] I. Sommer, U. Griebler, P. Mählknecht et al., "Socioeconomic inequalities in non-communicable diseases and their risk factors: an overview of systematic reviews," *BMC Public Health*, vol. 15, pp. 914–1012, 2015.
- [68] P. W. Franks and M. McCarthy, "Posing the exposures responsible for type 2 diabetes and obesity," *Science*, vol. 6308, no. 354, pp. 69–73, 2016.
- [69] S. Z. Gebreab, C. L. Vandeleur, D. Rudaz et al., "Psychosocial stress over the lifespan, psychological factors, and cardiometabolic risk in the community," *Psychosomatic Medicine*, vol. 80, no. 7, pp. 628–639, 2018.
- [70] A. Brahimaj, F. Rivadeneira, T. Muka et al., "Novel metabolic indices and incident type 2 diabetes among women and men: the Rotterdam Study," *Diabetologia*, vol. 62, no. 9, pp. 1581–1590, 2019.
- [71] C. J. Lavie, S. A. Lear, and C. E. Ndumele, "Obesity and cardiovascular disease," *AHA Journals*, vol. 143, no. 21, 2021.
- [72] E. Lazarus and H. E. Bays, "Cancer and obesity: an obesity medicine association (OMA) clinical practice statement (CPS) 2022," *Obesity Pillars*, vol. 3, Article ID 100026, 2022.
- [73] H. B. Overby and J. F. Ferguson, *Hypertension*, vol. 23, no. 2, 2022.
- [74] P. M. Masschelin, A. R. Cox, N. Chernis, and S. M. Hartig, "The impact of oxidative stress on adipose tissue energy balance," *Frontiers in Physiology*, vol. 10, pp. 1638–8, 2019.
- [75] I. Pérez-Torres, V. Castrejón-Téllez, M. E. Soto, M. E. Rubio-Ruiz, L. Manzano-Pech, and V. Guarner-Lans, "Oxidative stress, plant natural antioxidants, and obesity," *International Journal of Molecular Sciences*, vol. 22, no. 4, p. 1786, 2021.
- [76] M. Hasan, I. Sutradhar, R. D. Gupta, and M. Sarker, "Prevalence of chronic kidney disease in South Asia: a systematic review," *BMC Nephrology*, vol. 19, pp. 291–312, 2018.
- [77] R. Naomi, S. H. Teoh, H. Embong et al., "The role of oxidative stress and inflammation in obesity and its impact on cognitive impairments—a narrative review," *Antioxidants*, vol. 12, no. 5, p. 1071, 2023.
- [78] L. Baz, S. Algarni, M. Al-thepyani, A. Aldairi, and H. Gashlan, "Lycopene improves metabolic disorders and liver injury induced by a high-fat diet in obese rats," *Molecules*, vol. 27, no. 22, pp. 7736–7816, 2022.
- [79] K. E. Senkus, Y. Zhang, H. Wang, L. Tan, and K. M. Crowe-white, "Lycopene supplementation of maternal and weaning high-fat diets influences adipose tissue development and metabolic outcomes of Sprague-Dawley offspring," *Journal of nutritional science*, vol. 10, pp. e96–e10, 2021.
- [80] T. Albrahim and M. A. Alonazi, "Lycopene corrects metabolic syndrome and liver injury induced by high fat diet in obese rats through antioxidant, anti-inflammatory, anti-fibrotic pathways," *Biomedicine and Pharmacotherapy*, vol. 141, Article ID 111831, 2021.
- [81] R. A. M. Luvizotto, A. F. Nascimento, N. C. M. Miranda, X. D. Wang, and A. Ferreira, "Lycopene-rich tomato oleoresin modulates plasma adiponectin concentration and mRNA levels of adiponectin, SIRT1, and FoxO1 in adipose tissue of obese rats," *Human and Experimental Toxicology*, vol. 34, no. 6, pp. 612–619, 2015.
- [82] M. Sharifi-Rad, N. V. Anil Kumar, P. Zucca et al., "Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases," *Frontiers in Physiology*, vol. 11, pp. 694–721, 2020.

- [83] Z. Q. Liu, "Bridging free radical chemistry with drug discovery: a promising way for finding novel drugs efficiently," *European Journal of Medicinal Chemistry*, vol. 189, Article ID 112020, 2020.
- [84] C. A. Juan, J. M. Pérez de la Lastra, F. J. Plou, E. Pérez-Lebeña, and S. Reinbothe, "The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies," *International Journal of Molecular Sciences*, vol. 22, no. 9, p. 4642, 2021.
- [85] T. R. Kiran, O. Otlu, and A. B. Karabulut, "Oxidative stress and antioxidants in health and disease," *Journal of Laboratory Medicine*, vol. 47, no. 1, pp. 1–11, 2023.
- [86] Y. Gu, A. Singh, S. Bose, and N. Singh, "Pathogenic mutations in the glycosylphosphatidylinositol signal peptide of PrP modulate its topology in neuroblastoma cells," *Molecular and Cellular Neuroscience*, vol. 37, no. 4, pp. 647–656, 2008.
- [87] H. E. Leh and L. K. Lee, "Lycopene: a potent antioxidant for the amelioration of type II diabetes mellitus," *Molecules*, vol. 27, no. 7, p. 2335, 2022.
- [88] N. Francenia Santos-Sánchez, R. Salas-Coronado, C. Villanueva-Cañongo et al., "Antioxidant compounds and their antioxidant mechanism," *Antioxidants*, 2019.
- [89] H. S. Black, F. Boehm, R. Edge, and T. G. Truscott, "The benefits and risks of certain dietary carotenoids that exhibit both anti- and pro-oxidative mechanisms—a comprehensive review," *Antioxidants*, vol. 9, no. 3, p. 264, 2020.
- [90] L. I. Elvira-Torales, J. García-Alonso, and M. J. Periago-Castón, "Nutritional importance of carotenoids and their effect on liver health: a review," *Antioxidants*, vol. 8, no. 7, p. 229, 2019.
- [91] B. Poljšak and R. Fink, "The protective role of antioxidants in the defence against ROS/RNS-Mediated environmental pollution," *Oxidative Medicine and Cellular Longevity*, vol. 2014, Article ID 671539, 22 pages, 2014.
- [92] M. Lucas, M. Freitas, F. Carvalho, E. Fernandes, and D. Ribeiro, "Antioxidant and pro-oxidant activities of carotenoids," *Plant Antioxidants and Health*, pp. 123–148, 2022.
- [93] R. K. Saini, K. R. R. Rengasamy, F. M. Mahomoodally, and Y. S. Keum, "Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: an update on epidemiological and mechanistic perspectives," *Pharmacological Research*, vol. 155, Article ID 104730, 2020.
- [94] E. L. P. Varela, A. R. Q. Gomes, A. da Silva Barbosa dos Santos, E. P. de Carvalho, V. V. Vale, and S. Percário, "Potential benefits of lycopene consumption: rationale for using it as an adjuvant treatment for malaria patients and in several diseases," *Nutrients*, vol. 14, no. 24, p. 5303, 2022.
- [95] S. S. Gidding and N. B. Allen, "Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem," *Journal of the American Heart Association*, vol. 8, no. 11, pp. 0129244–e12933, 2019.
- [96] M. Vaduganathan, G. A. Mensah, J. V. Turco, V. Fuster, and G. A. Roth, "The global burden of cardiovascular diseases and risk," *Journal of the American College of Cardiology*, vol. 80, no. 25, pp. 2361–2371, 2022.
- [97] A. Mezbani, B. P. Kavan, A. Kiani, and B. Masouri, "Effect of dietary lycopene supplementation on growth performance, blood parameters and antioxidant enzymes status in broiler chickens," *Livestock Research for Rural Development*, vol. 31, 2019, <https://www.lrrd.org/lrrd31/1/bahma31012.html>.
- [98] F. Mannino, G. Pallio, D. Altavilla et al., "Atherosclerosis plaque reduction by lycopene is mediated by increased energy expenditure through AMPK and PPAR α in ApoE KO mice fed with a high fat diet," *Biomolecules*, vol. 12, no. 7, p. 973, 2022.
- [99] T. Albrahim, "Lycopene modulates oxidative stress and inflammation in hypercholesterolemic rats," *Pharmaceuticals*, vol. 15, no. 11, p. 1420, 2022.
- [100] P. Palozza, A. Catalano, R. E. Simone, M. C. Mele, and A. Cittadini, "Effect of lycopene and tomato products on cholesterol metabolism," *Annals of Nutrition and Metabolism*, vol. 61, no. 2, pp. 126–134, 2012.
- [101] T. Inoue, K. Yoshida, E. Sasaki, K. Aizawa, and H. Kamioka, "Effects of lycopene intake on HDL-cholesterol and triglyceride levels: a systematic review with meta-analysis," *Journal of Food Science*, vol. 86, no. 8, pp. 3285–3302, 2021.
- [102] W. Rattanavipanon, C. Nithiphongwarakul, P. Sirisuwansith et al., "Effect of tomato, lycopene and related products on blood pressure: a systematic review and network meta-analysis," *Phytomedicine*, vol. 88, Article ID 153512, 2021.
- [103] D. Beyoğlu and J. R. Idle, "Metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy," *Metabolites*, vol. 10, no. 2, p. 50, 2020.
- [104] A. Kalra, E. Yetiskul, C. J. Wehrle, and F. Tuma, "Physiology, liver," *StatPearls*, 2022.
- [105] K. H. Mohammed, "Liver structure, function and its interrelationships with other organs: a review," *International Journal Dental and Medical Sciences Research*, vol. 4, no. 1, pp. 88–92, 2022.
- [106] W. K. Seto and M. S. Mandell, "Chronic liver disease: global perspectives and future challenges to delivering quality health care," *PLoS One*, vol. 16, no. 1, pp. e0243607–e0243612, 2021.
- [107] M. Scorza, A. Elce, F. Zarrilli, R. Liguori, F. Amato, and G. Castaldo, "Genetic diseases that predispose to early liver cirrhosis," *International Journal of Hepatology*, vol. 2014, pp. 1–11, 2014.
- [108] X. Kong, L. Xie, H. Zhu et al., "Genotypic and phenotypic spectra of hemojuvelin mutations in primary hemochromatosis patients: a systematic review," *Orphanet Journal of Rare Diseases*, vol. 14, no. 1, pp. 171–224, 2019.
- [109] M. Bouche-careilh, "Alpha-1 antitrypsin deficiency-mediated liver toxicity: why do some patients do poorly? what do we know so far? Chronic Obstructive Pulmonary," *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation*, vol. 7, no. 3, pp. 172–181, 2020.
- [110] S. Pouwels, N. Sakran, Y. Graham et al., "Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss," *BMC Endocrine Disorders*, vol. 22, no. 1, pp. 63–69, 2022.
- [111] J. Maurice and P. Manousou, "Non-alcoholic fatty liver disease," *Clinical Medicine*, vol. 18, no. 3, pp. 245–250, 2018.
- [112] J. Spiers, J. H. Brindley, W. Li, and W. Alazawi, "What's new in non-alcoholic fatty liver disease?" *Frontline Gastroenterology*, vol. 13, no. e1, pp. E102–E108, 2022.
- [113] S. K. Han, S. K. Baik, and M. Y. Kim, "Non-alcoholic fatty liver disease: definition and subtypes," *Clinical and Molecular Hepatology*, vol. 29, pp. 5–16, 2023.
- [114] Z. Z. Li, X. Z. Lu, C. C. Ma, and L. Chen, "Serum Lycopene Levels in Patients with Diabetic Retinopathy," *European Journal of Ophthalmology*, vol. 20, no. 4, pp. 719–723, 2018.
- [115] M. S. Kadry, A. L. Mohamed, K. A. Tarek, M. N. Sherif, and Y. El-Sayed, "The molecular and biochemical insight view of lycopene in ameliorating tramadol-induced liver toxicity

- in a rat model: implication of oxidative stress, apoptosis, and MAPK signaling pathways," *Environmental science and pollution research international*, vol. 25, no. 33, pp. 33119–33130, 2018.
- [116] W. Jiang, M. Guo, and X. Hai, "Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat," *World Journal of Gastroenterology*, vol. 22, no. 46, pp. 10180–10188, 2016.
- [117] P. Gori, A. Patel, N. Solanki et al., "Protective effects of lycopene against adenine-induced chronic renal failure in rats," *Indian Journal of Physiology and Pharmacology*, vol. 65, no. 2, pp. 74–85, 2021.
- [118] C. Santos-araujo, L. Mendonça, D. S. Carvalho et al., "Twenty years of real-world data to estimate chronic kidney disease prevalence and staging in an unselected population," *Clinical Kidney Journal*, vol. 16, no. 1, pp. 111–124, 2023.
- [119] J. Jankowski, J. Floege, D. Fliser, M. Böhm, and N. Marx, "Cardiovascular disease in chronic kidney disease pathophysiological insights and therapeutic options," *Circulation*, vol. 143, no. 11, pp. 1157–1172, 2021.
- [120] S. S. Virani, A. Alonso, E. J. Benjamin et al., "Heart disease and stroke statistics-2020 update: a report from the American heart association," *Circulation*, vol. 141, no. 9, pp. e139–e596, 2020.
- [121] H. Warrens, D. Banerjee, and C. A. Herzog, "Cardiovascular complications of chronic kidney disease: an introduction," *European cardiology*, vol. 17, p. 13, 2022.
- [122] V. Ravarotto, F. Simioni, E. Pagnin, P. A. Davis, and L. A. Calò, "Oxidative stress – chronic kidney disease–cardiovascular disease: a vicious circle," *Life Sciences*, vol. 210, pp. 125–131, 2018.
- [123] O. M. Akchurin and F. Kaskel, "Update on inflammation in chronic kidney disease," *Blood Purification*, vol. 39, no. 1-3, pp. 84–92, 2015.
- [124] S. F. Rapa, B. R. Di Iorio, P. Campiglia, A. Heidland, S. Marzocco, and S. Marzocco, "Inflammation and oxidative stress in chronic kidney disease— potential therapeutic role of minerals, vitamins and plant-derived metabolites," *International Journal of Molecular Sciences*, vol. 21, no. 1, p. 263, 2019.
- [125] D. R. S. G. El-karim, "Presumptive ameliorative effect of lycopene on lead-induced nephro- toxicity in males wistar rats received: accepted," *Journal of Advanced Veterinary Research*, vol. 9, no. 3, pp. 91–96, 2019.
- [126] F. Bedir, H. Kocaturk, O. Turangezli et al., "The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats," *Brazilian Journal of Medical and Biological Research*, vol. 54, pp. e10660–e10668, 2021.
- [127] N. I. Khan, S. Noori, and T. Mahboob, "Efficacy of lycopene on modulation of renal antioxidant enzymes, ACE and ACE gene expression in hyperlipidaemic rats," *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 17, no. 3, Article ID 147032031666461, 2016.
- [128] S. Tabrez, K. Z. Al-Shali, and S. Ahmad, "Lycopene powers the inhibition of glycation-induced diabetic nephropathy: a novel approach to halt the AGE-RAGE axis menace," *BioFactors*, vol. 41, no. 5, pp. 372–381, 2015.
- [129] D. T. Pierine, M. E. L. Navarro, I. O. Minatel et al., "Lycopene supplementation reduces TNF- α via RAGE in the kidney of obese rats," *Nutrition and Diabetes*, vol. 4, no. 11, pp. e142–e146, 2014.
- [130] M. Bacanlı, N. Başaran, and A. A. Başaran, "Lycopene: is it beneficial to human health as an antioxidant?" *Turkish Journal of Pharmaceutical Sciences*, vol. 14, no. 3, pp. 311–318, 2017.
- [131] N. Mehta, P. Patani, and I. Singhvi, "A review on tomato lycopene," *International Journal of Pharmaceutical Sciences and Research*, vol. 9, no. 3, pp. 916–923, 2018.
- [132] F. Y. Erdayanti, D. R. Atmaka, and M. Kagawa, "The potential of phytochemicals lycopene in prevention of bone loss due to decreased estrogen hormone in humans and experimental animals," *Media Gizi Indonesia*, vol. 17, no. 2, pp. 191–203, 2022.
- [133] J. A. Cauley, D. Chalhoub, A. M. Kassem, and G. E. Fuleihan, "Geographic and ethnic disparities in osteoporotic fractures," *Nature Reviews Endocrinology*, vol. 10, no. 6, pp. 338–351, 2014.
- [134] S. Rai, O. Shaki, T. P. Gupta, B. K. Chakrabarty, and R. S. Negi, "To study the awareness of osteoporosis in postmenopausal Indian women in a Northeast part of India: an evaluation of the Osteoporosis Health Belief Scale," *Journal of Family Medicine and Primary Care*, vol. 10, no. 5, p. 1950, 2021.
- [135] A. Bhatnagar and A. L. Kekatpure, "Postmenopausal osteoporosis: a literature review," *Cureus*, vol. 14, no. 9, Article ID e29367, 2022.
- [136] E. M. Shihab, M. G. Al-abbassi, D. Abd, A. Wahab, and I. T. Ahmad, "Role of estrogen in the oxidation process in postmenopausal osteoporosis," *Journal of Global Pharma Technology*, vol. 10, no. 8, pp. 80–85, 2018.
- [137] U. S. Walallawita, F. M. Wolber, A. Ziv-gal, M. C. Kruger, and J. A. Heyes, "Potential role of lycopene in the prevention of postmenopausal bone loss: evidence from molecular to clinical studies," *International Journal of Molecular Sciences*, vol. 21, no. 19, p. 7119, 2020.
- [138] K. N. Tu, J. D. Lie, C. K. V. Wan et al., "Osteoporosis: a review of treatment options," *P and T: A Peer-Reviewed Journal for Formulary Management*, vol. 43, no. 2, pp. 92–104, 2018.
- [139] J. Godos, F. Giampieri, E. Chisari et al., "Alcohol consumption, bone mineral density, and risk of osteoporotic fractures: a dose – response meta-analysis," *International Journal of Environmental Research and Public Health*, vol. 19, no. 3, Article ID 1515, 2022.
- [140] A. Muñoz-garach, B. García-Fontana, and M. Muñoz-Torres, "Nutrients and dietary patterns related to osteoporosis," *Nutrients*, vol. 12, no. 7, p. 1986, 2020.
- [141] G. Wang, Z. Fang, D. Liu, S. F. Chu, H. L. Li, and H. X. Zhao, "Association between caffeine intake and lumbar spine bone mineral density in adults aged 20– 49: a cross-sectional study," *Frontiers in Endocrinology*, vol. 13, pp. 1008275–1008278, 2022.
- [142] J. Xu, C. Song, X. Song, X. Zhang, and X. Li, "Carotenoids and risk of fracture: a meta-analysis of observational studies," *Oncotarget*, vol. 8, no. 2, pp. 2391–2399, 2017.
- [143] C. Russo, Y. Ferro, S. Maurotti et al., "Lycopene and bone: an in vitro investigation and a pilot prospective clinical study," *Journal of Translational Medicine*, vol. 18, pp. 43–11, 2020.
- [144] B. Xia, R. Zhu, H. Zhang et al., "Lycopene improves bone quality and regulates AGE/RAGE/NF- κ B signaling pathway in high-fat diet-induced obese mice," *Oxidative Medicine and Cellular Longevity*, vol. 2022, Article ID 3697067, 14 pages, 2022.
- [145] G. S. M. M. Sadika M Tawfik Md, E. F. Salah Md, N. A. El-bakery, and E. F. Salah, "Histological study of the possible protective effect of lycopene on glucocorticoid-induced osteoporosis in adult male albino rat," *The*

- Medical Journal of Cairo University*, vol. 87, no. 3, pp. 2121–2134, 2019.
- [146] S. S. Qi, M. L. Shao, Z. Sun et al., “Lycopene ameliorates diabetic osteoporosis via anti-inflammatory, anti-oxidation, and increasing Osteoprotegerin/RANKL expression ratio,” *Journal of Functional Foods*, vol. 83, Article ID 104539, 2021.
- [147] L. Chen, H. Deng, H. Cui et al., “Inflammatory responses and inflammation-associated diseases in organs,” *Oncotarget*, vol. 9, no. 6, pp. 7204–7218, 2018.
- [148] F. R. Greten, S. I. Grivennikov, E. Therapy, C. Program, and F. Chase, “Inflammation and cancer: triggers, mechanisms, and consequences,” *Immunity*, vol. 51, no. 1, pp. 27–41, 2019.
- [149] V. Molnar, V. Mاتیسی, I. Kodvanj et al., “Cytokines and chemokines involved in osteoarthritis pathogenesis c,” pp. 1–23, 2021.
- [150] J. V. Fernandes, R. N. O. Cobucci, C. A. N. Jatobá, T. A. A. de Medeiros Fernandes, J. W. V. de Azevedo, and J. M. G. de Araújo, “The role of the mediators of inflammation in cancer development,” *Pathology and Oncology Research*, vol. 21, no. 3, pp. 527–534, 2015.
- [151] U. M. Khan, M. Sevindik, A. Zarrabi et al., “Lycopene: food sources, biological activities, and human health benefits,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 2713511, 10 pages, 2021.
- [152] J. Zhong and G. Shi, “Editorial: regulation of inflammation in chronic disease,” *Frontiers in Immunology*, vol. 10, pp. 737–742, 2019.
- [153] C. Franceschi, L. Ferrucci, D. W. Gilroy, A. Fasano, and W. Gary, “Chronic inflammation in the etiology of disease across the life span,” *Nature Medicine*, vol. 25, no. 12, pp. 1822–1832, 2020.
- [154] R. Agca, Y. Smulders, and M. Nurmoḥamed, “Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice,” *Heart*, vol. 108, no. 1, pp. 73–79, 2022.
- [155] Z. Karaköy, E. Cadirci, and B. Dincer, “A new target in inflammatory diseases: lycopene,” *The Eurasian Journal of Medicine*, vol. 54, no. 1, pp. S23–S28, 2023.
- [156] R. N. Ugbaja, A. S. James, E. I. Ugwor, A. J. Akamo, F. C. Thomas, and A. M. Kosoko, “Lycopene suppresses palmitic acid-induced brain oxidative stress, hyperactivity of some neuro-signalling enzymes, and inflammation in female Wistar rat,” *Scientific Reports*, vol. 11, pp. 15038–15113, 2021.
- [157] M. F. Hassan, S. A. Hussein, Y. El Senosi, M. K. Mansour, and A. Amin, “The role of lycopene as antioxidant and anti-inflammatory in protection of oxidative stress induced by metalaxyl,” *Open Journal of Medicinal Chemistry*, vol. 3, no. 1, pp. 26–36, 2018.
- [158] P. Yang, H. Chen, Y. Huang, C. Hsieh, and B. Wung, “Lycopene inhibits NF- κ B activation and adhesion molecule expression through Nrf2-mediated heme oxygenase-1 in endothelial cells,” *International Journal of Molecular Medicine*, vol. 39, no. 6, pp. 1533–1540, 2017.
- [159] H. Hashem, S. Hussein, and Y. El senosi, “Lycopene mitigates experimental colitis in rats by inhibiting oxidative stress-mediated inflammation and apoptosis,” *Benha Veterinary Medical Journal*, vol. 39, no. 1, pp. 16–21, 2020.
- [160] D. F. A. Rocha, P. A. Machado-Junior, A. B. F. Souza et al., “Lycopene ameliorates liver inflammation and redox status in mice exposed to long-term cigarette smoke,” *BioMed Research International*, vol. 2021, Article ID 7101313, 11 pages, 2021.
- [161] Y. Li, M. Zhan, J. Li, W. Zhang, and X. Shang, “Lycopene alleviates lipopolysaccharide-induced testicular injury in rats by activating the PPAR signaling pathway to integrate lipid metabolism and the inflammatory response,” *Translational Andrology and Urology*, vol. 12, no. 2, pp. 271–285, 2023.
- [162] P. Saeedi, I. Petersohn, P. Salpea et al., “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition,” *Diabetes Research and Clinical Practice*, vol. 157, Article ID 107843, 2019.
- [163] Y. Jin and R. Arroo, “The protective effects of flavonoids and carotenoids against diabetic complications— a review of in vivo evidence,” *Frontiers in Nutrition*, vol. 10, Article ID 1020950, 2023.
- [164] N. Sakran, Y. Graham, T. Pintar et al., “The many faces of diabetes,” *Is there a need for re-classification? A narrative review*, vol. 1–12, 2022.
- [165] O. Ozmen, S. Topsakal, M. Haligur, A. Aydogan, and D. Dincoglu, “Effects of caffeine and lycopene in experimentally induced diabetes mellitus,” *Pancreas*, vol. 45, no. 4, pp. 579–583, 2016.
- [166] D. E. Ejike, M. A. Adam, O. S. Sheu et al., “Lycopene attenuates diabetes-induced oxidative stress in Wistar rats,” *Journal of Diabetes and Endocrinology*, vol. 9, no. 2, pp. 11–19, 2018.
- [167] R. Xie, H. Zhang, X. Liu, J. Liu, and Q. Li, “Extraction of lycopene from tomato pomace and its protective effects on renal injury in diabetic rats,” *Food Science and Technology*, vol. 42, pp. 1–5, 2022.
- [168] M. Soleymanejad, S. G. Joursaraei, F. Feizi, and I. Jafari Anarkooli, “The effects of lycopene and insulin on histological changes and the expression level of bcl-2 family genes in the Hippocampus of streptozotocin-induced diabetic rats,” *Journal of Diabetes Research*, vol. 2017, Article ID 4650939, 9 pages, 2017.
- [169] Y. Yin, Z. Zheng, and Z. Jiang, “Effects of lycopene on metabolism of glycolipid in type 2 diabetic rats,” *Biomedicine and Pharmacotherapy*, vol. 109, no. 74, pp. 2070–2077, 2019.
- [170] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2022,” *CA: A Cancer Journal for Clinicians*, vol. 72, no. 1, pp. 7–33, 2022.
- [171] X. Xu, S. Li, and Y. Zhu, “Dietary intake of tomato and lycopene and risk of all-cause and cause-specific mortality: results from a prospective study,” *Frontiers in Nutrition*, vol. 8, Article ID 684859, 2021.
- [172] M. Mirahmadi, S. Azimi-Hashemi, E. Saburi, H. Kamali, M. Pishbin, and F. Hadizadeh, “Potential inhibitory effect of lycopene on prostate cancer,” *Biomedicine and Pharmacotherapy*, vol. 129, Article ID 110459, 2020.
- [173] N. P. Holzapfel, A. Shokoohmand, F. Wagner et al., “Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load,” *American Journal of Cancer Research*, vol. 7, no. 6, pp. 1322–1336, 2017.
- [174] O. H. Aktepe, T. K. Şahin, G. Güner, Z. Arik, and Ş. Yalçın, “Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor-kappa b (Nf- κ b) pathway,” *Turkish Journal of Medical Sciences*, vol. 51, no. 1, pp. 368–374, 2021.
- [175] A. N. Mekuria, A. K. Tura, B. Hagos et al., “Anti-cancer effects of lycopene in animal models of hepatocellular carcinoma: a systematic review and meta-analysis,” *Frontiers in Pharmacology*, vol. 11, Article ID 1306, 2020.
- [176] D. Ataseven, A. Öztürk, M. Özkaraca, and Z. Joha, “Anti-cancer activity of lycopene in HT-29 colon cancer cell line,” *Medical Oncology*, vol. 40, no. 5, p. 127, 2023.
- [177] M. Abbasi-Kangevari, N. Ahmadi, N. Fattahi et al., “Quality of care of peptic ulcer disease worldwide: a systematic

- analysis for the global burden of disease study 1990-2019," *PLoS One*, vol. 17, no. 8, pp. 02712844–e271315, 2022.
- [178] A. Tarasconi, F. Coccolini, W. L. Biffl et al., "Perforated and bleeding peptic ulcer: WSES guidelines," *World Journal of Emergency Surgery*, vol. 15, no. 1, pp. 3–24, 2020.
- [179] Z. Irshad, M. Sajjad Khan, Kamran et al., "Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers," *Pakistan Journal of Health Sciences*, pp. 147–151, 2023.
- [180] S. P. Lee, I. K. Sung, J. H. Kim, S. Y. Lee, H. S. Park, and C. S. Shim, "Risk factors for the presence of symptoms in peptic ulcer disease," *Clinical Endoscopy*, vol. 50, no. 6, pp. 578–584, 2017.
- [181] A. M Asali, M. A. Alghamdi, S. A. Fallatah et al., "Risk factors leading to peptic ulcer disease: systematic review in literature," *International Journal Of Community Medicine And Public Health*, vol. 5, no. 10, p. 4617, 2018.
- [182] M. H. Yim, K. H. Kim, and B. J. Lee, "The number of household members as a risk factor for peptic ulcer disease," *Scientific Reports*, vol. 11, no. 1, pp. 5274–5310, 2021.
- [183] S. Kumar, T. Theis, M. Tschang, V. Nagaraj, and F. Berthiaume, "Reactive oxygen species and pressure ulcer formation after traumatic injury to spinal cord and brain," *Antioxidants*, vol. 10, no. 7, pp. 1013–1015, 2021.
- [184] W. Zhang, Y. Lian, Q. Li et al., "Preventative and therapeutic potential of flavonoids in peptic ulcers," *Molecules*, vol. 25, no. 20, p. 4626, 2020.
- [185] R. Abdul-Majeed Al-Razzuqi, A. Rahma Abu-Rageef, W. Sami Mehasin, and T. Rafi Abdul-Majeed Al-Razzuqi, "Evaluation of gastroprotective effect of Vanadyl sulfate and Lycopene on rat model with ethanol-induced gastric mucosal lesions," *Biomedical and Pharmacology Journal*, vol. 11, no. 3, pp. 1291–1294, 2018.
- [186] X. Chen, Y. Zhao, K. Liu et al., "Lycopene aggravates acute gastric injury induced by ethanol," *Frontiers in Nutrition*, vol. 8, pp. 697879–697913, 2021.
- [187] R. N. L. Lamptey, B. Chaulagain, R. Trivedi, A. Gothwal, B. Layek, and J. Singh, "A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics," *International Journal of Molecular Sciences*, vol. 23, no. 3, p. 1851, 2022.
- [188] K. S. Cho, M. Shin, S. Kim, and S. B. Lee, "Recent advances in studies on the therapeutic potential of dietary carotenoids in neurodegenerative diseases," *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 4120458, 13 pages, 2018.
- [189] N. Duggirala, K. J. Ngo, S. M. Pagnoni, A. L. Rosa, and B. L. Fogel, "Spinocerebellar ataxia type 14 (SCA14) in an Argentinian family: a case report," *Journal of Medical Case Reports*, vol. 17, no. 1, pp. 168–176, 2023.
- [190] S. Dutta, M. Sklerov, C. E. Teunissen, and G. Bitan, "Editorial: trends in biomarkers for neurodegenerative diseases: current research and future perspectives," *Frontiers in Aging Neuroscience*, vol. 15, Article ID 1153932, 2023.
- [191] H. Liu, Y. Hu, Y. Zhang et al., "Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer's disease GWAS and self-report proxy phenotype GWAS," *Alzheimer's Research and Therapy*, vol. 14, no. 1, pp. 17–10, 2022.
- [192] M. Fricker, A. M. Tolkovsky, V. Borutaite, M. Coleman, and G. C. Brown, "Neuronal cell death," *Physiological Reviews*, vol. 98, no. 2, pp. 813–880, 2018.
- [193] E. O. Olufunmilayo, M. B. Gerke-Duncan, and R. M. D. Holsinger, "Oxidative stress and antioxidants in neurodegenerative disorders," *Antioxidants*, vol. 12, no. 2, pp. 517–530, 2023.
- [194] B. Zhao, H. Liu, J. Wang et al., "Lycopene supplementation attenuates oxidative stress, neuroinflammation, and cognitive impairment in aged CD-1 mice," *Journal of Agricultural and Food Chemistry*, vol. 66, no. 12, pp. 3127–3136, 2018.
- [195] E. M. El Morsy and M. A. E. Ahmed, "Protective effects of lycopene on hippocampal neurotoxicity and memory impairment induced by bisphenol A in rats," *Human and Experimental Toxicology*, vol. 39, no. 8, pp. 1066–1078, 2020.
- [196] Y. Guo, Z. Fan, S. Zhao et al., "Brain-targeted lycopene-loaded microemulsion modulates neuroinflammation, oxidative stress, apoptosis and synaptic plasticity in β -amyloid-induced Alzheimer's disease mice," *Neurological Research*, vol. 45, no. 8, pp. 753–764, 2023.
- [197] S. Przybylska and G. Tokarczyk, "Lycopene in the prevention of cardiovascular diseases," *International Journal of Molecular Sciences*, vol. 23, no. 4, p. 1957, 2022.
- [198] H. M. Cheng, G. Koutsidis, J. K. Lodge, A. W. Ashor, M. Siervo, and J. Lara, "Lycopene and tomato and risk of cardiovascular diseases: a systematic review and meta-analysis of epidemiological evidence," *Critical Reviews in Food Science and Nutrition*, vol. 59, no. 1, pp. 141–158, 2019.
- [199] H. M. Cheng, G. Koutsidis, J. K. Lodge, A. Ashor, M. Siervo, and J. Lara, "Tomato and lycopene supplementation and cardiovascular risk factors: a systematic review and meta-analysis," *Atherosclerosis*, vol. 257, pp. 100–108, 2017.
- [200] J. Lin, H.-X. Li, J. Xia et al., "The chemopreventive potential of lycopene against atrazine-induced cardiotoxicity: modulation of ionic homeostasis," *Scientific Reports*, vol. 6, no. 1, Article ID 24855, 2016.
- [201] Y. He, P. Xia, H. Jin, Y. Zhang, B. Chen, and Z. Xu, "Lycopene ameliorates transplant arteriosclerosis in vascular allograft transplantation by regulating the NO/cGMP pathways and rho-associated kinases expression," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 3128280, 9 pages, 2016.
- [202] Q. He, W. Zhou, C. Xiong, G. Tan, and M. Chen, "Lycopene attenuates inflammation and apoptosis in post-myocardial infarction remodeling by inhibiting the nuclear factor- κ B signaling pathway," *Molecular Medicine Reports*, vol. 11, no. 1, pp. 374–378, 2015.
- [203] P. R. Gajendragadkar, A. Hubsch, K. M. Mäki-Petäjä, M. Serg, I. B. Wilkinson, and J. Cheriyan, "Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial," *PLoS One*, vol. 9, no. 6, Article ID e99070, 2014.
- [204] K. K. D. Campos, C. de Oliveira Ramos, T. L. Martins et al., "Lycopene mitigates pulmonary emphysema induced by cigarette smoke in a murine model," *The Journal of Nutritional Biochemistry*, vol. 65, pp. 93–100, 2019.
- [205] W. W. Li, T. Y. Wang, B. Cao et al., "Synergistic protection of matrine and lycopene against lipopolysaccharide-induced acute lung injury in mice," *Molecular Medicine Reports*, vol. 20, no. 1, pp. 455–462, 2019.
- [206] J. Mustra Rakic, C. Liu, S. Veeramachaneni et al., "Dietary lycopene attenuates cigarette smoke-promoted nonalcoholic steatohepatitis by preventing suppression of antioxidant enzymes in ferrets," *The Journal of Nutritional Biochemistry*, vol. 91, Article ID 108596, 2021.
- [207] W. Ombelet, "WHO fact sheet on infertility gives hope to millions of infertile couples worldwide," *Facts, Views and Vision in ObGyn*, vol. 12, no. 4, pp. 249–251, 2020.

- [208] O. A. Ojo, P. I. Nwafor-Ezeh, D. E. Rotimi, M. Iyobhebhe, A. D. Ogunlakin, and A. B. Ojo, "Apoptosis, inflammation, and oxidative stress in infertility: a mini review," *Toxicology Reports*, vol. 10, pp. 448–462, 2023.
- [209] A. Babaei, R. Asadpour, K. Mansouri, A. Sabrivand, and S. Kazemi-Darabadi, "Lycopene improves testicular damage and sperm quality in experimentally induced varicocele: relationship with apoptosis, hypoxia, and hyperthermia," *Food Science and Nutrition*, vol. 10, no. 5, pp. 1469–1480, 2022.
- [210] Y. Yamamoto, K. Aizawa, M. Mieno et al., "The effects of tomato juice on male infertility," *Asia Pacific Journal of Clinical Nutrition*, vol. 26, no. 1, pp. 65–71, 2017.
- [211] C. Turkler, T. Onat, E. Yildirim et al., "An experimental study on the use of lycopene to prevent infertility due to acute oxidative ovarian damage caused by a single high dose of methotrexate," *Advances in Clinical and Experimental Medicine*, vol. 29, no. 1, pp. 5–11, 2020.
- [212] E. V. Osilla, J. L. Marsidi, and S. Sharma, "Physiology, temperature regulation," *StatPearls*, 2022.
- [213] A. Balić and M. Mokos, "Do we utilize our knowledge of the skin protective effects of carotenoids enough?" *Antioxidants*, vol. 8, no. 8, pp. 259–319, 2019.
- [214] R. M. Brand, P. Wipf, A. Durham, M. W. Epperly, J. S. Greenberger, and L. D. Faló, "Targeting mitochondrial oxidative stress to mitigate UV-induced skin damage," *Frontiers in Pharmacology*, vol. 9, Article ID 920, 2018.
- [215] M. P. Mogavero, L. M. DelRosso, F. Fanfulla, O. Bruni, and R. Ferri, "Sleep disorders and cancer: state of the art and future perspectives," *Sleep Medicine Reviews*, vol. 56, Article ID 101409, 2021.
- [216] K. Anbualakan, N. Q. Tajul Urus, S. Makpol et al., "A Scoping review on the effects of carotenoids and flavonoids on skin damage due to ultraviolet radiation," *Nutrients*, vol. 15, no. 1, pp. 1–17, 2023.
- [217] X. Zhang, Q. Zhou, Y. Qi et al., "The effect of tomato and lycopene on clinical characteristics and molecular markers of UV-induced skin deterioration: a systematic review and meta-analysis of intervention trials," *Critical Reviews in Food Science and Nutrition*, pp. 1–20, 2023.
- [218] K. K. Abu-Amero, A. A. Kondkar, and K. V. Chalam, "Resveratrol and ophthalmic diseases," *Nutrients*, vol. 8, no. 4, p. 200, 2016.
- [219] X. Gong, C. S. Draper, G. S. Allison, R. Marisiddaiah, and L. P. Rubin, "Effects of the macular carotenoid lutein in human retinal pigment epithelial cells," *Antioxidants*, vol. 6, no. 4, 2017.
- [220] A. Dammak, C. Pastrana, A. Martin-Gil et al., "Oxidative stress in the anterior ocular diseases: diagnostic and treatment," *Biomedicines*, vol. 11, no. 2, p. 292, 2023.
- [221] H. Jiang, Y. Yin, C. R. Wu et al., "Dietary vitamin and carotenoid intake and risk of age-related cataract," *The American Journal of Clinical Nutrition*, vol. 109, no. 1, pp. 43–54, 2019.
- [222] M. Rameshrad, B. M. Razavi, and H. Hosseinzadeh, "Protective effects of green tea and its main constituents against natural and chemical toxins: a comprehensive review," *Food and Chemical Toxicology*, vol. 100, pp. 115–137, 2017.
- [223] J. Briffa, E. Sinagra, and R. Blundell, "Heavy metal pollution in the environment and their toxicological effects on humans," *Heliyon*, vol. 6, no. 9, Article ID e04691, 2020.
- [224] N. Hedayati, M. B. Naeini, A. Nezami et al., "Protective effect of lycopene against chemical and natural toxins: a review," *BioFactors*, vol. 45, no. 1, pp. 5–23, 2019.
- [225] T. Y. Liu and S. B. Chen, "Sarcandra glabra combined with lycopene protect rats from lipopolysaccharide induced acute lung injury via reducing inflammatory response," *Bio-medicine & Pharmacotherapy*, vol. 84, pp. 34–41, 2016.
- [226] A. Karaca, S. Yilmaz, E. Kaya, and S. Altun, "The effect of lycopene on hepatotoxicity of aflatoxin B1 in rats," *Archives of Physiology and Biochemistry*, vol. 127, no. 5, pp. 429–436, 2019.
- [227] X. Wan, H. Ji, H. Ma et al., "Lycopene alleviates aflatoxin B1 induced liver damage through inhibiting cytochrome 450 isozymes and improving detoxification and antioxidant systems in broiler chickens," *Italian Journal of Animal Science*, vol. 21, no. 1, pp. 31–40, 2022.
- [228] O. Macar, T. Kalefetoğlu Macar, K. Çavuşoğlu, E. Yalçın, and K. Yapar, "Lycopene: an antioxidant product reducing dithane toxicity in *Allium cepa* L.," *Scientific Reports*, vol. 13, no. 1, p. 2290, 2023.
- [229] T. A. I. Ahmed, "Protective role of lycopene and vitamin E against diazinon-induced biochemical changes in *Oreochromis niloticus*," *African Journal of Environmental Science and Technology*, vol. 9, no. 6, pp. 557–565, 2015.
- [230] S. Y. Zhu, X. N. Li, Y. Zhao, X. Y. Dai, J. Y. Guo, and J. L. Li, "Lycopene ameliorate atrazine-induced oxidative damage in the B cell zone via targeting the miR-27a-3p/foxo1 Axis," *Journal of Agricultural and Food Chemistry*, vol. 70, no. 39, pp. 12502–12512, 2022.
- [231] W. Li, B. Jiang, X. Cao, Y. Xie, and T. Huang, "Protective effect of lycopene on fluoride-induced ameloblasts apoptosis and dental fluorosis through oxidative stress-mediated Caspase pathways," *Chemico-Biological Interactions*, vol. 261, pp. 27–34, 2017.
- [232] D. Jonker, C. F. Kuper, N. Fraile, A. Estrella, and C. Rodríguez Otero, "Ninety-day oral toxicity study of lycopene from *Blakeslea trispora* in rats," *Regulatory Toxicology and Pharmacology*, vol. 37, no. 3, pp. 396–406, 2003.
- [233] S. K. Gupta, D. Trivedi, S. Srivastava, S. Joshi, N. Halder, and S. D. Verma, "Lycopene attenuates oxidative stress induced experimental cataract development: an in vitro and in vivo study," *Nutrition*, vol. 19, no. 9, pp. 794–799, 2003.
- [234] C. Hanson, E. Lyden, J. Furtado et al., "Serum lycopene concentrations and associations with clinical outcomes in a cohort of maternal-infant dyads," *Nutrients*, vol. 10, no. 2, p. 204, 2018.
- [235] T. Kang, Y. Liu, X. Chen et al., "Dietary carotenoid intake and risk of developing preeclampsia: a hospital-based case-control study," *BMC Pregnancy and Childbirth*, vol. 22, no. 1, pp. 427–513, 2022.